Neuigkeiten von KOOL - 500 Beiträge pro Seite

[RudiDutschke]

An alle AktionärInnen und Interessierten,
zwei Neuigkeiten von thermogenesis:
1. Einreichen einer technischen Reihe
2. Verkauf von zwei BioArchiv Systems nach Japan.
Mehr bei stockpoint.com und thermogenesis.com

[CaptainChaos]

Thermogenesis hat heute mitgeteilt, dass zwei Bioarchivsysteme nach Japan verkauft worden sind. Zudem hat KOOL die technische Entwicklung eines neuen Bioarchivsystems für Blut und Plasma fertiggestellt. Thermogenesis geht von einem jährlichen weltweiten Marktsegment von 400 Mio. US-Dollar aus.

THERMOGENESIS CORP. Files for CE Mark On Fibrin Sealant
Processing Disposable
Business Editors
RANCHO CORDOVA, Calif.--(BUSINESS WIRE)--Nov. 13, 2000--
Regulatory Clearance Will Mark Commencement of CryoSeal(R)Fibrin Sealant ("FS") System Marketing Throughout the European Communities
THERMOGENESIS CORP. (Nasdaq: KOOL) today announced that the Company has submitted the Technical File to receive the CE Mark of conformity for the CP-2 Plasma Processing Disposable which, with the CryoSeal FS System , is used to prepare fibrin sealant from a single unit of human plasma in about 60 minutes. Fibrin sealant is a surgical hemostatic agent and tissue sealant. Based on independent marketing reports, the Company believes the global market for fibrin sealant to be approximately $400 million annually, of which Europe is estimated to be 25% or $100 million annually. Receipt of the CE Mark of conformity will allow THERMOGENESIS CORP. to market the CryoSeal FS System throughout the countries comprising the European Union.
Dr. James Godsey, President and COO of THERMOGENESIS CORP. commented, "filing for our CE Mark for this innovative product is one of the most important milestones in the Company`s recent history", noting further that "the European fibrin sealant market is the largest market in which one of the Company`s products has competed." Because of Europe`s ever increasing fear of contracting Mad Cow Disease (nvCJD) from pharmaceutical products which contain bovine-derived substances, Europe is now the fibrin sealant market in which autologous blood products are in the greatest demand. Godsey noted that "the CryoSeal FS System is the first product to prepare both components of fibrin sealant (fibrinogen and thrombin) from a single unit of plasma, thus eliminating the risk of viral/prion infection from animal proteins/tissues or large pools of human plasma. THERMOGENESIS CORP. will thus be the first company to offer a truly autologous fibrin sealant to the European fibrin sealant market place."
The design of the CP-2 Plasma Processing Disposable is based upon two of the Company`s recent technological breakthroughs enabling real time processing of blood products. The cryoprecipitation technology prepares fibrinogen-rich cryoprecipitate from plasma in as little as 40 minutes as compared to 2-3 days for standard blood center methodology, while the thrombin activation technology prepares activated human thrombin from a small aliquot of the same human plasma. When mixed together, fibrinogen and thrombin form a surgical hemostatic agent, sealant or adhesive for a wide array of surgical procedures. The fibrin sealant is applied to the wound site by the Company`s proprietary FS Applicator System. Once applied the fibrin sealant gels on the wound site to stop bleeding and is reabsorbed by the body within 2-4 weeks.
The Company plans to file an Investigational New Drug ("IND") with the U.S. FDA for the CryoSeal FS System early in calendar year 2001 to begin its pivotal human clinical trials in the United States.
Regulatory Status
The CryoSeal System is patent protected, and will require various regulatory clearances or approvals before marketing for specific indications. The Company obtained U.S. FDA clearance of its 510(k) pre-market application for automated preparation of Cryoprecipitated Anti-Hemophilic Factor (AHF) in February 1999. The Company has submitted preliminary material to the U.S. FDA for approval of its human clinical trials for the use of the CryoSeal FS System in the automated preparation of a fibrin sealant for surgical application. Until U.S. FDA approval, the CryoSeal FS System, including FS applicator kits, will be marketed outsideof the United States, as permitted under applicable foreign regulations, including CE certification for distribution in the European market.
About THERMOGENESIS CORP.
THERMOGENESIS CORP. has been a pioneer in designing, manufacturing and distributing equipment to collect, cryopreserve and archive highly sensitive blood products and biological tissue for more than 10 years.
The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.


THERMOGENESIS CORP. Places Fifth & Sixth BioArchive System in
Japan; University of Tokyo Will Acquire Two Additional BioArchive Systems for Their Cord Blood Stem Cell Bank
Business Editors/Medical Writers
RANCHO CORDOVA, Calif.--(BUSINESS WIRE)--Nov. 14, 2000-- THERMOGENESIS CORP. (Nasdaq:KOOL) announced the sale of two BioArchive(R) Systems to the Tokyo Cord Blood Bank at the University of Tokyo, in Tokyo, Japan. BioArchive Systems have also been purchased by the major Cord Blood Banks in Germany, United Kingdom, Belgium, Spain, Finland, China, Taiwan, Vietnam, Mexico, and in the U.S. pursuant to IND regulations.
According to Philip Coelho, chairman and CEO of the Company, "Recent research suggests that there are stem cells in a unit of cord blood that have the potential to produce other cells outside the hematopoietic system such as neural, liver and bone cells. Since there are serious ethical issues with sourcing stem cells from embryos and fetuses, scientists may begin to focus on cord blood as a superior, non-controversial source for these multi-potential stem cells. These will be the second and third systems installed at University of Tokyo, and the fifth and sixth systems in Japan."
The BioArchive System is demonstrably the international standard for collecting, processing, and archiving cryopreserved hematopoietic stem cells sourced from placental/cord blood ("PCB"). PCB stem cells are used to reconstitute the hematopoietic and immune systems of patients who have undergone high-dose chemotherapy and radiation to combat diseases such as leukemias, lymphomas, diverse inherited anemias, such as sickle cell anemia and thalassemia, and other genetic diseases.
The Tokyo Cord Blood Bank plans to store 10,000 PCB stem cell units over the next 3 years. Dr. James Godsey, president and COO of THERMOGENESIS CORP., commented, "We are pleased that the Tokyo Cord Blood Bank at the University of Tokyo has chosen to continue expanding their use of the BioArchive System for their cord blood banking program. Japanese PCB banks have already provided PCB units for more than 200 transplants and this source of hematopoietic stem cells is rapidly replacing bone marrow in Japan."
The BioArchive System uses THERMOGENESIS CORP.`s proprietary computer-driven liquid nitrogen robotic system to cryopreserve and archive up to 3,626 units that have been collected and preserved in proprietary sterile plastic bag sets. The BioArchive System tracks identification and location for each unit and performs robotic retrieval of each unique tissue-typed unit for use in life-saving transplantation. The BioArchive System operates to freeze, place and retrieve samples without exposing other archived samples to detrimental temperature changes. In the U.S., the THERMOGENESIS CORP. BioArchive System is a Class II exempt device intended for the preservation of blood components and blood products.
Regulatory Status
The BioArchive System is a Class II exempt blood component freezer, and has initially been distributed in the U.S. only to IND sites which have received FDA approvals for use with stem cell storage for transplant into unrelated patients. The BioArchive System has potential applications involving archiving, storing, managing and retrieving other kinds of biological specimens, that may include stem cells, dendritic cells, T-cells, cell lines, male sperm cells, female eggs, heart valves, corneas, virus samples, biopsy samples and other blood, tissue and saliva samples. The BioArchive System is currently intended for preservation of blood components and blood products and would require FDA 510(k) clearance for some additional claims.
About Tokyo Cord Blood Bank at the University of Tokyo
The Tokyo Cord Blood Bank, located in Tokyo, Japan, is a non-profit organization under the leadership of the immunogeneticist, Shigetatka Asano, MD, and the cryobiologist, Tsuneo Takahashi, Ph.D.
About THERMOGENESIS CORP.
THERMOGENESIS CORP. has been a pioneer in designing, manufacturing and distributing equipment to collect, cryopreserve and archive highly sensitive blood products and biological tissue for more than 10 years.
The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.

[RudiDutschke]

@CaptainChaos
danke für das Reinstellen der Artikel

[CaptainChaos]

@Rudi Dutschke,

1. da nich für

2. nützt nur heute leider nichts. In den USA "Sell on good News".

Gruss

CC

[RudiDutschke]

Guten Morgen,
gestern die Zahlen für das erste Quartal 2001:
$0,06 Verlust pro Aktie, im Vorjahr $0,08
Netto Verlust $1,423,000, mehr unter stockpoint.com
heute um 1.00 PST eine Konferenz
vielleicht kann ja jemand den Artikel hier reinstellen

[CaptainChaos]

@ Rudi Dutschke,

Third -Quarter-Results habe ich noch nicht auffinden können, jedoch nachfolgende "frische Meldung"

Gruss

CC


THERMOGENESIS CORP. Files for Surgical Applicator CE Mark; Taking Additional Step Toward Launching Fibrin Sealant Technology in Europe

Business Wire
November 15, 2000 6:01am
RANCHO CORDOVA, Calif., Nov 15, 2000 (BUSINESS WIRE) -- THERMOGENESIS CORP. (Nasdaq:KOOL) today announced that the Company has submitted the Technical File to receive the CE Mark of conformity for the FS Applicator System, a proprietary medical device that enables surgeons to precisely apply fibrin sealant to bleeding wound sites in surgery. The FS Applicator System is one of several disposables that comprise the Company`s CryoSeal FS System, which can prepare both the fibrinogen and thrombin components of fibrin sealant from a single unit of human plasma in as little as 60 minutes.

The Company expects to receive the certificate to begin using the CE Mark during the quarter ended March 31, 2001. Receipt of the CE Mark of conformity is required before THERMOGENESIS CORP. can market the CryoSeal FS System throughout the countries comprising the European Union. The CryoSeal FS System will enable THERMOGENESIS CORP. to become the first company to offer a truly autologous fibrin sealant for sale in the European Community. Fibrin sealant is indicated as a surgical hemostatic agent, a sealant and adhesive. Based on independent marketing reports, the Company believes the global market for fibrin sealant to be approximately $400 million annually, of which Europe is estimated to be 25% or $100 million annually.

Dr. James Godsey, President and COO of THERMOGENESIS CORP. commented, "the Company believes that the FS Applicator System provides the surgeon with a highly effective tool for applying our fibrin sealant with great precision in the surgical theater." Dr. Godsey goes on to say, "furthermore, by providing both the fibrin sealant and the optimal means for its application during surgery, we feel we have designed a complete system which meets the needs of surgeons, hospitals and local blood centers. The CryoSeal fibrin sealant and applicators will be extremely cost competitive versus the long standing entrenched competitive commercial fibrin sealants which are derived from large pools of plasma drawn from thousands of individuals."

The proprietary FS Applicator System was designed with direct input by the intended user, the surgeon, as reflected by the ergonomic gun-grip design of its handle and the ability to apply fibrin sealant in precise metered dosages. Furthermore, the handle is compatible with a variety of tip designs, which will enable the surgeon to spray or apply small or large volumes of fibrin sealant in any manner desired. Finally, the spray tips will be designed to control the rate at which the fibrin clot forms by carefully controlling the point at which mixing of the fibrinogen and thrombin occurs. Surgeons who typically deal with heavy bleeding wound sites desire rapid clot formation, while those surgeons who need to allow more time to adjust delicate skin grafts into precise positions to minimize scarring will want slower clot times. The entire fibrin sealant kit, including sealant, applicator, and tip is provided sterile to the surgeon and is discarded when the surgery is completed. No external source of pressurized air is required. The applicator is the first such device designed to dispense the sealant in precise metered dosage to allow the most cost effective usage of fibrin sealant by the surgeon.

The Company plans to file an Investigational New Drug ("IND") application with the U.S. FDA for the CryoSeal FS System, including pre-market clearance of its FS applicator kit, early in calendar year 2001 to begin its pivotal human clinical trials in the United States.



Regulatory Status

The CryoSeal System is patent protected, and will require various regulatory clearances or approvals before marketing for specific indications. The Company obtained U.S. FDA clearance of its 510(k) pre-market application for automated preparation of cryoprecipitated anti-hemophilic factor (AHF) in February 1999. The Company has submitted preliminary material to the U.S. FDA for approval of its human clinical trials for the use of the CryoSeal FS System in the automated preparation of a hemostatic agent for surgical application. Until U.S. FDA approval, the CryoSeal FS System, including FS applicator kits, will be marketed outside of the United States, as permitted under applicable foreign regulations, including CE certification for distribution in the European market.



About THERMOGENESIS CORP.

THERMOGENESIS CORP. has been a pioneer in designing, manufacturing and distributing equipment to collect, cryopreserve and archive highly sensitive blood products and biological tissue for more than 10 years.

The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.



CONTACT: THERMOGENESIS CORP.
James H. Godsey, Ph.D., 916/858-5100
[e-mail]
WWW.THERMOGENESIS.COM

URL: HTTP://WWW.BUSINESSWIRE.COM
TODAY`S News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2000 Business Wire. All rights reserved.
KEYWORD: CALIFORNIA INTERNATIONAL EUROPE INDUSTRY KEYWORD: MEDICAL MEDICAL DEVICES PRODUCT


Source: Business Wire

[RudiDutschke]

@CC
Ein weiteres Danke. Habe darauf spekuliert, dass du die Meldung reinstellst. Bezieht sich wohl auf
die gestrige Meldung, da das Thema da ja schon angesprochen wurde. Ist wohl jetzt alles etwas
konkreter. $100 Mio für den europäischen Markt hört sich ja ganz gut an. Wäre schön, könnte KOOL an
einem kleinen Teil davon partizipieren.
Schönen Gruss Rudi

[RudiDutschke]

Habe vergessen zu erwähnen, dass die Zahlen auch unter freerealtime.com stehen. Gruss Rudi

[CaptainChaos]

Quartalszahlen KOOL


Gruss

CC



THERMOGENESIS CORP. Announces Results for the Quarter Ended September 30, 2000Company reports continuing decrease in losses and a sales backlog of $954,000 -- Nov 14 2000


RANCHO CORDOVA, Calif., Nov 14, 2000 (BW HealthWire) -- THERMOGENESIS CORP.
(NASDAQ: KOOL) today announced results for its first quarter of fiscal 2001. The
Company reported a net loss of $1,423,000 or $0.06 per share and per diluted
share, compared to a net loss of $1,752,000 or $0.08 per share and per diluted
share, for the first quarter of fiscal 2000.

Net revenues for the three months ended September 30, 2000 were $801,000,
compared to $999,000 for the three months ended September 30, 1999, a decrease
of $198,000. The decrease is primarily due to the non refundable licensing fees
of $121,000 received from the distributor of the BioArchive system in Japan
which was included in net revenues for the three months ended September 30,
1999. BioArchive revenues increased as one unit was sold during the first
quarter of FY2001 versus none in the first quarter of FY2000. Offsetting the
increase in BioArchive revenues, freezer sales were down from the prior year as
orders for the company`s largest freezers were not received until late in the
quarter.

Commenting on the revenue results, the Company`s President and Chief Operating
Officer, James H. Godsey, Ph.D., stated, "Although we were disappointed in the
first quarter revenue results, we are pleased with the sales backlog we have
heading into the second quarter. The backlog is primarily the result of purchase
orders for BioArchive disposables and for eight MP2000 Plasma Freezers from
Aventis Bio-Services, Inc. Also, the Company moved to "make to order" for our
freezer product line last year which has resulted in lower inventory levels for
our freezers and better management of cash."

General and Administrative expenses for the three months ended September 30,
2000 decreased $88,000 or 17% from the corresponding fiscal 2000 period. This
decrease is primarily the result of personnel reductions which occurred during
the prior fiscal year and the Company has elected not to replace the vacant
positions. Selling and Service expenses decreased $86,000 or 15% from the
corresponding fiscal 2000 period due to personnel and other cost reductions
implemented to bring the selling and service expenses more in line with the
actual revenues produced.

Dr. Godsey, commenting on the overall performance, noted, "Due to the Company`s
cost reduction and cash management efforts, we reduced the net loss in spite of
a decrease in net revenues. With our significant backlog at quarter end, and our
continuing focus on keeping expenses down, we anticipate improvements in gross
margin and financial results."

The Company will hold an analyst and market conference call to review and
discuss the results of operations on Wednesday, November 15, 2000 at 1:00 PST.
Interested investors can listen to the conference call by dialing (412)
858-4600. Additionally, a taped playback of the conference call will be
available from November 15, 2000 @ 3:00pm PST to November 22, 2000 @ 9:00pm PST.
Access to the tape playback is available by dialing [phone]; Account No.:
511; Conference No.: 213373. If you have any questions or experience problems
accessing the taped playback, please contact Nitza Mihalus at [phone]
during the Company`s normal business hours.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the Company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.


THERMOGENESIS CORP.
Condensed Statements of Operations
(Unaudited)

Three Months Ended
September 30,
2000 1999


Net revenues $ 801,000 $ 999,000

Cost of revenues 926,000 1,251,000
----------- -----------
Gross profit (loss) (125,000) (252,000)
----------- -----------
Expenses:
General and administrative 415,000 503,000

Selling and service 478,000 564,000

Research and development 435,000 443,000
----------- -----------
Total expenses 1,328,000 1,510,000

Other income/expenses 30,000 10,000
----------- -----------
Net loss ($1,423,000) ($1,752,000)
=========== ===========
Preferred stock dividends 50,000 0
----------- -----------
Net loss to common
stockholders ($1,473,000) ($1,752,000)
=========== ===========

THERMOGENESIS CORP.
Condensed Balance Sheets
(Unaudited)

September 30, June 30,
2000 2000
ASSETS
Current assets:
Cash, cash equivalents and
short term investments $1,562,000 $2,550,000
Accounts receivable, net 668,000 627,000
Inventory 2,271,000 2,275,000
Other current assets 102,000 150,000
---------- ----------
Total current assets 4,603,000 5,602,000

Equipment 1,036,000 1,080,000

Other assets 52,000 53,000
---------- ----------
$5,691,000 $6,735,000
========== ==========

LIABILITIES AND SHAREHOLDERS` EQUITY

Current liabilities:
Accounts payable $ 568,000 $ 512,000
Other current liabilities 527,000 477,000
---------- ----------
Total current liabilities 1,095,000 989,000

Long-term portion of capital
lease obligations 54,000 54,000

Shareholders` equity 4,542,000 5,692,000
---------- ----------
$5,691,000 $6,735,000
========== ==========

CONTACT: THERMOGENESIS CORP.
Renee M. Ruecker, 916/858-5100
[e-mail]

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2000 Business Wire. All rights reserved.



KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: BIOTECHNOLOGY
MEDICAL
EARNINGS





Feedback

[RudiDutschke]

Guten Tag,
mal wieder etwas Neues von KOOL.
@CC
wenn du Zeit und Lust hast, zu finden unter stockpoint.com und freerealtime.com
Grüsse Rudi

[CaptainChaos]

Hallo Rudi, anscheinend sind wir die einzigen, die KOOL zu schätzen wissen. Ich versuche gleich noch eine Übersetzung reinzustellen.

Viele Grüsse und schon mal ein schönes Wochenende




THERMOGENESIS CORP. Files for Marketing Approval for the CryoSeal FS System in CanadaSeeking Regulatory License to Market The CryoSeal(R) Fibrin Sealant ("FS") System Throughout Canada
KOOL


RELATED QUOTES

KOOL 1.84 -0.09
RELATED TOPICS
biz
canada
contamination
export
fda
health
manufacturing
market
marketing
medical
patent
products
technology


RANCHO CORDOVA, Calif., Nov 17, 2000 (BW HealthWire) -- THERMOGENESIS CORP. (Nasdaq: KOOL ) today announced that the Company has filed an amendment to its Health Canada product license for approval to commence marketing activities of its CryoSeal FS System in Canada.

The CryoSeal FS System is intended for the preparation of fibrin sealant from a single unit of human plasma in approximately one hour. Fibrin sealant is a surgical hemostatic agent and tissue sealant. The Company estimates the global market for fibrin sealant to be approximately $400 million annually.

Dr. James Godsey, President and COO of THERMOGENESIS CORP. commented, "THERMOGENESIS is excited to have taken this critical step toward commercialization of the CryoSeal FS System in Canada and we see ourselves as being on plan to have a significant presence in the fibrin sealant marketplace outside of the United States." Dr. Godsey further noted that "like the United States, Canada has recently taken aggressive steps to protect its blood supply from the possible threat of nvCJD contamination, which we believe is an excellent indication of the level of demand for autologous blood products in this market place. THERMOGENESIS CORP.`s CryoSeal FS System will be the first product to deliver a truly autologous fibrin sealant, completely free of bovine-derived proteins found in pooled plasma-based fibrin sealants produced by competitors."

The design of the CP-2 Plasma Processing Disposable is based upon two of the Company`s technological breakthroughs enabling real time processing of blood products. The fibrinogen cryoprecipitation technology prepares fibrinogen-rich cryoprecipitate in approximately one hour as compared to two to three days for standard blood center methodology, while the thrombin activation technology represents the first medical device that can prepare concentrated human thrombin from a small aliquot of human plasma. When mixed together, fibrinogen and thrombin form a surgical hemostatic agent, sealant or adhesive for a wide array of surgical procedures. The fibrin sealant is applied to the wound site by the Company`s proprietary FS Applicator System. Once applied the fibrin sealant gels on the wound site to stop bleeding and is reabsorbed by the body within 2-4 weeks.

The Company plans to file an Investigational New Drug ("IND") with the U.S. FDA for the CryoSeal FS System early in calendar year 2001 to begin its pivotal human clinical trials in the United States.


Regulatory Status

The CryoSeal System is patent protected, and will require various regulatory clearances or approvals before marketing for specific indications. The Company obtained U.S. FDA clearance of its 510(k) pre-market application for automated preparation of cryoprecipitated anti-hemophilic factor (AHF) in February 1999. Until U.S. FDA approval, the CryoSeal FS System, including FS applicator kits, will be marketed outside of the United States, as permitted under U.S. Export Laws, applicable foreign regulations, including CE certification for distribution in the European market.


About THERMOGENESIS CORP.

THERMOGENESIS CORP. has been a pioneer in designing, manufacturing and distributing equipment to collect, cryopreserve and archive highly sensitive blood products and biological tissue for more than 10 years.

The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.


CONTACT: THERMOGENESIS CORP., Rancho Cordova
James H. Godsey, 916/858-5100
[e-mail]
or
www.thermogenesis.com

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2000 Business Wire. All rights reserved.

-0-


KEYWORD: CALIFORNIA INTERNATIONAL CANADA EUROPE
INDUSTRY KEYWORD: ADVERTISING/MARKETING
GOVERNMENT
MANUFACTURING
MEDICAL
DEVICES
MARKETING
AGREEMENTS
PRODUCT

[Phantasia]

Ihr seit nicht die Einzigen, ich bin auch noch da und verfolge eifrig euere News! Aber wo bleibt die Übersetzung?
Gruß
Phantasia

[ricox]

@ Phantasia

Für die, die kein Englisch könne, die gehen bitte auf die Seite
http://babel.altavista.com/translate.dyn
kopieren den Text da rein und lassen ihn sich übersetzen.


Gruß,
ricox

[Phantasia]

Vielen Dank ricox für den heißen Tipp. Allerdings wollte ich nur CaptainChaos ein wenig provozieren, der seinem Namen alle Ehre macht, wenn er einen Artikel in englisch ins Board stellt, gleich aber auch die Übersetzung dazu ankündigt.
Gruß
Phantasia

[CaptainChaos]

@Phantasia,

ich bin schliesslich schon Ü 30, da vergisst man schon mal etwas. Hier nun auszugsweise die Meldung in einer spannenden Babelfish - Übersetzung :

Ranch Cordova, Calif., Nov. 17, 2000 (Bw HealthWire) -- Thermogenesis Corp. (Nasdaq: KOOL) verkündete heute, daß die Firma eine Änderung zu seiner Gesundheit Kanada-Produktlizenz erreicht hat und damit Zustimmung Marketing-Aktivitäten seines CryoSeal-Rumpfstationsystems in Kanada beginnt. Das CryoSeal-Rumpfstationsystem ist für die Vorbereitung des Fibrindichtungsmittels von einer einzelnen Maßeinheit des menschlichen Plasmas in ungefähr einer Stunde bestimmt. Fibrindichtungsmittel ist ein chirurgisches blutstillendes Mittel und ein Gewebedichtungsmittel. Die Firma schätzt den globalen Markt, damit Fibrindichtungsmittel ungefähr $400 Million jährlich ist. Dr. James Godsey, Präsident und COO von THERMOGENESIS CORP. kommentierte, " THERMOGENESIS wird aufgeregt, diesen kritischen Jobstep in Richtung zur Kommerzialisierung des CryoSeal-Rumpfstationsystems in Kanada unternommen zu haben und wir sehen uns als, seiend auf Plan, um eine bedeutende Anwesenheit im Fibrindichtungsmittelmarkt außerhalb der Vereinigten Staaten zu haben. ", Weiteres des Dr. Godsey beachtet dem " wie die Vereinigten Staaten, Kanada hat vor kurzem konkurrenzfähige Jobsteps unternommen, um sein Blutzubehör vor der möglichen Drohung der nvCJD-Verschmutzung zu schützen, der wir sind eine ausgezeichnete Anzeige über die Stufe der Nachfrage nach autologous Blutprodukten in diesem Marktplatz glauben. Rumpfstationsystem THERMOGENESIS OCRcP.`s CryoSeal ist das erste Produkt zum Liefern eines wirklich autologous Fibrindichtungsmittels, vollständig frei von den Tier-berechneten Proteinen, die in den vereinigten Plasma-plasma-based Fibrindichtungsmitteln gefunden werden, die produziert werden von den Konkurrenten. ", Das Design der Verarbeitung des Plasmas CP-2, die Wegwerf ist, basiert nach zwei der technologischen Durchbrüche Company`s, die Echtzeitanwendung der Blutprodukte aktivierend. Die Fibrinogencryoprecipitationtechnologie bereitet Fibrinogen-reichen Kälteniederschlag in ungefähr einer Stunde verglichen mit zwei bis drei Tagen für Standardblutmittemethodenlehre vor, während die Thrombinaktivierung Technologie die erste medizinische Einheit darstellt, die starkes menschliches Thrombin von einer kleinen Aliquote menschlichem Plasma vorbereiten kann


Gruss

CC

[RudiDutschke]

Vielen Dank für die in der Tat sehr spannende Übersetzung. Schön, dass es mit Phantasias kleiner Provokation geklappt hat, nachdem du doch nur den Versuch einer Übersetzung angekündigt hast. Der Kurs scheint sich einigermassen zu halten, obwohl er im Tagesverlauf schon beängstigend fällt, um sich dann doch wieder zu fangen. Schönen Tag Rudi

[Phantasia]

@ Captain Chaos!

Danke für die Übersetzung. Wir haben eines gemeinsam, wir sind beide Ü 30, doch du bist der Größte in Sachen Übersetzung!! Ich hoffe, du steuerst das Schiff KOOL in den sicheren Hafen.

Gruß
Phantasia

[RudiDutschke]

Guten Morgen,
was sahen meine erfreuten Augen? KOOL +30% gestern in USA.
Wird wohl zum einen eine Reaktion auf die Talfahrt der letzten Tage und
Wochen gewesen sein, zum anderen endlich mal eine Reaktion auf die Meldungen der letzten Zeit.
Hoffe jetzt, dass die gestrigen Gewinne nicht sofort wieder abgegeben werden.

[RudiDutschke]

Guten Tag,
ich bin es nochmal. Scheint ja, als wäre jegliches Interesse rür Thermogenesis erloschen. Trotzden hier eine mögliche Erklärung für den Kursanstieg: Vom 1-5 Dez. hat in San Francisco ein BioArchive user meeting stattgefunden. Vielleicht mit guter Resonanz für KOOL. Gruss Rudi

[Phantasia]

Melde mich! Bin noch dabei. Vielleicht geben andere Investierte auch einmal ein Lebenszeichen von sich, sonst könnte man glauben, wir sind die einzigen Verbliebenen von KOOL. Auch wenn es keine News gibt, ein Aufmuntern hilft allemal.
Das Event am 1.-5. Dec. habe ich ebenfalls gelesen, leider fand ich keinen weiteren Kommentar dazu. Weißt du mehr darüber, Rudi?
Gruß Phantasia

[CaptainChaos]

Hallo ,

ich bin auch noch da. Mache mir um Kool keine Sorgen. Deshalb kann ich das derzeitige Kurstief ruhig aussitzen.

Kool mischt bei einem 400 - Millionen - Dollar -Markt mit entsprechend wahrscheinlicher Nachfrage mit. Warum soll ich mir auf dem derzeitigen Niveau hinsichtlich der nächsten Quartalszahlen als Parameter der Kursbewertung Sorgen machen. CryoSeal wird Beachtung finden, da bin ich mir sicher.

Gruss

CC

[Phantasia]

Alle guten Dinge sind 3 (KOOL-Verbliebene)! Danke, danke, danke CC für die immerhin "beachtliche" Aufmunterung.
Gruß
Phantasia

[RudiDutschke]

Hallo,
melde mich dann auch mal, um die Dreisamkeit perfekt zu machen.
Denke auch posistiv, was KOOL betrifft.
@Phantasia: leider weiss ich auch nicht mehr zu dem event.
Habe gestern mal die homepage durchgeforstet, konnte aber nichts finden.
Uns allen noch einen schönen Tag, Rudi

[Polar_bear]

Niemand is´ hier allein, nur in diesen "noch" düsteren Zeiten macht das posten nich´so viel Spaß!

[Phantasia]

Schön, Polar_bear, dass du ebenfalls im Boot sitzt.

Der Kurs steigt, könnte mir vielleicht jemand verraten warum, damit ich mit einem guten Gefühl der Hoffnung im Bauch für eine Weile Germany verlassen kann?

Gruß
Phantasia, die für 4 Monaten Germany den Rücken kehrt.

[CaptainChaos]

Ich wünsche alle Kool - Fans ein frohes Neues Jahr und steigende Kurse in 2001.

[RudiDutschke]

Tach Captain,
kann mich Deinen Wünschen nur anschliessen. Nach einem kurzen Zwischenhoch aufgrund guter Meldung pendelt sich der Kurs unter äusserst hohen Umsätzen in den letzten Sitzungen wieder ein. Bin zuversichtlich Rudi

[RudiDutschke]

Guten Tag. Hoffe ihr seid alle einigermassen ins neue Jahr gestartet. Habe soeben gelesen, dass KOOL ein viertes BioArchiveSystem an das New York Blood center verkauft hat. Captain, ich hoffe auf Dich, dass Du den Artikel hier reinstellen kannst. Gefunden unter stockpoint.com. Schönen Tag noch Rudi

[CaptainChaos]

Hallo Rudi,

frohes neues Jahr.
Hier die Meldung:

THERMOGENESIS CORP. Places Fourth BioArchive System With the New York Blood Center
KOOL


RELATED QUOTES

KOOL 1 5/8 1/16
RELATED TOPICS
biz
belgium
biomedical
cancer
cellular
china
clinical


RANCHO CORDOVA, Calif., Jan 3, 2001 (BUSINESS WIRE) --


Clinical success of placental cord blood ("PCB") stem cell transplants

justify need for expanded inventory

THERMOGENESIS CORP. (Nasdaq: KOOL ) announced the sale of a fourth BioArchive(R) System to the New York Blood Center ("NYBC"), which is collecting an inventory of 50,000 ethnically diverse PCB units to better serve the patients who suffer from diseases such as leukemias, lymphomas, diverse inherited anemias and hypoproliferative stem cell disorders. Phil Coelho, CEO of THERMOGENESIS CORP., noted that "... at the December 2000 American Society of Hematology ("ASH") conference, Dr. Pablo Rubinstein of NYBC analyzed the results of their 1,100 transplants and confirmed that better HLA matching of the PCB unit to the patient significantly improves patient outcome. Better matches can only be achieved through larger inventories of high quality cryopreserved PCB units."

Each BioArchive System is used by NYBC to process, cryopreserve and archive up to 3,626 PCB stem cell units. BioArchive Systems have also been chosen by the major Cord Blood Banks in Japan, China, Taiwan, Vietnam, Korea, Germany, Spain, Finland, U.K., Belgium, Mexico, as well as in the U.S.A. pursuant to Investigational New Drug ("IND") regulations. The BioArchive System is demonstrably the international standard for processing and archiving cryopreserved hematopoietic stem cells.

Phil Coelho further noted that "... recent research suggests that there are uncommitted or "neutral" stem cells that can be induced to produce other cells outside the hematopoietic system such as neural or hepatic cells. With the recent bio-ethical issues raised regarding embryonic stem cell research, cord blood may provide a source of stem cells for tissue regeneration without the ethical issues involved with embryos or fetuses. The greater the interest in this type of cellular therapy research, the greater potential we have for additional unit sales."


About the BioArchive System

The BioArchive System uses THERMOGENESIS CORP.`s proprietary computer-driven liquid nitrogen robotic system to cryopreserve and archive units of blood components that have been collected, processed and preserved in proprietary sterile plastic bag sets. The BioArchive System tracks identification and location for each unit and performs robotic retrieval of each unique tissue-typed unit for use. The BioArchive System operates to freeze, place and retrieve samples without exposing other archived samples to detrimental temperature changes.

The BioArchive System is a Class II exempt blood component freezer, and has initially been distributed in the U.S. only to institutions operating under FDA IND exemptions to provide PCB stem cell units for transplant. The BioArchive System has potential applications involving archiving, storing, managing and retrieving other kinds of biological specimens, that may include peripheral blood-derived stem-cells, cell lines, cancer vaccines, male sperm cells, female eggs, heart valves, corneas, virus samples, biopsy samples and other cellular therapy products.

THERMOGENESIS CORP. BioArchive System is currently intended for preservation of blood components and blood products and would require FDA approval or clearance for some additional claims.


About New York Blood Center

The NYBC is the country`s largest independent blood center and a world leader in biomedical research. The NYBC Placental Blood Program has pioneered the use of PCB as a source of stem cells for bone marrow restoration for such diseases as leukemia or inherited or acquired diseases of the blood and immune systems. The Placental Blood Program has collected more than 12,000 PCB donations and provided units for approximately 1,000 transplants since 1993.


About THERMOGENESIS CORP.

THERMOGENESIS CORP. has been a pioneer in designing, manufacturing and distributing equipment to collect, cryopreserve and archive highly sensitive blood products and biological tissue for more than 10 years.

The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.

[RudiDutschke]

Hallöchen, dachte nch etwas längerer Zeit melde ich mich mal wieder. Zufällig gibt es auch was Neues zu KOOL. Die Nachricht ist schon von gestern, deshalb wohl auch der Kursanstieg, habe sie aber erst heute entdeckt. Bin etwas im Stress, deshalb bitte selber nachsehen, melde mich evtl. später nochmal. Grüsse Rudi

[RudiDutschke]

Guten Tag,
möchte nochmal nachtragen, dass die news noch nicht auf der Homepage zu finden sind, auch nicht bei stockpoint.com. Habe sie bei freerealtime.com aufgestöbert. Geht mal wieder um ein Patent. Hoffe, es interessiert jemanden. Schönen Tag noch

[Sten]

Die Übersetzung :

Laut EUCH

Gut
schlecht ??


THERMOGENESIS CORP. verkündet Austeilung des Patents für Thrombinbestandteil des Fibrindichtungsmittels SystemTotally Cryoseal des menschlichen berechneten Fibrindichtungsmittels, um zu kommen zu vermarkten, während Länder Verbot der pharmazeutischer Produkte mit den Tiermaterialien wegen der Interessen über M betrachten


Ranch Cordova, Calif., Dez 19, 2000 (Geschäft Leitung) -- Thermogenesis Corp. (Nasdaq: KOOL) heute verkündet, daß es Begriff vom US-Patentamt der Austeilung eines Patents für eine Wegwerfeinheit für das Ernten des Thrombinbestandteils des Fibrindichtungsmittels von einer einzelnen Abgabe des menschlichen Plasmas in weniger als einer Stunde empfangen hat.

Das Beachten, daß die japanische Regierung ein Verbot auf den Drogen verkündet hat, die Tiermaterialien aus 28 Ländern, Dr. James Godsey, Präsident u. COO von THERMOGENESIS CORP. enthalten, angegeben, daß des Fibrin-Dichtungsmittels THERMOGENESIS CryoSeal(R) System (" Rumpfstation ") ist, des ersten Fibrindichtungsmittels produzierte nur aus den menschlichen Plasmaproteinen, verglichen mit im Handel erhältlichen chirurgischen Dichtungsmitteln, die Tiersubstanzen wie aprotinin, Kollagen, Thrombin oder Albumin enthalten, die die Gefahr auf Patienten der Viren- oder prioninfektion und/oder der allergischen Antworten erhöhen. Fibrindichtungsmittel ist ein anhaftendes Gel, das durch die Abhängigkeit des starken Fibrinogens und des Thrombins gebildet wird, um ein wirkungsvolles blutstillendes Mittel, ein Dichtungsmittel und einen Gewebekleber in der Chirurgie zu bilden. Die Firma schätzt den aktuellen globalen Markt für Fibrindichtungsmittel ist ungefähr $400 Million und entwickelt sich $800 zu Million durch 2004.

[RudiDutschke]

Wow. Was für eine Performance am heutigen Tag. +15% auf 2,75$. Hoffe, dass dieses Niveau ersteinmal gehalten wird. Bin aber wie immer positiv, es gab ja einige positive Nachrichten in letzter Zeit. Werde mich nochmal auf die Suche machen, ob es heute etwas Neues gab. Habe allerdings das Problem, dass nicht alle Quellen die aktuellsten Nachrichten haben. So ist z.B. die letzte mir bekannte Nachricht noch nicht auf stockpoint.com, und auch nicht auf der Homepage. Bei freerealtime.com gibt es auf einmal gar keine Einträge mehr zu Thermogenesis. Naja, mal sehen. Ein ob des Kursanstiegs hocherfreuter Rudi wünscht noch einen schönen Abend.

[Don Speculazio]

Was ist das denn für ein deutsch???
hat das ein Chinese mit Deutsch-VHS-Kurs oder irgend ein drittklassiges Übersetzungsprogramm übersetzt??
Hauptsache der Kurs von KOOL steigt
Umsätze lassen no´ch zu wünschen übrig, aber wenigstens gibts keinen Verkaufsdruck

HK

[RudiDutschke]

@Don Speculazio
Guten Abend. Stimmt, dass der heutige Umsatz etwas mau war, dafür aber in den letzten Sitzungen überdurchschnittlich. Das Übersetzungsprogramm scheint mir höchstens drittklassig. Schönen Abend noch

[CaptainChaos]

Hey Rudi, melde mich aus dem Urlaub zurück. Kool ist z.Zt sehr erfreulich. Wenn die News zur Systemzulassung kommen, denke ich, dass wir noch ein bis zwei Euro zulegen können.

Gruss
CC

[RudiDutschke]

Hallo Freunde der Nacht. Niemand mehr so richtig interessiert in Thermogenesis? Naja, Umsäztze in USA auch äusserst mager, wenigstens der Kurs bleibt einigermassen stabil, konnte heute auch eine grössere Order von 10000 Stück beobachten, werte das mal als gutes Zeichen. Besser wären natürlich Meldungen über Zulassungen. Wollte eigentlich nur mitteilen, dass ich heute eine mail von KOOL bekam, bezüglich der Zahlen. Sie kommen am 08-02, weiss allerding nicht ob nachbörslich, oder im Laufe des Tages. Kann auch keine Angaben über die Zahlen machen. Schönen Gruss Rudi

[RudiDutschke]

Hallo,
habe soeben die zahlen entdeckt auf www.freerealtime.com
Vielleicht kann sie jemand hier reinstellen, am besten mit Übersetzung.
Nach einem ersten Überfliegen hört es sich ganz gut an. Grüsse

[CaptainChaos]

Sind auch gut ! 32 % Umsatz - Plus !

THERMOGENESIS CORP. Announces 32% Increase in Revenues for the Quarter Ended December 31, 2000; ``Company Posts A 14% Improvement in Gross Profit Margin``
RANCHO CORDOVA, Calif.--(BUSINESS WIRE)--Feb. 9, 2001-- THERMOGENESIS CORP. (Nasdaq:KOOL) today announced results for its second quarter of fiscal 2001. The Company reported net revenues of 1,729,000 and 2,530,000 for the three and six months ended December 31, 2000, a 32 and 9 improvement over the comparable periods in the prior year. Gross profit as a percentage of net revenues increased to 18 from 4 and to 7 from (9) for the three and six months ended December 31, 2000, respectively.

Revenues increased due to greater sales of BioArchive and ThermoLine products. The number of BioArchive units sold doubled in the first six months of this fiscal year compared to last year. ThermoLine revenues increased 44 and 10 for the three and six months ended December 31, 2000, primarily due to a restructured sales department to include an experienced field-based sales executive to call on domestic customers. Ten MP2000 freezers, eight to Aventis Bio-Services, Inc., were sold in the three and six months ended December 31, 2000 versus one and five in the comparable periods in the prior year.

Commenting on the results, James H. Godsey, President and C.O.O., stated "Posting revenues of 1,729,000 represents our highest quarter since the initial launching of the BioArchive product line in FY1998. The increase in revenues is a direct result of the enhanced sales effort to BioArchive customers as well as Aventis` continued commitment to ThermoGenesis` ultra rapid freezing technology."

The improvement in the gross margin as a percentage of revenues was achieved through lower manufacturing overhead as a result of better inventory management and cost control measures implemented by the Company last year, as well as increased sales of products with higher margins, such as the MP2000 freezers.

General and Administrative expenses for the quarter ended December 31, 2000 decreased 3 from the corresponding fiscal 2000 period due to personnel reductions which occurred during the prior fiscal year and the Company has elected not to replace the vacant positions. Selling and Service expenses decreased 5 from the corresponding fiscal 2000 period as a result of cost control measures focused on reduction of travel related expenses and reduction in the use of outside consultants. Research and Development expenses increased 4 due to adding more resources in the Company`s regulatory department and other expenses associated with the CryoSeal Fibrin Sealant pre-clinical trials.

Dr. Godsey, commenting on the overall performance, noted, "With the increase in revenues, we are beginning to see the improvement in gross margin and operating results we have been working towards. We anticipate additional improvements in our financial results as the stem cell market begins to expand and the CryoSeal Fibrin Sealant product is launched in each major geographical area."

The Company will hold an analyst and market conference call to review and discuss the results of operations on Monday, February 12, 2001 at 1:00 PST. Interested investors can listen to the conference call by dialing [phone]. Additionally, a taped playback of the conference call will be available from February 12, 2001 6:00 pm EST through February 20, 2001 12:00 am EST. Access to the tape playback is available by dialing [phone] Account : 614 (pound sign) Conference: 224255 (pound sign). If you have any questions or experience problems accessing the taped playback, please contact Nitza Mihalus at [phone] during the Company`s normal business hours. The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the Company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.

For More Information Contact:
Investor Relations
THERMOGENESIS CORP.
Renee M. Ruecker, V.P. Finance: [e-mail]
(916) 8585100 THERMOGENESIS CORP.
Condensed Statements of Operations
(Unaudited) Three Months Ended Six Months Ended
December 31, December 31,
2000 1999 2000 1999Net revenues $1,729,000 $1,313,000 $2,530,000 $2,311,000
Cost of revenues 1,425,000 1,266,000 2,351,000 2,518,000 Gross profit 304,000 47,000 179,000 (207,000)Expenses:
General and
administrative 440,000 454,000 855,000 917,000
Selling and service 533,000 560,000 1,011,000 1,131,000
Research
and development 435,000 419,000 870,000 895,000 Total expenses 1,408,000 1,433,000 2,736,000 2,943,000Other income/expenses (6,000) 6,000 24,000 16,000Net loss before
preferred stock
dividend or discount
and cumulative effect
of accounting change ($1,110,000)($1,380,000)($2,533,000)($3,134,000)Preferred stock
dividend or discount 23,000 313,000 73,000 313,000
Cumulative effect
of accounting change 580,000 580,000 Net loss to
common stockholders ($1,713,000)($1,693,000)($3,186,000)($3,447,000) THERMOGENESIS CORP.
Condensed Balance Sheets
(Unaudited) December 31, June 30,
2000 2000
ASSETS
Current assets:
Cash, cash equivalents
and short term investments $2,555,000 $2,550,000
Accounts receivable, net 1,056,000 627,000
Inventory 2,080,000 2,275,000
Other current assets 154,000 150,000 Total current assets 5,845,000 5,602,000Equipment, net 947,000 1,080,000Other assets 52,000 53,000 $6,844,000 $6,735,000LIABILITIES AND SHAREHOLDERS` EQUITYCurrent liabilities:
Accounts payable $696,000 $512,000
Shortterm debt 1,634,000
Other current liabilities 541,000 477,000 Total current liabilities 2,871,000 989,000Longterm portion of
capital lease obligations 54,000 54,000Shareholders` equity 3,919,000 5,692,000 $6,844,000 $6,735,000

[RudiDutschke]

@Captain,
wie immer ist Verlass auf dich. Schön, dass du noch dabei bist. Grüsse und Dank

[RudiDutschke]

Nur kurz für alle Interessierten. Thermogenesis places first BioArchiveSystem in Malaysia. Nachzulesen unter freerealtime.com
Schönen Tag noch Rudi

[Phantasia]

@RudiDutschke
melde mich geschwind, bin über WAP und Infrarotschnittstelle auch noch dabei. Danke für die Neuigkeiten.
Grüße aus der Wildnis, wo es nicht so einfach einen Internetanschluß gibt.
Phantasia

[RudiDutschke]

Hallo,
kann irgendwer die hohen Umsätze bisher erklären? Schon 80.000 Stück. Darunter 3 grosse order, 35.000, 21.300, 13.700. Sollten dies Verkäufe von Vorstandsleuten o.ä. sein, müssten diese doch in den nächsten Tagen angezeigt werden. Ein leicht verwunderter wünscht noch einen schönen Tag.

[RudiDutschke]

RANCHO CORDOVA, Calif., Feb 27, 2001 (BW HealthWire) --
THERMOGENESIS CORP. (Nasdaq:KOOL) reports that, through its
French distributor, HEMOSYSTEM, the Company received orders for
two BioArchive(R) Systems from the Establissement Francais Du
Sang (EFS) in France, which will be installed at the Besancon and
Bordeaux Blood Centers. Elsewhere in Europe, BioArchive Systems
have been chosen by the major cord blood stem cell banks in
Germany, Spain, Finland, U.K., and Belgium. In Asia, BioArchive
Systems have been installed in Japan, China, Taiwan, Vietnam, and
South Korea, and shortly in Malaysia, and in the U.S.A. pursuant to
IND regulations. The BioArchive System is demonstrably the
international standard for collecting, processing, archiving and
transfusing cryopreserved stem cells to reconstitute the hematopoietic
and immune systems of patients who have undergone high-dose
chemotherapy and radiation to combat diseases such as leukemias,
lymphomas, diverse inherited anemias and hypoproliferative stem cell
disorders.

Professor Patrick Herve, MD, Chief Science Officer for the French
Blood Agency, EFS said, "...we are convinced that the
THERMOGENESIS CORP. BioArchive System represents the future
for the processing and storage of stem cell units sourced from
placental cord blood."

Dr. James Godsey, President & COO of the Company noted, "...the
first proof that cord blood could save the life of a patient requiring bone
marrow replacement took place in France when the eminent transplant
physician, Eliane Gluckman, cured a child of Fanconi Anemia, a lethal
genetic disease of the blood, with the cord blood from the patient`s newly born sibling.
Consequently, we are especially pleased that the EFS has chosen the BioArchive System for
their national cord blood processing and storage program. The BioArchive System will
undoubtedly play a key role in the regulatory and quality standards for processing stem cells
that are being adopted worldwide."

The BioArchive System uses THERMOGENESIS CORP.`s proprietary computer-driven liquid
nitrogen robotic system to archive up to 3,626 units that have been collected and processed
in proprietary sterile plastic bag sets. The BioArchive System performs a precise
controlled-rate freeze, tracks identification and archive location and performs robotic retrieval
of each unique tissue-typed unit for use in life-saving transplantation. The BioArchive System
operates to freeze, place and retrieve samples within liquid nitrogen while minimizing any
exposure to detrimental transient warming events (TWE) which can reduce cell viability.

According to Philip Coelho, Chairman and CEO of the Company, "Recent research suggests
that there are uncommitted or "neutral" stem cells in a unit of cord blood that may have the
potential to produce other cells outside the hematopoietic system such as neural or hepatic
cells. With the recent bio-ethical issues raised regarding embryonic stem cell research, cord
blood may provide a source of stem cells without the ethical issues involved with embryos or
fetuses. The greater the interest in cord blood research, the greater potential we have for
additional unit sales. Placement of the BioArchive System at Besancon and Bordeaux in
France moves the Company one step closer to its goal of setting the international standard
for the processing, archiving and managing of cryopreserved stem cells."

Regulatory Status

The BioArchive System is a Class II exempt blood component freezer, and has been
distributed in the U.S. to sites seeking IND with the FDA for use with stem cell storage for
transplant into unrelated patients. The BioArchive System has potential applications involving
archiving, storing, managing and retrieving other kinds of biological specimens, that may
include stem cells, dendritic cells, T-cells, cell lines, male sperm cells, female eggs, heart
valves, corneas, virus samples, biopsy samples and other blood, tissue and saliva samples.
The BioArchive System is currently intended for preservation of blood components and would
require FDA 510(k) clearance for some additional claims.

About HEMOSYSTEM

HEMOSYSTEM is a young and innovative Biotechnology company that distributes advanced
medical devices in France and is working on several pioneering projects, which will improve
the blood transfusion field:

-- A rapid and ultra sensitive bacteria detection system

-- A solution allowing longer storage of blood products

For More Information, contact Jean-Pierre Hermet, HEMOSYSTEM,
mailto:[e-mail] 011-33-491-117-200 or visit the web site at
http://www.hemosystem.com

About THERMOGENESIS CORP.

THERMOGENESIS CORP. has been a pioneer in designing, manufacturing and distributing
equipment to collect, cryopreserve and archive highly sensitive blood products and biological
tissue for more than 10 years.

The statements contained in this release which are not historical facts are forward-looking
statements that are subject to risks and uncertainties that could cause actual results to differ
materially from those expressed in the forward-looking statements, including, but not limited
to, certain delays beyond the company`s control with respect to market acceptance of new
technologies and products, delays in testing and evaluation of products, and other risks
detailed from time to time in the Company`s filings with the Securities and Exchange
Commission.

[RudiDutschke]

THERMOGENESIS CORP. Places First BioArchive System in NuStem Technologies
Cord Blood Banking ProgramNuStem Technologies Chose the Advanced
BioArchive System to Cryopreserve and Archive Their Cord Blood Stem Cell Units

RANCHO CORDOVA, Calif., Mar 22, 2001 (BUSINESS WIRE) -- THERMOGENESIS CORP.
(Nasdaq: KOOL) announced the sale of a BioArchive(R) System to NuStem
Technologies, Inc. ("NuStem") in Reno, Nev. Elsewhere in North America,
BioArchive Systems are placed at the New York Blood Center, Duke University
Medical Center, San Diego Blood Bank, and Coriell Institute for Medical Research
pursuant to IND regulations, and the National Transfusion Service Cord Blood
Bank in Mexico. In Europe, BioArchive Systems have also been placed at the major
Cord Blood Stem Cell Banks in Germany, United Kingdom, Belgium, France, Spain
and Finland, and in Asia BioArchive Systems have been chosen in Japan, China,
Taiwan, Vietnam, South Korea and Malaysia.

According to Philip Coelho, chairman and CEO of THERMOGENESIS CORP., "Recent
research by Dr. Esmail Zanjani, medical director of NuStem, suggests that there
are stem cells in a unit of cord blood that have the potential to produce other
cells outside the hematopoietic system such as neural, liver and bone cells.
Since there are serious ethical issues with sourcing stem cells from embryos and
fetuses, scientists may begin to focus on cord blood as a superior,
non-controversial source for these multi-potential stem cells."

The BioArchive System is demonstrably the international choice for collecting,
processing, and archiving cryopreserved hematopoietic stem cells sourced from
placental/cord blood ("PCB"). PCB stem cells are used to reconstitute the
hematopoietic and immune systems of patients who have undergone high-dose
chemotherapy and radiation to combat diseases such as leukemias, lymphomas,
diverse inherited anemias, such as sickle cell anemia and thalassemia, and other
genetic diseases.

Dr. James Godsey, president and COO of THERMOGENESIS CORP., commented, "We are
pleased that NuStem has chosen to use the BioArchive System for their cord blood
banking program." Dr. Alan Levine, president of NuStem, said, "...the
collection, storage, and distribution protocols used by NuStem are the same as
those specified by the National Institutes of Health (NIH) and the Food and Drug
Administration (FDA)...and because of our commitment to exceptional quality in
the collection, processing, handling and storage of cord blood, we have selected
the BioArchive System."

The BioArchive System uses THERMOGENESIS CORP.`s proprietary computer-driven
liquid nitrogen robotic system to cryopreserve and archive up to 3,626 units
that have been collected, processed and cryopreserved in proprietary sterile
plastic bag sets. The BioArchive System tracks identification and location for
each unit and performs robotic retrieval of each unique barcoded unit for use in
life-saving transplantation. The BioArchive System operates to freeze, place and
retrieve samples without exposing other archived samples to the Transient
Warming Events (TWEs), which can significantly reduce cell viability.


Regulatory Status

The BioArchive System is a Class II exempt blood component freezer, and has
initially been distributed in the U.S. only to sites seeking IND or which have
filed an IND with the FDA for use with stem cell storage for transplant into
unrelated patients. The BioArchive System has potential applications involving
archiving, storing, managing and retrieving other kinds of biological specimens,
that may include stem cells, dendritic cells, T-cells, cell lines, male sperm
cells, female eggs, heart valves, corneas, virus samples, biopsy samples and
other blood, tissue and saliva samples. The BioArchive System is currently
intended for preservation of blood components and blood products and would
require FDA 510(k) clearance for some additional claims.


About NuStem Technologies, Inc.

NuStem Technologies, Inc. is a privately-held, for-profit, allogeneic cord blood
bank. The firm collects, processes, cryogenically stores, and subsequently
distributes stem cells derived from the blood extracted from the umbilical cords
of newborn babies following a normal, healthy live birth. NuStem has established
a worldwide network of collection centers and intends to build an inventory of
50,000 cord blood units stored in the BioArchive System within a three-year
period. NuStem cord blood stem cells will be subjected to a battery of in vitro
and in vivo assays, including those developed by Dr. Esmail Zanjani, the head of
NuStem`s Scientific Advisory Board and director of Research.


About THERMOGENESIS CORP.

THERMOGENESIS CORP. has been a pioneer in designing, manufacturing and
distributing equipment to collect, cryopreserve and archive highly sensitive
blood products and biological tissue for more than 10 years.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.


CONTACT: THERMOGENESIS CORP.
James H. Godsey, Ph.D., 916/858-5100
[e-mail]
www.thermogenesis.com

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2001 Business Wire. All rights reserved.



KEYWORD: CALIFORNIA NEVADA
INDUSTRY KEYWORD: MEDICAL
BIOTECHNOLOGY
PRODUCT

[RudiDutschke]

Guten Tag,
da wussten doch gestern schon wieder einige mehr. 25%iger Anstieg, bei für KOOL riesigen Umsätzen. Bleibt die Frage, ob es heute heisst, sell on good news.
THERMOGENESIS CORP. Receives CE Mark for Two Fibrin Sealant ``FS``
Disposables; Company also announces receipt of ISO 9001/EN46001 Medical
Device Directive, Annex II Certification

RANCHO CORDOVA, Calif., Mar 28, 2001 (BUSINESS WIRE) -- THERMOGENESIS CORP.
(Nasdaq: KOOL) today announced that the Company has received the CE Mark of
conformity for its CP-2 plasma processing disposable and the FS Applicator
System. The CP-2 plasma processing disposable together with the previously CE
Marked CryoSeal CS-1 instrument is used to prepare fibrin sealant from a single
unit of human plasma in about 60 minutes. The FS Applicator System enables
surgeons to precisely apply fibrin sealant to bleeding wound sites in surgery.
Fibrin sealant is a surgical hemostatic agent and tissue sealant. Receipt of the
CE Mark of conformity allows THERMOGENESIS CORP. to immediately initiate market
launch activities of the CryoSeal FS System throughout the countries comprising
the European Union. Based on independent marketing reports, the Company believes
the global market for fibrin sealant to be approximately $400 million annually,
of which Europe is estimated to be 25% or $100 million annually.

Dr. James Godsey, President and COO of THERMOGENESIS CORP. commented, "Receipt
of our CE Mark for these innovative products is one of the most important
milestones in the Company`s recent history", noting further that "the European
fibrin sealant market is the largest market in which one of the Company`s
products has competed. Furthermore, the receipt of the ISO 9001/EN46001 Medical
Device Directive, Annex II certification will streamline future market launch
releases of new medical devices."

Because of Europe`s ever increasing fear of contracting Mad Cow Disease (nvCJD)
from pharmaceutical products which contain bovine-derived substances, Europe is
now the fibrin sealant market in which autologous blood products are in the
greatest demand. Dr. Godsey noted that "since filing for the CE Mark, the
concern over Mad Cow disease has continued to escalate in Europe where it has
spread to almost every major country and in the US, where concerns regarding the
safety of our food and blood supplies continue to mount." Furthermore, on
December 12, 2000 the Associated Press announced the government of Japan`s ban
of all pharmaceutical products from 28 countries which utilize animal
ingredients.

Unlike conventional fibrin sealants currently available which are sourced from
thousands of plasma units and which include aprotinin, derived form bovine lung
tissue, the CryoSeal FS System prepares both components of fibrin sealant
(fibrinogen and thrombin) solely from a single unit of plasma, and is thus
comprised of only proteins of human origin, thereby eliminating the risk of
viral/prion infection from animal proteins/tissues or large pools of human
plasma. THERMOGENESIS CORP. will be the first company to offer a truly
autologous fibrin sealant to the European fibrin sealant market place.

The design of the CP-2 Plasma Processing Disposable is based upon two of the
Company`s recent technological breakthroughs enabling real time processing of
blood products. The cryoprecipitation technology prepares fibrinogen-rich
cryoprecipitate from plasma in as little as 40 minutes as compared to two to
three days for standard blood center methodology, while the thrombin activation
technology simultaneously prepares activated human thrombin from a small aliquot
of the same human plasma. When mixed together, fibrinogen and thrombin form a
surgical hemostatic agent, sealant or adhesive for a wide array of surgical
procedures. The fibrin sealant is applied to the wound site by the Company`s
proprietary FS Applicator System. Once applied the fibrin sealant gels on the
wound site to stop bleeding and is reabsorbed by the body within 2-4 weeks.

The Company plans to file an Investigational Device Exemption ("IDE") with the
U.S. Food & Drug Administration ("FDA") for the CryoSeal FS System in the first
half of calendar year 2001 to begin its pivotal human clinical trials in the
United States.


Regulatory Status

The CryoSeal System is patent protected, and will require a pre-market approval
by the U.S. FDA before marketing. The Company obtained U.S. FDA clearance of its
510(k) pre-market notification for automated preparation of Cryoprecipitated
Anti-Hemophilic Factor (AHF) in February 1999. Until U.S. FDA approval, the
CryoSeal FS System, including FS applicator kits, will be marketed, as permitted
under U.S. Export Laws, applicable foreign regulations, in geographies including
Latin America, South America, Asian Pacific Rim, Australia and ROW.


About THERMOGENESIS CORP.

THERMOGENESIS CORP. has been a pioneer in designing, manufacturing and
distributing equipment to collect, cryopreserve and archive highly sensitive
blood products and biological tissue for more than 10 years.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.

[Don Speculazio]

kann mal jemand übersetzen
und wer hat die 400.000 stück gestern eingesammelt???

H.

[RudiDutschke]

Guten Tag, hier ein paar Termine:


Exibiting
Sponsorship only

Date
Product
Conference
Location
Booth #
March 8 - 10
ThermoLine™
South Central Assoc. of Blood Banks (SCABB)
Hyatt Downtown Houston
Houston, Texas
TBD
March 21 - 23
ThermoLine™
SEABB
Atlanta Marriott Century Center
Atlanta, Florida
TBD
April 5 - 7
CryoSeal®
28th Brazilian Congress,
Brazilian Society of Cardiovascular Surgery
Centro de Artes
National University of Ouro Preto
Ouro Preto, Brazil
TBD
April 21 - 26
CryoSeal®
American Association of Neurological Surgeons
Metro Toronto Convention Center
Toronto, Canada
TBD
April 26 - 28
ThermoLine™
Tennessee Association of Blood Banks
Hyatt Regency
Knoxville, Tennessee
TBD
April 30 - May 1
BioArchive®
Recent Developments in Cord Blood Stem
and Progenitor Cell Transplantation Workshop
University Place Conference Center and Hotel,
Indianapolis, Indiana
TBD
May 2 - 5
ThermoLine™
California Blood Bank Society
Queen Mary
Long Beach, California
TBD
May 6 - 8
CryoSeal®
American Association of Thoracic Surgery
San Diego Convention Center
San Diego, California
TBD
May 7 - 8
ThermoLine™
Massachusetts Association of Blood Banks
Westford Regency Inn & Conference Center,
Westford, Massachusetts
TBD
May 10 - 12
ThermoLine™
Florida Association of Blood Banks
Hotel Royal Plaza
Orlando, Florida
TBD
June 6 - 9
CryoSeal®
German Society of Thoracic Surgery
Berlin, Germany
TBD
June 7 - 8
ThermoLine™
Hearts of America Blood Banks
Embassy Suites Hotel,
Kansas City, Missouri

June 14 - 17
BioArchive®
ISHAGE
Quebec City, Canada
TBD
June 20 - 23
CryoSeal®
European Society for Cardiovascular Surgery /
International Society for Cardiovascular Surgery
Budapest Convention Center
Budapest, Hungary
TBD
June 25 - July 1
CryoSeal®
Rhinoplasty 2001, American Academy of Facial
Plastic and Reconstructive Surgery
Chicago, Illinois
TBD
July 15 - 18
BioArchive®
CryoSeal®
ISBT - European Meeting
Palais de Congres
Paris, France
TBD
Sept. 12 - 15
ThermoLine™
2001 Intermountain States Seminar
Virginian Lodge,
Jackson, Wyoming
TBD
Sept. 13 - 15
ThermoLine™
Michigan Association of Blood Banks
Romulus, Michigan
TBD
Sept. 16 - 19
CryoSeal®
European Association of Cardiothoracic Surgery /
European Society of Thoracic Surgery
Lisbon, Portugal
TBD
Oct. 13 - 17
All
American Association of Blood Banks
San Antonio, Texas
TBD
Dec. 7 - 11
BioArchive®
American Society of Hematology
Orlando, Florida
TBD

[Don Speculazio]

up H.--wo bleibt bitte die Übersetzung???

[RudiDutschke]

THERMOGENESIS CORP. Raises $7.1 Million Through Private Placement of
Common Stock

RANCHO CORDOVA, Calif., May 2, 2001 (BUSINESS WIRE) -- THERMOGENESIS CORP.
(Nasdaq: KOOL) announced completion of a private financing through the sale of
approximately 3,944,000 shares of its common stock and issuance of warrants. In
addition to the shares of common stock, the Company also issued five-year
warrants representing the right to acquire an additional 788,809 shares of
common stock, in the aggregate, at an exercise price of $2.88 per share. The
private placement was made directly by the Company to a group of institutional
and accredited investors led by Federated Kaufmann Fund and Atlas II, LP. By
making the placement directly the Company avoided the financing fees normally
incurred through the use of investment bankers.

The Company`s Chief Executive Officer, Philip H. Coelho, said that "the
Company`s ability to raise capital from existing and new institutional funds,
demonstrates the investors confidence in our products and management." The
proceeds will be used for execution of human clinical trials through an
independent Clinical Research Organization to support claims for its CryoSeal(R)
Fibrin Sealant ("FS") System, as well as for the expansion of the marketing of
the BioArchive(R) System in the cellular therapy marketplace and other general
working capital.

[RudiDutschke]

THERMOGENESIS CORP.`s BioArchive System Chosen by Reliance Industries`
Biotechnology Research Facility for Their Cord Blood Stem Cell Banking Program

RANCHO CORDOVA, Calif., May 10, 2001 (BW HealthWire) -- THERMOGENESIS CORP.
(Nasdaq: KOOL) announced the sale of a BioArchive System to the Cell Biology &
Tissue Engineering Group, a division of Reliance Industries ("Reliance"), the
largest private company in India. Dr. James Godsey, President and COO of
THERMOGENESIS CORP. commented, "Reliance represents the largest corporate entity
thus far to purchase a BioArchive System for their public cord blood banking
program. The country of India offers Reliance a large population base from which
to draw specimens. We look forward to working closely with Reliance to
successfully initiate public cord blood banking in India."

THERMOGENESIS` BioArchive System is an essential part of the enabling technology
for the collection and subsequent distribution of placental/cord blood ("PCB").
PCB stem cells are used to reconstitute the hematopoietic and immune systems of
patients who have undergone high-dose chemotherapy and radiation to combat
diseases such as leukemias, lymphomas, diverse inherited anemias, such as sickle
cell anemia and thalassemia, and other genetic diseases.

In North America, BioArchive Systems have been placed at the New York Blood
Center, Duke University Medical Center, San Diego Blood Bank, and Coriell
Institute for Medical Research pursuant to IND regulations, and the National
Transfusion Service Cord Blood Bank in Mexico. In Europe, BioArchive Systems
have also been placed at the major Cord Blood Stem Cell Banks in Germany, United
Kingdom, Belgium, France, Spain, and Finland, and in Asia BioArchive Systems
have been chosen in Japan, China, Taiwan, Vietnam, South Korea, and Malaysia.

According to Philip Coelho, Chairman and CEO of THERMOGENESIS CORP., "Recent
research suggests that there are stem cells in a unit of cord blood that have
the potential to produce other cells outside the hematopoietic system such as
neural, liver and bone cells. Since there are serious ethical issues with
sourcing stem cells from embryos and fetuses, scientists may begin to focus on
cord blood as a superior, non-controversial source for these multi-potential
stem cells."

The BioArchive System uses THERMOGENESIS CORP.`s proprietary computer-driven
liquid nitrogen robotic system to cryopreserve and archive up to 3,626 units
that have been collected, processed and cryopreserved in proprietary sterile
plastic bag sets. The BioArchive System tracks identification and location for
each unit and performs robotic retrieval of each unique barcoded unit for use in
life-saving transplantation. The BioArchive System operates to freeze, place and
retrieve samples without exposing other archived samples to the Transient
Warming Events (TWEs), which can significantly reduce cell viability.


Regulatory Status

The BioArchive System is a Class II blood component freezer exempt from the
pre-market notification procedures. The BioArchive System has potential
applications involving archiving, storing, managing and retrieving other kinds
of biological specimens, that may include stem cells, dendritic cells, T-cells,
cell lines, male sperm cells, female eggs, heart valves, corneas, virus samples,
biopsy samples and other blood, tissue and saliva samples. The BioArchive System
is currently intended for preservation of blood components and blood products
and would require FDA 510(k) clearance for additional indications for use.


About the Reliance Group

Reliance Group is India`s largest business house with total 2000 revenues of
$11.3 billion. In addition to life sciences, the group`s activities span
textiles, synthetic fibres, fibre intermediates, petro-chemicals, oil & gas
production, financial services, refining, power, telecom and infocom
initiatives. Reliance Life Sciences is a new millennium initiative of the
Reliance Group focused on:


-- Cell Therapy
-- Tissue Engineering
-- Therapeutic Proteins
-- Medicinal and Aromatic Plants
-- Enzymes
-- Biopolymers
-- Bioinformatics

About THERMOGENESIS CORP.

THERMOGENESIS CORP. has been a pioneer in designing, manufacturing and
distributing equipment to collect, cryopreserve and archive highly sensitive
blood products and biological tissue for more than 10 years.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.

[RudiDutschke]

THERMOGENESIS CORP. Revenues Double for the Quarter Ended March 31, 2001;
``European CryoSeal Market Launch Activities Underway``

RANCHO CORDOVA, Calif., May 11, 2001 (BUSINESS WIRE) -- THERMOGENESIS CORP.
(Nasdaq: KOOL) today announced results for its third quarter of fiscal 2001. The
company reported net revenues of $2,033,000 and $4,563,000 for the three and
nine months ended March 31, 2001, a 115% and 40% improvement over the comparable
periods in the prior year. Gross profit as a percentage of net revenues
increased to 16% from 4% and to 11% from (5%) for the three and nine months
ended March 31, 2001, respectively. We have initiated market launch activities
for the CryoSeal Fibrin Sealant system in Europe after receiving the CE Mark of
Conformity for the CP-2 Plasma Processing Disposable and the FS Applicator
System.

Revenues increased due to greater sales of BioArchive and ThermoLine products.
Five BioArchive systems were sold during the quarter ended March 31, 2001 versus
two for the quarter ended March 31, 2000. ThermoLine revenues increased 57% and
22% for the three and nine months ended March 31, 2001, primarily due to
increased sales to Europe. Specifically, our distributor to Russia accounted for
33% of the freezer sales for this quarter due to the return of the economy in
Russia.

Commenting on the results, James H. Godsey, president and C.O.O, stated, "We
have already surpassed the revenues posted for the entire year of fiscal 2000.
The increases were due to improvements and significant events in all three
product lines. The initial BioArchive sites have validated their systems and are
in routine use. The BioArchive is now a known product among the stem cell
research community, which is accelerating the sales pipeline. The upgrading of
sales personnel and our telemarketing strategies and tools has resulted in an
increase in our domestic sales of ThermoLine products. Additionally, our
distributor in Japan purchased another CryoSeal unit in preparation for human
clinical trials."

The improvement in the gross margin as a percentage of revenues was achieved
through a higher sales volume which absorbs more manufacturing overhead.
Additionally, all five BioArchive units were sold to new customers and included
a stocking order of accessories and disposables which carry a higher profit
margin.

General and administrative expenses for the quarter ended March 31, 2001
increased $28,000 from the corresponding fiscal 2000 period due to fees
associated with retaining an investment banker to assist the company in securing
strategic alliances. Selling and service expenses decreased $10,000 from the
corresponding fiscal 2000 period as a result of cost control measures focused on
reduction of travel related expenses and on the use of outside consultants.
Approximately $100,000 was spent on the CryoSeal Fibrin Sealant pre-clinical
trials which accounted for most of the Research and Development expenses
increase. Interest expense increased $204,000 from the corresponding fiscal 2000
period due to the amortization of the warrants, which is a non cash expense, and
interest charge for the debt financing which occurred in the previous quarter.

Philip Coelho, chief executive officer, commenting on the overall performance,
noted, "We are pleased with the results achieved during the quarter ended March
31, 2001. The significant increase in revenues demonstrates that our investment
in the sales force is beginning to pay off. The net loss for the quarter would
have been lower than the previous year, but for the pre clinical expenses and
the interest expense. We anticipate a continuing increase in revenues and
improved profitability as the CryoSeal FS system is accepted in Europe."

The company will hold an analyst and market conference call to review and
discuss the results of operations on Monday, May 14, 2001 at 1:00 p.m. PDT.
Interested investors can listen to the conference call by dialing 412/858-4600.
Additionally, a taped playback of the conference call will be available from May
14 at 6:00 p.m. EDT through May 22 at 12:00 am EDT. Access to the tape playback
is available by dialing 877/344-7529; Account: 233(pound sign); Conference:
236048(pound sign). If you have any questions or experience problems accessing
the taped playback, please contact Nitza Mihalus at 916/858-5100 during the
company`s normal business hours.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the Company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.


THERMOGENESIS CORP.

Condensed Statements of Operations
(Unaudited)


Three Months Ended
March 31,
2001 2000


Net revenues $ 2,033,000 $ 945,000
Cost of revenues 1,706,000 903,000
----------- -----------
Gross profit 327,000 42,000
----------- -----------

Expenses:

General and administrative 464,000 436,000
Selling and service 487,000 497,000
Research and development 476,000 309,000
----------- -----------
Total operating expenses 1,427,000 1,242,000

Other income/expenses (178,000) 21,000
----------- -----------

Net loss before preferred stock
dividend or discount and cumulative
effect of accounting change ($1,278,000) ($1,179,000)
=========== ===========

Preferred stock dividend or discount (19,000) (245,000)

Cumulative effect of accounting
change -- --
----------- -----------
Net loss to common stockholders ($1,297,000) ($1,424,000)
=========== ===========


Nine Months Ended
March 31,
2001 2000


Net revenues $ 4,563,000 $ 3,256,000
Cost of revenues 4,057,000 3,421,000
----------- -----------
Gross profit 506,000 (165,000)
----------- -----------

Expenses:
General and administrative 1,319,000 1,393,000
Selling and service 1,498,000 1,619,000
Research and development 1,346,000 1,171,000
----------- -----------
Total operating expenses 4,163,000 4,183,000

Other income/expenses (154,000) 37,000
----------- -----------
Net loss before preferred stock
dividend or discount and cumulative
effect of accounting change ($3,811,000) ($4,311,000)
=========== ===========

Preferred stock dividend or discount (92,000) (558,000)

Cumulative effect of accounting
change (580,000) --
----------- -----------

Net loss to common stockholders ($4,483,000) ($4,869,000)
=========== ===========


THERMOGENESIS CORP.

Condensed Balance Sheets
(Unaudited)

March 31, June 30,
2001 2000
------------ ------------
ASSETS

Current assets:
Cash, cash equivalents and
short term investments $1,590,000 $2,550,000
Accounts receivable, net 1,426,000 627,000
Inventory 1,844,000 2,275,000
Other current assets 106,000 150,000
---------- ----------
Total current assets 4,966,000 5,602,000

Equipment, net 923,000 1,080,000
Other assets 94,000 53,000
---------- ----------

$5,983,000 $6,735,000
========== ==========

LIABILITIES AND SHAREHOLDERS` EQUITY

Current liabilities:
Accounts payable $ 845,000 $ 512,000
Short-term debt 1,789,000 --
Other current liabilities 639,000 477,000
---------- ----------
Total current liabilities 3,273,000 989,000

Long-term portion of capital lease
obligations 48,000 54,000
Shareholders` equity 2,662,000 5,692,000
---------- ----------

$5,983,000 $6,735,000
========== ==========

[RudiDutschke]

ERMOGENESIS CORP. Announces Issuance of Patent for a Device and Method to
Improve Cryopreservation of Stem Cells

RANCHO CORDOVA, Calif., May 14, 2001 (BUSINESS WIRE) -- THERMOGENESIS CORP.
(Nasdaq: KOOL) announced today that it has received a patent from the U.S. Patent
Office for a three-dimensional, compartmentalized bag and method of manufacture,
configured to provide optimal cryoprotection for a stem cell rich fraction of
blood. THERMOGENESIS` patent portfolio includes 18 issued and 7 pending U.S.
patents.

Dr. James Godsey, president and COO of THERMOGENESIS CORP., noted, "This
improved cryopreservation bag set is already integrated into the BioArchive
System. The configuration of this cryopreservation container is optimal for
retaining cell viability during cryogenic freezing, and its multi-compartment
design permits ex-vivo expansion of a portion of the cryopreserved cells without
compromising the sterility of the remainder. The patent represents another
milestone in THERMOGENESIS` efforts to become the global standard of excellence
in cord blood processing and cryopreservation."

The BioArchive System has been selected as the basis for establishing national
cord blood banks in many countries around the world. In North America,
BioArchive Systems have been placed at the New York Blood Center, Duke
University Medical Center, San Diego Blood Bank, NuStem Technologies and Coriell
Institute for Medical Research pursuant to IND regulations, and the National
Transfusion Service Cord Blood Bank in Mexico. In Europe, BioArchive Systems
have also been placed at the major Cord Blood Stem Cell Banks in Germany, United
Kingdom, Belgium, France, Spain and Finland, and in Asia, Japan, China, Taiwan,
Vietnam, South Korea, Malaysia and India.

The BioArchive System is an enabling technology that plays a key role in the
emerging world standards that are being adopted for the processing and
validation of cellular therapy products. The BioArchive System uses
THERMOGENESIS CORP.`s proprietary computer-driven liquid nitrogen robotic system
to cryopreserve and archive up to 3,626 units that have been collected,
processed and cryopreserved in proprietary sterile plastic bag sets. The
BioArchive System tracks identification and location for each unit and performs
robotic retrieval of each unique barcoded unit for use in life-saving
transplantation. The BioArchive System operates to freeze, place and retrieve
samples without exposing other archived samples to the Transient Warming Events
(TWEs), which can significantly reduce cell viability.

According to Philip Coelho, chairman and CEO of the Company, "Recent research
suggests that there are stem cells in a unit of cord blood that have the
potential to produce other cells outside the hematopoietic system such as
neural, liver and bone cells. Since there are serious ethical issues with
sourcing stem cells from embryos and fetuses, scientists may begin to focus on
cord blood as a superior, non-controversial source for stem cells."

[RudiDutschke]

THERMOGENESIS CORP. Receives Canadian Approval for the CryoSeal FS System;
Company Initiates Market Launch Activities for the CryoSeal Fibrin Sealant -- FS --
System in Canada

RANCHO CORDOVA, Calif., May 16, 2001 (BUSINESS WIRE) -- THERMOGENESIS CORP.
(Nasdaq: KOOL) today announced receipt of a Medical Device License for the
CryoSeal(R) FS System from the Therapeutic Products Directorate, Medical Devices
Bureau of Health Canada. The CryoSeal FS System is used to prepare a surgical
hemostatic agent and tissue sealant from a single unit of human plasma in about
60 minutes. Based on independent marketing reports, the Company believes the
global market for fibrin sealant to be approximately $400 million annually. The
license allows THERMOGENESIS CORP. to market the CryoSeal FS System and the
Company`s fibrin sealant product in Canada.

Dr. James Godsey, president and COO of THERMOGENESIS CORP. commented, "We`re
pleased to begin the market launch activities for the CryoSeal FS System within
Canada. THERMOGENESIS CORP.`s FS System produces the only fibrin sealant product
commercially available in Canada that does not contain animal-based or synthetic
ingredients. In light of Canada`s concern over Mad Cow disease and blood safety
in general, we expect our fibrin sealant product to be very well received."
THERMOGENESIS CORP. plans to distribute the CryoSeal FS System through the
Canadian blood transfusion centers, which supply hospital surgeons with all
their existing blood component products. Godsey added, "By working directly
through the existing Canadian network of blood centers and blood banks, our
sales manager for Canada can implement our initial launch plans without any
additional layers of distribution, which will help us reach both our revenue and
profitability goals."

The CryoSeal FS System consists of the CryoSeal device and the CP-2 plasma
processing disposable. The design of the CP-2 Plasma Processing Disposable is
based upon two of the Company`s recent technological breakthroughs enabling real
time processing of blood products. Our cryoprecipitation technology prepares
fibrinogen-rich cryoprecipitate from plasma in as little as 40 minutes as
compared to two to three days for standard blood center methodology, while our
patented thrombin activation technology prepares activated human thrombin from a
small volume of the same human plasma. When mixed together, fibrinogen and
thrombin form a surgical sealant or adhesive that can be used in a wide array of
surgical procedures. The fibrin sealant is applied to the wound site using the
Company`s proprietary FS Applicator System. The Company has previously received
a medical device license on the FS Applicator System.

The CryoSeal FS System is not currently available for sale in the United States.
The Company plans to file an Investigational Device Exemption (IDE) with the
Food and Drug Administration for the CryoSeal FS System in the second half of
2001 to begin its pivotal human clinical trials in the United States.

[RudiDutschke]

THERMOGENESIS CORP. Worldwide Market Share for Processing and Archiving
Cord Blood IncreasesThe Central Blood Bank of the Magen David Adom in Ramat
Gan, Israel Becomes the First Cord Blood Stem Cell Bank in Israel to Adopt the
BioArchive(R) System

RANCHO CORDOVA, Calif., May 30, 2001 (BW HealthWire) -- THERMOGENESIS CORP.
(Nasdaq: KOOL) announced the receipt of an order for the BioArchive System from
the Central Blood Bank of the Magen David Adom ("MDA") in Ramat Gan, Israel.

In Europe, BioArchive Systems have been placed at the major Cord Blood Stem Cell
Banks in Germany, United Kingdom, Belgium, France, Spain, and Finland. In North
America, BioArchive Systems have been placed at the New York Blood Center, Duke
University Medical Center, San Diego Blood Bank, NuStem Technologies, Inc.,
Coriell Institute for Medical Research pursuant to IND regulations, and the
National Transfusion Service Cord Blood Bank in Mexico. Additionally in Asia,
BioArchive Systems have been chosen in Japan, China, Taiwan, Vietnam, South
Korea, Malaysia and India.

The Company estimates that more than 70% of the cord blood stem cell transplants
performed to date are from Cord Blood Banks who are now using the Company`s
BioArchive Systems, demonstrating that the BioArchive System is the
international choice for collecting, processing, and archiving cryopreserved
hematopoietic stem cells sourced from placental/cord blood ("PCB"). PCB stem
cells are used to reconstitute the hematopoietic and immune systems of patients
who have undergone high-dose chemotherapy and radiation to combat diseases such
as leukemias, lymphomas, diverse inherited anemias, such as sickle cell anemia
and thalassemia, and other genetic diseases.

Dr. James Godsey, president and COO of THERMOGENESIS CORP. commented, "This will
be the first BioArchive System to be installed in Israel. We are pleased that
the Central Blood Bank of the MDA has chosen the BioArchive System for their
cord blood processing and storage program. Placement of the BioArchive System at
this premier stem cell bank in Israel moves the Company one country closer to
its goal of establishing a global network of national cord blood bank programs
which have adopted the BioArchive System as their standard."

Professor Shinar, director of the Central Blood Bank, is planning for an October
2001 opening of the cord blood stem cell banking facility.

According to Philip Coelho, chairman and CEO of THERMOGENESIS CORP., "Recent
research suggests that there are stem cells in a unit of cord blood that have
the potential to produce other cells outside the hematopoietic system such as
neural, liver and bone cells. Since there are serious ethical issues with
sourcing stem cells from embryos and fetuses, we believe scientists may begin to
focus on cord blood as a superior, non-controversial source for these
multi-potential stem cells."

The BioArchive System uses THERMOGENESIS CORP.`s proprietary computer-driven
liquid nitrogen robotic system to cryopreserve and archive up to 3,626 units
that have been collected, processed and cryopreserved in proprietary sterile
plastic bag sets. The BioArchive System tracks identification and location for
each unit and performs robotic retrieval of each unique barcoded unit. The
BioArchive System freezes, places and retrieves stem cells without exposing them
and other archived samples to Transient Warming Events (TWEs), which can
significantly reduce their viability.

[RudiDutschke]

THERMOGENESIS CORP. Continues to Increase Its Market Share Worldwide for
Processing and Archiving Cord Blood Stem Cells

RANCHO CORDOVA, Calif., Jun 5, 2001 (BW HealthWire) --

Universite Catholique De Louvain Becomes the Third Cord Blood Bank in
Belgium and the Tenth in Europe to Adopt the BioArchive(R) System

THERMOGENESIS CORP. (Nasdaq: KOOL) announced the sale of a BioArchive System to
the Catholic University of Louvain in Brussels, Belgium.

This will be the third BioArchive System chosen by a placental/cord blood
("PCB") stem cell bank in Belgium, joining identical systems at the university
hospitals in Liege and Leuven. The BioArchive System is one of the enabling
technologies for cell therapy: the use of living cells to cure human disease.

Elsewhere in Europe, BioArchive Systems have been placed at the major Cord Blood
Stem Cell Banks in Germany, United Kingdom, France, Spain, and Finland. In North
America, BioArchive Systems are placed at the New York Blood Center, Duke
University Medical Center, San Diego Blood Bank, NuStem Technologies, Inc.,
Coriell Institute for Medical Research pursuant to IND regulations, and the
National Transfusion Service Cord Blood Bank in Mexico. Additionally in Asia,
BioArchive Systems have been chosen in Japan, China, Taiwan, Vietnam, South
Korea, Malaysia and India.

The Company estimates that more than 70% of the cord blood stem cell transplants
performed to date are from Cord Blood Banks that are now using the BioArchive
System, which demonstrates that the BioArchive System is the international
choice for collecting, processing, and archiving cryopreserved hematopoietic
stem cells sourced from PCB. PCB stem cells are used to restore immune systems
of patients who have undergone high-dose chemotherapy and radiation to combat
diseases such as leukemias, lymphomas, diverse inherited anemias, such as sickle
cell anemia and thalassemia, and other genetic diseases.

Dr. James Godsey, President and COO of THERMOGENESIS CORP. commented, "We are
pleased that Universite Catholique De Louvain has chosen to use the BioArchive
System for their cord blood banking program." Dr. Godsey further noted, "We
continue to implement our strategic plan of installing a worldwide base of
BioArchive systems. We derive additional disposable product revenue and
equipment revenue as these customers continue to grow their PCB cell therapy
programs. Since many of these programs are government funded, gaining entry puts
us in the favorable position of securing the customers because of the desire for
standardization."

According to Philip Coelho, Chairman and CEO of THERMOGENESIS CORP., "Recent
research suggests that there are stem cells in a unit of cord blood that have
the potential to produce other cells outside the hematopoietic system such as
neural, liver and bone cells. This holds the promise of an ever growing demand
for stem cell and regenerative medicine therapies which may be served by our
growing base of installations."

The BioArchive System uses THERMOGENESIS CORP.`s proprietary computer-driven
liquid nitrogen robotic system to cryopreserve and archive up to 3,626 units
that have been collected, processed and cryopreserved in proprietary sterile
plastic bag sets. The BioArchive System performs robotic insertion and retrieval
of each unique barcode identified stem cell unit. The unit subsequently can be
delivered world wide for transplant. + The BioArchive System operates to freeze,
place and retrieve samples without exposing other archived samples to the
Transient Warming Events (TWEs), which can significantly reduce cell viability.

[murmeltier]

Hi Rudi,

kannst du mir evtl. mal deine derzeitige Einschätzung zu KOOL geben? Außerdem ist mein Englisch ziemlich besch..., kannst du mir in etwa eine Zusammenfassung der letzten Neuigkeiten geben?

Vielen Dank

Murmeltier

[RudiDutschke]

Hallo murmeltier, schön, dass es noch einen KOOL-Interessierten gibt. Habe momentan nur ein sehr begrenztes Zeitbudget, werde aber versuchen bis heute Abend eine Übersetzung reinzustellen. Grüsse Rudi

[RudiDutschke]

Nochmal Guten Tag, hab mal das Übersetzungsprogramm von web.de versucht, ist aber äusserst mässig, so dass es mir unnütz scheint die Übersetzungen hier reinzustellen. Sollte jemand darauf bestehen, bitte melden. Die Nachricht vom 03-05-2001 bezieht sich auf eine Kapitalerhöhung von knapp 4 Mio. Stammaktien zu $7,1Mio., was einem Preis von $1,8 je Anteilsschein macht. Zusätzlich gibt die Gesellschaft eine 5-Jahres-Garantie über knapp 800tsd weiterer Anteile, zu einem Preis von $2,88 je Aktie. Diese Anteile gehen an eine Gruppe institutioneller und amtlich anerkannter Investoren. Der Erlös soll dazu benutzt werden, klinische Versuche für das CryoSealSystem durchzuführen, und um das Marketing für das BioArchiveSystem auszudehnen. Die News vom 11-05 sind zum einen die Zahlen für das dritte Quartal 2001, zum anderen der Verkauf eines BioArchiveSystemsnach Indien,ein weiters wurde am05-06 nach Brüssel verkauft. Am 14-05 Erteilung eines Patents vom Amerikanischen Patentamt. 16-05 Lizenz für das CryosealSystem in Kanada, die es erlaubt, das Produkt in Kanada zu vermarkten.
Soweit erstmal zu den letzten News. Meine Einschätzung ist auf jeden Fall positiv, nur sollte man wohl etwas Geduld haben. Unter $2 sollte der Kurs nichr mehr gehen, die $3 stellten schon zwei mal einen Widerstand dar. Problematisch ist es, dass das Handelsvolumen doch sehr gering ist. Unter hohen Umsätzen geht es meist steil nach oben, unter geringen dann wieder nach unten. Hoffe erstmal geholfen zu haben, habe mir vorgenommen in den nächsten Tagen etwas über die Produkte reizustellen. Bis dahin Rudi

[murmeltier]

Vielen Dank, Rudi.

Ist doch schonmal was.

[RudiDutschke]

Guten Abend, hast recht, ist ein Anfang, mit etwas mehr Zeit..... Heute in USA übrigens über200000Shares, könnte bald eine Meldung Kommen.

[RudiDutschke]

Taiwan Cord Blood Stem Cell Bank Adopts BioArchive SystemGene Born Biotech
Corp. Becomes the Second Cord Blood Bank in Taiwan and the Twelfth in Asia to
Adopt the BioArchive System

RANCHO CORDOVA, Calif., Jun 20, 2001 (BW HealthWire) -- THERMOGENESIS CORP.
(Nasdaq: KOOL) announced the receipt of an order for the BioArchive(R) System
from the Gene Born Biotech Corp. in Taipei, Taiwan. This will be the second
BioArchive System chosen by a placental/cord blood ("PCB") stem cell bank in
Taiwan, joining Buddhist Compassion Relief Tzu-Chi Foundation in Hualien. The
Gene Born Biotech Corp. Cord Blood Bank will be under the direction of Dr. Chen
Hui-chen. The BioArchive System is enabling technology for cell therapy: the use
of living cells to cure human disease.

Elsewhere in Asia, BioArchive Systems have been chosen in Japan, China, Vietnam,
South Korea, Malaysia and India. In North America, BioArchive Systems are placed
at the New York Blood Center, Duke University Medical Center, San Diego Blood
Bank, NuStem Technologies, Inc., Coriell Institute for Medical Research pursuant
to IND regulations, and the National Transfusion Service Cord Blood Bank in
Mexico. In Europe, BioArchive Systems have been placed at the major Cord Blood
Stem Cell Banks in Germany, United Kingdom, France, Spain, Belgium, and Finland.
The Company estimates that more than 70% of the cord blood stem cell transplants
performed to date are from Cord Blood Banks that are now using the BioArchive
System.

Dr. James Godsey, president and COO of THERMOGENESIS CORP. commented, "Gene Born
Biotech Corp. is an important addition to our global network of cord blood
banks." Dr. Godsey further noted, "The order demonstrates our continued success
in implementing our strategic plan of installing a worldwide base of BioArchive
Systems. We will derive additional disposable product revenue and equipment
revenue as these customers continue to grow their PCB cell therapy programs.
Since many of these programs are government funded, gaining entry puts us in the
favorable position of securing the customers because of the desire for
standardization."

According to Philip Coelho, chairman and CEO of THERMOGENESIS CORP., "Recent
research suggests that there are stem cells in a unit of cord blood that have
the potential to produce other cells outside the hematopoietic system such as
neural, liver and bone cells. This holds the promise of an ever growing demand
for stem cell and regenerative medicine therapies which may be served by our
growing base of installations."

The BioArchive System uses THERMOGENESIS CORP.`s proprietary computer-driven
liquid nitrogen robotic system to store and archive up to 3,626 units that have
been collected, processed and cryopreserved in proprietary sterile plastic bag
sets. The BioArchive System performs robotic insertion and retrieval of each
unique barcode identified unit. The BioArchive System operates to freeze, place
and retrieve samples without exposing other archived samples to the Transient
Warming Events (TWEs).


Regulatory Status

The BioArchive System is a Class II blood component freezer exempt from the
pre-market notification procedures. The BioArchive System has potential
applications involving archiving, storing, managing and retrieving other kinds
of biological specimens, that may include stem cells, dendritic cells, T-cells,
cell lines, male sperm cells, female eggs, heart valves, corneas, virus samples,
biopsy samples and other blood, tissue and saliva samples. The BioArchive System
is currently intended for preservation of blood components and blood products
and would require FDA pre-market clearance or approval for additional
indications for use in the United States.


About THERMOGENESIS CORP.

THERMOGENESIS CORP. has been a pioneer in designing, manufacturing and
distributing equipment to collect, cryopreserve and archive highly sensitive
blood products and biological tissue for more than 10 years.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.

[RudiDutschke]

Mahlzeit zusammen.
Nachdem der Kurs in den letzten Tagen, bzw. Wochen nur eine Richtung kannte, geht es heute hoffentlich mal wieder aufwärts. Die Meldung stelle ich sofort rein. Brief jetzt zu 2,4E, sowohl FSE als auch Ber. Weiter so. Schönen Tag noch.

[RudiDutschke]

Banking of Non-Controversial Neonatal Stem Cells IncreasesInstitut J. Bordet (ULB)
Brussels, Belgium becomes the fourth cord blood bank in Belgium and the tenth in
Europe to adopt THERMOGENESIS CORP.`s BioArchive(R) System

RANCHO CORDOVA, Calif., Aug 6, 2001 (BW HealthWire) -- THERMOGENESIS CORP.
(Nasdaq: KOOL) announced the receipt of an order for a BioArchive System from the
Institut J. Bordet ("ULB") in Brussels, Belgium under the direction of Dr. Alain
Del Forge. The system was purchased to process and archive units of neonatal
stem cells sourced from placental/cord blood ("PCB") as part of a joint project
with the Catholic University of Louvain ("UCL") in Brussels. This will be the
fourth BioArchive System chosen by a PCB stem cell bank in Belgium, joining
identical systems at the UCL and university hospitals in Liege and Leuven.

According to Philip Coelho, chairman and CEO of THERMOGENESIS CORP., "There are
in fact three distinct sources of stem cells: embryonic (from embryos and
fetuses), adult (from donations of adult tissue, bone marrow or blood), and
neonatal (from placenta and umbilical cord blood). What particularly
distinguishes the stem cells in donated cord blood is that, in biological age
and proliferative capacity, these neonatal stem cells are much closer to
embryonic tissue than adult stem cells and, since the placenta and umbilical
cord are normally discarded, it is the only source of stem cells that can be
collected without risk to any donor."

Elsewhere in Europe, BioArchive Systems have been placed at the major Cord Blood
Stem Cell Banks in Germany, United Kingdom, France, Spain and Finland. In North
America, BioArchive Systems are placed at the New York Blood Center, Duke
University Medical Center, San Diego Blood Bank, NuStem Technologies, Inc.,
Coriell Institute for Medical Research pursuant to IND regulations, and the
National Transfusion Service Cord Blood Bank in Mexico. Elsewhere, BioArchive
Systems have been chosen in Japan, China, Taiwan, Vietnam, South Korea,
Malaysia, India and Israel.

The company estimates that more than 70% of the cord blood stem cell transplants
performed to date are from Cord Blood Banks that are now using the BioArchive
System, which demonstrates that the BioArchive System is the international
choice for collecting, processing, and archiving cryopreserved hematopoietic
stem cells sourced from PCB. PCB stem cells are used to restore immune systems
of patients who have undergone high-dose chemotherapy and radiation to combat
diseases such as leukemias, lymphomas, diverse inherited anemias, such as sickle
cell anemia and thalassemia, and other genetic diseases.

Dr. James Godsey, president and COO of THERMOGENESIS CORP. commented, "We are
pleased that the ULB has chosen to use the BioArchive System for their cord
blood banking program." Dr. Godsey further noted, "We continue to implement our
strategic plan of installing a worldwide base of BioArchive Systems. We derive
additional disposable product revenue and equipment revenue as these customers
continue to grow their PCB cell therapy programs. Since many of these programs
are government funded, gaining entry puts us in the favorable position of
securing the customers because of the desire for standardization."

[RudiDutschke]

THERMOGENESIS CORP. -- KOOL -- Completes FDA Submission Requesting
Approval to Initiate Human Clinical Trials of the CryoSeal Fibrin Sealant -- ``FS`` --
SystemU.S. Fibrin Sealant Market is Expected to Rise to $400 Million by Year 2006

RANCHO CORDOVA, Calif., Aug 8, 2001 (BW HealthWire) -- THERMOGENESIS CORP.
(Nasdaq: KOOL) announced it completed pre-clinical trials, and has submitted an
Investigational Device Exemption ("IDE") to the U.S. Food and Drug
Administration ("FDA") requesting approval to initiate human clinical trials
with its CryoSeal(R) FS System. Based upon independent market reports, the
Company believes the U.S. fibrin sealant market to be approximately $100 million
annually and is expected to grow to $400 million over the next five years. The
CryoSeal FS System was recently approved for sale in Europe, where the annual
sales of commercial fibrin sealants is believed to be approximately $100 million
per annum.

FDA approval of the IDE will enable THERMOGENESIS CORP. to initiate human
clinical trials with the CryoSeal FS System in September 2001, or shortly
thereafter. The human trials are expected to take a minimum of 10 months to
complete at an estimated expense of $2.5 million. In May of this year, the
Company announced that it had raised $7.1 million to cover the costs of the U.S.
human clinical trials and ongoing operating costs.

Dr. James Godsey, president and COO of THERMOGENESIS CORP. commented, "The IDE
submission for the CryoSeal FS System`s human clinical trials for liver
resectioning is a critical milestone in the Company`s history, as it signals the
transformation of THERMOGENESIS CORP. into a late stage biopharmaceutical
company." The results of pre-clinical trials demonstrated the ability of
CryoSeal Fibrin Sealant to control bleeding of a resectioned pig liver in less
than four minutes. This rapid control of bleeding leads to minimal use of
transfusion blood products which are currently in short supply in the U.S. due
to a significant shortage in the availability of blood donors.

The CryoSeal FS System prepares both components (cryoprecipitate and thrombin)
of CryoSeal Fibrin Sealant from a single unit of human plasma in about an hour.
Once prepared, the CryoSeal Fibrin Sealant may be frozen or used immediately.
The use of single units of human plasma, rather than pools of plasma, such as
those used to manufacture commercially available fibrin sealants, which combine
10,000 or more units of plasma, also minimizes the risk of infectious disease
transmission if one of the donors has a viral or prion infection. Dr. Godsey
went on to state, "We believe that the production of fibrin sealant from a
single unit of blood offers both an attractive alternative to commercially
available fibrin sealants, and the first methodology to prepare a truly
autologous fibrin sealant, that will grow in demand as acceptable blood donors
continue to dwindle in number."

In contrast to commercially available fibrin sealants, the CryoSeal technology
enables the CryoSeal FS System to prepare CryoSeal Fibrin Sealant free of animal
proteins such as bovine aprotinin or bovine thrombin. Animal proteins are a
potential source of viral and prion contamination to blood products, the latter
of which are resistant to all forms of viral inactivation technology available
to fractionators at this time. With the threat of nvCJD continuing to mount in
Europe and the ever increasing possibility of nvCJD and/or Mad Cow disease
making their way to the U.S. as a result of unrestricted global air travel, the
Company feels that CryoSeal Fibrin Sealant is a product which meets the needs of
the biological sealant marketplace of today and tomorrow.

The Company has also developed a proprietary FS Applicator System to precisely
apply CryoSeal Fibrin Sealant to the wound site during surgery. The FS
Applicator System consists of a gun-like handle which delivers 200 micro-liter
metered doses of CryoSeal Fibrin Sealant to the bleeding surface.
Interchangeable spray tip and drop tip disposables, that provide essentially
instantaneously clotting, were designed for applying CryoSeal fibrin sealant to
large surface areas with oozing bleeding such as liver resection. The CryoSeal
FS System was designed to accommodate both autologous (patient`s own) plasma and
allogeneic (donor) plasma.

The design of the CryoSeal FS System is based upon two of the Company`s recent
technological breakthroughs enabling real time processing of blood products,
including: (a) automated cryoprecipitation technology which prepares
fibrinogen-rich cryoprecipitate from plasma in as little as 51 minutes, as
compared to two to three days for standard blood center methodology; and (b)
thrombin activation technology which prepares activated human thrombin from a
small aliquot of the same human plasma.

[RudiDutschke]

Guten Tag, habe noch einen weiteren Bericht über KOOL von gestern.
Thermogenesis Seeks FDA Trials ApprovalThe company has asked the FDA to
okay human clinical trials for its proprietary wound-and organ-sealing glue. Unlike
other fibrin sealants, the Thermogenesis product is quickly made from the patient`s
own blood

Vancouver, Aug 08, 2001 (smallcapcenter.com via COMTEX) -- Thermogenesis Corp.
(NASDAQ: KOOL) has asked the FDA to okay human clinical trials for its
proprietary wound- and organ-sealing glue. Unlike other fibrin sealants, the
Thermogenesis product is quickly made from the patient`s own blood.

The news has put a slight blush on KOOL. At 12:41 p.m. ET, KOOL was up 3.08% or
6 cents to $2.01 on moderate volume of 11,800 share as compared to its
three-month daily average of 32,000 shares. Its 52-week range is $3.938 set on
September 5, 2000 with a low of $1.25 recorded on December 5, 2000. Its
most-recent-quarter (mrq) per-share book value is $0.10.

Like other surgical sealants, Thermogenesis`s contender - the CryoSeal(R) fibrin
sealant - is based on natural coagulant factors (i.e. cryoprecipitate and
thrombin) found in blood. The idea is the same. Instead of waiting for Mother
Nature to slowly stop the drip, fibrin sealants super-power the process. A
couple of dabs and a surgeon can literally and quickly glue blood-rich organs
and wounds back together. For example, in recent animal trials, a `sectioned`
pig liver treated with CryoSeal stopped bleeding within four minutes.

For the surgeon, surgical glues mean less fuss and mess in the operating
theatre. For the hospitals and HMOs, it means fewer blood transfusions on the
books. As blood donations continue to decline, and the cost of screening this
blood for HIV, prions, viruses and other blood-borne nasties continues to rise,
so does the usefulness of surgical glues.

Today, the overall fibrin-sealant market in the United States alone is worth
about $100 million per annum and is expected to grow to $400 million within the
next five years. In Europe, where the idea of using glue instead of sutures or
staples has been slower to catch on, the commercial fibrin-sealant market is
worth about $100 million.

The components of most blood-based surgical sealants are extracted from
thousands of sources. Literal vats of blood, 10,000 plus units processed in each
manufacturing run. It`s not necessarily human blood either; blood products are
being extracted from bovine, porcine and other animal sources. Highly purified,
such products are finding increasing use in today`s hospitals.

However, some patients find the whole idea of a `communal` blood pool rather
disquieting and it`s this market Thermogenesis hopes to address. Rather then
dipping into these `pools of plasma`, the CryoSeal FS System extracts the vital
cryoprecipitate and thrombin from a single unit of human plasma in about an
hour. Once prepared, the sealant may be frozen or used immediately. Depending
upon the source, the sealant can be derived from `autologous` (patient`s own) or
allogeneic (donor) plasma

For the aforementioned patients, the option to drain off a pint now, to plug
themselves up later, could be quite appealing. Aside from the do-it-yourself
aspect, it also eliminates the fear of unwittingly contracting the
aforementioned viral or prion-based diseases. In Europe, where mad-cow disease
and its human variant, nvCJD, is on everyone`s mind and where anything remotely
cow-like is shunned, an alternative to any bovine-based or communal blood-bank
product could find a ready market.

Thermogenesis certainly hope so. In March of 2001, the CryoSeal FS System
received CE Mark approval from the European Union Competent Authorities to
initiate commercialization of the CryoSeal FS System in Europe. Pending FDA
approval, the CryoSeal FS System and applicator kits, will be marketed, as
permitted under U.S. Export Laws, in Latin America, South America, Asian Pacific
Rim and Australia. In May 2001, the CryoSeal FS System received a license to
market in Canada.

To help deliver the sales and the sealant, Theremogenesis has also developed the
aptly named CryoSeal FS Applicator System. Consisting of a gun-like device which
delivers 200 micro-liter metered doses of the sealant via a disposable and
interchangeable spray and drop tips, the system provides what the company
release calls "essentially instantaneously clotting" for "large surface areas
with oozing bleeding" such as liver resection.

Meanwhile, back in the United States, and assuming Thermogenesis snags the
requested Investigational Device Exemption (IDE) from the FDA and approval,
human clinical trials for `liver resectioning" with the CryoSeal system will
take place in September, 2001, or shortly after. The trials will take at least
10 months to complete and will cost Thermogenesis around $2.5 million. In May of
this year, Theremogenesis announced that it had raised and salted away $7.1
million to fund the U.S. clinical trials and the company`s own ongoing operating
costs.

Based inn Rancho Cordova, California, Thermogenesis Corporation designs,
manufactures and distributes equipment to process therapeutically valuable blood
components including stem cells and surgical sealants. Initially, the company
developed medical devices for ultra-rapid freezing and thawing of blood
components. The Ultra Rapid freezers and thawers use heat-transfer liquids,
rather than gases such as air, carbon dioxide or nitrogen, to transfer heat to
and from a biological substance via a patented flexible plastic membrane
interposed between the heat-transfer liquid and the container housing the blood
component. Today, the company manufactures and distributes these devices to
niche markets in the blood banks of 32 countries.

For the nine months ended March 31, 2001, Thermogenesis Corporation revenues
rose 40% to $4.6 million. Net loss applicable to common shares and before
accounting change fell 20% to $3.9 million. Revenues reflect increased sales of
BioArchive and ThermoLine products. Lower loss reflects cost reduction efforts.

There is no First Call covering analyst for Thermogenesis Corporation. However,
Smallcapcenter.com`s advanced research department gave KOOL a signal stockscore
of 33 at 11:53 a.m. EDT on Wednesday.

A company`s stockscore is an unbiased summary of numerous technical analysis
indicators like volume and momentum, which are combined to produce a value on a
scale of 1-100 with 100 being the highest level.


By David Leidl

Copyright 2001 Stockgroup.com, All rights reserved.

[RudiDutschke]

President Bush`s Focus On Stem Cells From Cord Blood a Boost For
THERMOGENESIS CORP.`s Cryopreservation Technology

RANCHO CORDOVA, Calif., Aug 13, 2001 (BW HealthWire) -- THERMOGENESIS CORP.
(Nasdaq: KOOL) today announced it is preparing to expand its manufacturing
capacity of the BioArchive(R) System in response to President Bush`s
recommendation to provide $250 million in research funds for umbilical cord
blood and other potential alternative sources of stem cells.

Since May 1998, THERMOGENESIS CORP. has provided a unique, totally integrated
system to public and national cord blood banks to enable the collecting and
preserving tissue-matched units of neonatal stem cells sourced from umbilical
cord blood. The Company`s BioArchive System consists of processing disposables,
ancillary equipment and a robotic cryopreservation system designed to
accommodate all of the steps of collection, processing, cryopreservation and
transplantation required in the cord blood banking process. To date, 36
BioArchive Systems have shipped to cord blood stem cell banks in 16 countries
around the world, thus establishing an inventory capacity of more than 130,000
cryopreserved units of stem cells. The Company estimates that the total global
inventory of cord blood specimens could grow to as high as 1,000,000 units.

Dr. James Godsey, president and COO of THERMOGENESIS CORP. stated,
"THERMOGENESIS CORP. is obviously elated by President Bush`s announcement to
provide research funding to cord blood related programs. To date the primary
demand for the stem cells stored in the BioArchive-based cord blood banks around
the world has been for the purpose of curing deadly diseases such as leukemia,
lymphomas, diverse inherited anemias, such as sickle cell anemia and
thalassemia, and other genetic diseases. However, as a result of the President`s
recent announcement, our BioArchive customers may soon find that the demand on
their inventory has significantly increased as National Institute of Health
("NIH") funded research programs come to them in order to source high quality
cord blood specimens. As our customers benefit, so too will the company
benefit."

According to Philip Coelho, chairman and CEO of THERMOGENESIS CORP., "There are
in fact three distinct sources of stem cells: embryonic (from embryos and
fetuses), adult (from donations of adult tissue, bone marrow or blood), and
neonatal (from placenta and umbilical cord blood). What particularly
distinguishes the stem cells in donated cord blood is that, in biological age
and proliferative capacity, these neonatal stem cells are much closer to
embryonic cells than adult stem cells and, since the placenta and umbilical cord
are normally discarded, it is the only source of stem cells that can be
collected without risk to any donor."


Regulatory Status

The BioArchive System is a Class II blood component freezer exempt from the
pre-market notification procedures. The BioArchive System has potential
applications involving archiving, storing, managing and retrieving other kinds
of biological specimens, that may include stem cells, dendritic cells, T-cells,
cell lines, male sperm cells, female eggs, heart valves, corneas, virus samples,
biopsy samples and other blood, tissue and saliva samples. The BioArchive System
is currently intended for preservation of blood components and blood products
and would require FDA pre-market clearance or approval for additional
indications for use in the United States.


About THERMOGENESIS CORP.

THERMOGENESIS CORP. has been a pioneer in designing and manufacturing medical
devices and sterile disposable bag sets to collect, cryopreserve and archive
blood products such as stem cells from cord blood, blood plasma, fibrin sealant
and other related blood products. After extensive research and development, two
new technology platforms (the BioArchive System and the CryoSeal(R) System) have
evolved products which provide new bio-material products to patients in need.
For more information visit the company`s web site at www.thermogenesis.com.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.

[RudiDutschke]

THERMOGENESIS CORP. Engages Quintiles, Inc. to Oversee the Human Clinical
Trials for the CryoSeal Fibrin Sealant SystemU.S. Fibrin Sealant Market is
Estimated to Be $400 Million Per Annum by 2006

RANCHO CORDOVA, Calif., Aug 15, 2001 (BUSINESS WIRE) -- THERMOGENESIS CORP.
(Nasdaq: KOOL) today announced it engaged Quintiles, Inc. as their Clinical
Research Organization ("CRO") for the CryoSeal(R) FS System human clinical
trials. Quintiles, Inc. will perform the duties of a clinical monitor for the
human clinical trials that were proposed in connection with the Company`s
Investigational Device Exemption ("IDE"), recently submitted to the U.S. Food
and Drug Administration ("FDA") for approval.

Dr. James Godsey, president and COO of THERMOGENESIS CORP., commented, "The
successful completion of the CryoSeal FS System pivotal clinical trials is
critical to the Company`s future, and we picked one of the world`s leading
clinical research organizations as the clinical monitor in recognition of the
importance of this key milestone." The Company expects to initiate human
clinical trials with the CryoSeal FS System in September 2001, or shortly
thereafter, following FDA approval for commencement. The human trials are
expected to take a minimum of 10 months to complete at an estimated expense of
$2.5 million. Previously this year, the Company announced that it had raised
$7.1 million to cover the costs of the U.S. human clinical trials and ongoing
operating costs.

The CryoSeal FS System prepares both components (cryoprecipitate and thrombin)
of CryoSeal Fibrin Sealant from a single unit of human plasma in about an hour.
Once prepared, the CryoSeal Fibrin Sealant may be frozen or used immediately.
The design of the CryoSeal FS System is based upon two of the Company`s recent
technological breakthroughs enabling real time processing of blood products,
including: (a) automated cryoprecipitation technology which prepares
fibrinogen-rich cryoprecipitate from plasma in as little as 51 minutes, as
compared to two to three days for standard blood center methodology; and (b)
thrombin activation technology which prepares activated human thrombin from a
small aliquot of the same human plasma.


Regulatory Status

In March of 2001, the CryoSeal FS System received CE Mark approval from the
European Union Competent Authorities to initiate commercialization of the
CryoSeal FS System in Europe. The CryoSeal System is patent-protected, and will
require a pre-market approval by the U.S. FDA before marketing in the U.S. The
Company submitted its IDE to the FDA on Aug. 6, 2001 requesting approval to
begin human clinical trials with the CryoSeal FS System. In May 2001, the
CryoSeal FS System received a license to market in Canada.

About Quintiles Transnational, Inc.



Quintiles Transnational is the world`s leading provider of information,
technology and services to help bring new medicines to patients faster and
improve healthcare. Headquartered near Research Triangle Park, N.C., Quintiles
employs a global workforce of 18,000 in 39 countries. Quintiles Transnational is
a member of the S&P 500 and Fortune 1000. For more information visit the
company`s Web site at www.quintiles.com.

[RudiDutschke]

Guten Tag, gibt es hier eigentlich noch Investierte, oder hat niemand interesse an KOOL? Schönen Tag noch

[murmeltier]

Hi Rudi!

Ich bin zwar immer noch nicht investiert in kool, dafür aber umso mehr interessiert an diesem Unternehmen. Habe die Kurssprünge der letzten Tage schon beobachtet und die Erklärung dann in einem Biotech-Letter vernommen (Leider kann ich mit dem ganzen Fach-Englisch aus den original adhocs nicht viel anfangen).


Naja, jedenfalls sieht das momentan sehr gut aus.

Ich beobachte weiter, habe in diesem Marktumfeld aber zur Zeit noch zuviel Angst, zu investieren.


Gruß

Murmeltier

[roger11]

Klar gibt es Investierte

Grüss Dich, Rudi!

War schon auf der Suche nach QUINTILES,Inc....

Weisst Du, was " Cord " genau bedeutet?


Gruss
Roger

[RudiDutschke]

Hallo nochmal, schön was zu hören, dachte schon ich bin allein hier. Cord bedeutet normalerweise Schnur, in diesem Zusammenhang ist die Nabelschnur gemeint.
@Murmeltier: Stand in dem Brief explizit etwas über Thermogenesis, oder allgemein über die Äusserungen von Bush zu Stammzellen? Stell es doch mal hier rein, wenn es dir möglich ist. Grüsse Rudi

[roger11]

Danke, Rudi

Werde mich jetzt öfters hier melden.

[murmeltier]

Hallo Leute,

hier ist der Artikel aus der Online-Ausgabe des Biotech-Reports (den man kostenlos über die Seiten von www.deraktionaer.de einmal wöchentlich gemailt bekommt):

Datum: 14.08.2001


Bush gibt Thermogenesis Auftrieb

Stammzellen aus dem Nabelschnurblut von Neugeborenen sollen künftig in der Forschung dominie-ren,
so will es jedenfalls die US-Regierung. Forscher die sich bei der Stammzellforschung künftig auf
diese Zellen konzentrieren, sollen eine staatliche Förderung erhalten. Präsident Bush persönlich ver-sprach
einen Förderungsbetrag in Höhe von $250 Mio. und fördert damit wohl indirekt auch die neue
Technologie des Unternehmens Thermogenesis Corp. Stammzellen aus Nabelschnurblut haben
gleich mehrere Vorteile, im Vergleich zu adulten Stammzellen ähneln sie in Alter und
Vermehrungsfähigkeit eher embryonalen Stammzellen, weisen jedoch nicht deren ethische
Problematik auf, da Plazenta und Nabelschnur nach der Geburt gewöhnlich verworfen werden.
Ursprünglich war Thermogenesis lediglich im Bereich der Herstellung ultraschneller Gefrier- und
Taugeräte für Krankenhäuser, Blutbanken, Bluttransfusionszentren und Blutplasmasammelstellen
tätig. Nach ausgedehnter
Forschung und Entwicklung ent-standen
zwei neue Technologie-Plattformen, das BioArchive System und das CryoSeal System. Mit
Hilfe dieser medizinischen Geräte konnten nun Biomaterialien für Patienten entwickelt werden, die
zur Wundheilung sowie zur Geweberegeneration dienen. Die mit Hilfe der beiden Systeme produ-zierten
Wirkstoffe reichen von Proteinen über Enzyme bis zu Stammzellen und wurden bis jetzt nur
zur Heilung schwerer Krankheiten eingesetzt. Besonders interessant ist das seit 1998 vermarktete
BioArchive System, welches zur Sammlung, Konservierung und Aufbewahrung von Stammzellen aus
Nabelschnurblut zur Anwendung kommt. Die Herstellungskapazitäten des vollständig automatisier-ten
Systems sollen nun auf Grund der Bush Entscheidung massiv ausgeweitet werden. Bis heute
wurden 86 BioArchive Systeme an Blutbanken für Stammzellen aus Nabelschnurblut in 16 Länder
verkauft, der Bestand an kryokonservierten Stammzellen aus Nabelschnurblut beläuft sich derzeit
auf etwa 130.000 Einheiten, zu wenig, um den bevorstehenden Forschungsansturm zu decken.
Thermogenesis geht davon aus, dass über kurz oder lang bis zu einer Million Stammzell-Einheiten
benötigt werden, was seinem BioArchive System einen rasanten Aufschwung verschaffen dürfte.
Thermogenesis ist auf den Ansturm gut vorbereitet, im Jahr 2000 investierte das Unternehmen in
Verkaufs- und Technikspezialisten für die Systeme BioArchive und CryoSeal. Mit einer erst kürzlich
erfolgten 50 prozentigen Reduktion der Vollzeitbeschäftigten hat sich das Unternehmen nun perfekt
positioniert, um möglichst schnell in die Profitzone zu gelangen. Ob die Rechnung wohl aufgeht?
I N F O B O X
WKN 883 496
US-Kürzel KOOL
Gewinn/Aktie 02e k.a.
www.thermogenesis.com
Bewertung ++++
Marktkap. 67,37 Mio. US-$
Akt. Kurs (13.08.2001) 2,18 US-$

[laloba]

@ murmeltier

Vielen Dank für den Bericht!!
Suche schon länger nach Infos!

Gruß auch an alle anderen.

l.

[roger11]

Hallo zusammen,

habe im Yahoo-KOOL-Board einen sehr interessanten Link bzgl. Cord Blood Banking gefunden. Unter " Future Developments " stehen Dinge, da kann einem schon anders werden. Im positiven Sinne.

http://www.nustem.com/

[RudiDutschke]

Guten Abend. Möchte mich mal kurz melden, auch ohne Neuigkeit. Sieht ja momentan recht hoffnungsvoll aus, was den Kurs unserer Aktie betrifft. Hoffe, dass die 2,35$ halten. Gestern zwei grössere Orders, zumindest für die Verhältnisse von Thermogenesis. 7500Stck. zu 2,4$, und 18000Stck. zu 2,42 ( Tageshöchstkurs ). So kann es weitergehen. Wünsche alles Investierten, und denen die es werden wollen noch einen schönen Abend, Grüsse Rudi

[FLOTSAM_AND_JETSAM_US]

Thursday September 6, 6:02 am Eastern Time


THERMOGENESIS CORP. Receives $2.6 Million Order From Aventis Bio-Services, Inc.

RANCHO CORDOVA, Calif.--(BUSINESS WIRE)--Sept. 6, 2001--THERMOGENESIS CORP. (Nasdaq:KOOL - news) announced that Aventis Bio-Services, Inc. (formerly Centeon Bio-Services, Inc.), one of the world`s largest fully integrated plasma collection companies, placed a $2.6 million order for thirty five (35) of THERMOGENESIS CORP.`s Plasma Freezers. The order includes certain services and other accessories, and is subject to an agreement between both parties. Aventis Bio-Services has now ordered more than 100 of THERMOGENESIS` Ultra Rapid Freezers for their global plasma collection centers and contracted with THERMOGENESIS exclusively for the service and maintenance of those units.

Dr. James Godsey, president and COO of THERMOGENESIS CORP., commented, ``We are pleased to see Aventis Bio-Services reward our efforts to continuously improve the quality of our freezer technology and post sales field support with an order of this magnitude. As THERMOGENESIS CORP. begins to move its biomaterials pipeline products into human clinical trials, it`s rewarding to see our original coreline products contributing significantly to strengthening our financials, especially our cashflow. On an historical basis, a $2.6 million order would have accounted for between 40 to 50% of our annual revenue trends. The MP2200 and MP1100 are THERMOGENESIS CORP.`s highest gross profit freezers, and an order quantity of 35 units will further improve our manufacturing efficiencies.``

About Aventis Bio-Services, Inc.

Aventis Bio-Services, Inc. is a wholly owned subsidiary of Aventis Behring L.L.C. Aventis Behring L.L.C. is a global leader in the plasma protein industry, providing a wide range of innovative, high quality therapies and unique support services to patients worldwide. Aventis Behring is dedicated to the research and development of proteins from human blood plasma and emerging technologies. For more information about Aventis Behring, visit its website at www.aventisbehring.com and for Aventis Bio-Services, www.aventisbioservices.com

[RudiDutschke]

Guten Tag, schön, dass mal jemand schneller war als ich. Grüsse Rudi

[fritzchenI]

bin kein English-Experte-Kann jemand übersetzen bitte

[fritzchenI]

Kaufen? was denkt ihr

[fritzchenI]

wer verkauft den jetzt so stark?

[murmeltier]

Hallo,

ich finde, daß sich KOOL in der momentanen fast schon panischen Phase sehr gut hält.

Wenn ich nur mehr über die Fundamentals von KOOl wüßte, wäre ich wahrscheinlich schon längst an Bord. Wie siehts z. B. mit den flüssigen Mitteln, wie mit den erwirtschafteten Umsätzen und evtl. eingetroffenen Prognosen aus?


Ein schönes Wochenende schonmal und viel Glück

Murmeltier

[fritzchenI]

die untere Meldung ist doch super murmeltier

[RudiDutschke]

Guten Tag, hier die Zahlen der letzten beide Jahre im Vergleich. Die Zahlen für das abgelaufene Geschäftsjahr müssten im Laufe des Monats bekanntgegeben werden.

http://www.thermogenesis.com/pressreleases/final_2000.html


Die Zahlen der ersten drei Viertel des Fiskaljahrs 2001 auf einen kurzen Blick:

1. Quartal: net loss $1.423.000 net revenues $ 801.000
2. Quartal: net loss $1,110,000 net revenues $1.729.000
3. Quartal: net loss $1.278.000 net revenues $2.033.000

Grüsse und schönen Tag noch, Rudi

[fritzchenI]

die aktie müsste doch nach dem auftrag von aventis
"ausnahmsweise nach oben" explodieren. Versteh ich nicht.
Profitierung evtl. auch durch den Anschlag und durch das
Amerikanische Sicherheitsdenken Stichwort"Blutbankarchivierung" oder lieg ich da falsch
Weis den hier niemand was konkretes
Ist nach meiner Ansicht kein Zockerwert,fundamental ist doch was vorhanden

[RudiDutschke]

Guten Tag, denke auch, dass die Aktie unter Wert notiert, aber es sind halt schlechte Zeiten. Mal die Jahreszahlen abwarten. Als Zockerwert ziemlich ungeeignet, da zu geringe Umsätze. Zum Glück, hält die 2$ Marke auf Schlusskursbasis. Denke, es ist das Beste abzuwarten. Wer Zeit hat, sollte eigentlich kaufen. Grüsse Rudi

[fritzchenI]

sieht alles andere als gut aus kursmässig-wann kommen den Zahlen

[fritzchenI]

seit langer Zeit starke Verkäufe in Amerika weiss da schon jemand mehr

[RudiDutschke]

ThermoGenesis Corp. CEO to Present at the UBS Warburg Global Life Sciences Conference

RANCHO CORDOVA, Calif., Sep 20, 2001 /PRNewswire via COMTEX/ -- ThermoGenesis
Corp. (Nasdaq: KOOL), a pioneer in the design, manufacture and distribution of
medical devices used to harvest biopharmaceutical products, today announced that
Chairman and Chief Executive Officer, Philip H. Coelho, will be presenting at
the UBS Warburg Global Life Sciences Conference on Thursday, October 11, 2001 at
4:20 p.m. at The Pierre Hotel in New York City.

Mr. Coelho will discuss the Company`s strategy to leverage the global network of
umbilical cord blood stem cell banks, which utilize the Company`s BioArchive(R)
System as their core enabling technology, into a broader technology position
within the emerging cell therapy industry. Mr. Coelho will also discuss the
status of the Company`s CryoSeal(R) Fibrin Sealant (FS) System, which recently
received approval for commercialization in Europe, a $100 MM fibrin sealant
market segment.


Der komplette Artikel unterhttp://quotes.freerealtime.com/rt/frt/N?symbol=KOOL&art=C200…

[fritzchenI]

und schon wieder ein griff ins Klo
wenn der Krs so weiter macht gibts die aktie in 3 Wochen nicht mehr der nasdaq hält sich dagegen blendend
Doch Zockeraktie

[fritzchenI]

rudi sieht so aus als wir die einzigen sind, die diesen Highflyer nach unten haben- was meinst du Übernahmekandidat
der Kurs wird systematisch von irgendeiner Seite gedrückt

[RudiDutschke]

Hallo fritzchenl, wir scheinen tatsächlich die einzigen, die diese super Performance mitmachen. Noch 20% zum ATL. Da ist es auch wenig tröstlich, dass es anderen Kursen ähnlich geht. Es grüsst ein etwas ratloser Rudi

[RudiDutschke]

hab vergessen zu erwähnen, dass heute knapp 7000 zu 1,5E verkauft wurden, obwohl Geld 1,65E in Berlin. Während ich das schreibe, zieht der Kurs in USA wieder etwas an.

[fritzchenI]

sag mal rudi
der aventis-auftrag könnte doch helfen
Wo liegt den der haken bei der aktie
Gruss

[fritzchenI]

hoffe das bald zahlen kommen und dem grauen ein ende macht

[RudiDutschke]

Guten Morgen, bald sind die Zahlen da:

THERMOGENESIS CORP. to Announce Fiscal Year-End 2001 Financial Results On September 27,
2001

RANCHO CORDOVA, Calif., Sep 24, 2001 /PRNewswire via COMTEX/ -- THERMOGENESIS
CORP. (Nasdaq: KOOL), a pioneer in the design, manufacture and distribution of
medical devices used to harvest biopharmaceutical products, will report results
for the fiscal year-ended June 30, 2001 before the open of the market on
Thursday, September 27, 2001.

Management will host a conference call Thursday, September 27th, after the close
of the market, at approximately 1:45 p.m. PDT to review year-end financial
results. The call can be accessed by dialing 800-633-8137 and giving the
conference name, "THERMOGENESIS." Philip Coelho, Chairman & Chief Executive
Officer, and James Godsey, Ph.D., President and Chief Operating Officer, will be
on-line to discuss the year-end results and other corporate events, followed by
a Q&A session. Participants are asked to call the assigned number approximately
10 minutes before the conference call begins. The conference call will also be
available over the Internet at http://www.thermogenesis.com in the Investor
section of the site or at http://www.mkr-group.com . A replay of the conference
call will also be available two hours after the call for the following two
business days by dialing 800-633-8284 and entering the following reservation
number: 19750273. Also, an instant replay of the conference call will be
available over the Internet at http://www.thermogenesis.com in the Investor
section of the site or by going to http://www.mkr-group.com .

About THERMOGENESIS CORP.

THERMOGENESIS CORP. has been a pioneer in designing and manufacturing medical
devices and sterile disposable bag sets to collect, cryopreserve and archive
single units of blood products such as stem cells from cord blood, blood plasma,
fibrin sealant and other related blood products. After extensive research and
development, two new technology platforms (the BioArchive(R) System and the
CryoSeal System) have evolved products that provide new bio-material products to
patients in need. For more information visit the company`s web site at
www.thermogenesis.com.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.

[RudiDutschke]

Guten Abend, nach dem heutigen Tag dürften die Zahlen wohl recht gut ausfallen. Hoffe, dass esdann nicht heisst: sell on good news.
@fritzchenl: doch nicht so schlecht, diese Performance mitzumachen. Ist halt ein volatiler Wert. Zurücklehnen und abwarten heisst wohl das Motto. Grüsse Rudi

[RudiDutschke]

Hallo zusammen, die Zahlen sind da.

Thermogenesis Corp. Announces Fiscal Year 2001 ResultsRevenues Increase 38% Over Prior
Year - Company to Begin U.S. Clinical Trials For New Product Line

RANCHO CORDOVA, Calif., Sep 27, 2001 /PRNewswire via COMTEX/ -- THERMOGENESIS
CORP. (Nasdaq: KOOL) today announced financial results for the year ended June
30, 2001. The highlights include: net revenues for the year ended June 30, 2001
increased 38% to $5,792,000, compared to $4,211,000 for fiscal 2000. The Company
also improved its cost of revenues, which decreased from the prior fiscal year
to 87% of revenues. The Company`s net loss from operations of $4,891,000
represented a $963,000 improvement from the prior year amount of $5,854,000.

Philip Coelho, the Company`s Chief Executive Officer, commented, "We made
significant progress during fiscal 2001. We significantly improved our operating
results over the prior year by increasing our focus on sales. I am confident
that fiscal 2002 will show a substantial increase in revenues. We also
strengthened the Company`s balance sheet during the year ending with a record
working capital amount of $7 million which positions the Company to initiate and
conclude human clinical trials for our CryoSeal Fibrin Sealant ("FS") product
for use in the United States."

The Company reported a net loss of $6,153,000, which includes the cumulative
effect of accounting change under SAB 101 of $282,000, this compared to a
$5,818,000 net loss for the year ended June 30, 2000. After including the
preferred stock discount and dividends and cumulative effect of accounting
change under EITF 00-27, net loss to common stockholders was $6,833,000 or $0.25
basic and diluted per share, which compared to $6,723,000 or $0.30 basic and
diluted per share for the prior year.

The increase in revenues was primarily a result of increases in sales of the
BioArchive and ThermoLine (plasma freezers and thawers) products. BioArchive
revenues increased 44% over the prior year due to resources and marketing
efforts implemented in fiscal year 2000. Additionally, the Company has $220,000
in deferred revenue representing the gross margins of BioArchive systems, which
have been shipped but not yet installed.

Mr. Coelho continued, "Our strong results demonstrate the continuing improvement
to overall operations, cash management for clinical trials, and emphasis on
sales revenue that will bring us to profitability. With the European market
launch of the CryoSeal FS System, and FDA approval to initiate U.S. clinical
trials expected this fiscal year, we remain very optimistic about the future of
the company."

Increased sales and focused cost control enabled the Company to generate
$780,000 of gross margin, 87% of revenues. The Company had a small gross margin
loss in the prior year. Dr. James H. Godsey, the Company`s Chief Operating
Officer, commented, "In addition to the improved revenue growth we experienced,
we also continue to focus on operating efficiencies to improve our cost of
revenues and emphasize sales of our higher margin products."

Interest expense increased approximately $1,000,000 due to the debt financing
which occurred in December 2000. The amortization of the warrants and the
beneficial conversion feature, which are non-cash charges, accounted for
$1,013,000 of interest expense. The entire debt, which generated this interest
expense, has been paid back as of June 30, 2001. General and administrative
expenses decreased $232,000 due to personnel reductions, which occurred during
the prior fiscal year, and the Company has elected not to replace the vacant
positions. Research and development expenses increased $158,000. The pre
clinical trials for the CryoSeal FS system accounted for approximately $55,000
of the increase. The additional increase is due to the addition of personnel
engaged in regulatory and quality system activities.

Dr. Godsey added, "A key component of the Company`s growth was put in place
during fiscal 2000, where we added sales and technical resources to the
BioArchive product line to assist customers in gaining government approvals to
establish Cord Blood Banks. This positioned us for growth in 2001 and the years
after. Our 36 BioArchive system placements in 28 umbilical cord blood stem cell
banks world wide will be able to archive 130,000 units of the world`s inventory
of umbilical cord blood stem cell specimens, whose value was significantly
enhanced by the President`s August 9th speech. We intend to leverage our
position in this key marketplace into a broader play in the newly emerging cell
therapy marketplace, which we believe will lead to rapid growth in revenues
going forward."

The foregoing discussion should be read in conjunction with the attached
condensed financial statements and the Company`s annual report on Form 10-K.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the Company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.

The Company will hold an analyst and market conference call to review and
discuss the results of operations for the year-end on Thursday, September 27,
2001 after the market closes. The call can be accessed by dialing 800-633-8137
and giving the conference name, "THERMOGENESIS." A taped playback of the
conference call will be available from September 27, 2001 @ 3:30 p.m. PDT to
October 5, 2001 @ 12:00 a.m. PDT. Access to the tape playback is available by
dialing 800-633-8284 and enter reservation no.: 19750273. Also, an instant
replay of the conference call will be available over the Internet at
http://www.thermogenesis.com in the Investor section of the site or by going to
http://www.mkr-group.com .


THERMOGENESIS CORP.
Condensed Balance Sheets

June 30, June 30,
2001 2000
ASSETS
Current assets:
Cash, cash equivalents and short
term investments $5,366,000 $2,550,000
Accounts receivable, net 1,369,000 627,000
Inventory 1,843,000 2,275,000
Other current assets 96,000 150,000

Total current assets 8,674,000 5,602,000

Equipment, net 811,000 1,080,000

Other assets 68,000 53,000

$9,553,000 $6,735,000

LIABILITIES AND SHAREHOLDERS` EQUITY

Current liabilities:
Accounts payable $709,000 $512,000
Other current liabilities 867,000 477,000

Total current liabilities 1,576,000 989,000

Long-term portion of capital lease
obligations 45,000 54,000

Shareholders` equity 7,932,000 5,692,000

$9,553,000 $6,735,000


THERMOGENESIS CORP.
Condensed Statements of Operations

Year Ended
June 30,
2001 2000

Net revenues $5,792,000 $4,211,000

Cost of revenues 5,012,000 4,246,000

Gross profit (loss) 780,000 (35,000)

Expenses:
General and administrative 1,860,000 2,092,000

Selling and service 2,029,000 2,103,000

Research and development 1,782,000 1,624,000

Total operating expenses 5,671,000 rred stock dividend or
discount (100,000) (905,000)

Cumulative effect of accounting
change under
EITF 00-27 (580,000) 0

Net loss to common stockholders ($6,833,000) ($6,723,000)

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X30112376

SOURCE Thermogenesis Corp


CONTACT: Renee M. Ruecker, V.P. Finance of THERMOGENESIS CORP.,
[phone], or [e-mail]; or Charles Messman,
[phone], or [e-mail], or Todd Kehrli, [phone],
or [e-mail], both of MKR Group, for THERMOGENESIS CORP.

URL: http://www.thermogenesis.com
http://www.prnewswire.com

[fritzchenI]

War das alles Rudi was meinst du
Gruss

[RudiDutschke]

ThermoGenesis Corp. Announces Order for Fifth BioArchive(R) System From The New York
Blood CenterClinical Success of Placental Cord Blood Stem Cell Transplants Drives Need
For Expanded Inventory

RANCHO CORDOVA, Calif., Oct 10, 2001 /PRNewswire via COMTEX/ -- ThermoGenesis
Corp. (Nasdaq: KOOL) today announced the receipt of an order for a fifth
BioArchive System from the New York Blood Center ("NYBC"), which is collecting
an inventory of 50,000 ethnically diverse Placental Cord Blood ("PCB") units to
better serve patients who suffer from diseases such as leukemia, lymphomas,
diverse inherited anemia and hypoproliferative stem cell disorders.

"We are very pleased with the additional order from the NYBC for our BioArchive
System," said Philip Coelho, CEO of ThermoGenesis Corp. "This additional order
again shows the growing need and necessity for our BioArchive Systems in cord
blood banks worldwide. Dr. Pablo Rubinstein of NYBC recently provided clinical
outcome data for 1,100 transplants to the U.S. Food & Drug Administration
("FDA") for their review. The data confirmed that better Human Leukocyte Antigen
("HLA") matching of PCB units to the patient will significantly improve the
patient outcome driving the need for an expanded inventory of PCB units."

The BioArchive System is used to process, cryopreserve and archive up to 3,626
blood and blood component units. BioArchive Systems have also been chosen by the
major cord blood banks in Japan, China, Taiwan, Vietnam, So. Korea, Malaysia,
Germany, Spain, Finland, U.K., Belgium, France, Mexico, India, and Israel as
well as in the U.S.A. pursuant to Investigational New Drug ("IND") regulations.
The BioArchive System is the international choice for processing and archiving
cryopreserved blood and blood components.

Mr. Coelho added, "With the recent bio-ethical issues raised regarding embryonic
stem cell research, cord blood may provide a source of stem cells for tissue
regeneration without the ethical issues involved with embryos or fetuses. We
believe our BioArchive Systems position us well in the growing cell therapy
market."

[fritzchenI]

danke Rudi für die News- so wies aussieht bringt uns auch diese Meldung nichts, es sieht eher danach aus das der Kurs langsam aber stetig gegen Null läuft sogar bei steigender Nasdaq. Ist die Aktie zu uninterresant was meinst du

[fritzchenI]

Lebst du noch Rudi spiele mit dem Gedanken wieder auzusteigen, die Biotechralley hab ich verpasst bei Kool
läuft nichts mehr

[fritzchenI]

Bin ich der letzte hier

[fritzchenI]

huhu, ich bin der letzte

[RudiDutschke]

Guten Tag, mit Verspätung:


Korean Cord Blood Stem Cell Bank Orders BioArchive(R) SystemCell & Tissue Bank
Becomes Second Cord Blood Stem Cell Bank in Korea And Fourteenth in Asia to Adopt the
BioArchive System

RANCHO CORDOVA, Calif., Oct 25, 2001 /PRNewswire via COMTEX/ -- ThermoGenesis
Corp. (Nasdaq: KOOL) today announced it has received an order for its BioArchive
System from JR Global Inc., one of the Company`s agents in Seoul, Korea which is
being placed at C.T.B. (Cell & Tissue Bank) in Seoul. This will be the second
BioArchive System chosen by a placental/cord blood ("PCB") stem cell bank in
Korea, joining Medipost which is located in Kyungki-do. The BioArchive System is
enabling technology for cell therapy: the use of living cells to cure human
disease.

In the Asia region, our BioArchive Systems have been deployed in Japan, China,
Taiwan, Vietnam, South Korea, Malaysia and India. Throughout North America,
BioArchive Systems have been deployed at the New York Blood Center, Duke
University Medical Center, San Diego Blood Bank, NuStem Technologies, Inc.,
Coriell Institute for Medical Research pursuant to Investigational New Device
("IND") regulations, and the National Transfusion Service Cord Blood Bank in
Mexico. In Europe, BioArchive Systems have been placed at the major Cord Blood
Stem Cell Banks in Germany, United Kingdom, France, Spain, Belgium, and Finland.
The Company estimates that more than 70% of the cord blood stem cell transplants
performed to date are from Cord Blood Banks that are now using the BioArchive
System.

Dr. James Godsey, President and COO of ThermoGenesis Corp. commented, "C.T.B. is
an important addition to our global network of cord blood banks. This order
again demonstrates our continued success in implementing our strategic plan of
installing a worldwide base of BioArchive Systems. From this extensive installed
base we derive additional disposable product revenue, and equipment revenue as
customers continue to grow their PCB cell therapy programs. As most of these
programs are government funded, this puts us in an additional favorable position
of securing new customers, due to the desire for standardization in the
industry."

Philip Coelho, Chairman and CEO of ThermoGenesis Corp. said, "We are very
pleased with the additional implementation of our BioArchive system in Korea.
Recent research has shown that there are stem cells in a unit of cord blood that
have the potential to produce other cells outside the hematopoietic system such
as neural, liver and bone cells. This holds the promise of an ever growing
demand for stem cells and regenerative medicine therapies which may be served by
our growing base of installations."

The BioArchive System uses ThermoGenesis Corp.`s proprietary computer-driven
liquid nitrogen robotic system to store and archive up to 3,626 units of blood
and blood components that have been collected, processed and cryopreserved in
proprietary sterile plastic bag sets. The BioArchive System performs robotic
insertion and retrieval of each unique barcode identified unit. The BioArchive
System operates to freeze, place and retrieve samples without exposing other
archived samples to the Transient Warming Events (TWEs).

Regulatory Status

The BioArchive System is a Class II blood and blood component freezer exempt
from the pre-market notification procedures. The BioArchive System has potential
applications involving archiving, storing, managing and retrieving other kinds
of biological specimens, that may include stem cells, dendritic cells, T-cells,
cell lines, male sperm cells, female eggs, heart valves, corneas, virus samples,
biopsy samples and other blood, tissue and saliva samples. The BioArchive System
is currently intended for preservation of blood and blood components. Additional
indications for use would require U.S. FDA clearance or approval.

About JR Global

JR Global, based in Seoul, Korea, and its affiliated businesses develop markets
and sell medical, biotech, and pharmaceutical products to the Korean and
international healthcare markets.

About ThermoGenesis Corp.

ThermoGenesis Corp. has been a pioneer in designing and manufacturing medical
devices, and designing sterile disposable bag sets to collect, cryopreserve and
archive blood products such as stem cells from cord blood, blood plasma, fibrin
sealant and other related blood products. After extensive research and
development, two new technology platforms (the BioArchive System and the
CryoSeal(R) System) have evolved products which provide new bio-material
products to patients in need.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.


MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X56666414

SOURCE ThermoGenesis Corp.


CONTACT: James H. Godsey, Ph.D. of ThermoGenesis Corp., [phone],
or [e-mail]; or Charles Messman, [phone], or
[e-mail], or Todd Kehrli, [phone], or
[e-mail], both of MKR Group, for ThermoGenesis Corp.

URL: http://www.thermogenesis.com
http://www.prnewswire.com

[RudiDutschke]

news von heute:

ThermoGenesis Corp. and Kourion Therapeutics GmbH Announce Strategic Collaboration for Fast
Track Development of Stem Cell ProductsCollaboration to Expedite Cell Therapy Products
Compliant With FDA`s Good Tissue Practice (cGTP) Regulations

RANCHO CORDOVA, Calif., Oct 26, 2001 /PRNewswire via COMTEX/ -- ThermoGenesis
Corp. (Nasdaq: KOOL), and Kourion Therapeutics GmbH ("Kourion") announced today
that they will collaborate on two new development projects to address future
therapeutic cell treatments for such diseases as: Parkinson`s, Diabetes,
Alzheimer and Strokes.

The first project is focused on the development of sterile disposable processing
sets and cryopreservation protocols to provide cryopreserved therapeutic doses
of cell populations, which will be derived from Kourion`s proprietary
unrestricted somatic stem cells ("USSC") that are isolated from placental/
umbilical cord blood ("PCB").

The second project will be the development of sterile disposable delivery
devices, which may use ThermoGenesis Corp.`s CryoSeal(R) autologous surgical
sealant as a biological carrier for transplants of USSC cell populations at
orthopedic wound sites.

Philip Coelho, Chairman & CEO of ThermoGenesis Corp., said, "Based on early
analysis, we consider the tissue regeneration cell populations derived from
Kourion`s USSC to be the most promising in the world today. We look forward to
assisting Kourion in the development of processing, cryopreservation, and
delivery systems to assure their final product cell populations are compliant
with the FDA`s cGTP regulations. We are excited about working with Kourion to
bring their Cell Therapy products to market."

Ernst Boehnlein, Ph.D., CEO of Kourion, said, "This is a very important
strategic relationship in the evolution of our company. ThermoGenesis Corp. is
by far the leader in the processing and cryopreservation of cord blood products.
Finding a partner with this technical expertise will tremendously accelerate the
development of Kourion`s cell therapy product lines. We believe that the
engineering skills available at ThermoGenesis Corp. will also help us design our
ready to use and easy to apply cell therapeutics tailored for the broad range of
indications from Parkinson`s disease to complicated bone fractures."

CryoSeal Regulatory Status

In March of 2001, the CryoSeal FS System received CE Mark approval from the
European Union Competent Authorities to initiate commercialization of the
CryoSeal FS System in Europe. In May 2001, the CryoSeal FS System received a
license to market in Canada. The CryoSeal System is patent-protected, and will
require a pre-market approval by the U.S. FDA before marketing in the U.S. The
Company submitted its IDE to the FDA in August 2001 requesting approval to begin
human clinical trials with the CryoSeal FS System.

BioArchive(R) Regulatory Status

The BioArchive System is a Class II blood and blood component freezer exempt
from the pre-market notification procedures. The BioArchive System has potential
applications involving archiving, storing, managing and retrieving other kinds
of biological specimens, that may include stem cells, dendritic cells, T-cells,
cell lines, sperm cells, female eggs, heart valves, corneas, virus samples,
biopsy samples and other blood, tissue and saliva samples. The BioArchive System
is currently intended for preservation of blood and blood components. Additional
indications for use would require U.S. FDA clearance or approval.

About Kourion Therapeutics GmbH

Kourion Therapeutics GmbH`s R&D pipeline is based on proprietary multi-lineage
potential (unrestricted), neonatal somatic stem cells isolated from placental
cord blood (unrestricted somatic stem cell; USSC). The Company has established
isolation and expansion technologies for these proprietary neonatal somatic stem
cells and ex vivo induction protocols to differentiate USSCs into cells of the
hematopoietic and neural lineages. The Company can also demonstrate
differentiation of USSCs into osteoblasts, chondrocytes, endothelial, smooth
muscle, and oval cells (liver-pancreas progenitors) in vitro. The Company
operates a GMP facility to develop its cell therapeutics. Kourion also develops
scale-up technologies for ex-vivo expansion and selective induction of relevant
cell types for drug screening assays including gene expression analyses. The
Company is supporting two Phase I clinical trials at the Heinrich-Heine Medical
Center, Duesseldorf.

[RudiDutschke]

THERMOGENESIS CORP. to Announce Fiscal 2002 First Quarter Financial Results On November
13, 2001

RANCHO CORDOVA, Calif., Nov 5, 2001 /PRNewswire via COMTEX/ -- THERMOGENESIS
CORP. (Nasdaq: KOOL), a pioneer in the design, manufacture and distribution of
medical devices used to produce bioptherapeutic products, will report results
for the fiscal 2002 first quarter-ended September 30, 2001 on Tuesday, November
13, 2001.

Management will host a conference call Tuesday, November 13th, after the close
of the market, at approximately 1:45 p.m. PST to review first quarter financial
results. The call can be accessed by dialing 800-340-5808 and giving the
conference name, "THERMOGENESIS." Philip Coelho, Chairman & Chief Executive
Officer, and James Godsey, Ph.D., President and Chief Operating Officer, will be
on-line to discuss the first quarter results and other corporate events,
followed by a Q&A session. Participants are asked to call the assigned number
approximately 10 minutes before the conference call begins. The conference call
will also be available over the Internet at http://www.thermogenesis.com in the
Investor section of the site or at http://www.mkr-group.com . A replay of the
conference call will also be available two hours after the call for the
following two business days by dialing 800-633-8284 and entering the following
reservation number: 19966818. Also, an instant replay of the conference call
will be available over the Internet at http://www.thermogenesis.com in the
Investor section of the site or by going to http://www.mkr-group.com .

[fritzchenI]

Da verschrotten die amerikaner die gespendeten Blutkonserven, anstatt auf Tehrmogenesis- Kühlzellen zurückzugreifen- einfach zum Mäusemelken

[RudiDutschke]

Hallo fritzchenI, hätte dem Kurs sicherlich gutgetan. Rechne allesdings vor den Zahlen noch mit steigenden Kursen, bevor es dann wieder zu Gewinnmitnahmen kommt. Grüsse Rudi

[RudiDutschke]

Hallo, heute 2 Meldungen. Hier erstmal eine:

ThermoGenesis Corp. Announces Order for BioArchive System From the Alternativas
Hematologicas (CALHESA)Becomes Second Cord Blood Stem Cell Bank in Mexico and Seventh In
North America to Adopt the BioArchive(R) System

RANCHO CORDOVA, Calif., Nov 13, 2001 /PRNewswire via COMTEX/ -- ThermoGenesis
Corp. (Nasdaq: KOOL) today announced it has received an order for its BioArchive
System from Alternativas Hematologicas (CALHESA), a private company based in
Mexico City, Mexico. Their objective is to supply cord blood units for
transplant to private hospitals throughout Mexico. This will be the second
BioArchive System chosen by a placental/cord blood ("PCB") stem cell bank in
Mexico, joining Centro Nacional de la Transfusion Sanguinea Blood Bank, which is
also located in Mexico City. The BioArchive System is enabling technology for
cell therapy: the use of living cells to cure human disease. In North America,
BioArchive Systems have been deployed at the New York Blood Center, Duke
University Medical Center, San Diego Blood Bank, NuStem Technologies, Inc.,
Coriell Institute for Medical Research pursuant to Investigational New Device
("IND") regulations, and the National Transfusion Service Cord Blood Bank in
Mexico. In Europe, BioArchive Systems have been placed at the major Cord Blood
Stem Cell Banks in Germany, United Kingdom, France, Spain, Belgium, and Finland.
In the Asia region, our BioArchive Systems have been deployed in Japan, China,
Taiwan, Vietnam, South Korea, Malaysia and India. The Company estimates that
more than 70% of the cord blood stem cell transplants performed to date are from
Cord Blood Banks that are now using the BioArchive System.

Dr. James Godsey, President and COO of ThermoGenesis Corp. commented, "CALHESA
is an important addition to our global network of cord blood banks. This order
again demonstrates our continued success in implementing our strategic plan of
installing a worldwide base of BioArchive Systems. The total stem cell unit
capacity of the current installed base exceeds 130,000. From this extensive
installed base we derive additional disposable product revenue, and equipment
revenue as customers continue to grow their PCB cell therapy programs. As most
of these programs are government funded, this puts us in an additional favorable
position of securing new customers, due to the desire for standardization in the
industry.

"Philip Coelho, Chairman and CEO of ThermoGenesis Corp. said, "We are very
pleased with the additional implementation of our BioArchive system in Mexico.
Recent research has shown that there are stem cells in a unit of cord blood that
have the potential to produce other cells outside the hematopoietic system such
as neural, liver and bone cells. This holds the promise of an ever growing
demand for stem cells and regenerative medicine therapies which may be served by
our growing base of installations."

The BioArchive System uses ThermoGenesis Corp.`s proprietary computer-driven
liquid nitrogen robotic system to store and archive up to 3,626 units of blood
and blood components that have been collected, processed and cryopreserved in
proprietary sterile plastic bag sets. The BioArchive System performs robotic
insertion and retrieval of each unique barcode identified unit. The BioArchive
System operates to freeze, place and retrieve samples without exposing other
archived samples to the Transient Warming Events (TWEs).

[RudiDutschke]

ThermoGenesis Corp. Announces First Quarter ResultsRevenues Increase 76% Over Prior Year -
Backlog of $3 Million at Quarter End

RANCHO CORDOVA, Calif., Nov 13, 2001 /PRNewswire via COMTEX/ -- ThermoGenesis
Corp. (Nasdaq: KOOL) today announced results for its first quarter of fiscal
2002. Net revenues for the quarter ended September 30, 2001 increased 76% to
$1,517,000, which compared to $864,000 for the first quarter of fiscal 2001. The
Company also improved its cost of revenues significantly, to 84% of revenues,
down from the prior year`s fiscal first quarter of 106% of revenues.

The increase in BioArchive installations plus disposables sold to existing
customers accounted for $550,000 of the increase in revenues for the quarter.
Three BioArchive installations were completed versus one in the first quarter of
fiscal 2001. The increase in number of installations provides evidence that the
additional sales resources working the BioArchive product line are effectively
moving BioArchive customers through the sales prospect pipeline.

The Company reported a net loss of $1,413,000 or $0.04 for the quarter ended
September 30, 2001, as compared to a net loss of $1,631,000, which includes the
cumulative effect of accounting change under SAB 101 of $282,000, for the prior
year`s first quarter.

The Company had a backlog at September 30, 2001 of $3,079,000. One order that
includes 30 MP2200 and 4 MP1100 freezers left to ship accounted for
approximately $2.5 million of the backlog. The Company anticipates completing
this order in the current fiscal year.

"I am pleased with the first quarter results and the progress the Company
continues to make with our strategic initiatives," said Phil Coelho, Chairman
and CEO of ThermoGenesis. "We continued to expand our BioArchive installations
around the world where we now have 28 PCB stem cell banks using our product. We
also signed a strategic agreement with Kourion Therapeutics GmbH (`Kourion`) to
collaborate on two new development projects addressing future therapeutic cell
treatments."

Mr. Coelho concluded, "Looking forward, our pipeline for our BioArchive Systems
remains very strong and we are pleased with the reception the CryoSeal FS
marketing effort is having in Europe."

The Company will hold an analyst and market conference call to review and
discuss the results of operations on Tuesday, November 13, 2001 at 1:45 PST.
Interested investors can listen to the conference call by dialing 800-340-5808.
Additionally, a taped playback of the conference call will be available for the
following two business days. Access to the tape playback is available by dialing
800-633-8284; Reference 19966818. Also, an instant replay of the conference call
will be available over the Internet at http://www.thermogenesis.com in the
Investor section of the site or by going to http://www.mkr-group.com .

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the Company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.


THERMOGENESIS CORP.
Condensed Balance Sheets
(Unaudited)

September 30, June 30,
2001 2001
ASSETS
Current assets:
Cash, cash equivalents and short
term investments $4,347,000 $5,366,000
Accounts receivable, net 703,000 1,369,000
Inventory 2,700,000 1,843,000
Other current assets 295,000 96,000

Total current assets 8,045,000 8,674,000

Equipment, net 745,000 811,000

Other assets 67,000 68,000

$8,857,000 $9,553,000

LIABILITIES AND SHAREHOLDERS` EQUITY

Current liabilities:
Accounts payable $899,000 $709,000
Other current liabilities 1,384,000 867,000

Total current liabilities 2,283,000 1,576,000

Long-term portion of capital lease
obligations 42,000 45,000

Shareholders` equity 6,532,000 7,932,000

$8,857,000 $9,553,000


THERMOGENESIS CORP.
Condensed Statements of Operations
(Unaudited)

Three Months Ended
30-Sep

Restated
2001 2000
Net revenues $1,517,000 $864,000

Cost of revenues 1,269,000 915,000

Gross profit (loss) 248,000 (51,000)

Expenses:
General and administrative 486,000 415,000

Selling and service 607,000 478,000

Research and development 601,000 435,000

Total operating expenses 1,694,000 1,328,000

Interest and other income/expenses 33,000 30,000

Net loss before cumulative effect of
accounting
change under SAB 101 (1,413,000) (1,349,000)

Cumulative effect of accounting
change under
SAB 101 0 (282,000)

Net loss ($1,413,000) ($1,631,000)

Per share data:
Net loss before preferred stock
dividend ($1,413,000) ($1,631,000)

Preferred stock dividend 0 (50,000)

Net loss to common stockholders ($1,413,000) ($1,681,000)


MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X148818

[fritzchenI]

Wenn ich doch nur besser English könnte, das ist ein Akt

[RudiDutschke]

Hallo FritzchenI, stimmt, ist etwas mühselig. Probier doch einfach mal ein Übersetzungsprogramm, z.B. bei http://www.web.de
Ist zwar etwas zerstückelt, aber immerhin. Grüsse Rudi

[fritzchenI]

Rudi bemerkenswert ist das es zu Thermogenesis überhaupt keine analystenkommentare gibt- das kann man jetzt positiv oder negativ sehen, na ja bei meim glück an der börse wohl
zweiteres
Gruss
Schön das es 2 Koól-Aktionäre in Deutschland gibt

[RudiDutschke]

Hallo FritzchenI, habe mal auf einer Seite Analysen über KOOL gefunden, waren allerdings kostenpflichtig. Bin momentan leicht im Stress, so dass ich nicht genau weiss, wann ich dazu komme sie zu suchen. Das mit dem Glück an der Börse ist so eine Sache. Aber lass dich nicht verrückt machen, hier im Board hat natürlich keiner im letzten Jahr Verluste gemacht, und alle posten hier nur noch, weil sie noch nicht wissen, wohin mit all ihrem Geld. Falls du noch in KOOL investiert bist, lass sie einfach liegen, und schau sie dir in einigen Jahren wieder an. Ist halt schwer mit der Aktie kurzfristig was zu machen, weil Umsätze bei uns zu niedrig, und in den USA sehr volatil. Runter mit meistens kleinen Stückzahlen, rauf unter Höheren Umsätzen. Also, liegenlassen und warten, wird bestimmt was. Versuche evtl. am Sonntag mal die Seite mit den Analysen zu finden, bis dahin lass es dir guz gehn, Grüsse Rudi

[fritzchenI]

Rudi eine analyse über aktiencheck.de kenn ich
Kaufen von Biotech-World vom August 2001
Gruss

[fritzchenI]

Sieht so aus als KOOL ausbluten soll,kann jemand ein Interesse daran haben?

[RudiDutschke]

äusserst miserable Kursentwicklung, kann mir auch keine Reim drauf machen.
Hier mal eine Seite mit Informationen über KOOL:
http://www.biospace.com/company_profile.cfm?CompanyID=2783
Grüsse

[fritzchenI]

und wieder 6% minus, das schon wochenlang spätestens
2002 Pennystock die Aktie ist der absolute Griff ins Klo

[RudiDutschke]

hallo, gestern 1cent im plus geschlossen, bei über 50000 gehandelten shares. da dürfte wohl heute oder morgen eine melgung kommen. und dann weiter richtung keller? grüsse

[Don Speculazio]

Chance auf Doppelboden + auf dem Gebiet Stammzellen tätig= MEGA Chance
KOOL wird sicher noch seinen weg machen
H.

[RudiDutschke]

gehe auch davon aus, dass sie ihren Weg macht. Liegenlassen, wer sie hat, kaufen, wer sie nicht hat. Grüsse

[fritzchenI]

Worin liegt der sinn eine aktie liegen zu lassen
wenn der Kurs jeden Tag steil nach unten geht
versteh euch nicht

[fritzchenI]

und wieder 5% minus, kontinuität pur
immer abwechelnd 5-6% minus am nächsten tag +- o dann wieder
5-6%Minus und das jetzt schon seit Monaten- sollte dies so weitergehen ist der Kurs mitte 2002 bei 0

[fritzchenI]

Was denkt ihr ab wann ist die Aktie Pennystock

[fritzchenI]

Hab ich was verpennt erstes Mal seit Monaten das Thermog
steigt gibts was neues

[fritzchenI]

30% plus mit starken Umsätzen weiss jemand was

[v2a]

Thermogenesis Gets FDA OK For CryoSeal Human Trials

RANCHO CORDOVA, Calif. -(Dow Jones)- ThermoGenesis Corp. (KOOL) received Investigational Device Exemption approval from the Food and Drug Administration to begin a pivotal human clinical trial in the U.S for the CryoSeal FS System.

In a press release Friday, the company said the human trials are expected to take a minimum of 10 months to complete.

The results of pre-clinical trials demonstrated the CryoSeal Fibrin Sealant`s ability to control bleeding of a resectioned pig liver in less than four minutes.

Rapid control of bleeding leads to minimal use of transfusion blood products, which are currently in short supply in the U.S. due to a significant shortage in the availability of acceptable blood donors.

The CryoSeal system is approved for sale in Europe.

ThermoGenesis hired Quintiles Inc. to monitor the trials.

Shares of ThermoGenesis recently traded at $1.95, up 40 cents or 25.8%, on heavy Nasdaq Small Cap volume of 394,900 shares, well above the average daily volume of 30,286 shares.

-Carrie Kocik, Dow Jones Newswires; 201-938-5388

(This story was originally published by Dow Jones Newswires)


Copyright (c) 2001 Dow Jones & Company, Inc.
All Rights Reserved



mfg
v2a

[RudiDutschke]

Hallo zusammen, mit guten Nachrichten im Rücken melde ich mich zurück. Insgesamt drei news. Die erste hier:
ThermoGenesis Corp. Receives Notice of Allowance of Second Patent For Autologous
Thrombin Kit Autologous Thrombin, an Alternative to Bovine Thrombin in $40 Million Market

RANCHO CORDOVA, Calif., Dec 19, 2001 /PRNewswire via COMTEX/ -- ThermoGenesis
Corp. (Nasdaq: KOOL) announced today that it has received notice from the U.S.
Patent Office of the allowance of 116 patent claims for the second patent on a
small handheld disposable device that produces approximately 8.5 ml of activated
thrombin from 10 ml of patient plasma in less than one hour. The Thrombin
Activation Device ("TAD") is expected to be available for sale in Europe in the
second quarter of 2002.

Dr. James Godsey, President & COO of ThermoGenesis Corp., said the Company hopes
to provide a safer thrombin to surgeons who use it to control surgical bleeding.
Currently, the only thrombin available to most surgeons worldwide is sourced
from bovine blood, which recent medical reports have identified as a significant
health risk to patients.

"Immunologic impact and clinical outcomes after surgical exposure to bovine
thrombin"
http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_u
ids=11141230&dopt=Abstract

"Risk and clinical significance of developing antibodies induced by topical
thrombin preparations"
http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_u
ids=9786349&dopt=Abstract

"Exposure of mice to topical bovine thrombin induces systemic autoimmunity"
http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_u
ids=11696457&dopt=Abstract

Dr. Godsey noted that these clinical studies report an initial exposure to
bovine thrombin sets up an increased risk of adverse bleeding or autoimmune
event in patients exposed again in a subsequent medical procedure. The increase
in risk is significant both in the severity of the potential event and in the
percentage of patients who developed the seropositive response to the bovine
proteins. Unless the patients become fully aware of the "at risk" condition,
which they will likely incur upon a first exposure, they would not be able to
alert another physician who may be intending to also use bovine thrombin in a
later medical procedure on that patient.

Dr. Godsey further noted that earlier this year, the Japanese government
announced a ban on drugs containing bovine materials from 28 countries over
fears that "mad cow disease" would be transmitted to patients -- indicating that
the market acceptance of an autologous thrombin might be positive.

Regulatory Status

In March of 2001, the CryoSeal(R) FS System received CE Mark approval from the
European Union Competent Authorities to initiate commercialization of the
CryoSeal FS System, which utilizes the TAD System to provide thrombin for the
CryoSeal fibrin sealant product. The CryoSeal FS System and TAD are not
available in the United States. It will require a pre-market approval by the
U.S. FDA before marketing in the U.S. The TAD is currently being prepared for CE
Mark approval for commercialization in the European community.

[RudiDutschke]

Die zweite hier:

ThermoGenesis Stops the Bleeding; Literally The company says the U.S. Patent
Office has allowed 116 patent claims for the second patent on a small handheld
disposable device that quickly transforms a vial of one`s own blood into the
blood-clotting ag

Vancouver, Dec 20, 2001 (smallcapcenter.com via COMTEX) -- ThermoGenesis Corp.
(NASDAQ: KOOL) has received notice from the U.S. Patent Office of the allowance
of 116 patent claims for the second patent on a small handheld disposable device
that quickly transforms a vial of one`s own blood into the blood-clotting agent
thrombin.

The system is designed to simplify the surgical process of stopping bleeding,
and promoting healing. Because the thrombin is autologous (you literally made it
yourself) it won`t cause any immune reaction, it will clot the bleeding . . .
and you won`t have a cow worrying about trans-species infections.

Surgeons, obviously, like to minimize blood loss during surgery. If an artery or
vein is the culprit, it`s fairly simple to put in a stitch or two. Stanching the
steady ooze from freshly exposed muscle or other dense tissue is another matter
entirely; capillaries are tiny and numerous. Until they clot and seal
themselves, the leak goes on.

For surgeons in such a situation, the slow remedy is to have someone stand
there, compress in hand, bearing down on the wound while the body`s own clotting
agents go to work. The quicker way is to slather on thrombin, Mother Nature`s
prime clotting agent, and watch it seal itself.

Enter modern medicine, literally on the back of a cow: bovine thrombin.
Manufactured from cows` blood, bovine thrombin is the only medical thrombin
available to surgeons worldwide. But although the supply of raw material is
almost limitless, the condensed blood-clotter comes with its own inherent
problems. . . . it`s made from cows` blood. The quick way hasn`t proven to be
entirely the best way.

Even if mad-cow disease didn`t exist, a number of recent clinical studies report
that exposure to bovine thrombin carries other immunological risks. Once the
foreign protein gets into one`s system, there is a risk you may become
unknowingly become allergic to it. Should you ever go under the knife again and
should the surgeon unwitting use bovine thrombin, the result could be most
unpleasant. Rather than clotting it as before, the bovine thrombin is rejected
and the wound bleeds anew . . . or worse. Luckless you might be hit with an
`auto-immune event` or if you`re really, really luckless, there`s a small chance
you might pick up a few prions. (Prions are `distorted` proteins that have been
linked to several neurodegenerative diseases including mad-cow`s disease and the
human equivalent, Creutzfeldt-Jakob disease.)

ThermoGenesis avoids the problem, the prions and the fears via its Thrombin
Activation Device. The TAD produces approximately 8.5 ml of activated thrombin
from 10 ml of patient plasma in less than one hour. TADs should be available for
sale in Europe (a.k.a the epicenter of the mad cows) in Q2 of 2002.

Pointing to a number of recent medical reports which underline the possible risk
of using bovine thrombin, ThermoGenesis President and COO Dr. James Godsey
helpfully adds that the risk and severity of a bovine thrombin reaction
increases upon subsequent use. Unless a patient is fully aware of the "at risk"
condition incurred upon a first exposure to the thrombin, said patient would not
be able to alert another physician who may be intending to also use the stuff in
a later medical procedure on that patient.

Meanwhile, over in Europe, in March of 2001 the company`s CryoSeal(R) FS System
received CE Mark approval from the European Union Competent Authorities to
initiate commercialization. (The CryoSeal FS System utilizes the TAD System to
provide thrombin for the CryoSeal fibrin sealant product.). In May of that same
year, the Canadian government gave the device a similar nod.

Although the CryoSeal FS System and TAD are not yet available in the United
States, ThermoGenesis believes that the announcement from the U.S. Patent Office
has helped strengthen its proprietary hold on TAD as it nears possible approval
in the very large U.S. marketplace. On August 16, 2001, ThermoGenesis filed an
Investigational Device Exemption (IDE) with the FDA requiring permission to
begin human clinical trials.

Dr. Godsey further noted that earlier this year, the Japanese government went
through the lists and banned drugs containing bovine materials from 28 countries
over fears these drugs might transmit mad cow disease to Japanese patients. As
the good doctor put it, this move "indicates that the market acceptance of an
autologous thrombin might be positive."

But if so in the market, eventually, not quite yet on the Street.

At 10:30 a.m. ET, KOOL was down 1.86% or 3 cents to $1.58 on average volume of
6,700 shares as against the three-month daily average of 30,227 shares. Its
52-week range is $3.00 set on April 3, 2001 with the $1.45 low set on December
18, 2001. Its most-recent-quarter (mrq) per-share book value is $0.20.

Based in Rancho Cordova, California, ThermoGenesis Corp. designs, manufactures
and distributes medical devices and companion sterile single-use disposables
that its customers use to harvest and cryopreserve biomaterials from single
units of blood. These therapeutically valuable products include stem cells,
surgical sealants and growth factors. The company`s products can be broken down
into three general categories: stem cell; surgical sealants; and plasma freezers
and thawers. The CryoSeal Fibrin Sealant (FS) System produces and dispenses a
surgical sealant or glue; it received CE Mark approval in March of 2001 and
Canadian approval in May of 2001, thus allowing commercialization activities to
begin in each of these important markets. ThermoGenesis is currently undergoing
its European and Canadian market launches. The company`s BioArchive System is
utilized in 16 countries to process and cryopreserve cord blood stem cell units
for bone-marrow transplants.

For the three months ended September 30, 2001, ThermoGenesis revenues rose 76%
to $1.5 million. Net loss applicable to common shares and before accounting
change rose 1% to $1.4 million. Revenues reflect more installations of
BioArchive with losses associated with costs involved in the completion of the
CryoSeal FS pre-clinical trials.

There is no First Call covering analyst for ThermoGenesis Corporation. However,
Smallcapcenter.com`s advanced research department gave KOOL a signal stockscore
of 34 at 10:32 a.m. EDT on Thursday.

A company`s stockscore is an unbiased summary of numerous technical analysis
indicators like volume and momentum, which are combined to produce a value on a
scale of 1-100 with 100 being the highest level.


By David Leidl


Copyright 2001 Stockgroup.com, All rights reserved.

[RudiDutschke]

Hier die dritte, obwohl schon gepostet:

hermoGenesis Corp. (KOOL) Receives Approval From the FDA to Initiate Human Clinical Trials of
the CryoSeal(R) FS System

RANCHO CORDOVA, Calif., Dec 21, 2001 /PRNewswire via COMTEX/ -- ThermoGenesis
Corp. (Nasdaq: KOOL) announced it received Investigational Device Exemption
(IDE) approval from the Food and Drug Administration (FDA) for the CryoSeal FS
System to begin a pivotal human clinical trial in the United States. Based upon
independent market reports, the Company believes the U.S. fibrin sealant market
to be approximately $100 million annually and is expected to grow to $400
million over the next five years. The CryoSeal FS System was approved for sale
in Europe, where the annual sales of commercial fibrin sealants is believed to
be approximately $100 million per annum.

The human trials are expected to take a minimum of 10 months to complete. The
company has hired Quintiles Inc. to monitor the human clinical trials. Dr. James
Godsey, President and COO of ThermoGenesis Corp. commented, "The FDA`s approval
of the CryoSeal FS System`s IDE is a critical milestone in the Company`s
history, as it signals the transformation of ThermoGenesis Corp. into a late
stage biopharmaceutical company." The results of pre-clinical trials
demonstrated the ability of CryoSeal Fibrin Sealant to control bleeding of a
resectioned pig liver in less than four minutes. Rapid control of bleeding leads
to minimal use of transfusion blood products which are currently in short supply
in the U.S. due to a significant shortage in the availability of acceptable
blood donors.

The Company believes the CryoSeal FS System produces a "new generation" fibrin
sealant. The system prepares both components (cryoprecipitate and thrombin) of
fibrin sealant from a single unit of human plasma in about an hour. Once
prepared, the CryoSeal Fibrin Sealant may be frozen or used immediately. The use
of single units of the patient`s own plasma, rather than pools of plasma, such
as those used to manufacture commercially available fibrin sealants, which
combine 10,000 or more units of plasma, virtually eliminates the risk of
infectious disease transmission. Dr. Godsey went on to state, "We believe that
the production of fibrin sealant from a single unit of the patient`s own blood
offers both an attractive alternative to commercially available fibrin sealants,
and the first methodology to prepare a truly autologous fibrin sealant, that
will grow in demand as acceptable blood donors continue to dwindle in number."

In contrast to commercially available fibrin sealants, the CryoSeal technology
enables the CryoSeal FS System to prepare fibrin sealant free of animal proteins
such as bovine aprotinin or bovine thrombin. Bovine thrombin has recently been
documented as a cause of spontaneous bleeding episodes in patients undergoing
repeat therapy with this drug. Animal proteins are a potential source of viral
and prion contamination to blood products, the latter of which are resistant to
all forms of viral inactivation technology available to fractionators at this
time. With the threat of nvCJD continuing to mount in Europe and the
ever-increasing possibility of the spread of nvCJD and/or Mad Cow disease to the
U.S., the Company feels the CryoSeal Fibrin Sealant is a product which meets the
needs of the biological sealant marketplace of today and tomorrow.

The CryoSeal FS System also includes a proprietary FS Applicator System to apply
CryoSeal Fibrin Sealant to the wound site during surgery. The FS Applicator
System provides for metered or non-metered dosing of CryoSeal Fibrin Sealant to
the bleeding surface. Interchangeable spray tip and drop tip disposables that
provide essentially instantaneously clotting, were designed for applying
CryoSeal Fibrin Sealant to large surface areas with oozing bleeding such as
liver resection. The FS Applicator system is totally disposable, no ancillary
pneumatic devices are required to spray the fibrin sealant in the surgical
field.

The design of the CryoSeal FS System is based upon two of the Company`s recent
technological breakthroughs enabling real time processing of blood products,
including: (a) automated cryoprecipitate technology which prepares
fibrinogen-rich cryoprecipitate from plasma in as little as 51 minutes, as
compared to two to three days for standard blood center methodology; and (b)
thrombin activation technology which prepares activated human thrombin from a
small aliquot of the same human plasma.

Regulatory Status

In March of 2001, the CryoSeal FS System received CE Mark approval from the
European Union Competent Authorities to initiate commercialization of the
CryoSeal FS System in Europe. The CryoSeal System is patent-protected, and will
require a pre-market approval by the U.S. FDA before marketing in the U.S. In
May 2001, the CryoSeal FS System received a license to market in Canada.

[RudiDutschke]

Egal wohin der Kurs in den nächsten Wochen geht, fest steht, dass wenn es mit den Patenten und Zulassungen erfolgreich weitergeht, eine Marktkapitalisierung von 63Mio.$ bei einem Kurs von 2$ ein absoluter witz ist. Lest euch doch mal durch auf wieviel $ der Markt geschätzt wird, und die erwartete Steigerung in fünf Jahren. Das sollte was werden, zumal ich immer von einem Langzeitinvestment ausging. Allen noch einen schönen Abend, Rudi.

[fritzchenI]

Rudi wie begründest das sich für Kool bisher zumindest
absolut niemand interresiert
Gruss und schöne Weihnachten

[fritzchenI]

warum gibt es denn überhaupt keine Analysen dazu-
pennen die analytsen den völlig?

[Don Speculazio]

ohne neue Meldungen auf 2,41$ an Silvester!:O
entweder wird jetzt noch ne Nachricht dazu nachgelegt-oder die pennenden Analysten sind aufgewacht!?

Frohes Neues Jahr!
H.

[RudiDutschke]

ThermoGenesis Corp. Names Edward G. Cape, Ph.D. to Board of Directors Will Also
Serve One-Year Appointment as Executive Vice President Of Corporate Strategy

RANCHO CORDOVA, Calif., Jan 8, 2002 /PRNewswire via COMTEX/ -- ThermoGenesis
Corp. (Nasdaq: KOOL) today announced that Edward Cape, Ph.D., has joined the
Board of Directors of the Company. Cape is a Co-Founder and General Partner of
the Sapphire Group, a privately held firm engaging in investments and strategic
advisory services for companies in the bioactive device and bioimaging sectors.

In order to enhance his contributions to the Company at this critical stage in
its development, Cape will serve a one year term as Executive Vice President of
Corporate Strategy, reporting directly to the Company Chairman and CEO, Philip
Coelho. In this capacity he will be a major contributor in the development and
execution of an overall corporate strategy for the Company as it completes its
ongoing transition from a medical equipment company to a company with approved
products in the bioactive devices market and enabling technologies for the
emerging stem and immune cell therapy space.

Cape brings to ThermoGenesis more than 10 years of experience in bio- and
medical-technology spaces, covering financial, strategic, and scientific
perspectives:



-- Prior to forming the Sapphire Group, he was a Healthcare Investment

Banker for four years at UBS Warburg LLC, the largest and most active

Healthcare Group on Wall Street. During this time he focused his

activities on the Medical Technology and Biotechnology spaces and was

involved in numerous mergers, acquisitions and financings.

-- During the two years prior to UBS Warburg, Cape completed and published

strategic research on Managing Innovation and Disruptive Technologies

at the Harvard Business School, and developed White Papers on

Technology Diffusion in the Global Economics Department at Merrill

Lynch.

-- Prior to HBS, he was the founding director of the Cardiac Dynamics

Laboratory at the Children`s Hospital of Pittsburgh, an entity engaged

in research and consulting for companies including Baxter, Medtronic,

Acuson, ATL, and GE. During this five-year period he also held faculty

appointments in the Schools of Medicine and Engineering at the

University of Pittsburgh. Cape has published more than 40 articles in

peer-reviewed journals, seven textbook chapters, and over 100

conference abstracts. He has also served as an invited reviewer for

such publications as Circulation, the research journal of the American

Heart Association, and the Journal of the American College of

Cardiology.

Cape holds B.S. and Ph.D. degrees in engineering from the Georgia Institute of
Technology and an MBA from the Harvard Business School.

Regarding the appointment, ThermoGenesis CEO Philip Coelho commented, "We are
very excited to welcome Ted Cape to ThermoGenesis as he brings a wealth of
experience and knowledge in the biomedical technology sector, which he has
approached from diverse and multiple angles in his career to date. His current
interest in the convergence of traditional medical device technology and the
emerging bioactive technologies is particularly important during ThermoGenesis`
present stage of development."

About ThermoGenesis Corp.

After extensive research, ThermoGenesis Corp.`s newly introduced technology
platforms lead the world in their ability to produce bioactive products from
single units of blood. Cord blood banks are utilizing the Company`s
BioArchive(R) System as a critical enabling technology for the harvesting,
processing and cryogenic archiving of stem cells for transplant while its
CryoSeal(R) System is used to prepare hemostatic and adhesive surgical sealants
from patient blood in less than an hour. ThermoGenesis has been a leading
supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to
hospitals and blood banks since 1992.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.

[fritzchenI]

Rudi was meinst du eine Kursvervielfachung müsste eigentlich doch drin sein.
Wünsch dir ein Super neues Börsenjahr

[fritzchenI]

Warum gibt es den nahezu keine Analystenmeinungen zu diesem Wert- über jeden Schrott wird sonst diskutiert , hat jemand ne Erklärung für mich, die Aktie ist doch kein Langweiler

[Osker]

Hallo fritz. was willst du nur mit Analystenmeinungen.Diese Spinner empfehlen dir eine (Evotec)
im sommer 2000 beim kurs von 120 als strong buy mit kursziel 180.Die selben Grundschüler sagen nur ein Jahr später beim kurs von 15 Euro strong sell.Also halte dich bloß nicht an Analysten.Mit Kool machst du bestimmt nichts falsch-wenn das mit der S.zellenforschung richtig los geht wird Kool sich vervielfachen.Langfristig Denken und Geduld,Geduld.Gruß an alle hier im Board.

[fritzchenI]

ich muss dir recht geben 100Punkte
Gruss

[RudiDutschke]

Guten Abend, auch dir fritzchenl ein schönes neues Jahr, und natürlich auch Erfolg an der Börse. Schön, dass etwas Leben in diesen Thread kommt. Wie ich ja auch schon des öfteren geschrieben hab, sollte langfristig eine Menge drin sein. Kurzfristig aber immer wieder Schwankungen, da sehr geringes Handelsvolumen. Seit gestern auch wieder Rückläufig, hoffe, dass der Kurs hält, da es ja meistens unter hohen Umsätzen hoch, und dann unter geringen immer wieder ordentlich runter geht. Das mit den Analysten ist so eine Sache. Glaub ihnen nicht, wir haben ja gesehen, wo das hingeführt hat. Hab mal vor einigen Monaten eine Seite mit kostenpflichtigen Empfehlungen über Thermogenesis gefunden, weiss aber nicht mehr wo. Wenig Zeit momentan, evtl. nächste Woche. Schluss in USA 2,33$, denke damit können wir fürs erste leben. Allen Investierten, und denen, die es noch werden wollen einen schönen Abend. Grüsse Rudi

[fritzchenI]

Mensch Rudi du bist ja schon ne halbe Ewigkeit in diesem Wert-auf lange Sicht wars ne recht stabile Aktie ein echter
Blue-chip sozusagen like BASF und Konsorten
Aber verdient hast du auch noch nichts
Es sind wahrscheinlich Aktien zum Vererben-Viellcht freuen
sich deine URUrUrenkel einmal
Gruss

[Osker]

Hallo fritzchen,Bin auch schon längere zeit in KOOL investiert.bin mit gut 60% im plus,ich denke wir werden bis zum sommer noch die 3,50 sehen.also nachkaufen wenn der kurs kurzfristig unter 2Euro fällt.

[RudiDutschke]

ThermoGenesis Corp. Announces Order for BioArchive System From Shenzhen Cord
Blood Bank



Third Cord Blood Stem Cell Bank in China

And Fourteenth in Asia to Adopt the BioArchive(R) System

RANCHO CORDOVA, Calif., Jan. 14 /PRNewswire-FirstCall/ -- ThermoGenesis Corp.
(Nasdaq: KOOL) today announced it has received an order for a BioArchive System
from Shenzhen Cord Blood Bank ("SCBB") in China. SCBB plans to store 10,000
placental/cord blood ("PCB") samples over the next five years to be used in cell
therapy procedures. This will be the third BioArchive System chosen by a PCB
stem cell bank in China, joining Guangdong Hematopoietic Stem Cell Technology
Center and Tianjing Institute of Hematology and Hospital of Blood Diseases. The
BioArchive System is utilized as a critical enabling technology for the banks
production of their cell therapy products, used for the treatment of leukemias,
lymphomas, diverse inherited anemias, such as sickle cell anemia and
thalassemia, and other genetic diseases.

"We are very pleased with the additional implementation of our BioArchive System
in China. Recent research has shown that there are stem cells in a unit of cord
blood that have the potential to produce other cells outside the hematopoietic
system such as neural, liver and bone cells," said Philip Coelho, Chairman and
CEO of ThermoGenesis Corp. "This holds the promise of an ever growing demand for
stem cells and regenerative medicine therapies which may be served by our
growing base of BioArchive installations."

In the Asia region, our BioArchive Systems have been deployed in Japan, China,
Taiwan, Vietnam, South Korea, Malaysia and India. In North America, BioArchive
Systems have been deployed at the New York Blood Center, Duke University Medical
Center, San Diego Blood Bank, NuStem Technologies, Inc., Coriell Institute for
Medical Research pursuant to Investigational New Device ("IND") regulations, and
the National Transfusion Service Cord Blood Bank in Mexico. In Europe,
BioArchive Systems have been placed at the major Cord Blood Stem Cell Banks in
Germany, United Kingdom, France, Spain, Belgium, Finland, and Israel. The
Company estimates that more than 70% of the cord blood stem cell transplants
performed to date are from Cord Blood Banks that are now using the BioArchive
System.

Dr. James Godsey, President and COO of ThermoGenesis Corp. commented, "SCBB is
an important addition to our global network of cord blood banks. This order
again demonstrates our continued success in implementing our strategic plan of
installing a worldwide base of BioArchive Systems. The total stem cell unit
capacity of our current installed base exceeds 140,000. From this extensive
installed base we derive additional disposable product revenue, and equipment
revenue as customers continue to grow their PCB cell therapy programs. We feel
that we are in a favorable position for securing new customers as Cord Blood
Banks can use their government funding to purchase our BioArchive systems, and
because of their desire for standardization in the industry."

The BioArchive System uses ThermoGenesis Corp.`s proprietary computer-driven
liquid nitrogen robotic system to store and archive up to 3,626 units of blood
and blood components that have been collected, processed and cryopreserved in
proprietary sterile plastic bag sets. The BioArchive System performs robotic
insertion and retrieval of each unique barcode identified unit. The BioArchive
System operates to freeze, place and retrieve samples without exposing other
archived samples to the Transient Warming Events (TWEs). These placental/cord
blood samples can then be used in cell therapy procedures to treat diseases such
as leukemias, lymphomas, diverse inherited anemias, such as sickle cell anemia
and thalassemia, and other genetic diseases.

Regulatory Status

The BioArchive System is a Class II blood and blood component freezer exempt
from the pre-market notification procedures. The BioArchive System has potential
applications for processing, cryopreserving and archiving many kinds of
biological specimens, such as stem cells, dendritic cells, T-cells, cell lines,
male sperm cells, female eggs, heart valves, corneas, virus samples, biopsy
samples and other blood, tissue and saliva samples. The BioArchive System is
currently intended for preservation of blood and blood components. Additional
indications for use would require U.S. FDA clearance or approval.

About ThermoGenesis Corp.

After extensive research, ThermoGenesis Corp.`s newly introduced technology
platforms lead the world in their ability to produce bioactive products from
single units of blood. Cord blood banks are utilizing the Company`s BioArchive
System as a critical enabling technology for the harvesting, processing and
cryogenic archiving of stem cells for transplant, while its CryoSeal(R) System
is used to prepare hemostatic and adhesive surgical sealants from patient blood
in less than an hour. ThermoGenesis Corp. has been a leading supplier of
state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and
blood banks since 1992.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.

[RudiDutschke]

Guten Tag, denke, dass es nach einem Anstieg um 50% mal zu Gewinnmitnahmen kommen darf, mehr aber auch bitte nicht. In 2 Wochen wird im Bundestag über den Import embryonaler Stammzellen abgestimmt. Möglich, dass im Zuge von Diskussionen auch ein paar Unternehmensnamen fallen, die mit Stammzellen zu tun haben. Dies könnte KOOLs Bekanntheitsgrad etwas steigern. Schönen Tag noch, Rudi

[fritzchenI]

Rudi ich lese durch deine Postings pro Woche ca. 2 gute
Meldungen und dies wird im Kurs doch nicht berücksichtigt
den 50%Kursanstieg seh ich auch nicht, hab höher im spathsommer eingekauft- du meinst wohl kool ist zuvor um
50% ungerechtfertigter Weise gefallen ohne news
Gruss
Das einzige positive ist zuir Zeit das es im Herbst jetzt
eine schwarz-gelbe Regierung gibt, hoffe die 18% von
Möllemann werden mal erreicht
Das ist ja grausam an der Börse- ichs sehs schon kommen alle Zinssenkungen waren noch für die Katz

[fritzchenI]

Was drückt den diesen Kurs den so sieht so aus als kool unbedingt nach unten muss

[RudiDutschke]

ThermoGenesis Corp. and Interpore Cross Partner to Provide Revolutionary Autologous Thrombin
Preparation Device



Device to Address Thrombin Shortage Outside U.S.;

Thrombin a Key Ingredient in Interpore Cross` AGF(TM) Technology

IRVINE, Calif., and RANCHO CORDOVA, Calif., Jan. 17 /PRNewswire-FirstCall/ --
Interpore Cross International (Nasdaq: BONZ) and ThermoGenesis Corp. (Nasdaq:
KOOL) today jointly announced that ThermoGenesis has agreed to be an OEM
supplier to Interpore Cross of the Thrombin Activation Device ("TAD"), a
proprietary-patented handheld disposable device that produces 8.5 ml of
activated thrombin from patient plasma in less than one hour. Interpore Cross
will use the TAD to provide thrombin as part of its Autologous Growth
Factors(TM) (AGF(TM)) Technology, which derives from a patient`s blood a
cocktail of naturally occurring growth factors and proteins in high
concentrations to enhance the formation of new bone cells and promote healing at
bone graft sites. The TAD is expected to be available for sale in Europe in the
second quarter of 2002, subject to the receipt of CE Mark Certification by
Interpore Cross. ThermoGenesis already has received a CE Mark for the TAD as
part of its CryoSeal(R) Fibrin Sealant (FS) System, which is beginning human
clinical trials in the U.S. See prior release at:
http://www.mkr-group.com/thermogenesis/press_12_21_01.html

Thrombin is used in the AGF Technology to gel the fibrinogen-rich AGF
concentrate. In the U.S., bovine-derived thrombin is typically available from
the hospital supply. However, in many countries outside the U.S., especially in
Europe and Japan, it is generally not available. Interpore Cross` distribution
of the TAD, initially in Europe, will enable surgeons to prepare autologous
thrombin during AGF procedures, thereby addressing the lack of bovine-derived
thrombin.

David C. Mercer, Chairman and Chief Executive Officer of Interpore Cross, said,
"Our ability to address the thrombin shortage problem in Europe as a result of
this agreement is a breakthrough in our efforts to penetrate this market with
our AGF Technology. European surgeon interest in AGF has been very high, but we
have been generally unable to fulfill this demand because of the lack of
thrombin availability. We believe the use of the patient`s own thrombin in
concert with their own growth factors is very compelling, and is a solution that
will provide the greatest peace of mind to both patient and clinician. We`re
very excited about this opportunity to market a revolutionary product developed
by ThermoGenesis Corp., a leader in autologous blood technologies."

ThermoGenesis` TAD technology was developed initially as a component of its
CryoSeal System for the automated production of an autologous fibrin sealant
used to achieve hemostasis and tissue adhesion in surgical applications. The
activated thrombin produced by the device is an essential component of clotting
when mixed with concentrated clotting proteins also derived from a patient`s
plasma. This thrombin meets a compelling market demand in that it is derived
from the patient`s own blood and therefore addresses the thrombin issues
occurring in Europe. See prior release at:
http://www.mkr-group.com/thermogenesis/press_12_19_01.html

"Our ability to find additional alternative markets for our existing technology
will improve our over-all performance, and provide further validation of our
innovation in medical devices and applications," said Dr. James Godsey,
President & COO of ThermoGenesis Corp. "As the first disposable to produce
autologous human thrombin, the TAD will be a key component in Interpore`s
cutting edge technology."

Regulatory Status

In March of 2001, the CryoSeal FS System received CE Mark approval from the
European Union Competent Authorities to initiate commercialization of the
CryoSeal FS System, which utilizes the TAD technology to provide thrombin for
the production of CryoSeal Fibrin Sealant. The TAD is not available in the
United States. It will require a pre-market approval by the U.S. FDA before
marketing in the U.S. can commence. The TAD has received CE Mark approval as
part of ThermoGenesis` CryoSeal Fibrin Sealant (FS) System, and Interpore Cross
will seek its own CE Mark approval for commercialization of the TAD in the
European Community.

About Interpore Cross International

Interpore Cross International (www.interpore.com) is a medical device company
that designs, manufactures and markets spinal implant devices and orthobiologic
products on a worldwide basis. The spinal products are used to treat
degenerative conditions, deformities and trauma of the spine. The orthobiologic
products are used for bone and soft tissue repair in orthopedic and other
applications.

About ThermoGenesis Corp.

After extensive research, ThermoGenesis Corp.`s (www.thermogenesis.com) newly
introduced technology platforms lead the world in their ability to produce
bioactive products from single units of blood. Cord blood banks are utilizing
the Company`s BioArchive System as a critical enabling technology for the
harvesting, processing and cryogenic archiving of stem cells for transplant,
while its CryoSeal(R) System is used to prepare a hemostatic and adhesive
surgical sealant from patient blood in less than an hour. ThermoGenesis Corp.
has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma
Freezers and Thawers to hospitals and blood banks since 1992.

This news release contains forward-looking statements as that term is defined in
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements include but are not limited to statements that relate to both
Companies` timing of future product introductions, potential size of markets and
pricing assumptions, profitability and growth, demand for their products or
services, growth in the markets they serve or any other statements that relate
to the intent, belief, plans or expectations of the Companies or their
management teams, or that are not a statement of historical fact. Any
forward-looking statements in this news release are based on current
expectations and beliefs and are subject to numerous risks and uncertainties
that could cause actual results to differ materially. Other factors that could
cause the Companies` actual results to differ materially are discussed in the
Companies` recent filings with the Securities and Exchange Commission. The
Companies disclaim any obligation to update any forward-looking statements as a
result of developments occurring after the date of this press release.

[RudiDutschke]

Hallo, hier eine interessante Seite mit Berichten und Analysen über KOOL, einfach mal anklicken.


http://ecom.zacks.com/reports/store/store.php3?stage=result&…

[RudiDutschke]

Wer den Link im votigen Beitrag angeklickt hat, wird auch auf diese Seite hier gestossen sein. Ist recht interessant, da gibt es eigentlich jede Einzelheit zu Thermogenesis.

http://www.wsrn.com


Beim Suchbegriff einfach KOOL eingeben. Grüsse

[fritzchenI]

schon wieder runter- die Aktie will anscheinend nicht ausbrechen

[fritzchenI]

ich begreis einfach nicht

[Osker]

Hallo fritzchen. Bitte tu uns ein gefallen und hör mit dem ewigen jammern auf.Am besten du schaust dir diesen wert erst wieder in 6 Monaten an.Damit du wieder ruhig schlafen kannst.Kool ist ein Unternehmen mit unglaublichen Potenzial.Wenn die Geißel der Menscheit wie Parkinson oder Alzheimer geheilt werden sollen kommt man an Unternehmen wie KOOL auf keinen fall mehr vorbei. gruß Osker

[RudiDutschke]

Guten Tag, auch für diesen Thread einige neuere Informationen über die Aktionärsstruktur von Thermogenesis. 8,6% werden von institutionellen Anlegern gehalten, ca. 3% (958000) von 9 Insider Ownern.


8.6% of TSO
Held by 16 Institutions.

Total Shares Outstanding (in Millions): 32
Market Capitalization (in ): $73


Owner Name
Select a name below for more information.
Date
Shares Held
Change
(Shares)
% Change
(Shares)
Value
($1000)
EMERALD ADVISERS INC...
9/30/2001
568,500
70,700
14.20%
$1,308
KAUFMANN FUND INC
3/31/2001
556,400
0
0.00%
$1,280
FEDERATED INVESTORS ...
9/30/2001
556,400
0
0.00%
$1,280
PEQUOT CAPITAL MANAG...
9/30/2001
300,000
0
0.00%
$690
U S TRUST CORP /NY
9/30/2001
280,005
0
0.00%
$644
BARCLAYS GLOBAL INVE...
9/30/2001
100,284
0
0.00%
$231
GINTEL ASSET MANAGEM...
12/31/2001
100,000
0
0.00%
$230
COMMONWEALTH OF PENN...
9/30/2001
95,000
0
0.00%
$219
HSBC HOLDINGS PLC
9/30/2001
80,000
80,000
New
$184
NORTHERN TRUST CORP
9/30/2001
38,650
0
0.00%
$89
EDWARDS A G INC
9/30/2001
18,000
18,000
New
$41
WELLS FARGO BANK N A
3/31/2001
15,000
0
0.00%
$35
WELLS FARGO & CO/MN
9/30/2001
10,000
5,000
New
$23
CAPE ANN SAVINGS BAN...
12/31/2001
8,500
0
0.00%
$20
TAUNUS CORP
9/30/2001
3,850
1,567
68.64%
$9
MERRILL LYNCH & CO I...
9/30/2001
58
(4,942)
(98.84%)
$0

Schönen Tag noch, Rudi

[RudiDutschke]

Guten Tag, es gibt mal wieder News, und morgen dann auch die Quartalszahlen. Grüsse, und meldet euch doch mal wieder hier im Thread.

THERMOGENESIS CORP. Announces Order for BioArchive(R) System From Florida Blood
Services Florida Blood Services (FBS) Chooses BioArchive System For New Public Stem Cell
Bank

RANCHO CORDOVA, Calif., Feb 12, 2002 /PRNewswire-FirstCall via COMTEX/ --
THERMOGENESIS CORP. (Nasdaq: KOOL) today announced it has received an order for
a BioArchive System from Florida Blood Services (FBS) in Tampa, Florida. FBS has
provided private cord blood storage since 1996, however, it will install the
state-of-the art, high volume, BioArchive System for its public bank program,
scheduled to be launched later this year. This will be the fifth Cord Blood stem
cell bank in the US to have chosen the BioArchive System. The BioArchive System
is utilized as a critical enabling technology for the banks production of their
cell therapy products, used for the treatment of leukemias, lymphomas, diverse
inherited anemias, such as sickle cell anemia and thalassemia, and other genetic
diseases.

Dr. Buff Mair, FBS Associate Medical Director and head of the cord blood
program, said, "Our plans for cord blood are to continue our private storage
program, but also to develop a large, ethnically-diverse inventory of cord blood
that will be available to the public similar to the way the National Marrow
Donor Program operates. The FBS Foundation has launched a major fund raising
initiative, with some funds already received, to finance this new public cord
blood storage program."

"We are very pleased that FBS has chosen the BioArchive System for its new
public cord blood bank," said Philip Coelho, Chairman and CEO of THERMOGENESIS
CORP. "Recent research has shown that there are stem cells in a single unit of
cord blood that have the potential to produce neural, liver and bone cells for
use in tissue regeneration therapies. Our growing base of BioArchive
installations is helping to create an ethnically-diverse inventory of stem cells
for use in the rapidly expanding cell therapy market."

In North America, BioArchive Systems have been deployed at the New York Blood
Center, Duke University Medical Center, San Diego Blood Bank, NuStem
Technologies, Inc., Coriell Institute for Medical Research pursuant to
Investigational New Drug ("IND") regulations, and the National Transfusion
Service Cord Blood Bank and Altenativas Hematologicas in Mexico. In the Asia
region, our BioArchive Systems have been deployed in Japan, China, Taiwan,
Vietnam, South Korea, Malaysia and India. In Europe, BioArchive Systems have
been placed at the major Cord Blood Stem Cell Banks in Germany, United Kingdom,
France, Spain, Belgium, Finland, and Israel. The Company estimates that more
than 75% of the cord blood stem cell transplants performed worldwide to date are
from Cord Blood Banks that are now using the BioArchive System.

Dr. James Godsey, President and COO of THERMOGENESIS CORP. commented, "FBS is an
important addition to our global network of cord blood banks and not only
represents a new product sale for THERMOGENESIS, but also represents the
potential for additional disposable product revenue, and equipment revenue as
they and their customers continue to grow their PCB cell therapy programs."

The BioArchive System uses THERMOGENESIS CORP.`s proprietary computer- driven
liquid nitrogen robotic system to store and archive up to 3,626 units of blood
and blood components that have been collected, processed and cryopreserved in
proprietary sterile plastic bag sets. The BioArchive System performs robotic
insertion and retrieval of each unique barcode identified unit. The BioArchive
System operates to freeze, place and retrieve samples without exposing other
archived samples to the Transient Warming Events (TWEs).

Regulatory Status

The BioArchive System is a Class II blood and blood component freezer exempt
from the pre-market notification procedures. The BioArchive System has potential
applications for processing, cryopreserving and archiving many kinds of
biological specimens, such as stem cells, dendritic cells, T-cells, cell lines,
male sperm cells, female eggs, heart valves, corneas, virus samples, biopsy
samples and other blood, tissue and saliva samples. The BioArchive System is
currently intended for preservation of blood and blood components. Additional
indications for use would require U.S. FDA clearance or approval.

About THERMOGENESIS CORP.

After extensive research, THERMOGENESIS CORP.`s newly introduced technology
platforms lead the world in their ability to produce bioactive products from
single units of blood. Cord blood banks are utilizing the Company`s BioArchive
System as a critical enabling technology for the harvesting, processing and
cryogenic archiving of stem cells for transplant, while its CryoSeal(R) System
is used to prepare hemostatic and adhesive surgical sealants from patient blood
in less than an hour. THERMOGENESIS CORP. has been a leading supplier of
state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and
blood banks since 1992.

About Florida Blood Services Florida Blood Services, created in 1994 through the
merger of three community blood banks that had served individual Tampa Bay area
communities for nearly 50 years, is the fourth largest transfusion service in
the United States. In addition to serving as a blood center for 34 hospitals and
80 ambulatory care centers in the Tampa Bay area, FBS` laboratories provide
donor blood and confirmatory testing for 36 blood centers and medical facilities
along the East Coast of the U.S. and Puerto Rico.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.

[RudiDutschke]

Guten Abend, bisher gepflegte 6% im Plus in USA, allerdings könnte der Umsatz etwas höher sein. Hoffe, mein Optimismus ist nicht verfrüht, aber so kannes weitergehen. Grüsse Rudi

[RudiDutschke]

THERMOGENESIS CORP. Announces Second Quarter Results Revenues Increase 54% and Net
Loss to Common Stockholders Improves by 42% From Prior Year`s Fiscal Second Quarter

RANCHO CORDOVA, Calif., Feb 13, 2002 /PRNewswire-FirstCall via COMTEX/ --
THERMOGENESIS CORP. (Nasdaq: KOOL) today announced results for its second
quarter of fiscal year 2002, ended December 31, 2001. The Company reported net
revenues for the second quarter of $2,467,000, a 54% increase when compared to
$1,597,000 reported in the second quarter of last year. The Company reported a
net loss applicable to common stockholders of $955,000 or $0.03 per basic and
diluted share for the 2002 fiscal second quarter, down from $1,642,000 or $0.06
per basic and diluted share for the prior year`s comparable period. Gross profit
as a percentage of net revenues increased to 25% from 23% for the three months
ended December 31, 2001 as compared to the three months ended December 31, 2000.

For the six months ended December 31, 2001 the Company`s net revenues increased
a record 62% to $3,984,000, which compared to $2,461,000 for the first six
months of the prior year. The Company reported a net loss applicable to common
stockholders of $2,368,000 or $0.07 per basic and diluted share for the six
months ended December 31, 2001, down significantly from $3,323,000 or $0.13 per
basic and diluted share reported for the prior year`s comparable period. For the
six months ended December 31, 2001, gross profit as a percentage of net revenues
increased to 22% from 13% for the comparable period in the prior year.

"I am very pleased with the second quarter results and the progress the Company
continues to make with regards to its strategic initiatives," said Phil Coelho,
Chairman and CEO of THERMOGENESIS. "As we begin sales of our CryoSeal FS System
overseas and continue to see traction for our BioArchive Systems we are
projecting solid revenue growth for the remainder of the year."

"We have achieved five consecutive quarters of increased revenues from the
BioArchive product line," stated Dr. James Godsey, President and COO. "With 39
systems installed in 16 countries and the increase in BioArchive revenues, we
believe we have now achieved the market leader position in the public cord blood
banking industry." BioArchive revenues increased $725,000 or 307% and $1,276,000
or 311% for the three and six months ended December 31, 2001, when compared to
the prior year`s comparable period.

Mr. Coelho concluded, "Looking forward, the sales forecast for our BioArchive
Systems remains very strong and we are excited about the positive results we
have seen from the initial surgical procedures performed using the CryoSeal
Fibrin Sealant System in Europe. With these two product lines we look forward to
continued strong growth resulting in record revenues for this fiscal year."

Company Conference Call

Management will host a conference call today, February 13, 2002 at 1:45 pm PST
(4:45 pm EST) to review the fiscal second quarter financial results and other
corporate events, followed by a Q&A session. The call can be accessed by
dialing: [phone]. Participants are asked to call the assigned number
approximately 10 minutes before the conference call begins. The conference call
will also be available over the Internet at http://www.thermogenesis.com in the
Investor Relations area of the site. A replay of the conference call will be
available two hours after the call for the following two business days by
dialing: [phone] and entering the following passcode: 20298134. Also, an
instant replay of the conference call will be available over the Internet at
http://www.thermogenesis.com in the investor relations area of the site or by
going to http://www.mkr-group.com .

About THERMOGENESIS CORP.

After extensive research THERMOGENESIS CORP. ( www.thermogenesis.com ) newly
introduced technology platforms lead the world in their ability to produce
bioactive products from single units of blood. Cord blood banks are utilizing
the Company`s BioArchive System as a critical enabling technology for the
harvesting, processing and cryogenic archiving of stem cells for transplant,
while it`s CryoSeal(R) System is used to prepare a hemostatic adhesive surgical
sealant from patient blood in less than an hour. THERMOGENESIS CORP. has been a
leading supplier of state-of-the-art Ultra- Rapid Blood Plasma Freezers and
Thawers to hospitals and blood banks since 1992.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the Company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.



THERMOGENESIS CORP.

Condensed Statements of Operations

(Unaudited)



Three Months Ended Six Months Ended

December 31, December 31,

2001 2000 2001 2000

Restated Restated



Net revenues $2,467,000 $1,597,000 $3,984,000 $2,461,000



Cost of revenues 1,841,000 1,222,000 3,110,000 2,137,000



Gross profit 626,000 375,000 874,000 324,000



Expenses:



General and

administrative 644,000 440,000 1,130,000 855,000



Selling and service 512,000 533,000 1,119,000 1,011,000



Research and

development 455,000 435,000 1,056,000 870,000



Total expenses 1,611,000 1,408,000 3,305,000 2,736,000



Other income/

(expenses) 30,000 (6,000) 63,000 24,000



Net loss before

cumulative effect

of accounting change

under SAB 101 (955,000) (1,039,000) (2,368,000) (2,388,000)



Cumulative effect of

accounting change

under SAB 101 -- -- -- (282,000)



Net loss $(955,000) $(1,039,000) $(2,368,000) $(2,670,000)



Per share data:

Net loss before

preferred stock

dividend and

cumulative effect

of accounting

change under

EITF 00-27 $(955,000) $(1,039,000) $(2,368,000) $(2,670,000)



Preferred stock

dividend -- (23,000) -- (73,000)



Cumulative effect

of accounting change

under EITF 00-27 -- (580,000) -- (580,000)



Net loss to common

stockholders $(955,000) $(1,642,000) $(2,368,000) $(3,323,000)





THERMOGENESIS CORP.

Condensed Balance Sheets

(Unaudited)



December 31, June 30,

2001 2001

ASSETS

Current assets:

Cash, cash equivalents and short term

investments $2,251,000 $5,366,000

Accounts receivable, net 1,420,000 1,369,000

Inventory 3,092,000 1,843,000

Other current assets 223,000 96,000



Total current assets 6,986,000 8,674,000



Equipment, net 671,000 811,000



Other assets 67,000 68,000



$7,724,000 $9,553,000



LIABILITIES AND STOCKHOLDERS` EQUITY



Current liabilities:

Accounts payable $907,000 $709,000

Other current liabilities 1,201,000 867,000



Total current liabilities 2,108,000 1,576,000



Long-term portion of capital lease

obligations 39,000 45,000



Stockholders` equity 5,577,000 7,932,000



$7,724,000 $9,553,000

[RudiDutschke]

Hallo zusammen, nach einem ersten überfliegen der Zahlen muss ich sagen, dass alles im Lot ist, glücklicherweise. Wie schon mehrmals erwähnt, als Langfristanlage ist hier kaum etwas falsch zu machen. So gibt es zwei Passagen im Text, die einem das Herz höher schlagen lassen.

"We have achieved five consecutive quarters of increased revenues from the
BioArchive product line," stated Dr. James Godsey, President and COO. "With 39
systems installed in 16 countries and the increase in BioArchive revenues, we
believe we have now achieved the market leader position in the public cord blood
banking industry."

"Looking forward, the sales forecast for our BioArchive
Systems remains very strong and we are excited about the positive results we
have seen from the initial surgical procedures performed using the CryoSeal
Fibrin Sealant System in Europe. With these two product lines we look forward to
continued strong growth resulting in record revenues for this fiscal year."

[fritzchenI]

bei der Häufung von guten Meldungen des Unternehmens
ist der Kurs ein absoluter Witz

[RudiDutschke]

Hallo fritzchenl, auch noch dabei? Sieht doch recht passabel aus im Mioment. KOOL bewegt sich knapp unterhalb des52 Wochen Tiefs von 3$. Grüsse

[RudiDutschke]

Es gibt Neuigkeiten. Muss sie erstmal durcharbeiten, stelle sie dann rein.

[RudiDutschke]

Hier die Nachricht:


THERMOGENESIS CORP. Signs Strategic European Distribution Agreement For World`s First
Autologous or Single Donor Fibrin Sealant System Revolutionary Fibrin Sealant Addresses Mad
Cow Concerns; Dideco S.p.A. to Sell CryoSeal(R) Fibrin Sealant in Europe

RANCHO CORDOVA, Calif., Feb 28, 2002 /PRNewswire-FirstCall via COMTEX/ --
THERMOGENESIS CORP. (Nasdaq: KOOL) today announced that it has signed a
distribution agreement with Dideco S.p.A., a Snia Group company located in
Mirandola, Italy to begin immediate commercialization of its CryoSeal Fibrin
Sealant (FS) System in Europe, Eastern Europe, portions of Scandinavia and the
Middle East, and Africa. The new system radically reduces Mad Cow concerns by
providing a fibrin sealant sourced from either the patient`s own blood or from a
single donor without any bovine additive. The company believes the annualized
worldwide market for fibrin sealant is approximately $500 million, of which $100
million is consumed by Europe alone.

"This is another important step for THERMOGENESIS as we continue our move from a
late stage Research and Development company to a revenue generating company,"
said Phil Coelho, Chief Executive Officer and Chairman of THERMOGENESIS CORP.
"Dideco is a leading European supplier of surgical blood management devices,
disposables, and services whose very large and established customer base will be
targets for the CryoSeal FS systems." Dr. Godsey, COO of THERMOGENESIS noted,
"The company believes CryoSeal Fibrin Sealant will be welcomed by patients and
surgeons in Europe because conventional fibrin sealants are sourced from `pools`
of thousands of purchased units of plasma plus a bovine additive." THERMOGENESIS
initiated a Phase III clinical trial of the CryoSeal FS system this quarter in
the U.S.

According to Dr. Mario Garzella, President and CEO of Dideco S.p.A., "The
ability to provide a `second generation` autologous and single donor fibrin
sealant into the European marketplace, where announcements of the spread of mad
cow disease, vCJD, and other infectious pathogens throughout Europe have caused
great concern, will provide Dideco with a major product differentiation point
and thus an advantage when selling into our large customer base." As part of its
contract evaluation process, Dideco conducted human clinical studies on the
CryoSeal FS system over a 6-month period.

The European fibrin sealant market is a mature market comprised primarily of two
large competitors, Baxter`s Tissucol and Aventis` Beriplast, with Baxter
International possessing the larger market share. Both competitors utilize
traditional fractionation processing to manufacture a first generation fibrin
sealant sourced from "pooled" plasma purchased from thousands of individuals, to
which bovine aprotinin has been added. Dideco will promote THERMOGENESIS`
CryoSeal Fibrin Sealant for use in both the autologous (using the patient`s own
plasma) and the allogeneic (using single donor plasma) settings, emphasizing the
ease of use of the product, the increased safety due to the lack of bovine
substances (or any other non-human proteins), and the benefits of having
additional wound healing proteins present at the wound site.

About THERMOGENESIS CORP.

After extensive research, THERMOGENESIS CORP.`s newly introduced technology
platforms lead the world in their ability to produce biotherapeutic products
from single units of blood. Cord blood banks are utilizing the Company`s
BioArchive(R) System as a critical enabling technology for the harvesting,
processing and cryogenic archiving of hematopoietic stem cells for bone marrow
rescue transplants while its CryoSeal System is used to prepare hemostatic and
adhesive surgical sealants from patient blood in about an hour. THERMOGENESIS
CORP. has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma
Freezers and Thawers to hospitals and blood banks since 1992.

About Dideco S.p.A.

Dideco is a world leader in the design and production of oxygenators and
extracorporeal blood circulation systems, which provide life support during open
heart surgery, taking over the functions normally performed by the patient`s
heart and lungs. Dideco manufactures a complete line of high performance
products for the surgical blood processing for adults and children. In 1993,
Dideco became the first company in the world to introduce a neonatal oxygenator.
The company also produces equipment and sterile disposable processing sets for
the therapeutic treatment of blood, which are used for self-transfusion and
apheresis applications.

Regulatory Status

In March of 2001, the CryoSeal FS System received CE Mark approval from the
European Union Competent Authorities to initiate commercialization of the
CryoSeal FS System in Europe. The CryoSeal System is patent-protected, and will
require a pre-market approval by the U.S. FDA before marketing in the U.S. In
May 2001, the CryoSeal FS System received a license to market in Canada.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.

[RudiDutschke]

Hallo, der Vollständigkeit wegen. Platz 22 bei den meistdiskutierten Aktien. Wohl nur bis morgen, aber immerhin. Grüsse

[RudiDutschke]

Guten Morgen, stelle hier mal einige Charts rein.

3 Monate


1 Jahr


3 Jahre


5 Jahre

[fritzchenI]

scheiss Chartechnik-Bollingerbender lässt einen ausbruch nicht zu-jetzt müssen Hammernews kommen

[RudiDutschke]

Die 3$ werden wirklich schwer, zumindest sie zu halten, sollte es mal drüber gehen. Wünsche allen ein schönes WE, bin ziemlich geschafft, da ich heute wider Erwarten sehr viel Stress hatte. Bis wahrscheinlich Mo, Rudi

[fritzchenI]

Kool ist in 2 Monaten Pennystock, weiss jemand warum
so draufgeprügelt wird

[fritzchenI]

Berichtigung so wies aussieht in 1 Monat
aber irgendetwas lief wohl voll daneben

[RudiDutschke]

THERMOGENESIS CORP. Announces Order for BioArchive(R) System From the Sanquin
Bloodbank Southeast, Leiden, The Netherlands Chooses BioArchive System for Their Public Cord
Blood Stem Cell Bank

RANCHO CORDOVA, Calif., Mar 21, 2002 /PRNewswire-FirstCall via COMTEX/ --
THERMOGENESIS CORP. (Nasdaq: KOOL) today announced it has received an order for
a BioArchive System from the Sanquin Bloodbank Southeast located in Leiden, the
Netherlands. Sanquin is the foundation responsible for the blood supply in the
Netherlands and has two Cord Blood Banks (CBB) in its organization. The CBB in
Leiden was the first public Cord Blood Bank in the Netherlands. The BioArchive
System is utilized as a critical enabling technology for the banks production of
their cell therapy products, used for the treatment of leukemias, lymphomas,
diverse inherited anemias, such as sickle cell anemia and thalassemia, and other
genetic diseases. This will be the first BioArchive System placed in the
Netherlands. Their plans for cord blood are to store 600 units of cord stem cell
products annually with more than 70% of the volume stored at the Leiden CBB.

Dr. James Godsey, President and COO of THERMOGENESIS CORP. commented, "the
Sanquin Bloodbank Southeast is an important addition to our global network of
cord blood banks and not only represents a new product sale for THERMOGENESIS,
but also represents the potential for additional disposable product revenue, and
equipment revenue as they and their customers continue to grow their cord blood
cell therapy programs."

"We are very pleased that the Sanquin Bloodbank Southeast has chosen the
BioArchive System for its new public cord blood bank," said Philip Coelho,
Chairman and CEO of THERMOGENESIS CORP. "Recent research has shown that there
are stem cells in a single unit of cord blood that have the potential to produce
neural, liver and bone cells for use in tissue regeneration therapies. Our
growing base of BioArchive installations is helping to create an
ethnically-diverse inventory of stem cells for use in the rapidly expanding cell
therapy market."

In Europe, BioArchive Systems have been placed at the major Cord Blood Stem Cell
Banks in Germany, United Kingdom, France, Spain, Belgium, Finland, and Israel.
The Company estimates that more than 75% of the cord blood stem cell transplants
performed worldwide to date are from Cord Blood Banks that are now using the
BioArchive System. In North America, BioArchive Systems have been deployed at
the New York Blood Center, Duke University Medical Center, San Diego Blood Bank,
NuStem Technologies, Inc., Coriell Institute for Medical Research pursuant to
Investigational New Drug ("IND") regulations, and the National Transfusion
Service Cord Blood Bank and Altenativas Hematologicas in Mexico. In the Asia
region, our BioArchive Systems have been deployed in Japan, China, Taiwan,
Vietnam, South Korea, Malaysia and India.

The BioArchive System uses THERMOGENESIS CORP.`s proprietary computer-driven
liquid nitrogen robotic system to store and archive up to 3,626 units of blood
and blood components that have been collected, processed and cryopreserved in
proprietary sterile plastic bag sets. The BioArchive System performs robotic
insertion and retrieval of each unique barcode identified unit. The BioArchive
System operates to freeze, place and retrieve samples without exposing other
archived samples to the Transient Warming Events (TWEs).

Regulatory Status

The BioArchive System is a Class II blood and blood component freezer exempt
from the pre-market notification procedures. The BioArchive System has potential
applications for processing, cryopreserving and archiving many kinds of
biological specimens, such as stem cells, dendritic cells, T-cells, cell lines,
male sperm cells, female eggs, heart valves, corneas, virus samples, biopsy
samples and other blood, tissue and saliva samples. The BioArchive System is
currently intended for preservation of blood and blood components. Additional
indications for use would require U.S. FDA clearance or approval.

About THERMOGENESIS CORP.

After extensive research, THERMOGENESIS CORP.`s newly introduced technology
platforms lead the world in their ability to produce bioactive products from
single units of blood. Cord blood banks are utilizing the Company`s BioArchive
System as a critical enabling technology for the harvesting, processing and
cryogenic archiving of stem cells for transplant, while its CryoSeal(R) System
is used to prepare hemostatic and adhesive surgical sealants from patient blood
in about an hour. THERMOGENESIS CORP. has been a leading supplier of
state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and
blood banks since 1992.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.

[RudiDutschke]

ThermoGenesis Corp. Ships First CryoSeal Fibrin Sealant Systems To European, Scandinavian
and Asian Distributors The Company`s Distributors Initiate Market Launch Activities in Key Fibrin
Sealant Markets

RANCHO CORDOVA, Calif., Apr 3, 2002 /PRNewswire-FirstCall via COMTEX/ --
THERMOGENESIS CORP. (Nasdaq: KOOL) today announced it has initiated shipment of
the CryoSeal Fibrin Sealant (FS) System and its associated disposables to its
European, Scandinavian and Chinese distributors. These shipments provide the
first revenues for the CryoSeal FS System, which received CE Mark approval
earlier in 2001 and recently began a Phase III clinical trial in the United
States. The combined size of the European, Scandinavian and Asian Fibrin Sealant
market (outside of Japan) is estimated in excess of $150 MM annually.

Dr. Godsey, COO of ThermoGenesis noted that, "These first CryoSeal systems will
be used to train the respective sales organizations in each country and to
initiate routine use of the product with key influence leaders, as part of a
comprehensive market launch program." Dr. Godsey went on to comment, "With the
recent news that Mad Cow prions were discovered in the muscle tissue of mice,
there is now heightened concern that these prions may have infected the muscle
tissue of cows in addition to nervous system tissues and thus have avoided
detection. As a result, a number of key countries in the European and Asian
communities are aggressively reassessing the safety of their food and blood
supply. The CryoSeal Fibrin Sealant System radically reduces Mad Cow concerns by
providing a fibrin sealant sourced from single units of either the patient`s or
a single donor`s blood without the need for any bovine additive."

"These shipments represent another important milestone for ThermoGenesis as we
continue our move to profitability," said Phil Coelho, Chief Executive Officer
and Chairman of THERMOGENESIS CORP. "The European, Scandinavian and Asian fibrin
sealant markets have been studied extensively over the last nine months in order
to develop a market strategy which fits well with our customers, our
distributors and our own capabilities." Dr. Godsey, COO of ThermoGenesis noted,
"The company believes CryoSeal Fibrin Sealant will be welcomed by patients and
surgeons in Europe and Asia because the currently available commercial fibrin
sealants are comprised of `pools` of thousands of purchased units of plasma plus
a bovine additive."

ThermoGenesis` CryoSeal Fibrin Sealant is the first system to prepare both
components of fibrin sealant (thrombin and fibrinogen) from the patient`s own
plasma, or alternatively viral screened or viral inactivated, single donor
allogeneic plasma. Additionally, the distributor`s marketing plans will
emphasize the ease of use of the product in the operating room, the system`s
proprietary disposable fibrin sealant applicator system, the increased safety
due to the lack of bovine substances (or any other non-human proteins), and the
benefits of having additional wound healing proteins such as fibronectin,
present at the wound site.

Regulatory Status

In March of 2001, the CryoSeal FS System received CE Mark approval from the
European Union Competent Authorities to initiate commercialization of the
CryoSeal FS System in Europe. The CryoSeal System is patent-protected, and will
require a pre-market approval by the U.S. FDA before marketing in the U.S. In
May 2001, the CryoSeal FS System received a license to market in Canada.

[RudiDutschke]

THERMOGENESIS CORP. Announces $7 Million Financing Funds to Provide Additional Capital to
Support FDA Human Clinical Trials And Continued Growth in Europe, Asia and South America

RANCHO CORDOVA, Calif., Apr 5, 2002 /PRNewswire-FirstCall via COMTEX/ --
THERMOGENESIS CORP. (Nasdaq: KOOL) announced today that it has completed a $7
million private placement of equity to support the pivotal human clinical trial
in the United States of its CryoSeal(R) Fibrin Sealant ("FS") System and new
marketing initiatives for the CryoSeal(R) FS System in Europe, Asia and South
America. The funds will also be used to support the introduction of new
BioArchive(R) platform products into the cell therapy marketplace, and add
additional working capital for the company.

The transaction included both current and new institutional investors led by
Pequot Capital, Federated Kaufmann Fund, Clarion Capital and DMG Partners. Under
the terms of the financing, the investors purchased approximately 3,500,000
shares of common stock at $2.00 per share and also received warrants to purchase
an additional 723,362 shares of common stock at $3.07 per share. In April, the
Company expects to file a registration statement with the SEC covering the
common stock sold as well as the common stock issuable upon the exercise of the
warrants.

"I am pleased to announce the completion of this financing as it will enhance
the Company`s balance sheet and support our efforts to complete the Phase III
clinical trials of our CryoSeal FS System here in the United States, as well as,
enhance our market penetration efforts for the CryoSeal and BioArchive products
overseas," said Philip H. Coelho, ThermoGenesis Corp.`s Chief Executive Officer.
"We are especially pleased with the Company`s ability to raise capital
predominantly from institutional investors that have previously invested in
ThermoGenesis demonstrating again their continued confidence in our products and
management."

CryoSeal System

The CryoSeal(R) FS System produces, from single units of autologous or single
donor blood, "second generation" fibrin sealant kits for surgical hemostasis and
tissue adhesion. Furthermore, the FS System includes a complete line of
disposable applicators for applying this improved biological sealant in the
surgical field. In contrast to commercially available fibrin sealants, the
CryoSeal FS System prepares fibrin sealant free of animal proteins such as
bovine aprotinin or bovine thrombin. Bovine thrombin has recently been
documented as a cause of spontaneous bleeding episodes in patients undergoing
repeat therapy with this drug. Animal proteins are a potential source of viral
and prion contamination to blood products, the latter of which are resistant to
all forms of viral inactivation technology available to fractionators at this
time.

The European market launch of the CryoSeal FS System began with the appointment
of Dideco Sp.A. as distributor in March 2002. The worldwide fibrin sealant
market is estimated at $500 MM and is expected to grow to $800 MM over the next
3-5 years. In the U.S., the Company is initiating a 150 patient Phase III human
clinical trial to investigate the use of CryoSeal Fibrin Sealant to stop
bleeding in liver surgery.

BioArchive System

The BioArchive(R) System provides a number of important enabling technologies,
including cryopreservation, archiving, cell selection, and compatibility with ex
vivo expansion, that may potentially obtain broad, perhaps universal, usage by
cell therapy companies. The system includes: (1) sterile plastic disposable bag
sets for the collection, concentration, cryopreservation, and transfusion of
blood cells e.g. hematopoietic stem cells sourced from placental/umbilical cord
blood (PCB); and (2) robotic freezing, barcode scanning and archiving systems
which deliver optimal cell viability, barcode-determined inventory tracking, and
cGMP compliance to the end user, The BioArchive System has been adopted by the
major PCB banks in the United States, Europe and Asia, which account for ~70% of
all collections and processing of stem cells sourced from PCB for allogeneic
transplant. Additionally, the BioArchive System has potential applications for
processing, cryopreserving and archiving many kinds of biological specimens,
such as stem cells, dendritic cells, T-cells, cell lines, sperm cells, eggs,
heart valves, corneas, virus samples, biopsy samples and other blood, tissue and
saliva samples.

Regulatory Status

The CryoSeal System is patent protected, and will require a pre-market approval
by the U.S. Food & Drug Administration ("FDA") before marketing in the U.S. The
Company obtained the CE Mark of conformity for the CP-3 plasma processing
disposable and the FS Applicator System in calendar 2001, and is thus able to
initiate commercial activities in Europe. Until U.S. FDA approval, the CryoSeal
FS System, including FS applicator kits, will be marketed, as permitted under
U.S. Export Laws, applicable foreign regulations, in geographies including Latin
America, South America, Asian Pacific Rim, Australia and ROW. The Company
received Investigational Device Exemption ("IDE") approval from the U.S. FDA in
December 2001, permitting the CryoSeal FS System to begin its pivotal human
clinical trials in the United States. The initial pilot study of eight patients
is currently underway at the University of Miami.

The BioArchive System is a Class II blood and blood component freezer exempt
from the pre-market notification procedures. The BioArchive System is currently
intended for the cryopreservation of blood and blood components. Additional
indications for use would require U.S. FDA clearance or approval

About THERMOGENESIS CORP.

After extensive research, THERMOGENESIS CORP.`s newly introduced technology
platforms lead the world in their ability to produce bioactive products from
single units of blood. Umbilical cord blood banks are utilizing the Company`s
BioArchive System as a critical enabling technology for the harvesting,
processing and cryogenic archiving of stem cells for transplant, while its
CryoSeal(R) System is used to prepare hemostatic and adhesive surgical sealants
from patient blood in about an hour. THERMOGENESIS CORP. has been a leading
supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to
hospitals and blood banks since 1992.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.

[RudiDutschke]

THERMOGENESIS Announces Additional Order of BioArchive System Third Cord Blood Stem
Cell Bank in Korea and 15th in Asia to Adopt The BioArchive(R) System; JR Global Purchases
Their Second BioArchive System

RANCHO CORDOVA, Calif., Apr 29, 2002 /PRNewswire-FirstCall via COMTEX/ --
THERMOGENESIS CORP. (Nasdaq: KOOL) today announced it has received an order for
its BioArchive System from JR Global Inc., one of the Company`s agents in Seoul,
Korea. This will be the third BioArchive System chosen by a placental/cord blood
("PCB") stem cell bank in Korea. The BioArchive System is enabling technology
for cell therapy: the use of living cells to cure human disease.

In Asia, BioArchive Systems have been deployed in Japan, China, Taiwan, Vietnam,
South Korea, Malaysia and India. In North America, BioArchive Systems have been
deployed at the New York Blood Center, Duke University Medical Center, San Diego
Blood Bank, NuStem Technologies, Inc., Coriell Institute for Medical Research
pursuant to Investigational New Device ("IND") regulations, and the National
Transfusion Service Cord Blood Bank in Mexico. In Europe, BioArchive Systems
have been placed at the major Cord Blood Stem Cell Banks in Germany, United
Kingdom, France, Spain, Belgium, and Finland. The Company estimates that more
than 70% of the cord blood stem cell transplants performed to date are from Cord
Blood Banks that are now using the BioArchive System.

Dr. James Godsey, President and COO of THERMOGENESIS CORP. commented, "JR Global
`s follow-on purchase of our BioArchive System represents a new trend we are
seeing as large businesses move into the Cord Blood arena, expanding their
networks to multi-sites. This gives Thermogenesis a larger addressable market
with a streamlined and shortened sales process. This order again demonstrates
our continued success in implementing the strategic plan of installing a
worldwide base of BioArchive Systems. With this installed base, we derive
additional disposable product revenue and equipment revenue as customers grow
their PCB cell therapy programs."

Philip Coelho, Chairman and CEO of THERMOGENESIS CORP. said, "We are very
pleased with the additional implementation of our BioArchive system in Korea.
Recent research has shown that there are stem cells in a unit of cord blood that
have the potential to produce other cells outside the hematopoietic system such
as neural, liver and bone cells. This holds the promise of an ever growing
demand for stem cells and regenerative medicine therapies which may be served by
our growing base of installations."

The BioArchive System uses THERMOGENESIS CORP.`s proprietary computer- driven
liquid nitrogen robotic system to store and archive up to 3,626 units of blood
and blood components that have been collected, processed and cryopreserved in
proprietary sterile plastic bag sets. The BioArchive System performs robotic
insertion and retrieval of each unique barcode identified unit. The BioArchive
System operates to freeze, place and retrieve samples without exposing other
archived samples to the Transient Warming Events (TWEs).

Regulatory Status

The BioArchive System is a Class II blood and blood component freezer exempt
from the pre-market notification procedures. The BioArchive System has potential
applications involving archiving, storing, managing and retrieving other kinds
of biological specimens, that may include stem cells, dendritic cells, T-cells,
cell lines, sperm cells, eggs, heart valves, corneas, virus samples, biopsy
samples and other blood, tissue and saliva samples. The BioArchive System is
currently intended for storage of blood and blood components. Additional
indications for use would require U.S. FDA clearance or approval.

About JR Global

JR Global, based in Seoul, Korea, and its affiliated businesses develop markets
and sell medical, biotech, and pharmaceutical products to the Korean and
international healthcare markets.

[RudiDutschke]

THERMOGENESIS CORP. to Announce Fiscal Third Quarter Financial Results On May 13,
2002

RANCHO CORDOVA, Calif., May 6, 2002 /PRNewswire-FirstCall via COMTEX/ --
THERMOGENESIS CORP. (Nasdaq: KOOL), a pioneer in the design, manufacture and
distribution of medical devices used in the development and delivery of Cell
Therapy products, will report financial results for its fiscal third
quarter-ended March 31, 2002, after the close of market on Monday, May 13, 2002.

Management will host a conference call at approximately 1:45 p.m. PT to review
the fiscal third quarter financial results. The call can be accessed by dialing
[phone] and giving the conference name, "THERMOGENESIS." Philip Coelho,
Chairman & Chief Executive Officer, and James Godsey, Ph.D., President and Chief
Operating Officer, will be on-line to discuss the third quarter results and
other corporate events, followed by a Q&A session. Participants are asked to
call the assigned number approximately 10 minutes before the conference call
begins. The conference call will also be available over the Internet at
http://www.thermogenesis.com in the Investor section of the site or at
http://www.mkr-group.com . A replay of the conference call will also be
available two hours after the call for the following two business days by
dialing [phone] and entering the following reservation number: 20580996.
Also, an instant replay of the conference call will be available over the
Internet at http://www.thermogenesis.com in the Investor section of the site or
by going to http://www.mkr-group.com .

[RudiDutschke]

THERMOGENESIS Announces Sale of First BioArchive(R) System in Canada Stem
Sciences, Inc. Becomes First Cord Blood Stem Cell Bank in Canada With BioArchive
System

RANCHO CORDOVA, Calif., May 8, 2002 /PRNewswire-FirstCall via COMTEX/ --
THERMOGENESIS CORP. (Nasdaq: KOOL) today announced it has received an order for
its BioArchive System from Stem Sciences, Inc., a private cord blood bank
located in Toronto, Canada. The order represents the first BioArchive System
chosen by a cord blood stem cell bank in Canada. Stem Sciences cord blood bank,
under the direction of Dr. Lew Pliamm, chose the BioArchive System because it is
a critical enabling technology for cell therapy, which uses living cells to cure
human disease.

In North America, BioArchive Systems have been deployed at the New York Blood
Center, Duke University Medical Center, San Diego Blood Bank, NuStem
Technologies, Inc., Coriell Institute for Medical Research pursuant to
Investigational New Device ("IND") regulations, and the National Transfusion
Service Cord Blood Bank in Mexico. In Europe, BioArchive Systems have been
placed at the major Cord Blood Stem Cell Banks in Germany, United Kingdom,
France, Spain, Belgium, and Finland. In Asia, BioArchive Systems have been
deployed in Japan, China, Taiwan, Vietnam, South Korea, Malaysia and India. The
Company estimates that more than 70% of the cord blood stem cell transplants
performed to date are from Cord Blood Banks that are now using the BioArchive
System.

Dr. James Godsey, President and COO of THERMOGENESIS CORP. commented, "Stem
Sciences` purchase of our BioArchive System represents a significant milestone
for THERMOGENESIS, as it demonstrates that the Private Cord Blood banking sector
is beginning to choose the same state-of-the-art cell processing and
cryopreservation technology as the public cord blood banks who have preformed
the vast majority of cord blood stem cell transplants in the world to date."

"We are very pleased with this adoption of the BioArchive technology in Canada,"
said Philip Coelho, Chairman and CEO of THERMOGENESIS CORP. "The network of
BioArchive installations continues to expand around the world, giving us a large
customer base from which to derive additional disposable product and equipment
revenues. This placement further demonstrates the growing demand for stem cells
and regenerative medicine therapies around the world."

The BioArchive System uses THERMOGENESIS CORP.`s proprietary liquid nitrogen
robotic system to store and archive up to 3,626 units of blood and blood
components that have been collected, processed and cryopreserved in proprietary
sterile plastic bag sets. The BioArchive System performs robotic insertion and
retrieval of each unique barcode identified unit and operates to freeze, place
and retrieve samples without exposing other archived samples to the Transient
Warming Events (TWEs), which could damage cells.

Regulatory Status

The BioArchive System is a Class II blood and blood component freezer exempt
from the premarket notification procedures. The BioArchive System has potential
applications involving archiving, storing, managing and retrieving other kinds
of biological specimens, that may include stem cells, dendritic cells, T-cells,
cell lines, sperm cells, eggs, heart valves, corneas, virus samples, biopsy
samples and other blood, tissue and saliva samples. The BioArchive System is
currently intended for storage of blood and blood components. Additional
indications for use would require U.S. FDA clearance or approval.

About STEM SCIENCES INC.

Stem Sciences, Inc. is a Toronto based company that is dedicated to providing
its private banking customers the highest quality cord blood processing
available anywhere in the world.

[RudiDutschke]

THERMOGENESIS CORP. Announces Third Quarter Results Revenues Increase 61% and
Gross Profit Increases 148% From Prior Year`s Fiscal Third Quarter

RANCHO CORDOVA, Calif., May 13, 2002 /PRNewswire-FirstCall via COMTEX/ --
THERMOGENESIS CORP. (Nasdaq: KOOL), a pioneer in the design, manufacture and
distribution of medical devices used in the development and delivery of Cell
Therapy products, today announced results for its third quarter ended March 31,
2002. The Company reported a 61% increase in net revenues to a record $2,735,000
for the third quarter of 2002. This compared to $1,703,000 reported in the
fiscal third quarter of last year. The Company reported a net loss applicable to
common stockholders of $1,200,000 or $0.04 per basic and diluted share for the
2002 fiscal third quarter, down from $1,368,000 or $0.05 per basic and diluted
share for the prior year`s comparable period. Gross profit as a percentage of
net revenues increased to 23% from 15% for the three months ended March 31, 2002
as compared to the three months ended March 31, 2001. Gross profits for the
quarter increased 148% over the fiscal third quarter of 2001 due to increased
product sales. The Company ended the quarter with over $7 million in cash and
short-term investments and working capital of $10 million.

For the nine months ended March 31, 2002 the Company`s net revenues increased
61% to $6,720,000, which compared to $4,164,000 for the first nine months of the
prior year. The Company reported a net loss applicable to common stockholders of
$3,568,000 for the nine months ended March 31, 2002 down significantly from
$4,691,000 reported for the prior year`s comparable period. For the nine months
ended March 31, 2002, gross profit as a percentage of net revenues increased to
22% from 14% for the comparable period in the prior year.

"I am very pleased with the third quarter results and the overall progress the
Company continues to make with regards to its strategic initiatives," said Phil
Coelho, Chairman and CEO of ThermoGenesis. "During the quarter we signed a
strategic alliance with Dideco S.p.A, and as a result saw the first sales of our
CryoSeal FS System in Europe. Additionally, the Company initiated the pivotal
human clinical trials for the CryoSeal FS System in the United States. We have
already surpassed the revenues posted for the entire year of fiscal 2001 and
with the strong growth projected in the fourth quarter, we continue to
anticipate record revenues for this fiscal year."

"During the quarter we were pleased that we delivered approximately $1 million
in revenue to Aventis Bio-Services, Inc, in partial fulfillment of the September
2001 order," commented Dr. James Godsey, President and COO of ThermoGenesis,
"Our continued success with Aventis demonstrates the strong demand for our
freezer product line in the marketplace."

Dr. Godsey continued, "For the nine months ended March 31, 2002, our BioArchive
revenues have reached record levels having increased $1,245,000 or 122% when
compared to the prior year`s comparable period. With 41 systems installed in 16
countries, we believe ThermoGenesis is the market leader in the public cord
blood banking industry, and with our recent order from Stem Sciences, Inc. in
Canada, we have opened up a new market in the private cord blood banking
industry, further expanding our market leadership."

Company Conference Call

Management will host a conference call today, May 13, 2002 at 1:45 pm PDT (4:45
pm EDT) to review the fiscal third quarter financial results and other corporate
events, followed by a Q&A session. The call can be accessed by dialing: (800)
621-5346. Participants are asked to call the assigned number approximately 10
minutes before the conference call begins. The conference call will also be
available over the Internet at http://www.thermogenesis.com in the Investor
Relations area of the site. A replay of the conference call will be available
two hours after the call for the following two business days by dialing: (800)
633-8284 and entering the following passcode: 20580996. Also, an instant replay
of the conference call will be available over the Internet at
http://www.thermogenesis.com in the investor relations area of the site or by
going to http://www.mkr-group.com .

About ThermoGenesis Corp.

THERMOGENESIS CORP. has been a pioneer in designing and manufacturing medical
devices, and designing sterile disposable bag sets to collect, cryopreserve and
archive blood products such as stem cells from cord blood, blood plasma, fibrin
sealant and other related blood products for use in Cell Therapy. After
extensive research and development, two new technology platforms (the BioArchive
System and the CryoSeal(R) FS System) have evolved products, which provide new
bio-material products to patients in need.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the Company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.



THERMOGENESIS CORP.

Condensed Statements of Operations

(Unaudited)



Three Months Ended Nine Months Ended

March 31, March 31,

2002 2001 2002 2001

Restated Restated



Net revenues $2,735,000 $1,703,000 $6,720,000 $4,164,000



Cost of revenues 2,101,000 1,447,000 5,211,000 3,584,000



Gross profit 634,000 256,000 1,509,000 580,000



Expenses:



General and

administrative 683,000 464,000 1,813,000 1,319,000



Selling and service 501,000 487,000 1,620,000 1,498,000



Research and

development 652,000 476,000 1,708,000 1,346,000



Total expenses 1,836,000 1,427,000 5,141,000 4,163,000



Other income/

(expenses) 2,000 (178,000) 64,000 (154,000)



Net loss before

cumulative effect of

accounting change

under SAB 101 (1,200,000) (1,349,000) (3,568,000) (3,737,000)



Cumulative effect of

accounting change

under SAB 101 -- -- -- (282,000)



Net loss $(1,200,000) $(1,349,000) $(3,568,000) $(4,019,000)



Per share data:

Net loss before

preferred stock

dividend and

cumulative effect

of accounting

change under

EITF 00-27 $(1,200,000) $(1,349,000) $(3,568,000) $(4,019,000)



Preferred stock

dividend -- (19,000) -- (92,000)



Cumulative effect

of accounting change

under EITF 00-27 -- -- -- (580,000)



Net loss to common

stockholders $(1,200,000) $(1,368,000) $(3,568,000) $(4,691,000)







THERMOGENESIS CORP.

Condensed Balance Sheets

(Unaudited)



March 31, June 30,

2002 2001

ASSETS

Current assets:

Cash, cash equivalents and

short term investments $7,092,000 $5,366,000

Accounts receivable, net 2,285,000 1,369,000

Inventory 3,082,000 1,843,000

Other current assets 98,000 96,000



Total current assets 12,557,000 8,674,000



Equipment, net 604,000 811,000



Other assets 63,000 68,000



$13,224,000 $9,553,000



LIABILITIES AND STOCKHOLDERS` EQUITY



Current liabilities:

Accounts payable $1,055,000 $709,000

Other current liabilities 1,341,000 867,000



Total current liabilities 2,396,000 1,576,000



Long-term portion of capital lease

obligations 35,000 45,000



Stockholders` equity 10,793,000 7,932,000



$13,224,000 $9,553,000





MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X48353031

SOURCE THERMOGENESIS CORP.



CONTACT: Renee M. Ruecker, V.P. Finance of THERMOGENESIS CORP.,

[phone], [e-mail]; or Charles Messman,

[phone], [e-mail], or Todd Kehrli,

[phone], [e-mail], both of MKR Group, LLC, for

THERMOGENESIS CORP.



URL: http://www.mkr-group.com

http://www.thermogenesis.com

http://www.prnewswire.com

[RudiDutschke]

ThermoGenesis Corp. Announces Order for BioArchive(R) System
From Shanghai Red Cross Cord Blood Stem Cell Bank

Fourth Cord Blood Stem Cell Bank in China and Fifteenth in Asia
To Adopt the BioArchive System

RANCHO CORDOVA, Calif., June 10 /PRNewswire-FirstCall/ --
ThermoGenesis Corp. (NASDAQ:KOOL) today announced that it has shipped a
BioArchive System to the Shanghai Red Cross ("SRC") in China. This will be
the fourth BioArchive System chosen by a Cord Blood stem cell bank in China,
joining Guangdong Hematopoietic Stem Cell Technology Center, Tianjing
Institute of Hematology and Hospital of Blood Diseases, and Shenzhen Cord
Blood Bank. The BioArchive System is utilized as a critical enabling
technology for the production of cell therapy products used for the treatment
of leukemias, lymphomas, diverse inherited anemias, such as sickle cell anemia
and thalassemia, and other genetic diseases. The Company estimates that more
than 70% of the cord blood stem cell transplants performed to date have used
CB samples from Cord Blood Banks that are now using the BioArchive System to
process, cryopreserve, archive and transfuse their stem cell units.
Dr. Wu Kai, Director of the SRC Cord Blood Bank remarked, "SRC plans to
build an inventory of 50,000 cord blood ("CB") stem cell units to be used in
cell therapy procedures." One BioArchive System can process, cryopreserve and
archive up to 3,626 CB samples.
Philip Coelho, Chairman & CEO of ThermoGenesis Corp. remarked, "We are
very pleased with the additional implementation of our BioArchive System in
China. Recent research has shown that there are stem cells in a unit of
umbilical cord blood that have the potential to produce other cells such as
heart, neural, liver and bone cells. As a critical enabling technology we
believe the BioArchive system is advancing the promise of cell therapy and
regenerative medicine therapies by creating a worldwide inventory of CB stem
cell samples which can be used to treat a variety of lethal diseases."
In the Asia region, ThermoGenesis` BioArchive Systems have been deployed
in Japan, China, Taiwan, Vietnam, South Korea, Malaysia and India. In
North America, BioArchive Systems have been deployed at the New York Blood
Center, Duke University Medical Center, San Diego Blood Bank, NuStem
Technologies, Inc., Coriell Institute for Medical Research, Florida Blood
Services pursuant to Investigational New Device ("IND") regulations, the
National Transfusion Service Cord Blood Bank and Alternativas Hematologicas
(CALHESA) in Mexico, and the Stem Sciences in Canada. In Europe and the
Middle East, BioArchive Systems have been placed at the major Cord Blood Stem
Cell Banks in Germany, United Kingdom, France, Spain, Belgium, Finland,
Netherlands and Israel.
Dr. James Godsey, President and COO of ThermoGenesis Corp. commented,
"SRC is an important addition to our global network of cord blood banks and
increases the total stem cell unit capacity of our BioArchive customers to
over 170,000. From this extensive installed base we can derive additional
disposable product revenue, and equipment revenue as customers continue to
grow their CB cell therapy programs. We also believe that SRC`s adoption of
the BioArchive system further demonstrates the desire for standardization in
the industry as they become the 37th cord blood bank worldwide to adopt this
critical enabling technology."
The BioArchive System uses ThermoGenesis Corp.`s proprietary
computer-driven liquid nitrogen robotic system to store and archive up to
3,626 units of blood and blood components that have been collected, processed
and cryopreserved in proprietary sterile plastic bag sets. The
BioArchive System performs robotic insertion and retrieval of each unique
barcode identified unit. The BioArchive System operates to freeze, archive
and retrieve samples without exposing any sample to Transient Warming Events
(TWEs), which can reduce the viability of the cells.

[RudiDutschke]

ThermoGenesis Corp. Announces Executive Management Changes

RANCHO CORDOVA, Calif., June 17 /PRNewswire-FirstCall/ -- ThermoGenesis
Corp. (NASDAQ:KOOL) today announced that James Godsey, Ph.D. has resigned
from the Company to join Gen-Probe, a leading manufacturer of molecular
diagnostics. Dr. Godsey will remain with the Company through the beginning of
July 2002, to help ensure a smooth transition with his predecessor. The
Company is currently interviewing several candidates and anticipates having
one in place in the near future. Philip H. Coelho, ThermoGenesis` Chairman
and Chief Executive Officer, will resume direction of day-to-day operations of
the Company.
"We would like to thank Dr. Godsey for his service with the Company as its
President, and his overall efforts on the Board of Directors," said Philip
Coelho, Chairman and CEO of ThermoGenesis. "Our management team over the past
five years has developed and implemented an internal structure that has
demonstrated solid performance and improvement as we move from a late stage
Research and Development firm, to a revenue generating operating company."
Mr. Coelho concluded, "I am encouraged that we will continue to grow the
Company to the next level with the excellent talent of our executive team."
The Company earlier announced the appointment of Edward Cape, Ph.D., who
is serving a one-year term as Executive Vice President of Corporate Strategy,
reporting directly to the Company`s Chairman and CEO. Cape is on the Board of
Directors of the Company. Also reporting to Coelho following the management
changes will be Renee Ruecker, the Company`s V.P. of Finance, Sam Acosta, V.P.
Manufacturing Operations, and Dan Segal, V.P. Sales and Marketing.

[RudiDutschke]

HERMOGENESIS Continues Expansion of Global Stem Cell Network

Korean Stem Cell Institute Purchases Second BioArchive(R) System
For their Cord Blood Stem Cell Bank

RANCHO CORDOVA, Calif., June 24 /PRNewswire-FirstCall/ --
THERMOGENESIS CORP. (NASDAQ:KOOL) announced today that the Company received
an order for a second BioArchive System from Medipost Cryo-Stem Cell Institute
located in Kyungki-do, South Korea. The BioArchive System is utilized as a
critical enabling technology for the production of cell therapy products used
for the treatment of leukemias, lymphomas, diverse inherited anemias, such as
sickle cell anemia and thalassemia, and other genetic diseases.
Mr. Sung Hun Lee, General Manager of the new Cord Blood Bank said, "We are
convinced that the THERMOGENESIS CORP. BioArchive System is the industry
standard for the processing and storage of stem cells from placental cord
blood, and are committed to this technology as we continue to grow our
operations."
Dan Segal, Vice President, Sales & Marketing of THERMOGENESIS CORP.
commented, "Medipost was our first BioArchive Customer in Korea, and is one of
the fastest growing Cord Blood Banks in Asia. Medipost has already provided
stem cell units for more than 70 transplants."
"Recent research suggests that there are stem cells in a unit of cord
blood that have the potential to produce other cells outside the hematopoietic
system such as neural, liver and bone cells," said Philip Coelho, Chairman and
CEO of THERMOGENESIS. "Since there are serious ethical issues with sourcing
stem cells from embryos and fetuses, scientists may begin to focus on cord
blood as a superior, non-controversial source for these multi-potential stem
cells."
In the Asia region, THERMOGENESIS` BioArchive Systems have been deployed
in Japan, China, Taiwan, Vietnam, South Korea, Malaysia and India. In North
America, BioArchive Systems have been deployed at the New York Blood Center,
Duke University Medical Center, San Diego Blood Bank, NuStem Technologies,
Inc., Coriell Institute for Medical Research, Florida Blood Services pursuant
to Investigational New Device ("IND") regulations, the National Transfusion
Service Cord Blood Bank and Alternativas Hematologicas (CALHESA) in Mexico,
and the Stem Sciences in Canada. In Europe and the Middle East, BioArchive
Systems have been placed at the major Cord Blood Stem Cell Banks in Germany,
United Kingdom, France, Spain, Belgium, Finland, Netherlands and Israel. The
Company estimates that more than 70% of the cord blood stem cell transplants
performed to date have used CB samples from Cord Blood Banks that are now
using the BioArchive System to process, cryopreserve, archive and transfuse
their stem cell units.
The BioArchive System plays a key role in the emerging world standards
that are being adopted for the processing and validation of stem cell units.
It uses a computer-driven robotic system to archive up to 3,626 PCB stem cell
units in -196.C liquid nitrogen that have been collected and processed in
proprietary sterile plastic bag sets. The BioArchive System performs a
precise controlled-rate freeze, tracks identification and archive location and
performs robotic storage and retrieval of each unique tissue-typed PCB unit
for use in life-saving transplantation. A specialized transfusion bag set is
used to administer the stem cells to the patient. The BioArchive System can
freeze, place and retrieve samples within liquid nitrogen without exposing the
samples to detrimental transient warming events (TWE), which can reduce cell
viability. PCB stem cells are used to reconstitute the hematopoietic and
immune systems of patients who have undergone high-dose chemotherapy and
radiation to combat diseases such as leukemias, lymphomas, diverse inherited
anemias and hypoproliferative stem cell disorders.

Regulatory Status
The BioArchive System is a Class II blood and blood component freezer
exempt from the pre-market notification procedures. The BioArchive System has
potential applications involving archiving, storing, managing and retrieving
other kinds of biological specimens, that may include stem cells, dendritic
cells, T-cells, cell lines, sperm cells, eggs, heart valves, corneas, virus
samples, biopsy samples and other blood, tissue and saliva samples. The
BioArchive System is currently intended for storage of blood and blood
components. Additional indications for use would require U.S. FDA clearance
or approval.

[RudiDutschke]

C-Davis researcher arrested for embezzlement, stealing trade secrets

DAVIS, Calif., May 23, 2002 (The California Aggie, U-WIRE via COMTEX) -- A
University of California-Davis postgraduate researcher was arraigned on Monday
on charges of embezzlement and theft of a trade secret for allegedly stealing
sensitive research that could lead to the restoration of vision in badly damaged
eyes.

Bin Han, a 40-year-old researcher who came to UCD in March 2000, was arrested
Saturday morning on accusations that he stole 20 vials of human protein samples
from ThermoGenesis Corporation, a Rancho Cordova-based laboratory which has
partnered with the UCD department of ophthalmology for human vision research.

According to campus police, Han was supposed to deliver 40 vials of human
protein for the research from ThermoGenesis to UCD, but when 20 of the vials
turned up missing, Han became a suspect. A search of Han`s home on Friday
revealed the missing vials in his freezer.

The search also turned up a plane ticket for a flight scheduled depart for China
on Sunday, raising fears that he was bringing the research there.

"It was good police work in acting very quickly to respond to a need of a campus
department," UCD Police Department spokesperson Paul Pfotenhauer said.

Dr. Mark Mannis, the vice chairman of the UCD department of ophthalmology, said
the research is aimed at coming up with new technologies to resurface eyes in
diseased states in which the ocular surface is adversely damaged, thus restoring
vision.

"It`s important to remember that this is very important research that will have
a tremendous impact on world blindness," Mannis said. "As you can imagine, there
is a great deal of interest on behalf of many laboratories and countries for
this kind of information."

Mannis said that, to his recollection, this was the first time anything like
this ever happened to the department, calling it a "rare and unusual event."

"[The research] is quite groundbreaking," Mannis said. "It is an area of
ophthalmology that is extremely important. There are several labs in the United
States and labs abroad -- including China -- where this research effort is being
hotly pursued."

Pfotenhauer said a UCDPD sergeant told him that in 18 years, he had never seen a
case like this.

Mannis said he did not know how much the contents of the vials are worth.

In addition to embezzlement and theft of a trade secret, Han was also accused of
possession of stolen property, but the charge was dropped by the Yolo County
District Attorney`s Office.

According to Yolo County Deputy District Attorney Davis Akulian, the maximum
penalty for embezzlement and theft of a trade secret is three years in state
prison. However, if convicted of both crimes, Han could serve up to 3 years, 8
months.

The District Attorney`s Office would not comment on the specifics of the case.

[RudiDutschke]

U.S. Researchers Develop Bioengineered Cornea Cell Implant Utilizing
ThermoGenesis` Gel Technology

Revolutionary Autologous Cell Therapy Procedure Holds Potential to Restore
Vision Loss Due to Ocular Surface Disease and Trauma

RANCHO CORDOVA, Calif., July 1 /PRNewswire-FirstCall/ --
ThermoGenesis Corp. (NASDAQ:KOOL) today announced that a research team at the
University of California at Davis (UC Davis) has successfully used
ThermoGenesis` CryoSeal(R) FS System in conjunction with human corneal stem
cells to create a corneal cell matrix for potential use with patients whose
corneas have been irreparably damaged by disease or traumatic injury.
It is estimated that approximately 35,000 adults and children in the U.S.
and Europe suffer from blindness or severely impaired vision resulting from
irreparable corneal injury, according to Dr. Ivan Schwab, Ophthalmologist at
UC Davis.
Reporting in the July issue of Cornea, Drs. Schwab and Rivkah Isseroff
have described multiple advantages of this novel fibrin/fibronectin gel
matrix, which is prepared with corneal stem cells and a spectrum of key
clotting proteins isolated from the patient`s own ("autologous") plasma using
the Company`s proprietary CryoSeal FS System:

-- The growth factor-enriched fibrin/fibronectin gel scaffolding
supports and promotes logarithmic growth of embedded corneal stem
cells;
-- Despite a thickness of less than 1 mm, the gel vehicle for corneal
stem cells is soft, pliable and elastic, permitting it both to
conform to the eye and to be sutured in place;
-- As a 100% autologous product, the gel-based corneal stem cell matrix
reduces the risk of transmitting pathogenic viruses, bacteria or
prions;
-- The biodegradable proteinaceous gel is expected to protect embedded
corneal stem cells, and then naturally reabsorb after implantation,
leaving the confluent monolayer of stem cells to further divide and
differentiate into transparent corneal epithelial cells.

This UC Davis research team has previously demonstrated that corneal
epithelial stem cells harvested from a patient`s non-affected eye could be
cultured on an amnionic membrane to make a bioengineered replacement tissue,
which improved vision in a number of patients following implantation.
Explaining their integration of the CryoSeal FS System into this
procedure, the investigators focused on the fact that the CryoSeal FS gel
consists of multiple, biologically active plasma proteins -- fibronectin,
Factor VIII, Factor XIII as well as thrombin and fibrinogen -- which can be
sourced from a single unit of the patient`s blood plasma. In contrast,
conventional fibrin sealants include only fibrinogen and thrombin, and are
manufactured from "pools" of thousands of units of plasma from paid
individuals. "Fibronectin dramatically influences [corneal cell] attachment
and spreading," the authors noted.
"We are very pleased with this publication describing the use of the
CryoSeal FS System to potentially produce therapeutic corneal stem cell
transplants," ThermoGenesis Corp. Chairman and CEO, Philip Coelho commented.
"Not only does it provide new hope of restoring vision for patients so
desperately in need, but it clearly demonstrates how the Company`s two key
product areas may be intertwined. The rapidly emerging regenerative therapy
market -- as much as a $30 billion future industry by some estimates -- needs
optimal vehicles for growing and delivering stem cells to their target body
sites." The Company is currently in the Phase III study of the CryoSeal FS
System required for commercial release in the US, and also manufactures and
sells the industry-leading BioArchive(R) System to stem cell cord blood banks
throughout the world.
"While the CryoSeal FS System was principally designed to compete in the
growing surgical sealants market, we are excited about the prospects of
important new applications in the emergent cell therapy industry," commented
Coelho. "While the technology described in the report by Drs. Schwab and
Isseroff has yet to be tested in human subjects, their work provides a first
proof-of-principle for what may prove to be an effective regenerative therapy
product for blindness and vision loss resulting from corneal damage," Coelho
concluded.

Regulatory Status of CryoSeal FS System
ThermoGenesis Corp. received Food and Drug Administration (FDA) approval
in December 2001 to initiate a pivotal U.S. human clinical trial of the
CryoSeal FS System. A Phase III study is currently in progress to evaluate
the use of a fully autologous fibrin sealant prepared with the CryoSeal FS
System for controlling bleeding during elective liver surgery. That trial is
expected to be completed early in 2003.
In March, ThermoGenesis Corp. signed an agreement with Dideco S.p.A. to
distribute the newly CE marked CryoSeal FS System and associated disposables
in Europe, where it is licensed for the production of autologous or
single-donor fibrin sealant products.

About ThermoGenesis Corp.
ThermoGenesis Corp. is a designer and manufacturer of technologically
advanced medical devices and accompanying sterile disposables. The Company`s
BioArchive System enables blood, stem cell and tissue banks to efficiently
collect, cryopreserve and archive therapeutic blood products. The CryoSeal
product platform can produce a range of products based on human thrombin,
fibrinogen and other major coagulation proteins present in human plasma.

The statements contained in this release which are not historical facts
are forward-looking statements that are subject to risks and uncertainties
that could cause actual results to differ materially from those expressed in
the forward-looking statements, including, but not limited to, certain delays
beyond the company`s control with respect to market acceptance of new
technologies and products, delays in testing and evaluation of products, and
other risks detailed from time to time in the Company`s filings with the
Securities and Exchange Commission.

[fritzchenI]

rudi sag mal bin am überlegen zu verkaufen ist ja frustrierend der Aktienverlauf-gibts keine Phantasie mehr im Wert

[RudiDutschke]

By PAUL ELIAS AP Biotechnology Writer SAN FRANCISCO
(AP) - The case against a former University of
California, Davis scientist originally accused of economic
espionage charges dwindled to a single misdemeanor
charge Tuesday. A Yolo County judge reduced the
felony embezzlement charge against Bin Han, a
naturalized citizen from China, during an afternoon
hearing in Woodland. Han, 40, was originally charged
with the theft of trade secrets and accused of stealing
20 vials of a protein gel school researchers are using in
their attempts to grow replacement corneas for the
blind. Campus police raided Han`s Davis home on May 17
and found the vials in his freezer and a plane ticket to
his native China. Because he was considered a flight
risk, Han was held without bail until June 4 when Yolo
County prosecutors dropped the most serious charges
against him, leaving just the embezzlement charge
intact. The judge on Tuesday reduced the remaining
charge to a misdemeanor because the gel Han is
accused of stealing was given to the university by
Sacramento biotechnology company Thermogenesis
Corp. at no cost. The case has drawn criticism from
some as ethnically motivated and critics compared it to
the saga of the former Los Alamos National Laboratory
scientist Wen Ho Lee. Lee, who was prosecuted for
making copies of sensitive nuclear weapons data,
pleaded guilty to a single count of downloading data to
computer tape at Los Alamos National Laboratory. He
has said he made copies to protect data from being
erased. Lee was held in solitary confinement for nine
months, though never charged with spying. He was
sentenced to time served. Stewart Katz, Han`s
attorney, said Han innocently stored the vials in his
freezer just as any employee stores work-issued
equipment. Katz said the plane ticket to China was
bought weeks before the raid on his house and was to
be used to visit his ailing parents. Katz said Han`s legal
woes are result of a falling out he had with his bosses
at UC Davis over credit for research. Han worked in
various university labs since 1989. UC Davis spokesman
Paul Pfotenhauer said the school was never motivated
by ethnicity or personality clashes in pursuing Han.
``The university stands by its claim that there was no
discrimination evident in this case,`` Pfotenhauer said.
``We clearly feel this was a case of missing university
property.`` The Yolo County District Attorney`s office did
not return telephone calls.

[RudiDutschke]

hermoGenesis to Expand CryoSeal(R) Fibrin Sealant
Pivotal Trial to Multiple Sites

RANCHO CORDOVA, Calif., July 31 /PRNewswire-FirstCall/ --
ThermoGenesis Corp. (NASDAQ:KOOL) announced today that an independent Data
Safety Monitoring Board (DSMB) comprised of surgeons, a biostatistician and an
ethicist recommends proceeding with the multicenter pivotal trial for the
CryoSeal FS System. The DSMB recommendation is based on the demonstrated
safety of the pilot study data from patients undergoing liver resections.
The pivotal trial, which the company hopes to complete within six months,
will examine safety and efficacy of the Fibrin Sealant prepared by the
CryoSeal FS System as an adjunct to hemostasis on the excised surface of a
resected liver. In a blinded trial, one hundred patients will receive
CryoSeal fibrin Sealant and fifty patients will receive the control. All
patients will be followed 30-days post operatively after which data on all
patients will be compiled and submitted for FDA regulatory review and
approval.
"We are very pleased with the recommendation from the DSMB as their review
of the pilot study clinical data was very comprehensive, and their advice was
supportive and constructive," said Philip Coelho, CEO of ThermoGenesis Corp.
"We look forward to the expanded trial and its results," concluded Mr. Coelho.
The CryoSeal FS System utilizes a single-use sterile closed processing set
to prepare both components of the CryoSeal Fibrin Sealant (thrombin and
cryoprecipitate) from a single unit of autologous human plasma in about an
hour. Once prepared, the CryoSeal Fibrin Sealant may be frozen or used
immediately as a hemostatic agent for patients undergoing liver resection. In
contrast, conventional fibrin sealants source their components from "pools" of
10,000 or more units of plasma and add bovine Aprotinin, which increases the
vulnerability of these products to new and re-emerging infections. Several
newly discovered hepatitis viruses and agents of transmissible spongiform
encephalopathies may pose risks to the safety of pooled plasma. Infection of
surgical patients with Parvovirus B-19 contaminated conventional fibrin
sealant has been recently reported in the Annals of Thoracic Surgery (2002).
The CryoSeal technology was also designed to provide an attractive
alternative to "Surgeon Prepared" fibrin sealants, which are made up of
Cryoprecipitated AHF and bovine thrombin combined at the bleeding site by the
surgeon. Numerous recently published reports describe adverse bleeding or
autoimmune events in patients exposed to a subsequent medical procedure using
bovine thrombin. Only the CryoSeal System can provide the patient and the
surgeon with a fibrin sealant made from the patient`s own blood and free of
any bovine or "pooled" human ingredients.

[RudiDutschke]

ThermoGenesis Corp. Signs Canadian Distribution Agreement with Minogue Medical
for CryoSeal(R) Fibrin Sealant System

Revolutionary Fibrin Sealant Addresses Mad Cow Concerns

RANCHO CORDOVA, Calif., Aug. 12 /PRNewswire-FirstCall/ --
ThermoGenesis Corp. (NASDAQ:KOOL) announced that it has signed a distribution
agreement with Minogue Medical, a surgical specialty distributor with offices
in Montreal and direct multilingual sales people throughout Canada, to begin
immediate commercialization of its CryoSeal Fibrin Sealant (FS) System in
Canada. The new system provides a "2nd Generation" fibrin sealant, sourced
from either the patient`s own blood or from a single human donor, without any
bovine ingredients radically reducing concerns over Mad Cow disease, vCJD and
other emerging pathogens. The Company believes the current annualized
worldwide market for fibrin sealant, used by surgeons to stop bleeding and
seal tissues, is approximately $500 million.
"Minogue Medical`s influential presence in the operating room will be
utilized to create surgeon demand for CryoSeal Fibrin Sealant kits which will
be produced in the hospital`s Blood Bank," said Dan Segal, Vice President,
Sales & Marketing for ThermoGenesis. According to Danny Minogue, President of
Minogue Medical, "We will promote CryoSeal Fibrin Sealant by emphasizing the
ease of use of the product and the increased safety." Conventional fibrin
sealants are sourced from thousand unit "pools" of human and bovine tissue
which increase the probability of contamination by infectious pathogens, such
as transmissible spongiform encephalopathy (TSE) prions. Infection of
surgical patients with Parvovirus B-19 contaminated conventional fibrin
sealant has been recently reported in the Annals of Thoracic Surgery (2002).
"This is another important step for ThermoGenesis as we transition from an
R & D company to a revenue generating company," said Philip Coelho, CEO of
ThermoGenesis Corp. "Earlier this year we signed an agreement with Dideco,
SPA for the distribution of the CryoSeal System in Europe and have also
initiated a Phase III clinical trial of the CryoSeal FS system in the U.S."

About ThermoGenesis Corp.
After extensive research, ThermoGenesis Corp.`s technology platforms lead
the world in their ability to produce blood component products from single
units of blood. Cord blood banks are utilizing the Company`s BioArchive(R)
System as a critical enabling technology for the harvesting, processing and
cryogenic storage of hematopoietic stem cells for bone marrow rescue
transplants while its CryoSeal System is used to prepare hemostatic and
adhesive surgical sealants from patient blood in about an hour. ThermoGenesis
Corp. has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma
Freezers and Thawers to hospitals and blood banks since 1992.

About Minogue Medical Inc.
Minogue Medical Inc. has been in business for 16 years and is a
distributor of specialty surgical devices that are used across several
surgical specialties including vascular surgery, cardiovascular surgery,
general and gynecological procedures. Minogue has offices in Montreal with 10
sales representatives across Canada. They provide 24/7 technical support via a
bilingual hotline

Regulatory Status
In March of 2001, the CryoSeal FS System received CE Mark approval from
the European Union Competent Authorities to initiate commercialization of the
CryoSeal FS System in Europe. The CryoSeal System is patent-protected, and
will require a pre-market approval by the U.S. FDA before marketing in the
U.S. In May 2001, the CryoSeal FS System received a license to market in
Canada.

The statements contained in this release which are not historical facts
are forward-looking statements that are subject to risks and uncertainties
that could cause actual results to differ materially from those expressed in
the forward-looking statements, including, but not limited to, certain delays
beyond the company`s control with respect to market acceptance of new
technologies and products, delays in testing and evaluation of products, and
other risks detailed from time to time in the Company`s filings with the
Securities and Exchange Commission.

[fritzchenI]

rudi warum wird die Aktie heut so verdroschen-weist du warum
die Aktie nicht vorankommt

[fritzchenI]

rudi die verkäufe sind ja verherend

[fritzchenI]

Rudi bist du raus-ich hab den Absprung verpasst

[fritzchenI]

nur noch verkäufe da ist was faul

[fritzchenI]

rudi sag mir wenigstens ob du den mist noch hältst

[RudiDutschke]

ThermoGenesis Corp. Announces Order for Sixth BioArchive(R) System From The
National Cord Blood Program at the New York Blood Center

Clinical Success of Placental Cord Blood Stem Cell Transplants Drives Need For
Expanded Inventory

RANCHO CORDOVA, Calif., Sept. 25 /PRNewswire-FirstCall/ --
ThermoGenesis Corp. (NASDAQ:KOOL) today announced the receipt of an order for
a sixth BioArchive System from the National Cord Blood Program at the New York
Blood Center ("NYBC"), which intends to collect an inventory of more than
50,000 ethnically diverse Placental Cord Blood ("PCB") units to better serve
patients who suffer from diseases such as leukemia, lymphomas, diverse
inherited anemias and hypoproliferative stem cell disorders.
"We are very pleased that The National Cord Blood Program at NYBC
continues to choose our BioArchive System as a means of processing and
cryopreserving their cord blood stem cell units as they are not only the first
and largest public cord blood bank in the world, but have provided more than
1,200 units for transplant. They have pioneered cord blood banking as a
source of readily available stem cells for bone marrow rescue transplants and
are the model for the rest of the world`s cord blood banks," said Dan Segal,
Vice President, Sales & Marketing of ThermoGenesis Corp.
The BioArchive System is used to process, cryopreserve and archive up to
3,626 blood and blood component units. BioArchive Systems have also been
chosen by the major cord blood stem cell banks in Japan, China, Taiwan,
Vietnam, So. Korea, Malaysia, Germany, Spain, Finland, U.K., Belgium, France,
Mexico, India, and Israel as well as in the U.S.A. pursuant to Investigational
New Drug ("IND") regulations. The BioArchive System is the international
choice for processing and archiving cryopreserved cord blood.
Mr. Segal added, "Cord blood may provide a source of stem cells for tissue
regeneration cell therapy unencumbered by the ethical issues involved with
harvesting stem cells from embryos or fetuses. We believe our BioArchive
Systems position us well in the growing cell therapy market."

Regulatory Status
The BioArchive System is a Class II blood and blood component freezer
exempt from the pre-market notification procedures. The BioArchive System has
potential applications involving archiving, storing, managing and retrieving
other kinds of biological specimens, that may include stem cells, dendritic
cells, T-cells, cell lines, sperm cells, eggs, heart valves, corneas, virus
samples, biopsy samples and other blood, tissue and saliva samples. The
BioArchive System is currently intended for storage of blood and blood
components. Additional indications for use would require U.S. FDA clearance
or approval.

About New York Blood Center
The NYBC is the country`s largest independent blood center and a world
leader in biomedical research. The National Cord Blood Program at the NYBC
has pioneered the use of cord blood as a source of stem cells for bone marrow
restoration for such diseases as leukemia or inherited or acquired diseases of
the blood and immune systems and has collected more than 17,000 PCB donations
and provided units for more than 1,200 transplants since 1993.

[RudiDutschke]

Network with Fiftieth BioArchive(R) System
26 Sep 2002, 09:01am ET
E-mail or Print this story


- - - - -

/FROM PR NEWSWIRE SAN FRANCISCO 415-543-7800/
[STK] KOOL
[IN] MTC BIO HEA
[SU] CON
TO BUSINESS AND MEDICAL EDITORS:

ThermoGenesis Continues Expansion of Global Stem Cell Network with Fiftieth
BioArchive(R) System

Austrian Red Cross Purchases BioArchive System for Their Cord Blood Stem Cell
Bank

RANCHO CORDOVA, Calif., Sept. 26 /PRNewswire-FirstCall/ --
ThermoGenesis Corp. (NASDAQ:KOOL) announced today that the Company received
an order for the BioArchive System from the Austrian Red Cross in Linz,
Austria. The BioArchive System is utilized as a critical enabling technology
for the production of cell therapy products used for the treatment of
leukemias, lymphomas, diverse inherited anemias, such as sickle cell anemia
and thalassemia, and other genetic diseases.
The Austrian Red Cross, which will operate the first public cord blood
stem cell bank in Austria under the direction of Dr. Christian Gabriel, plans
to collect and store up to 5,000 samples over the next few years.
Dan Segal, Vice President, Sales & Marketing of ThermoGenesis Corp.
commented, "We are very pleased to add the Austrian Red Cross to our growing
base of customers in Europe. With the continuing adoption of our technology
worldwide, we look forward to a growing demand for our disposable devices
specifically designed for the BioArchive System."
"Recent research suggests that there are stem cells in a unit of cord
blood that have the potential to produce other cells outside the hematopoietic
system such as neural, liver and bone cells," said Philip Coelho, Chairman and
CEO of ThermoGenesis Corp. "Since there are serious ethical issues with
sourcing stem cells from embryos and fetuses, scientists may begin to focus on
cord blood as a superior, non-controversial source for these multi-potential
stem cells."
In Europe and the Middle East, BioArchive Systems have been placed at the
major Cord Blood Stem Cell Banks in Germany, United Kingdom, France, Spain,
Belgium, Finland, Netherlands and Israel. The Company estimates that more than
70% of the cord blood stem cell transplants performed to date have used cord
blood samples from Cord Blood Banks that are now using the BioArchive System
to process, cryopreserve, archive and transfuse their stem cell units. In the
Asia region, ThermoGenesis` BioArchive Systems have been deployed in Japan,
China, Taiwan, Vietnam, South Korea, Malaysia and India. In North America,
BioArchive Systems have been deployed at the New York Blood Center, Duke
University Medical Center, San Diego Blood Bank, NuStem Technologies, Inc.,
Coriell Institute for Medical Research, Florida Blood Services pursuant to
Investigational New Device ("IND") regulations, the National Transfusion
Service Cord Blood Bank and Alternativas Hematologicas (CALHESA) in Mexico,
and the Stem Sciences in Canada.
The BioArchive System plays a key role in the emerging world standards
that are being adopted for the processing and validation of stem cell units.
It uses a computer-driven robotic system to archive up to 3,626 PCB stem cell
units in -196 degrees Celsius liquid nitrogen that have been collected and
processed in proprietary sterile plastic bag sets. The BioArchive System
performs a precise controlled-rate freeze, tracks identification and
archive location and performs robotic storage and retrieval of each unique
tissue-typed PCB unit for use in life-saving transplantation. A specialized
transfusion bag set is used to administer the stem cells to the patient. The
BioArchive System can freeze, place and retrieve samples within liquid
nitrogen without exposing the samples to detrimental transient warming events
(TWE), which can reduce cell viability. PCB stem cells are used to
reconstitute the hematopoietic and immune systems of patients who have
undergone high-dose chemotherapy and radiation to combat diseases such as
leukemias, lymphomas, diverse inherited anemias and hypoproliferative stem
cell disorders.

Regulatory Status
The BioArchive System is a Class II blood and blood component freezer
exempt from the pre-market notification procedures. The BioArchive System has
potential applications involving archiving, storing, managing and retrieving
other kinds of biological specimens, that may include stem cells, dendritic
cells, T-cells, cell lines, sperm cells, eggs, heart valves, corneas, virus
samples, biopsy samples and other blood, tissue and saliva samples. The
BioArchive System is currently intended for storage of blood and blood
components. Additional indications for use would require U.S. FDA clearance or
approval.

[RudiDutschke]

27 Sep 2002, 07:00am ET
E-mail or Print this story


- - - - -

/FROM PR NEWSWIRE NEW YORK 800-776-8090/
[STK] KOOL
[IN] HEA MTC
[SU] ERN CCA
TO BUSINESS EDITOR:

ThermoGenesis Corp. Announces Fiscal Year 2002 Results

Revenues Increase 65%, Gross Profit Increases 155% and Net
Loss Decreases 18% from Prior Year

RANCHO CORDOVA, Calif., Sept. 27 /PRNewswire-FirstCall/ --
ThermoGenesis Corp. (NASDAQ:KOOL), a pioneer in the design, manufacture and
distribution of medical devices used to process therapeutically valuable blood
components, today announced results for its fiscal year ended June 30, 2002.
The Company reported a 65% increase in net revenues for a record $9,549,000,
compared to $5,792,000 reported in the prior year. Gross profit as a
percentage of net revenues increased to 21% from 13% for the year ended
June 30, 2002 as compared to the year ended June 30, 2001. The Company
reported a net loss to common stockholders of $5,038,000 or $0.15 per basic
and diluted share for fiscal 2002, down from $6,833,000 or $0.25 per basic and
diluted share for the prior year. The Company ended the year with over
$6 million in cash and short term investments and working capital of
$9.6 million.
"I am very pleased with our results for fiscal 2002 and the significant
progress made by the Company in our strategic initiatives" said Philip Coelho,
Chairman and CEO of ThermoGenesis. "We have strengthened the Company`s
balance sheet and significantly improved our revenues and gross profit margin
by our focus on sales. We saw the first sales of our CryoSeal (R) FS System
in Europe, and we successfully completed the pre-clinical and pilot study for
the CryoSeal FS human clinical trials. "
The increase in revenues was due to growth in all three of the Company`s
product lines, BioArchive (R), CryoSeal and ThermoLine (plasma freezers and
thawers). BioArchive revenues increased $1 million from the prior year due to
four additional device installations and the increasing volume of recurring
disposables. Revenues generated from the sales of plasma freezers increased
$2 million, primarily from the large order received from Aventis Bio-Services,
Inc., announced in September 2001.
Research and Development expenses increased $501,000 from $1,782,000 in
the prior year due to costs associated with the CryoSeal FS pre-clinical
trials and the pilot study of the human clinical trials which accounted for
approximately $700,000 of the research and development expenses. General and
administrative expenses increased $800,000 primarily due to a $205,000
non-cash stock compensation expense recorded as a result of extending certain
options, professional fees which included the investor relations firm brought
in during the first quarter and the hiring of additional personnel to
implement corporate strategic objectives.
Mr. Coelho continued, "Our strong results demonstrate the progress the
Company has made as we continue our move from a company focused on research
and development activities to one focused on revenue generation that will
bring us to profitability. With the European market launch of the CryoSeal FS
System underway and the continuing adoption of our BioArchive System by
leading cord blood banks, we remain optimistic about the future of the
Company."
The foregoing discussion should be read in conjunction with the attached
condensed financial statements and the Company`s annual report on Form 10-K.

Company Conference Call
Management will host a conference call today, September 27, 2002 at 11:00
am PDT (2:00 pm EDT) to review the year end financial results and other
corporate events, followed by a Q&A session. The call can be accessed by
dialing: [phone]. Participants are asked to call the assigned number
approximately five minutes before the conference call begins. A replay of the
conference call will be available two hours after the call for the following
five business days by dialing: [phone] and entering the following:
134# 1 295828#.

About ThermoGenesis Corp.
ThermoGenesis Corp. has been a pioneer in designing and manufacturing
medical devices, and designing sterile disposable bag sets to collect,
cryopreserve and archive blood products such as stem cells from cord blood,
blood plasma, fibrin sealant and other related blood products. After
extensive research and development, two new technology platforms (the
BioArchive System and the CryoSeal System) have evolved products, which
provide new bio-material products to patients in need.

The statements contained in this release which are not historical facts
are forward-looking statements that are subject to risks and uncertainties
that could cause actual results to differ materially from those expressed in
the forward-looking statements, including, but not limited to, certain delays
beyond the Company`s control with respect to market acceptance of new
technologies and products, delays in testing and evaluation of products and
other risks detailed from time to time in the Company`s filings with the
Securities and Exchange Commission.


THERMOGENESIS CORP.
Condensed Balance Sheets

June 30, June 30,
2002 2001
ASSETS
Current assets:
Cash, cash equivalents and short
term investments $6,726,000 $5,366,000
Accounts receivable, net 1,916,000 1,369,000
Inventory 2,887,000 1,843,000
Other current assets 115,000 96,000

Total current assets 11,644,000 8,674,000

Equipment, net 537,000 811,000

Other assets 58,000 68,000

$12,239,000 $9,553,000

LIABILITIES AND STOCKHOLDERS` EQUITY

Current liabilities:
Accounts payable $995,000 $765,000
Other current liabilities 1,018,000 811,000

Total current liabilities 2,013,000 1,576,000

Long-term portion of capital lease
obligations 33,000 45,000

Stockholders` equity 10,193,000 7,932,000

$12,239,000 $9,553,000


THERMOGENESIS CORP.
Condensed Statements of Operations

Years Ended
June 30,
2002 2001

Net revenues $9,549,000 $5,792,000
Cost of revenues 7,558,000 5,012,000
Gross profit 1,991,000 780,000

Expenses:
General and administrative 2,667,000 1,860,000
Sales and marketing 2,176,000 2,029,000
Research and development 2,283,000 1,782,000
Total expenses 7,126,000 5,671,000

Other income/(expenses) 97,000 (980,000)
Net loss before cumulative effect of
accounting change under SAB 101 (5,038,000) (5,871,000)
Cumulative effect of accounting
change under SAB 101 0 (282,000)
Net loss ($5,038,000) ($6,153,000)

Per share data:
Net loss before preferred stock
dividend or discount and
cumulative effect of accounting
change under EITF 00-27 ($5,038,000) ($6,153,000)
Preferred stock dividend
or discount 0 (100,000)
Cumulative effect of accounting
change under EITF 00-27 0 (580,000)
Net loss to common stockholders ($5,038,000) ($6,833,000)

Basic and diluted net
loss per share before
cumulative effect
of accounting changes ($0.15) ($0.22)
Cumulative effect of
accounting change
under SAB 101 0.00 (0.01)
Cumulative effect of
accounting change
under EITF 00-27 0.00 (0.02)
Basic and diluted net loss
per common share ($0.15) ($0.25)

Shares used in computing
per share data 32,844,292 27,668,523

Pro forma amounts assuming
the accounting change under
SAB 101 is applied
retroactively:
Net loss to common stockholders ($5,038,000) ($6,551,000)
Basic and diluted net
loss per share ($0.15) ($0.24)

[RudiDutschke]

Network
15 Oct 2002, 06:01am ET
E-mail or Print this story


- - - - -

/FROM PR NEWSWIRE SAN FRANCISCO 415-543-7800/
[STK] KOOL
[IN] HEA MTC BIO
[SU] LIC
TO BUSINESS AND MEDICAL EDITORS:

ThermoGenesis Continues Expansion of Global Stem Cell Network

Healthbanks (formerly Gene Born Biotech Inc.) Purchases 2nd
BioArchive(R) System for Their Cord Blood Stem Cell Bank

RANCHO CORDOVA, Calif., Oct. 15 /PRNewswire-FirstCall/ --
ThermoGenesis Corp. (NASDAQ:KOOL) announced today that the Company received
an order for a second BioArchive System from Healthbanks in Taipei, Taiwan.
The BioArchive System is utilized as a critical enabling technology for the
production of cell therapy products used for the treatment of leukemias,
lymphomas, diverse inherited anemias, such as sickle cell anemia and
thalassemia, and other genetic diseases.
Dan Segal, Vice President, Sales & Marketing of ThermoGenesis Corp.
commented, "We are very pleased that Healthbanks is increasing their
commitment to the BioArchive System as they continue to grow their operation
into one of the premier cord blood banks in Asia."
"Recent research suggests that there are stem cells in a unit of cord
blood that have the potential to produce other cells outside the hematopoietic
system such as neural, liver and bone cells," said Philip Coelho, Chairman and
CEO of ThermoGenesis Corp. "Since there are serious ethical issues with
sourcing stem cells from embryos and fetuses, scientists may begin to focus on
cord blood as a non-controversial source for these multi-potential stem
cells."
In the Asia region, THERMOGENESIS` BioArchive Systems have been deployed
in Japan, China, Taiwan, Vietnam, South Korea, Malaysia and India. In North
America, BioArchive Systems have been deployed at the New York Blood Center,
Duke University Medical Center, San Diego Blood Bank, NuStem Technologies,
Inc., Coriell Institute for Medical Research, Florida Blood Services pursuant
to Investigational New Device ("IND") regulations, the National Transfusion
Service Cord Blood Bank and Alternativas Hematologicas (CALHESA) in Mexico,
and the Stem Sciences in Canada. In Europe and the Middle East, BioArchive
Systems have been placed at the major Cord Blood Stem Cell Banks in Germany,
United Kingdom, France, Spain, Belgium, Finland, Netherlands and Israel. The
Company estimates that more than 70% of the cord blood stem cell transplants
performed to date have used cord blood samples from Cord Blood Banks that are
now using the BioArchive System to process, cryopreserve, archive and
transfuse their stem cell units.
The BioArchive System plays a key role in the emerging world standards
that are being adopted for the processing and validation of stem cell units.
It uses a computer-driven robotic system to archive up to 3,626 PCB stem cell
units in -196.C liquid nitrogen that have been collected and processed in
proprietary sterile plastic bag sets. The BioArchive System is used by cord
blood banks to freeze, track identification and perform robotic storage and
retrieval of each unique tissue-typed cord blood stem cell unit.
The BioArchive System can freeze, place and retrieve samples within liquid
nitrogen without exposing the samples to detrimental transient warming events
(TWE), which can reduce cell viability.

Regulatory Status
The BioArchive System is a Class II blood and blood component freezer
exempt from the pre-market notification procedures. The BioArchive System has
potential applications involving archiving, storing, managing and retrieving
other kinds of biological specimens, that may include stem cells, dendritic
cells, T-cells, cell lines, sperm cells, eggs, heart valves, corneas, virus
samples, biopsy samples and other blood, tissue and saliva samples. The
BioArchive System is currently intended for storage of blood and blood
components. Additional indications for use would require U.S. FDA clearance or
approval.

[RudiDutschke]

Sandgrain Securities Initiates Coverage of ThermoGenesis with a Speculative Buy
Rating

RANCHO CORDOVA, Calif., Nov 5, 2002 /PRNewswire-FirstCall via COMTEX/ --
ThermoGenesis Corp. (Nasdaq: KOOL) announced today that Sandgrain Securities
Inc. has initiated coverage of ThermoGenesis with a speculative buy rating. A
complete text of the research report prepared by Sandgrain can be viewed in the
Investor Relations/Analyst Coverage section of the Company`s website
www.thermogenesis.com. Contact information for research analysts, Ninan Kiriyan,
is available at the conclusion of the report.

About ThermoGenesis Corp.

ThermoGenesis Corp. has been a pioneer in designing, manufacturing and marketing
micro-manufacturing systems which utilize robotic devices and sterile disposable
bag sets to collect, cryopreserve and archive blood products such as
hematopoietic stem cells, fibrin sealant and other related blood products from
single units of donor blood.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.

[RudiDutschke]

die komplette analyse gibt es hier:

http://www.thermogenesis.com/IR/thermogenesis.html

einfach auf analysts coverage klicken

[RudiDutschke]

12-monats-kursziel: $ 3,64

[fritzchenI]

und wie kommst du auf dieses Kursziel-die aktie ist doch nicht gewollt

[RudiDutschke]

schau doch mal in die analyse. das kursziel ist nicht von mir, sondern ist dort angegeben. gruss

[fritzchenI]

seiht eher danach aus das es vollends gegen o läuft-heute noch unter 1 eur.

[RudiDutschke]

ThermoGenesis Corp. Announces First Quarter Results

Revenues Increase 35% Over Prior Year - Fiftieth BioArchive(R) System
Installed - Phase III Trial Advances

RANCHO CORDOVA, Calif., Nov. 12 /PRNewswire-FirstCall/ --
THERMOGENESIS CORP. (NASDAQ:KOOL) today announced results for its first
quarter of fiscal 2003. Net revenues for the quarter ended September 30, 2002
increased 35% to $2,053,000, which compared to $1,517,000 for the first
quarter of fiscal 2002. The Company reported a net loss of $1,362,000 or
$0.04 per basic and diluted share for the quarter ended September 30, 2002,
compared to $1,413,000 or $0.04 per basic and diluted share for the first
quarter last year. During the three months ended September 30, 2002, the
Company made pre-payments totaling $385,000 for the Phase III clinical trials.
The increase in revenues was due to increases in the BioArchive and
CryoSeal(R) FS System product lines. Revenues generated by the CryoSeal
product line were $251,000 versus none for the prior year`s first quarter.
Four BioArchive installations were completed versus three in the first quarter
of fiscal 2002. The installations plus disposables sold to existing customers
produced an increase in BioArchive revenues of $246,000 or 34% over the prior
year`s first quarter.
"Installing our fiftieth BioArchive system was a major milestone for the
Company," said Phil Coelho, Chairman and CEO of ThermoGenesis. "We believe
ThermoGenesis is the market leader for the public cord blood banking industry.
Our installed base provides a growing demand for our disposable devices
specifically designed for the BioArchive system. Our first quarter CryoSeal
sales were significant in two respects: we have reached 75% of the product
line revenues generated during the entire fiscal 2002 year and we delivered
our first Thrombin Activation Devices to Interpore Cross."
Mr. Coelho concluded, "Looking forward, the sales pipeline for our
BioArchive System remains very strong and we are pleased with the reception
the CryoSeal FS System is having in Europe."

Management will host a conference call Tuesday, November 12, 2002 at
approximately 11:00 AM (PST) to review the first quarter financial results.
The call can be accessed by dialing [phone] within the U.S. or (412)
858-4600 outside the U.S. and giving the conference name, "THERMOGENESIS."
Philip Coelho, Chairman & Chief Executive Officer and Renee Ruecker, Vice
President of Finance, will be on-line to discuss the first quarter results and
other corporate events, followed by a Q&A session. Participants are asked to
call the assigned number approximately 5 minutes before the conference call
begins.
A replay of the conference call will also be available two hours after the

call for the following 6 business days by dialing [phone] within the
U.S. and [phone] outside the U.S. and entering the following
reservation information:

-- Enter `923` when prompted for the account number followed by the
# sign.
-- Press `1` to play the recorded conference.
-- Enter `300751` when prompted to enter the conference number followed by
the # sign.

About ThermoGenesis Corp.
ThermoGenesis Corp. has been a pioneer in designing, manufacturing and
marketing micro-manufacturing systems which utilize robotic devices and
sterile disposable bag sets to collect, cryopreserve and archive blood
products such as hematopoietic stem cells, fibrin sealant and other related
blood products from single units of donor blood.

The statements contained in this release which are not historical facts
are forward-looking statements that are subject to risks and uncertainties
that could cause actual results to differ materially from those expressed in
the forward-looking statements, including, but not limited to, certain delays
beyond the company`s control with respect to market acceptance of new
technologies and products, delays in testing and evaluation of products, and
other risks detailed from time to time in the Company`s filings with the
Securities and Exchange Commission.


THERMOGENESIS CORP.
Condensed Statements of Operations
(Unaudited)

Three Months Ended
September 30,
2002 2001

Net revenues $2,053,000 $1,517,000

Cost of revenues 1,697,000 1,269,000

Gross profit 356,000 248,000

Expenses:
Selling, general and administrative 1,184,000 1,093,000

Research and development 562,000 601,000

Total operating expenses 1,746,000 1,694,000

Interest and other income/(expenses) 28,000 33,000

Net loss ($1,362,000) ($1,413,000)

Basic and diluted net loss per common
share ($0.04) ($0.04)

Shares used in computing per share
data 35,265,271 31,802,547


THERMOGENESIS CORP.
Condensed Balance Sheets
(Unaudited)

September 30, June 30,
2002 2002
ASSETS
Current assets:
Cash, cash equivalents and short
term investments $5,213,000 $6,726,000
Accounts receivable, net 1,515,000 1,916,000
Inventory 3,609,000 2,887,000
Other current assets 409,000 115,000

Total current assets 10,746,000 11,644,000

Equipment, net 499,000 537,000

Other assets 53,000 58,000

$11,298,000 $12,239,000

LIABILITIES AND STOCKHOLDERS` EQUITY

Current liabilities:
Accounts payable $1,302,000 $995,000
Other current liabilities 1,096,000 1,018,000

Total current liabilities 2,398,000 2,013,000

Long-term portion of capital lease
obligations 29,000 33,000

Stockholders` equity 8,871,000 10,193,000

$11,298,000 $12,239,000

[RudiDutschke]

ThermoGenesis Continues Expansion of Global Stem Cell Network

First BioArchive(R) in South America

RANCHO CORDOVA, Calif., Jan. 20 /PRNewswire-FirstCall/ --
ThermoGenesis Corp. (NASDAQ:KOOL) announced today that the Company has
recently shipped its first BioArchive order to Brazil. The Company`s
distributor, CEI Ltda in Rio de Janeiro ordered the system for installation at
CordLife, a newly formed cord blood bank in Sao Paulo. The BioArchive System
will be utilized as a critical enabling technology for our customer`s
production of therapeutic units of cord blood stem cells for the treatment of
leukemias, lymphomas, diverse inherited anemias, such as sickle cell anemia
and thalassemia, and other genetic diseases.
Kevin Simpson, President and COO of ThermoGenesis Corp. commented, "We are
excited to have our first sale of the BioArchive System in South America.
Brazil represents the 20th country to acquire the system as we continue to see
adoption of the BioArchive System as a standard for cord blood banking
customers worldwide."
Ana Paula Pacheco, Vice President of CEI commented, "CEI is dedicated to
offering our customers high quality, leading edge technology and we are
convinced that the BioArchive System represents the future for the processing
and storage of stem cell units sourced from placental cord blood."
"Recent research suggests that there are stem cells in a unit of cord
blood that have the potential to produce other cells outside the hematopoietic
system such as neural, liver and bone cells," said Philip Coelho, Chairman and
CEO of ThermoGenesis Corp. "Since there are serious ethical issues with
sourcing stem cells from embryos and fetuses, scientists may begin to focus on
cord blood as a non-controversial source for these multi-potential stem
cells."
BioArchive Systems have previously been deployed throughout North America,
Europe, Middle East, and Asia. The Company estimates that more than 70% of the
cord blood stem cell transplants performed to date have been supplied by Cord
Blood Banks that are now using the BioArchive System to process, cryopreserve,
and archive their stem cell units.
The BioArchive System plays a key role in the emerging world standards
that are being adopted for the processing and validation of stem cell units.
It uses a computer-driven robotic system to archive up to 3,626 units in
-196 degrees C liquid nitrogen. The BioArchive System is used by cord blood
banks to freeze, track identification and perform robotic storage and
retrieval of each unit.
The BioArchive System can freeze, place and retrieve samples within liquid
nitrogen without exposing the samples to detrimental transient warming events
(TWE), which can reduce cell viability.

[RudiDutschke]

Chinese Stem Cell Banks Embrace Key U.S. Technology

Seventh Cord Blood Stem Cell bank, in Taiwan and China, Chooses the
BioArchive(R) System

RANCHO CORDOVA, Calif., Jan. 22 /PRNewswire-FirstCall/ --
ThermoGenesis Corp. (NASDAQ:KOOL) announced today that the Company has
recently received its fourth, 4th BioArchive order from Taiwan. The Company`s
Distributor, Cosmo Medical, ordered the System for its customer Taiwan Advance
Biopharmaceutical who now joins Healthbanks and the Tzu-Chi Foundation Cord
Blood Bank as the 3rd CBB in Taiwan to select the BioArchive System for their
cord blood program. An additional 4 cord blood stem cell banks in mainland
China had also acquired these advanced systems as a critical enabling
technology for the production of therapeutic units of cord blood stem cells
for the treatment of leukemias, lymphomas, diverse inherited anemias, such as
sickle cell anemia and thalassemia, and other genetic diseases.
Kevin Simpson, President and COO, said that, "It was recently announced
that a new stem cell project in China alone, was planning to create an
inventory of one million samples. This recent order from Taiwan is evidence
that Asia is and will continue to be an important driver of our BioArchive
business as they continue to build new cord blood banks and establish growing
inventories of cord blood samples."
Mr. Simpson further noted that, "We expect to see continued demand for
BioArchive in Asia, which have always been under served by traditional US and
European bone marrow registries. Cord blood serves as a readily available
source of stem cells for bone marrow rescue treatment, especially for diseases
such as Thalassemia, which occurs at an incredibly high rate in Asia.
Further, recent research suggests that there are stem cells in cord blood that
have the potential to produce other cells outside the hematopoietic system
such as neural, liver, heart and bone cells. Because there are serious
ethical issues with sourcing stem cells from embryos and fetuses, scientists
appear to be focusing on cord blood as a non-controversial source for these
multi-potential stem cells."
The BioArchive System plays a key role in the emerging world standards
that are being adopted for the processing and validation of stem cell units.
It provides sterile cell processing disposables and a computer-driven robotic
system to allow users to cryopreserve and archive up to 3,626 units of cord
blood stem cells in -196 degrees Celsius liquid nitrogen.
The BioArchive System can cryopreserve, archive and retrieve samples
within liquid nitrogen without exposing the samples to detrimental transient
warming events (TWE), which can reduce cell viability.

[RudiDutschke]

ThermoGenesis Corp. Announces Second Quarter Results

BioArchive(R) and CryoSeal(R) Sales Increase, ThermoLine(TM) Revenues Decline

RANCHO CORDOVA, Calif., Feb. 14 /PRNewswire-FirstCall/ --
THERMOGENESIS CORP. (NASDAQ:KOOL) today announced results for its second
quarter of fiscal year 2003, ended December 31, 2002. The Company reported
net revenues for the second quarter of $2,350,000, a 5% decrease when compared
to $2,467,000 reported in the second quarter of last year. For the six months
ended December 31, 2002 the Company`s net revenues increased 11% to $4,403,000
compared to $3,984,000 for the first six months of the prior year.
"Revenues increased in our two pipeline product lines, BioArchive and
CryoSeal, for the three and six months ended December 31, 2002," stated
Kevin Simpson, the Company`s new President and COO as of January 7, 2003.
"However, the increasing momentum in BioArchive and CryoSeal sales was not
enough to completely offset the decline in ThermoLine revenues primarily due
to a large order for plasma freezers received from Aventis Bio-Services, Inc.,
in the prior year. We will continue to see the decrease in ThermoLine revenue
compared to the prior year through the end of this fiscal year. However,
revenues from BioArchive and CryoSeal disposables sold to existing customers
increased 240% over the prior year second quarter and we anticipate continuing
growth in these products."
"I am optimistic about the future of ThermoGenesis," stated Phil Coelho,
Chairman and CEO, "worldwide interest for the BioArchive System is rising, as
are the sales of the BioArchive disposables. We anticipate increased sales of
the CryoSeal System in Europe and the U.S. CryoSeal FS human clinical trials
are continuing. Most importantly, Mr. Simpson is aggressively pursuing cost
reduction programs which should increase our gross profit margin and decrease
non clinical operating expenses."

Company Conference Call
Management will host a conference call today, February 14, 2003 at
11:00 am PST (2:00 pm EST) to review the fiscal second quarter financial
results and other corporate events, followed by a Q&A session. The call can
be accessed by dialing: 1-800-860-2442 or 412-858-4600. Participants are
asked to call the assigned number approximately 5 minutes before the
conference call begins. A replay of the conference call will be available two
hours after the call for the following five business days by dialing:
877-344-7529 or 412-858-1440 and entering the following account number:
140 and the following passcode: 308684.

About ThermoGenesis Corp.
ThermoGenesis Corp. has been a pioneer in designing, manufacturing and
marketing micro-manufacturing systems which utilize robotic devices and
sterile disposable bag sets to collect, cryopreserve and archive blood
products such as hematopoietic stem cells, fibrin sealant and other related
blood products from single units of donor blood.

The statements contained in this release which are not historical facts
are forward-looking statements that are subject to risks and uncertainties
that could cause actual results to differ materially from those expressed in
the forward-looking statements, including, but not limited to, certain delays
beyond the Company`s control with respect to market acceptance of new
technologies and products, delays in testing and evaluation of products and
other risks detailed from time to time in the Company`s filings with the
Securities and Exchange Commission.


THERMOGENESIS CORP.
Condensed Statements of Operations
(Unaudited)

Three Months Ended Six Months Ended
December 31, December 31,
2002 2001 2002 2001

Net revenues $2,350,000 $2,467,000 $4,403,000 $3,984,000

Cost of revenues 1,938,000 1,841,000 3,635,000 3,110,000

Gross profit 412,000 626,000 768,000 874,000

Expenses:

Selling, general and
administrative 1,185,000 1,156,000 2,369,000 2,249,000

Research and
development 826,000 455,000 1,388,000 1,056,000

Total operating
expenses 2,011,000 1,611,000 3,757,000 3,305,000

Interest and other
income/(expenses) 15,000 30,000 43,000 63,000

Net loss $(1,584,000) $(955,000) $(2,946,000) $(2,368,000)

Basic and diluted net
loss per common share ($0.04) ($0.03) ($0.08) ($0.07)

Shares used in computing
per share data 35,266,004 31,606,436 35,265,837 31,704,492


THERMOGENESIS CORP.
Condensed Balance Sheets
(Unaudited)

December 31, June 30,
2002 2002
ASSETS
Current assets:
Cash, cash equivalents and short term
investments $3,450,000 $6,726,000
Accounts receivable, net 1,423,000 1,916,000
Inventory 3,742,000 2,887,000
Other current assets 458,000 115,000

Total current assets 9,073,000 11,644,000

Equipment, net 521,000 537,000

Other assets 48,000 58,000

$9,642,000 $12,239,000

LIABILITIES AND STOCKHOLDERS` EQUITY

Current liabilities:
Accounts payable $1,379,000 $995,000
Other current liabilities 921,000 1,018,000

Total current liabilities 2,300,000 2,013,000

Long-term obligations 55,000 33,000

Stockholders` equity 7,287,000 10,193,000

$9,642,000 $12,239,000

[RudiDutschke]

ThermoGenesis Provides Clinical Update on the CryoSeal(R) FS System

RANCHO CORDOVA, Calif., Feb. 14 /PRNewswire-FirstCall/ --
ThermoGenesis Corp. (NASDAQ:KOOL), announced today a progress report on the
CryoSeal FS System pivotal trials. A blinded, randomized multicenter clinical
trial for the CryoSeal Fibrin Sealant System is actively enrolling patients.
The pivotal trial will evaluate the safety and efficacy of the Fibrin
Sealant prepared by the CryoSeal FS System as an adjunct to hemostasis for
patients undergoing liver resections. One hundred fifty patients will be
followed 30-days post operatively, after which the data will be compiled and
submitted for FDA regulatory review and approval.
ThermoGenesis Corp. has entered into contracts with six prominent cancer
centers including, University of Miami`s Sylvester Cancer Center, Johns
Hopkins Cancer Center, Memorial Sloan-Kettering Cancer Center, University of
Southern California, St. Vincent`s Medical Center, and the University of
Chicago.
"These cancer centers are amongst the most prominent in performing these
extensive surgeries and we expect an accurate assessment of our technology to
result from their efforts," said Kevin Simpson, President and COO of
ThermoGenesis Corp. Two additional cancer centers are expected to join the
trial in March of 2003.
The CryoSeal FS System prepares both components (cryoprecipitate and
thrombin) of CryoSeal Fibrin Sealant from a single unit of autologous human
plasma in about an hour. Once prepared, the CryoSeal Fibrin Sealant may be
frozen or used immediately as a hemostatic agent for patients undergoing liver
resection. Conventional fibrin sealants, which combine 10,000 or more units of
plasma remain vulnerable to new and re-emerging infections. Several newly
discovered hepatitis viruses and agents of transmissible spongiform
encephalopathies may pose risks to the safety of homologous and pooled plasma.
There have been reports of parvovirus B-19 transmission to surgical patients
receiving fresh frozen plasma.
In contrast to commercially available fibrin sealants, the CryoSeal
technology enables the CryoSeal FS System to prepare CryoSeal Fibrin Sealant
free of animal proteins such as bovine aprotinin or bovine thrombin. Animal
proteins are a potential source of viral and prion contamination to blood
products, the latter of which are resistant to all forms of viral inactivation
technology available to fractionators at this time. Additionally, recently
published research indicates an increased risk of adverse bleeding or
autoimmune events in patients exposed to subsequent medical procedure using
bovine thrombin.

Regulatory Status
In March of 2001, the CryoSeal FS System received CE Mark approval from
the European Union Competent Authorities to initiate commercialization of the
CryoSeal FS System in Europe. The CryoSeal System is patent-protected, and
will require a pre-market approval by the U.S. FDA before marketing in the
U.S. Until U.S. FDA approval, the CryoSeal FS System, including FS applicator
kits, will be marketed, as permitted under U.S. Export Laws, applicable
foreign regulations, in geographies including Latin America, South America,
Asian Pacific Rim, Australia and ROW. In May 2001, the CryoSeal FS System
received a license to market in Canada.

[RudiDutschke]

THERMOGENESIS Continues Expansion of Global Stem Cell Network

First BioArchive(R) System in Russia

RANCHO CORDOVA, Calif., Feb. 18 /PRNewswire-FirstCall/ --
THERMOGENESIS CORP. (NASDAQ:KOOL) announced today that the Company has
recently received its first BioArchive order from Russia. The Company`s
distributor, Delrus Medical, ordered the system on the instructions of the
Moscow government for installation in Moscow, which will be the first public
cord blood bank in Russia. The BioArchive System will be utilized as a
critical enabling technology for our customer`s production of therapeutic
units of cord blood stem cells for the treatment of leukemias, lymphomas,
diverse inherited anemias, such as sickle cell anemia and thalassemia, and
other genetic diseases.
Dr. Olga Maiorova of the Russian Medical University Research Institute for
Pediatric Haematology is slated to head up the cord blood bank operations.
They plan to collect around 700 cords the first year, with plans to collect a
total of 10,000 units over the next three years.
Kevin Simpson, President and COO of THERMOGENESIS CORP. commented, "We are
excited to have our first sale of the BioArchive System in Russia. Russia
represents the 21st country to acquire the system as we continue to see
adoption of the BioArchive System as a standard for cord blood banking
customers worldwide."
"Recent research suggests that there are stem cells in a unit of cord
blood that have the potential to produce other cells outside the hematopoietic
system such as neural, liver and bone cells," said Philip Coelho, Chairman and
CEO of THERMOGENESIS CORP. "Since there are serious ethical issues with
sourcing stem cells from embryos and fetuses, scientists may begin to focus on
cord blood as a non-controversial source for these multi-potential stem
cells."
BioArchive Systems have previously been deployed throughout North America,
Europe, Middle East, and Asia. The Company estimates that more than 70% of
the cord blood stem cell transplants performed to date have been supplied by
Cord Blood Banks that are now using the BioArchive System to process,
cryopreserve, and archive their stem cell units.
The BioArchive System plays a key role in the emerging world standards
that are being adopted for the processing and validation of stem cell units.
It uses a computer-driven robotic system to archive up to 3,626 units in
-- 196 degrees C liquid nitrogen. The BioArchive System is used by cord blood
banks to freeze, track identification and perform robotic storage and
retrieval of each unit. The BioArchive System can freeze, place and retrieve
samples within liquid nitrogen without exposing the samples to detrimental
transient warming events (TWE), which can reduce cell viability.

[RudiDutschke]

ThermoGenesis` Network of Stem Cell Banks in Asia Continues to Expand

New Cord Blood Stem Cell Bank in Korea Chooses the BioArchive(R) System

RANCHO CORDOVA, Calif., Feb. 28 /PRNewswire-FirstCall/ --
ThermoGenesis Corp. (NASDAQ:KOOL) announced today that the Company has
received its fifth BioArchive order from Korea. The system was ordered by
Innocell Corporation, a leader in cell biology and technology based in Seoul.
Innocell becomes the fourth Korean Cord Blood Stem Cell Bank to select the
BioArchive System for their cord blood program.
Kevin Simpson, President and COO of ThermoGenesis Corp. said that "this
recent order from Korea is evidence that Asia is and will continue to be an
important driver of our BioArchive business as new cord blood stem cell banks
choose the BioArchive System to cryopreserve and archive their growing
inventories of cord blood samples. Our customer base in Asia continues to grow
and now includes eighteen cord blood banks in seven countries."
Mr. Simpson further noted that "we expect to see continued demand for
BioArchive in Asia as this area of the world has been under served by
traditional bone marrow registries. Cord blood serves as a readily available
source of stem cells for bone marrow rescue for hematological cancers and
genetic diseases such as Thalassemia, which occurs at an incredibly high rate
in Asia. Further, recent research suggests that there are stem cells in cord
blood that have the potential to produce other cells outside the hematopoietic
system such as neural, liver, heart and bone cells. Because there are serious
ethical issues with sourcing stem cells from embryos and fetuses, scientists
appear to be focusing on cord blood as a non-controversial source for these
multi-potential stem cells."
The BioArchive System plays a key role in the emerging world standards
that are being adopted for the processing and validation of stem cell units.
It provides sterile cell processing disposables and a computer-driven robotic
system to allow users to cryopreserve and archive up to 3,626 units of cord
blood stem cells in -196.C liquid nitrogen.
The BioArchive System can cryopreserve, archive and retrieve samples
within liquid nitrogen without exposing the samples to detrimental transient
warming events (TWE), which can reduce cell viability.

Regulatory Status
The BioArchive System is a Class II blood and blood component freezer
exempt from the pre-market notification procedures. The BioArchive System has
potential applications involving archiving, storing, managing and retrieving
other kinds of biological specimens, that may include stem cells, dendritic
cells, T-cells, cell lines, sperm cells, eggs, heart valves, corneas, virus
samples, biopsy samples and other blood, tissue and saliva samples. The
BioArchive System is currently intended for storage of blood and blood
components. Additional indications for use would require U.S. FDA clearance or
approval.

About ThermoGenesis Corp.
ThermoGenesis Corp. has been a pioneer in designing, manufacturing and
marketing micro-manufacturing systems which utilize robotic devices and
sterile disposable bag sets to collect, cryopreserve and archive blood
products such as hematopoietic stem cells, fibrin sealant and other related
blood products from single units of donor blood.

The statements contained in this release which are not historical facts
are forward-looking statements that are subject to risks and uncertainties
that could cause actual results to differ materially from those expressed in
the forward-looking statements, including, but not limited to, certain delays
beyond the company`s control with respect to market acceptance of new
technologies and products, delays in testing and evaluation of products, and
other risks detailed from time to time in the Company`s filings with the
Securities and Exchange Commission.

[RudiDutschke]

THERMOGENESIS` NETWORK OF STEM CELL BANKS IN ASIA CONTINUES TO EXPAND
New Cord Blood Stem Cell Bank in Korea Chooses the BioArchive® System



RANCHO CORDOVA, California (March 17, 2003) – THERMOGENESIS CORP. (Nasdaq: KOOL),
announced today that the Company has received its sixth BioArchive order from Korea. The system was
ordered by the Company`s distributor JR Global, for installation at a new Cord Blood Bank being formed in
Korea. The new Cord Blood Bank will be the fifth Korean Cord Blood Stem Cell Bank to select the
BioArchive System for their cord blood program.

Kevin Simpson, President and COO of THERMOGENESIS CORP. said that “this recent order from Korea is
evidence that Asia is and will continue to be an important driver of our BioArchive business as new Cord
Blood Stem Cell Banks choose the BioArchive System to cryopreserve and archive their growing inventories
of cord blood samples. Our customer base in Asia continues to grow and now includes nineteen cord blood
banks in seven countries.”

Mr. Simpson further noted that “we expect to see continued demand for BioArchive in Asia as this area of
the world has been under served by traditional bone marrow registries. Cord blood serves as a readily
available source of stem cells for bone marrow rescue for hematological cancers and genetic diseases such
as Thalassemia, which occurs at an incredibly high rate in Asia. Further, recent research suggests that there
are stem cells in cord blood that have the potential to produce other cells outside the hematopoietic system
such as neural, liver, heart and bone cells. Because there are serious ethical issues with sourcing stem cells
from embryos and fetuses, scientists appear to be focusing on cord blood as a non-controversial source for
these multi-potential stem cells.”

The BioArchive System plays a key role in the emerging world standards that are being adopted for the
processing and validation of stem cell units. It provides cell processing disposables and a computer-driven
robotic system to allow users to cryopreserve and archive up to 3,626 units of blood components in –196°C
liquid nitrogen.

The BioArchive System can cryopreserve, archive and retrieve samples within liquid nitrogen without
exposing the samples to detrimental transient warming events (TWE), which can reduce cell viability.

Regulatory Status
The BioArchive System is a Class II blood and blood component freezer exempt from the pre-market
notification. The BioArchive System has potential applications involving archiving, storing, managing and
retrieving other kinds of biological specimens, that may include stem cells, dendritic cells, T-cells, cell lines,
sperm cells, eggs, heart valves, corneas, virus samples, biopsy samples and other blood, tissue and saliva
samples. The BioArchive System is currently intended for storage of blood and blood components.
Additional indications for use would require U.S. FDA clearance or approval.

About THERMOGENESIS CORP.
THERMOGENESIS CORP. has been a pioneer in designing, manufacturing and marketing
micro-manufacturing systems which utilize robotic devices and sterile disposable bag sets to collect,
cryopreserve and archive blood products such as hematopoietic stem cells, fibrin sealant and other related
blood products from single units of donor blood.

The statements contained in this release which are not historical facts are forward-looking statements that
are subject to risks and uncertainties that could cause actual results to differ materially from those
expressed in the forward-looking statements, including, but not limited to, certain delays beyond the
company`s control with respect to market acceptance of new technologies and products, delays in testing
and evaluation of products, and other risks detailed from time to time in the Company`s filings with the
Securities and Exchange Commission.

[RudiDutschke]

THERMOGENESIS CORP. ANNOUNCES $4.8 MILLION FINANCING


RANCHO CORDOVA, California (March 21, 2003) – THERMOGENESIS CORP. (Nasdaq: KOOL),
announced completion of a private financing through the sale of approximately 3.1 million shares of its
common stock. In addition to the shares of common stock, the Company also issued three-year warrants
representing the right to acquire an additional 11,976 shares of common stock, in the aggregate, at an
exercise price of $2.39 per share. CDC Securities acted as the placement agent for the offering.
ThermoGenesis Corp. intends to use the net proceeds for working capital.

The private placement was solely with institutional investors. The transaction included new institutional
investors from Europe and certain current institutional stockholders. The Company reserves the right to close
on an additional $3.2 million in proceeds from institutions in discussion with the Company, no later than
March 31, 2003.

“We are pleased with the Company`s ability to continue to attract institutional investors, both existing and
new investors from Europe, further demonstrating confidence in our products and strategic direction,” said
Philip H. Coelho, ThermoGenesis Corp.’s Chief Executive Officer. “The placement will enhance the
Company’s balance sheet and support our efforts to execute a plan to bring the company to self sufficiency.
This plan, assembled by Kevin Simpson, President and COO, will include several margin improvement
activities, completion of the clinical trials of our CryoSeal® FS System here in the United States and
expansion of the marketing efforts of our BioArchive® System throughout the world. In a later press release
we will detail the components of this self sufficiency plan.”

About THERMOGENESIS CORP.
THERMOGENESIS CORP. has been a pioneer in designing, manufacturing and marketing
micro-manufacturing systems which utilize robotic devices and sterile disposable bag sets to collect,
cryopreserve and archive blood products such as hematopoietic stem cells, fibrin sealant and other related
blood products from single units of donor blood.

[RudiDutschke]

RAPIDLY GROWING CORD BLOOD STEM CELL MARKET IN ASIA CREATING STRONG
DEMAND FOR BIOARCHIVE® SYSTEM
New Korean Cord Blood Stem Cell Bank Chooses BioArchive® System





RANCHO CORDOVA, California (March 24, 2003) -- THERMOGENESIS CORP. (Nasdaq: KOOL)
announced today that the Company has received its seventh BioArchive order from Korea. The system was
ordered by the Company`s distributor Mirr SciTech, for installation at a new Cord Blood Bank being formed
by Boryung Biopharm in Korea. The new Cord Blood Bank will be the sixth Korean Cord Blood Stem Cell
Bank to select the BioArchive System for their cord blood program.

Kevin Simpson, President and COO of THERMOGENESIS
CORP. said that “this is our third order from Korea this quarter
and is evidence that this region is and will continue to be an
important driver of our BioArchive business as new cord blood
stem cell banks choose the BioArchive System to cryopreserve
and archive their growing inventories of cord blood samples.
Our customer base in Asia now includes twenty cord blood banks in seven countries.”

Mr. Simpson further noted that “we expect to see continued demand for BioArchive in Asia as this area of
the world has been under served by traditional bone marrow registries. Cord blood serves as a readily
available source of stem cells for bone marrow rescue for hematological cancers and genetic diseases such
as Thalassemia, which occurs at an incredibly high rate in Asia. Further, recent research suggests that there
are stem cells in cord blood that have the potential to produce other cells outside the hematopoietic system
such as neural, liver, heart and bone cells. Because there are serious ethical issues with sourcing stem cells
from embryos and fetuses, scientists appear to be focusing on cord blood as a non-controversial source for
these multi-potential stem cells.”

The BioArchive System plays a key role in the emerging world standards that are being adopted for the
processing and validation of stem cell units. It provides sterile cell processing disposables and a
computer-driven robotic system to allow users to cryopreserve and archive up to 3,626 units of blood
components in –196 degrees C liquid nitrogen. The BioArchive System can cryopreserve, archive and
retrieve samples within liquid nitrogen without exposing the samples to detrimental transient warming
events (TWE), which can reduce cell viability.

Regulatory Status
The BioArchive System is a Class II blood and blood component freezer exempt from the pre-market
notification procedures. The BioArchive System has potential applications involving archiving, storing,
managing and retrieving other kinds of biological specimens, that may include stem cells, dendritic cells,
T-cells, cell lines, sperm cells, eggs, heart valves, corneas, virus samples, biopsy samples and other blood,
tissue and saliva samples. The BioArchive System is currently intended for storage of blood and blood
components. Additional indications for use would require U.S. FDA clearance or approval.

About THERMOGENESIS CORP.
THERMOGENESIS CORP. has been a pioneer in designing, manufacturing and marketing
micro-manufacturing systems which utilize robotic devices and sterile disposable bag sets to collect,
cryopreserve and archive blood products such as hematopoietic stem cells, fibrin sealant and other related
blood products from single units of donor blood.

[RudiDutschke]

hermoGenesis Corp. Announces Closing of Equity Financing

RANCHO CORDOVA, Calif., April 1 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. ,
announced completion of a private financing involving the sale of its common stock to
institutional investors. The Company closed on an aggregate of approximately $5.8 million
in gross proceeds, including the previously reported $4.8 million. CDC Securities acted as
the placement agent for the offering and received a 7% fee, based on gross proceeds.
The Company issued a total of 3,807,565 shares of restricted common stock, and issued
three-year warrants representing the right to acquire an additional 11,976 shares of
common stock in the aggregate, exercisable at $2.39 per share. The Company will use
the net proceeds for working capital and implementation of operational plans. The
offering was a straight equity offering, and the terms did not contain any re-pricing
provisions.

The private placement was made solely with institutional investors including Deutsche
Bank and Clarion Capital Corporation. Terms and conditions of the offering are further
detailed in the Company`s filing on Form 8-K with the Securities and Exchange
Commission.

Philip Coelho, the Company`s CEO, commented, "We are very pleased with the interest
from a more varied group of investors in ThermoGenesis. This additional capital will allow
us to strengthen the company`s balance sheet and aid in creating more exposure to a
wider group of investors going forward. Kevin Simpson, President and COO, stated
further, "The receipt of these funds are timely as we are progressing towards conclusion
of our clinical trials, and sales revenues from our BioArchive(R) System continue to
increase, as international efforts continue to focus on newer technologies and
therapeutics that use umbilical cord blood stem cells. The additional working capital will
also aid in efforts to complete certain restructuring activities and implementation of
several cost reduction programs, particularly those directed towards increasing gross
profits and ultimate profitability, based on future events."

[RudiDutschke]

PharmaStem`s European Patent
10 Apr 2003, 06:00am ET
E-mail or Print this story


- - - - -

PharmaStem`s (Previously Named Biocyte) European Patent Revoked

RANCHO CORDOVA, Calif., April 10 /PRNewswire-FirstCall/ -- THERMOGENESIS
CORP. (Nasdaq: KOOL) announced today that on Monday, April 7, 2003, the
European Patent Office ("EPO") confirmed the revocation of PharmaStem
Corporation`s European patent on cryopreserved cord blood compositions and
uses thereof by dismissing PharmaStem`s appeal of an earlier ruling of the EPO
which revoked all 68 claims of the patent. The EPO announced the decision
at the end of a day long hearing during which it heard arguments from
PharmaStem as well as opposers of the patent, THERMOGENESIS CORP. and
Stitching Eurocord. The EPO determined that the cryopreserved cord blood
compositions and uses for such blood claimed in the PharmaStem Patent had
previously been discovered by others who had published their results and,
therefore, PharmaStem was not entitled to the patent. The decision of the
EPO is final and not appealable and applies throughout Europe.

According to Philip Coelho, Chief Executive Officer of THERMOGENESIS, "After
a four-year legal battle, the EPO has agreed with our position that the
PharmaStem patent should never have been issued in the first place." Cord
blood banks in Europe no longer need to fear they will be required to pay
onerous fees to PharmaStem in order to provide the life saving cord blood
stem cells to transplant patients suffering from leukemias, lymphomas, diverse
inherited anemias, such as sickle cell anemia and thalassemia, and other
genetic diseases.

About THERMOGENESIS CORP.

After extensive research, THERMOGENESIS CORP.`s newly introduced
technology platforms lead the world in their ability to produce biological
products from single units of blood. Umbilical cord blood banks are utilizing the
Company`s BioArchive System as a critical enabling technology for the
harvesting, processing and cryogenic archiving of stem cells for transplant,
while its CryoSeal(R) System is used to prepare hemostatic and adhesive
surgical sealants from patient blood in about an hour. THERMOGENESIS CORP.
has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma
Freezers and Thawers to hospitals and blood banks since 1992.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays
beyond the company`s control with respect to market acceptance of new
technologies and products, delays in testing and evaluation of products, and
other risks detailed from time to time in the Company`s filings with the
Securities and Exchange Commission.

[RudiDutschke]

Gibt es hier noch irgendjemanden?



ThermoGenesis Corp. Announces Order for 4th
BioArchive(R) System From Carolinas Cord Blood Bank at
Duke University Medical Center
29 Apr 2003, 09:34am ET
E-mail or Print this story


- - - - -

Clinical Success of Cord Blood Stem Cell Transplants Drives Need for Expanded
Inventory

RANCHO CORDOVA, Calif., April 29 /PRNewswire-FirstCall/ -- ThermoGenesis
Corp. (Nasdaq: KOOL) today announced the receipt of an order for a fourth
BioArchive System from Carolinas Cord Blood Bank which is part of the
Pediatric Bone Marrow Stem Cell Transplant (BMST) Program at Duke
University Medical Center. Under the direction of Joanne Kurtzberg, M.D., the
pediatric BMST program at Duke is an internationally recognized program
dedicated to providing outstanding care and support to pediatric patients who
can be helped by transplantation therapy. The program is known to be a
leader in both established techniques and research initiatives.

Kevin Simpson, President & COO of ThermoGenesis Corp. noted that, "We are
very pleased that the Carolinas Cord Blood Bank exclusively chooses our
BioArchive System as a means of processing and cryopreserving their cord
blood stem cell units as they are one of the world`s leading cord blood banks
and transplant services. Under the direction of Dr. Joanne Kurtzberg, the
pediatric BMST program has pioneered the use of cord blood as a source of
readily available stem cells for bone marrow rescue transplants and a variety
of other metabolic diseases."

Dr. Kurtzberg commented, "The BioArchive System represents
state-of-the-art technology for the processing, storage and retrieval of cord
blood stem cell units and supports FDA`s proposed GTP`s ("Good Tissue
Practices") within the Carolinas Cord Blood Bank. Using a variety of
approaches our transplant program has pioneered the use of both matched
and mismatched umbilical cord blood stem cells in patients who do not have a
sibling donor, thus extending this life-saving therapy to many more patients.
We know that sometimes quick identification can be very important for
patients with inborn errors of metabolism, bone marrow failure,
immunodeficiency syndromes, or advanced leukemias. The cord blood program
allows us to identify unrelated donors quickly (generally within a few weeks)."

The BioArchive System plays a key role in the emerging world cord blood
standards that are being adopted for the processing and storage of stem cell
units. A computer-driven robotic system to allow users to cryopreserve and
archive up to 3,626 units of blood components in -196 degrees C liquid
nitrogen. The BioArchive System can cryopreserve, archive and retrieve
samples within liquid nitrogen without exposing the samples to detrimental
transient warming events (TWE), which can reduce cell viability.

Regulatory Status

The BioArchive System is a Class II blood and blood component freezer
exempt from the pre-market notification procedures. The BioArchive System
has potential applications involving archiving, storing, managing and retrieving
other kinds of biological specimens, that may include stem cells, dendritic
cells, T-cells, cell lines, sperm cells, eggs, heart valves, corneas, virus
samples, biopsy samples and other blood, tissue and saliva samples. The
BioArchive System is currently intended for storage of blood and blood
components. Additional indications for use would require U.S. FDA clearance
or approval.

About Pediatric BMST at Duke University Medical Center

The program provides transplant as a treatment option for a variety of
acquired and congenital disorders of children and young adults including
hematopoietic malignancies and solid tumors, inherited immune deficiency
syndromes, bone marrow failure syndromes, and inherited metabolic diseases.
Allogeneic and autologous bone marrow, eripheral stem cell and umbilical cord
blood transplants have been performed for pediatric patients to treat these
diseases. Under the direction of Joanne Kurtzberg, M.D., the program has
performed approximately 900 autologous and allogeneic transplants in children
with cancer or genetic diseases since 1990.

About ThermoGenesis Corp.

After extensive research, ThermoGenesis Corp.`s newly introduced technology
platforms lead the world in their ability to produce biological products from
single units of blood. Umbilical cord blood banks are utilizing the Company`s
BioArchive System as a critical enabling technology for the harvesting,
processing and cryogenic archiving of stem cells for transplant. The
CryoSeal(R) FS System is used to prepare hemostatic and adhesive surgical
sealants from patient blood in about an hour. ThermoGenesis Corp. has been
a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and
Thawers to hospitals and blood banks since 1992.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays
beyond the company`s control with respect to market acceptance of new
technologies and products, delays in testing and evaluation of products, and
other risks detailed from time to time in the Company`s filings with the
Securities and Exchange Commission.

SOURCE ThermoGenesis Corp.

[RudiDutschke]

14 May 2003, 06:00am ET
E-mail or Print this story


- - - - -

BioArchive(R) Revenues Significantly Increased, Restructuring Plan
Initiated and Balance Sheet Strengthened

RANCHO CORDOVA, Calif., May 14 /PRNewswire-FirstCall/ -- THERMOGENESIS CORP.
(Nasdaq: KOOL) today announced results for its third quarter of fiscal year 2003,
ended March 31, 2003. The Company reported net revenues for the third quarter of
$2,886,000, a 6% increase when compared to $2,735,000 reported in the third
quarter of last year. For the nine months ended March 31, 2003 the Company`s net
revenues increased 8% to $7,289,000 compared to $6,720,000 for the first nine
months of the prior year.

This quarter represents the first three months of operations under the direction of
Kevin Simpson, the Company`s new President and COO who has more than 20 years of
executive management experience in the field of life sciences, 12 years specifically in
the blood industry.

"Revenues continued to increase in our two pipeline product lines, BioArchive and
CryoSeal(R), for the three and nine months ended March 31, 2003," stated Kevin
Simpson. "We are especially pleased that the increasing momentum in BioArchive and
CryoSeal sales offset the decline in ThermoLine revenues which were inflated in the
prior year as a result of a large order for plasma freezers received from Aventis
Bio-Services, Inc. Additionally, revenues from BioArchive and CryoSeal disposables
sold to existing customers increased 216% over the prior year third quarter and we
anticipate continuing growth in these products."

Despite the increase in revenues, the Company`s gross profit decreased $123,000
from the quarter ended March 31, 2002 to the quarter ended March 31, 2003. The
decrease was primarily due to the higher overhead resulting from lower units produced
in-house and increased contract service expenses. In order to improve future gross
profit margins, the Company has implemented a restructuring plan designed to
achieve the improvements in overall gross profit margins necessary for the Company
to achieve self-sufficiency and profitable growth. This plan will be executed in three
parts: (1) focus the Company`s marketing and sales efforts to improve the revenues
and selling prices of the CryoSeal and BioArchive product lines, (2) reduce the
in-house direct and overhead costs of manufacturing, and (3) identify alternative
OEM supplier relationships that will provide low cost and high quality disposables. As
part of the restructuring plan, on April 9, 2003, the Company reduced the personnel
costs in manufacturing overhead by approximately $500,000 and direct labor by
$100,000 on an annual basis.

The Company`s balance sheet was strengthened upon completion of an equity
financing during the third quarter of fiscal year 2003, which generated $5.3 million in
net proceeds. "Our ability to raise funds in the current market speaks to the investors
confidence in the Company`s restructuring plan and strategic direction," stated Philip
Coelho, Chairman and CEO. "Additionally, we initiated efforts in the third quarter to
promote the federal financing of a National Cord Blood Stem Cell Bank Network. The
proposed legislation would provide for the collection and cryogenic archiving of
200,000 cord blood stem cell units to be used in the treatment of life threatening
diseases to replace the bone marrow of victims of radiation exposure from potential
terrorist attacks." Although uncertain in light of current fiscal and budgetary debates
in Congress, the Company is hopeful that a bill providing for the funding will be
introduced over the next six months.

Company Conference Call

Management will host a conference call today, March 14, 2003 at 11:00 am PDT
(2:00 pm EDT) to review the fiscal third quarter financial results and other corporate
events, followed by a Q&A session. The call can be accessed by dialing:
800-860-2442 within the U.S. or 412-858-4600 outside the U.S. Participants are
asked to call the assigned number approximately 5 minutes before the conference call
begins. A replay of the conference call will be available two hours after the call for
the following five business days by dialing: 877-344-7529 within the U.S. or
412-858-1440 outside the U.S. and entering the following account number: 715 and
the following passcode: 317050.

About ThermoGenesis Corp.

After extensive research, ThermoGenesis Corp.`s newly introduced technology
platforms lead the world in their ability to produce biological products from single units
of blood. Umbilical cord blood banks are utilizing the Company`s BioArchive System as
a critical enabling technology for the processing and cryogenic archiving of stem cells
for transplant. The CryoSeal FS System is used to prepare hemostatic and adhesive
surgical sealants from patient blood in about an hour. CryoSeal FS System is not
available in the United States. ThermoGenesis Corp. has been a leading supplier of
state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and
blood banks since 1992.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that could
cause actual results to differ materially from those expressed in the forward-looking
statements, including, but not limited to, certain delays beyond the Company`s
control with respect to market acceptance of new technologies and products, delays
in testing and evaluation of products and other risks detailed from time to time in the
Company`s filings with the Securities and Exchange Commission.

THERMOGENESIS CORP.
Condensed Statements of Operations
(Unaudited)

Three Months Ended Nine Months Ended
March 31, March 31,
2003 2002 2003 2002

Net revenues $2,886,000 $2,735,000 $7,289,000 $6,720,000

Cost of revenues 2,375,000 2,101,000 6,010,000 5,211,000

Gross profit 511,000 634,000 1,279,000 1,509,000

Expenses:

Selling, general and
administrative 1,386,000 1,184,000 3,755,000 3,433,000

Research and
development 795,000 652,000 2,183,000 1,708,000

Total operating
expenses 2,181,000 1,836,000 5,938,000 5,141,000

Interest and other
income/(expenses) 4,000 2,000 47,000 64,000

Net loss $(1,666,000) $(1,200,000) $(4,612,000) $(3,568,000)

Basic and diluted net
loss per common share ($0.05) ($0.04) ($0.13) ($0.11)

Shares used in
computing per
share data 36,570,697 32,745,103 35,700,791 32,051,362


THERMOGENESIS CORP.
Condensed Balance Sheets
(Unaudited)

March 31, June 30,
2003 2002
ASSETS
Current assets:
Cash, cash equivalents and short
term investments $7,208,000 $6,726,000
Accounts receivable, net 2,041,000 1,916,000
Inventory 2,896,000 2,887,000
Other current assets 615,000 115,000

Total current assets 12,760,000 11,644,000

Equipment, net 472,000 537,000

Other assets 54,000 58,000

$13,286,000 $12,239,000

LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $1,028,000 $995,000
Other current liabilities 1,218,000 1,018,000

Total current liabilities 2,246,000 2,013,000

Long-term obligations 49,000 33,000

Stockholders` equity 10,991,000 10,193,000

$13,286,000 $12,239,000

[RudiDutschke]

BioArchive(R) System Use Expands to 46 Cord Blood
Banks (CBB) in 21 Countries To Cryopreserve and Archive
Their Units of Stem Cells Derived from Cord Blood and
Other Sources
22 May 2003, 06:00am ET
E-mail or Print this story


- - - - -

Medical College of Georgia Chooses the BioArchive System for Their Stem Cell
Research Laboratory

RANCHO CORDOVA, Calif., May 22 /PRNewswire-FirstCall/ -- ThermoGenesis
Corp. (Nasdaq: KOOL) announced today that the Company received an order
for the BioArchive System from the Institute of Molecular Medicine and
Genetics (IMMAG) of Medical College of Georgia. The BioArchive System is
utilized as a critical enabling technology for the processing and storage of
cell therapy products used for the treatment of leukemias, lymphomas,
diverse inherited anemias, such as sickle cell anemia and thalassemia, and
other genetic diseases.

A group of scientists led by the director of institute, Dr. Robert Yu is starting
the first stem cell bank in Georgia. "Recent advancement in stem cell
research motivates us to strengthen our efforts in the application of basic
stem cell biology. Our Institute is a multidisciplinary research institute
devoted to both basic and clinical biomedical science. I think this integrative
environment will foster us the success in stem cell research, and the
establishment of the stem cell bank is a milestone of this endeavor," said Dr.
Sean Liour, a stem cell scientist and the co-director of the proposed stem
cell bank. "We are happy to use ThermoGenesis Corp.`s proprietary
technology as our cord blood stem cell storage solution."

Kevin Simpson, President & COO of ThermoGenesis Corp. commented, "We
are very pleased to add the IMMAG at the Medical College of Georgia as one
of our newest customers. It is encouraging for us to see the BioArchive
System incorporated in new research programs in addition to our standard
cord blood bank customers."

There are now 46 CBB in 21 countries that have chosen the BioArchive
System. In North and South America, BioArchive Systems have been
deployed in the US, Canada, Mexico, and Brazil. In Europe and the Middle
East, BioArchive Systems have been placed at the major Cord Blood Stem
Cell Banks in Austria Germany, United Kingdom, France, Spain, Belgium,
Finland, Netherlands, Russia and Israel. In the Asia region, ThermoGenesis`
BioArchive Systems have been deployed in Japan, China, Taiwan, Vietnam,
South Korea, Malaysia and India.

The BioArchive System plays a key role in the emerging world cord blood
standards that are being adopted for the processing and storage of stem cell
units. A computer-driven robotic system to allow users to cryopreserve and
archive up to 3,626 units of blood components in -196 degrees C liquid
nitrogen. The BioArchive System can cryopreserve, archive and retrieve
samples within liquid nitrogen without exposing the samples to detrimental
transient warming events (TWE), which can reduce cell viability.

Regulatory Status

The BioArchive System is a Class II blood and blood component freezer
exempt from the pre-market notification procedures. The BioArchive System
has potential applications involving archiving, storing, managing and
retrieving other kinds of biological specimens, that may include stem cells,
dendritic cells, T-cells, cell lines, sperm cells, eggs, heart valves, corneas,
virus samples, biopsy samples and other blood, tissue and saliva samples.
The BioArchive System is currently intended for storage of blood and blood
components. Additional indications for use would require U.S. FDA clearance
or approval.

About ThermoGenesis Corp.

After extensive research, ThermoGenesis Corp.`s newly introduced
technology platforms lead the world in their ability to produce biological
products from single units of blood. Umbilical cord blood banks are utilizing
the Company`s BioArchive System as a critical enabling technology for the
harvesting, processing and cryogenic archiving of stem cells for transplant.
The CryoSeal(R) FS System is used to prepare hemostatic and adhesive
surgical sealants from patient blood in about an hour. ThermoGenesis Corp.
has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma
Freezers and Thawers to hospitals and blood banks since 1992.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays
beyond the company`s control with respect to market acceptance of new
technologies and products, delays in testing and evaluation of products, and
other risks detailed from time to time in the Company`s filings with the
Securities and Exchange Commission.

[RudiDutschke]

Meinungen zum Kursverlauf???

[RudiDutschke]

18 Klicks, aber keine Meinungen?

[RudiDutschke]

ThermoGenesis Scientific Advisory Board Members to
Present at June 12, 2003 Senate Hearing
12 Jun 2003, 06:00am ET
E-mail or Print this story


- - - - -

ThermoGenesis Scientific Advisory Board Members Present Clinical Data

On the Use of Cryopreserved Cord Blood Stem Cells in the Treatment of
Lethal

Diseases at June 12, 2003 Senate Hearing

RANCHO CORDOVA, Calif., June 12 /PRNewswire-FirstCall/ --
ThermoGenesis Corp. (Nasdaq: KOOL) announced today that this Senate
Hearing will feature clinical data from Dr.`s Pablo Rubinstein (New York
Blood Center (NYBC)) and Joanne Kurtzberg (Duke University Medical
Center) who pioneered this form of cell therapy on the use of neonatal
cord blood stem cells in the treatment of malignant (i.e., leukemia,
lymphoma), genetic (immunodeficiencies like the "boy in the bubble",
hemoglobinopathies like sickle cell anemia and thalassemia, and metabolic,
such as Hurler`s and Krabbe`s diseases) and acquired diseases like
refractory aplastic anemia. Cord blood as a source of stem cells is available
faster than bone marrow and provides survival rates for patients with
uniformly fatal diseases that can be as good as those following adult donor
bone marrow donations through the registries.

In addition to the presentations of data, three patients treated with cord
blood transplants (one with sickle cell anemia, another with chronic
myelogenous leukemia (CML) and the father of four-year-old with
adrenoleukodystrophy (ALD)) will provide personal testimony.

According to Dr. Pablo Rubinstein of NYBC, "While this research utilized
stem cells sourced from cord blood, we believe all other stem cell sources
should be investigated on their own merits. Our perspective is that the
cord blood transplants, that are helping cure lethal diseases and are
currently available for hundreds of U.S. patients each year, should become
available to the thousands of patients who need them and cannot
currently get them from the "walking donor" bone marrow registries (as
disclosed in the GAO Report, October 2002). To achieve that goal will
require increasing the available cryopreserved inventory to 100-200,000
units of cord blood with federal funding. This inventory will be a National
treasure."

Philip Coelho, Chairman & CEO of ThermoGenesis Corp commented, "The
evolution of this unique cell therapy is an excellent demonstration of U.S.
medical research functioning well -- with both federal health agencies and
academic research institutions each fulfilling their roles in promoting and
accomplishing promising research through to tangible health benefits for
U.S. citizens. The role of ThermoGenesis has been the development of the
BioArchive(R) System -- an advanced robotic method of cryopreservation
and long-term storage used by the major Cord Blood Banks in 22 countries.
Following the first sibling-donor cord blood transplant in 1988, the NIH
approved Dr. Rubinstein`s grant proposal to develop the worlds first cord
blood program at the New York Blood Center, in order to establish the
inventory of stem cell units necessary to provide unrelated, matched grafts
for patients (1992). In 1993, Dr. Joanne Kurtzberg of Duke University
Medical Center performed the first two successful cord blood transplants,
in the unrelated setting, one of which cured a patient with acute
lymphoblastic leukemia (ALL). By 1996, with more than 300 unrelated
transplants accomplished, the FDA accepted the New York Blood Center`s
request for an Investigational New Drug (IND) Exemption which allowed the
expansion of the clinical use of cord blood under conditions that
documented the critical processing protocols and the clinical outcome data
which would allow the FDA to understand how best to regulate this
promising cell therapy. Today, the FDA, with these clinical outcome data in
hand, is considering the licensing of this cell therapy product. The
Agency`s involvement will assure that cord blood stem cell units to be
utilized in routine patient treatment will be in compliance with the
necessary standards."

"We believe the best way to rally public support for stem cell research is to
publicize the wonderful results already obtained with the clinical application
of cord blood stem cells to the dread diseases mentioned above."
Legislation to provide the funds necessary to build the inventory of cord
blood stem cells for our ethnically diverse community is being prepared for
introduction early this summer.

The BioArchive System plays a key role in the emerging world cord blood
standards that are being adopted for the processing and storage of blood
components. A computer-driven robotic system to allow users to
cryopreserve and archive up to 3,626 units of blood components in -196
degrees C liquid nitrogen. The BioArchive System can cryopreserve, archive
and retrieve samples within liquid nitrogen without exposing the samples to
detrimental transient warming events (TWE), which can reduce cell
viability.

About ThermoGenesis Corp.

After extensive research, ThermoGenesis Corp.`s newly introduced
technology platforms lead the world in their ability to produce biological
products from single units of blood. Umbilical cord blood banks are utilizing
the Company`s BioArchive System as a critical enabling technology for the
harvesting, processing and cryogenic archiving of stem cells for transplant.
The CryoSeal(R) FS System is used to prepare hemostatic and adhesive
surgical sealants from patient blood in about an hour. ThermoGenesis Corp.
has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma
Freezers and Thawers to hospitals and blood banks since 1992.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays
beyond the company`s control with respect to market acceptance of new
technologies and products, delays in testing and evaluation of products,
and other risks detailed from time to time in the Company`s filings with the
Securities and Exchange Commission.

[RudiDutschke]

ThermoGenesis Corp.`s CryoSeal(R) FS System Receives
Product Registration In Brazil
19 Jun 2003, 2:17pm ET
E-mail or Print this story


- - - - -

Company Initiates Market Launch Activities for the CryoSeal Fibrin Sealant
(FS) System in Brazil

RANCHO CORDOVA, Calif., June 19 /PRNewswire-FirstCall/ -- ThermoGenesis
Corp. (Nasdaq: KOOL) today announced that its Brazilian distributor, CEI, based
in Rio de Janeiro, has successfully completed registration of the CryoSeal FS
System with the Brazilian Ministry of Health. This will now permit the import of
the system into Brazil and allow sales efforts to commence.

Kevin Simpson, President and COO of ThermoGenesis Corp. commented, "We`re
pleased that CEI has obtained the required regulatory approval. CEI is a
well-respected sales and marketing organization of medical devices and blood
processing disposables, with strong ties to both the blood bank and surgical end
user customers for the CryoSeal FS System in Brazil. This registration will allow
CEI to begin the clinical evaluations at leading surgery hospitals required for a
successful product launch."

Ana Pacheco, Vice President for CEI commented, "We are pleased to be able to
market the first total human fibrin sealant into the Brazilian market. Now that we
have completed the registration process, we can begin placing systems at
selected locations to begin the evaluations that are needed for launching the
product. While we expect it to take some time to develop the concept of
Autologous and single donor Homologous fibrin sealant, our pre-marketing
activities have shown us that there is a demand for this product and we will
work closely with our partner ThermoGenesis to assure a successful market
entry."

The CryoSeal FS System prepares both components (cryoprecipitate and
thrombin) of CryoSeal Fibrin Sealant from a single unit of autologous human
plasma in about an hour. Once prepared, the CryoSeal Fibrin Sealant may be
frozen or used immediately as a hemostatic agent for patients undergoing liver
resection.

Conventional fibrin sealants, which are sourced from pooled plasma of 10,000 or
more units, remain vulnerable to new and re-emerging pathogens. Newly
discovered hepatitis viruses, such as parvovirus B-19, and other agents of
transmissible spongiform encephalopathies have been known to compromise the
safety of homologous plasma provided in the form of fresh frozen plasma to
surgical patients.

In contrast to commercially available fibrin sealants, CryoSeal Fibrin Sealant is
free of animal proteins such as bovine thrombin or bovine aprotinin. Animal
proteins are a potential source of viral and prion contamination to blood
products, the latter of which are resistant to all forms of viral inactivation
technology available to fractionators at this time.

Regulatory Status

In March of 2001, the CryoSeal FS System received CE Mark approval from the
European Union Competent Authorities to initiate commercialization of the
CryoSeal FS System in Europe. The CryoSeal System is patent-protected, and
will require a pre-market approval by the U.S. FDA before marketing in the U.S.
Until U.S. FDA approval, the CryoSeal FS System, including FS applicator kits,
will be marketed, as permitted under U.S. Export Laws, applicable foreign
regulations, in geographies including Latin America, South America, Asian Pacific
Rim, Australia and ROW. In May 2001, the CryoSeal FS System received a
license to market in Canada.

About ThermoGenesis Corp.

After extensive research, ThermoGenesis Corp.`s newly introduced technology
platforms lead the world in their ability to produce biological products from single
units of blood. Umbilical cord blood banks are utilizing the Company`s
BioArchive(R) System as a critical enabling technology for the harvesting,
processing and cryogenic archiving of stem cells for transplant. The CryoSeal FS
System is used to prepare hemostatic and adhesive surgical sealants from
patient blood in about an hour. ThermoGenesis Corp. has been a leading supplier
of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals
and blood banks since 1992.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company`s control with respect to market acceptance of new technologies
and products, delays in testing and evaluation of products, and other risks
detailed from time to time in the Company`s filings with the Securities and
Exchange Commission.

[RudiDutschke]

ThermoGenesis Corp. Announces New Marketing
Direction for CryoSeal(R) in Japan
20 Jun 2003, 09:00am ET
E-mail or Print this story


- - - - -

Asahi Marketing and Distribution Relationship Ended

RANCHO CORDOVA, Calif., June 20 /PRNewswire-FirstCall/ --
ThermoGenesis Corp. (Nasdaq: KOOL) announced today that its marketing
and distribution relationship with Asahi Medical Co. Ltd. has ended
pursuant to the terms of the agreement, opening up new avenues for the
Company to distribute its CryoSeal product in Japan. The Company
intends to aggressively pursue a new partner for the Japanese CryoSeal
market that will include consideration of their manufacturing capacity to
supply Japan and other Asian markets.

Philip Coelho, the Company`s CEO, commented that, "Japan represents an
important market for ThermoGenesis` CryoSeal product and we look
forward to a smooth transition to a new partner that will further the
Company`s goal of increasing its CryoSeal sales outside of the U.S.
market." Kevin Simpson, President and COO, further noted that, "the
recent addition of working capital from our March financing, allows us to
implement specific restructuring activities around the CryoSeal directed
toward increased future revenues, cost reduction programs, and
profitability."

[fritzchenI]

Rudi lebst du auch noch altes Haus-weisst -dies ist die
einzige Aktie bei mir im Stall die halbwegs im rahmen liegt-sonst hab ich nur totalausfälle
Meinst du das endlich mal höhere Kurse zu sehen sind-hab die aktie jetzt 2,5 Jahre ca. und es hat sich eigentlich nichts bewegt-was ja eigentlich hervorragend schon ist
-siehst du potential
Gruss

[analle]

solangsam wirds richtig kool. Habe die Aktie schon lange im Depot, eine der wenigen, die sich richtig gut gehalten hat.

[RudiDutschke]

Collaboration With ThermoGenesis For CryoSeal(R) in
Japan
1 Jul 2003, 1:13pm ET
E-mail or Print this story


- - - - -

Marketing and Distribution Relationship Continues in Full Force and Effect

TOKYO, Japan, July 1 /PRNewswire/ -- ASAHI MEDICAL COMPANY LTD.
announced that, contrary to earlier reports, its marketing and distribution
relationship with ThermoGenesis (Nasdaq: KOOL) would continue into the
foreseeable future. ThermoGenesis`s earlier announcement on June 20,
2003 that its marketing and distribution relationship with Asahi had ended
was simply mistaken. The Distribution and Manufacturing License
Agreement is still in force. Under the Agreement, Asahi Medical has the
exclusive right to market the CryoSeal(R) System, including the CryoStat
freezing and thawing thermodynamic device and Auto-Cryo Kit in Japan.

Asahi Medical is excited and enthusiastic about the System, and is
currently conducting multi-center clinical trial in Japan in order to apply to
the Ministry of Health, Labour and Welfare (MHLW) and to commercialize
the System in the near future.

About ASAHI MEDICAL COMPANY LTD.

Asahi Medical is a world leader in research, development, and production
of devices and systems for blood treatment and purification based on
advanced membrane separation and adsorption technologies. It serves
the global market with dialysis products, plasma therapy products, and
blood transfusion products for medical therapy in many countries. Asahi
Medical was founded in 1974 as a wholly owned subsidiary of Asahi Kasei
Corporation. Asahi Medical`s tradition of leadership in membrane and
related blood treatment technologies spans several decades, and its
dedicated and continuing research and development draw and build upon
the underlying strengths of its parent company Asahi Kasei, which is a
world leader in fibers, biotechnology, and other materials and process
technologies.

[RudiDutschke]

Quarter
3 Jul 2003, 06:00am ET
E-mail or Print this story


- - - - -

48 Cord Blood Stem Cell Banks in 21 Countries Have Now Adopted ThermoGenesis
Technology

RANCHO CORDOVA, Calif., July 3 /PRNewswire-FirstCall/ -- ThermoGenesis Corp.
(Nasdaq: KOOL), announced today that the Company received orders for five (5)
BioArchive Systems in June bringing to seven (7) the total number of orders
received in the fourth quarter. The seven orders came from four (4) repeat
customers and three (3) new customers bringing the total number of cord blood
banks who have chosen the BioArchive System to a record of 48 in 21 countries.

Kevin Simpson, President & COO of ThermoGenesis Corp. commented, "We are
very pleased with the addition of three new cord blood banks to our existing
base of 45 centers who have chosen the BioArchive System for the processing
and storage of umbilical cord blood stem cells. This is further evidence that the
BioArchive System is rapidly becoming the international standard in this area."

In North and South America, BioArchive Systems have been deployed in the US,
Canada, Mexico, and Brazil. In Europe and the Middle East, BioArchive Systems
have been placed at the major Cord Blood Stem Cell Banks in Austria Germany,
United Kingdom, France, Spain, Belgium, Finland, Netherlands, Russia and Israel.
In the Asia region, ThermoGenesis` BioArchive Systems have been deployed in
Japan, China, Taiwan, Vietnam, South Korea, Malaysia and India.

Dan Segal, Vice President of Sales & Marketing commented, "Despite some
slowdown in our BioArchive sales activity in Asia due to SARS, we continue to
see strong demand for the BioArchive System from new customers as well as
from our installed base customers in North America and Europe. We believe this
demonstrates our success in developing a demand for this product that is global
and broad based."

The BioArchive System plays a key role in the emerging world standards that are
being adopted for the processing and storage of cord blood stem cell units. It
features a computer-driven robotic system which the cord blood banks use to
cryopreserve and archive up to 3,626 units of cord blood stem cells at -196
degrees C. The BioArchive System can cryopreserve, archive and retrieve
samples within liquid nitrogen without exposing the samples to detrimental
transient warming events (TWE), which can reduce cell viability.

Regulatory Status

The BioArchive System is a Class II blood and blood component freezer exempt
from the pre-market notification procedures. The BioArchive System has
potential applications involving archiving, storing, managing and retrieving other
kinds of biological specimens, that may include stem cells, dendritic cells,
T-cells, cell lines, sperm cells, eggs, heart valves, corneas, virus samples, biopsy
samples and other blood, tissue and saliva samples. The BioArchive System is
currently intended for storage of blood and blood components. Additional
indications for use would require U.S. FDA clearance or approval.

About ThermoGenesis Corp.

After extensive research, ThermoGenesis Corp.`s newly introduced technology
platforms lead the world in their ability to produce biological products from single
units of blood. Umbilical cord blood banks are utilizing the Company`s
BioArchive(R) System as a critical enabling technology for the harvesting,
processing and cryogenic archiving of stem cells for transplant, while its
CryoSeal System is used to prepare hemostatic and adhesive surgical sealants
from patient blood in about an hour. ThermoGenesis Corp. has been a leading
supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to
hospitals and blood banks since 1992.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company`s control with respect to market acceptance of new technologies
and products, delays in testing and evaluation of products, and other risks
detailed from time to time in the Company`s filings with the Securities and
Exchange Commission.

[analle]

[analle]

Geld 3,10

Brief 3,40

weiter gehts.

[RudiDutschke]

Clearance for Thawing of Frozen Red Blood Cells
9 Jul 2003, 08:00am ET
E-mail or Print this story


- - - - -

Prime Application for Military Use

RANCHO CORDOVA, Calif., July 9 /PRNewswire-FirstCall/ --
THERMOGENESIS CORP. (Nasdaq: KOOL) announced today that the Food
and Drug Administration (FDA) cleared the ThermoGenesis Medical Thawer
for use with frozen glycerolized red blood cells (RBC).

Originally FDA cleared to thaw frozen blood plasma, these sophisticated
heat transfer devices provide fast, efficient thawing of plasma and
glycerolized RBC without damaging delicate cells or proteins -- 12 minutes
for a frozen 250ml plasma bag and 35 minutes for a frozen 450ml
glycerolized RBC bag. Three models (MT202, MT204 and MT210) provide
simultaneous thawing for two, four or ten frozen units, respectively.

This new RBC clearance will benefit the Armed Services Whole Blood
Processing Laboratories (ASWBPL) in their efforts to supply the
Department of Defense`s frozen blood reserves to support military
contingency requirements.

Kevin Simpson, President and COO indicated, "This clearance opens up a
new market for our Medical Thawer product line which we expect to drive
additional unit sales. The military`s frozen blood supply is managed by the
Joint Blood Program Office (JBPO) through the Blood Products Depots
(BPD). The BPDs are charged with maintaining and processing large
quantities of frozen blood for use during armed conflicts and emergencies.
With this clearance we will now begin our marketing efforts to the JBPO
and to our existing blood center customers who currently thaw red cells
for their hospitals accounts."

About THERMOGENESIS CORP.

After extensive research, ThermoGenesis Corp.`s newly introduced
technology platforms lead the world in their ability to produce biological
products from single units of blood. Umbilical cord blood banks are utilizing
the Company`s BioArchive(R) System as a critical enabling technology for
the harvesting, processing and cryogenic archiving of stem cells for
transplant, while its CryoSeal(R) System is used to prepare hemostatic
and adhesive surgical sealants from patient blood in about an hour.
ThermoGenesis Corp. has been a leading supplier of state-of-the-art
Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and blood
banks since 1992.

The statements contained in this release which are not historical facts
are forward-looking statements that are subject to risks and uncertainties
that could cause actual results to differ materially from those expressed in
the forward-looking statements, including, but not limited to, certain
delays beyond the company`s control with respect to market acceptance
of new technologies and products, delays in testing and evaluation of
products, and other risks detailed from time to time in the Company`s
filings with the Securities and Exchange Commission.

[analle]

mal wieder noch besser,* alle andere.

[RudiDutschke]

Introduced in the House of Representatives (HR 2852)
25 Jul 2003, 06:00am ET
E-mail or Print this story


- - - - -

Clinical Data Presentations by ThermoGenesis Scientific Advisory Board Members
Persuasive to Congress

RANCHO CORDOVA, Calif., July 25 /PRNewswire-FirstCall/ -- ThermoGenesis
Corp. (Nasdaq: KOOL) announced today that HR 2852 titled "Cord Blood Stem
Cell Act of 2003" was introduced in the House of Representatives "to establish
a National Cord Blood Stem Cell Bank network to prepare, store and distribute
human umbilical cord blood stem cells for the treatment of patients and to
support peer-reviewed research using such cells." The lead sponsors were
Congressmen Chris Smith (R, NJ), Richard Burr (R, NC), Artur Davis (D, AL),
Edolphus Towns (D, NY) and Congresswoman Anna Eshoo (D, CA).

According to Philip Coelho, CEO, this landmark legislation was in response to the
June 12th Senate Hearing presentations of clinical data from Dr.`s Pablo
Rubinstein (New York Blood Center (NYBC)) and Joanne Kurtzberg (Duke
University Medical Center) who pioneered this form of cell therapy. Neonatal
cord blood stem cells were used in the treatment of genetic, metabolic and
blood diseases, such as leukemia, lymphoma, sickle cell anemia, and
immunodefeciencies ("boy in the bubble"). Cord blood as a source of stem cells
is available faster than bone marrow and provides survival rates for patients
with uniformly fatal diseases that can be as good as those following adult donor
bone marrow donations through the registries.

Philip Coelho further commented, "The federal financing of this large inventory
of cord blood stem cell units provided by this legislation will complete the
evolution of this unique cell therapy from pure research to routine clinical
practice and is an excellent demonstration of U.S. medical research functioning
well -- with both federal health agencies and academic research institutions
each fulfilling their roles in promoting promising research through to tangible
health benefits for U.S. citizens."

Kevin Simpson, President and COO of ThermoGenesis, noted that, "Cord blood
transplants are currently curing hundreds of U.S. patients from these otherwise
lethal diseases each year. However, the 150,000-unit inventory which will be
collected pursuant to this legislation should provide life saving stem cell
transplant for the thousands of patients each year who need them and cannot
currently get them from the `walking donor` bone marrow registries (as disclosed
in the GAO Report, October 2002). This inventory will be a National treasure."

The role of ThermoGenesis has been the development of the BioArchive(R)
System -- an advanced robotic method of cryopreservation and long-term
storage used by the major Cord Blood Banks in 21 countries. Following the first
sibling-donor cord blood transplant in 1988, the NIH approved Dr. Rubinstein`s
grant proposal to develop the world`s first cord blood program at the NYBC, in
order to establish the inventory of stem cell units necessary to provide
unrelated, matched grafts for patients (1992). In 1993, Dr. Joanne Kurtzberg
performed the first two successful cord blood transplants, in the unrelated
setting, one of which cured a patient with acute lymphoblastic leukemia (ALL).
By 1996, with more than 300 unrelated transplants accomplished, the FDA
accepted the NYBC`s request for an Investigational New Drug (IND) Exemption
which allowed the expansion of the clinical use of cord blood under conditions
that documented the critical processing protocols and the clinical outcome data
which would allow the FDA to understand how best to regulate this promising
cell therapy. Today, the FDA, with these clinical outcome data in hand, is
considering the licensing of this cell therapy product. The Agency`s involvement
will assure that cord blood stem cell units to be utilized in routine patient
treatment will be in compliance with the necessary standards.

Simpson further noted, "We believe the best way to rally public support for
stem cell research is to publicize the wonderful results already obtained with
the clinical application of cord blood stem cells to the dreaded diseases
mentioned above."

The BioArchive System plays a key role in the emerging world cord blood
standards that are being adopted for the processing and storage of blood
components. A computer-driven robotic system to allow users to cryopreserve
and archive up to 3,626 units of blood components in -196 degrees C liquid
nitrogen. The BioArchive System can cryopreserve, archive and retrieve
samples within liquid nitrogen without exposing the samples to detrimental
transient warming events (TWE), which can reduce cell viability.

About ThermoGenesis Corp.

After extensive research, ThermoGenesis Corp.`s newly introduced technology
platforms lead the world in their ability to produce biological products from
single units of blood. Umbilical cord blood banks are utilizing the Company`s
BioArchive System as a critical enabling technology for the harvesting,
processing and cryogenic archiving of stem cells for transplant. The
CryoSeal(R) FS System is used to prepare hemostatic and adhesive surgical
sealants from patient blood in about an hour. ThermoGenesis Corp. has been a
leading supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and
Thawers to hospitals and blood banks since 1992.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company`s control with respect to market acceptance of new technologies
and products, delays in testing and evaluation of products, and other risks
detailed from time to time in the Company`s filings with the Securities and
Exchange Commission.

[analle]

[fritzchenI]

Rudi siehst du langfristig weiteres Kurspotential
Gruss

[RudiDutschke]

ThermoGenesis Corp. Receives Notice of Allowance of European Patent for CryoSeal(R) FS System
15 Aug 2003, 06:00am ET
E-mail or Print this story prnewswire
- - - - -

CryoSeal Invention Produces Personalized Surgical Glue from a Unit of the
Patient`s Plasma in About One Hour

RANCHO CORDOVA, Calif., Aug. 15 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL) announced today that it has received notice from the European Patent Office of the allowance of 43 additional patent claims for the CryoSeal System, a thermodynamic medical device and a companion single-use sterile disposable device that harvests and concentrates the clotting and adhesive proteins fibrinogen, fibronectin, Factor VIII, Factor XIII, von Willebrands Factor and thrombin from a unit of patient plasma in about one hour. These wound healing proteins can be used by surgeons to stop tissue bleeding and to seal tissues.

Kevin Simpson, President & COO of ThermoGenesis Corp., said the Company is now providing the CryoSeal products to its distributor, Dideco S.p.A of Mirandola, Italy. In contrast to the "personalized" CryoSeal surgical sealant, the conventional fibrin sealants, which combine 10,000 or more units of plasma, remain vulnerable to new and re-emerging infections. Several newly discovered hepatitis viruses; parvovirus B-19 and agents of transmissible spongiform encephalopathies may pose risks to the safety of homologous and pooled plasma. By using the CryoSeal FS System, these risks are eliminated by using autologous or patient`s own blood for the preparation of protein sealants.

Mr. Simpson also remarked that "these conventional sealants also contain ingredients sourced from bovine lung tissue and noted that in 2002, the Japanese government announced a ban on drugs containing bovine materials from 28 countries over fears that the human variant of `mad cow disease` would be transmitted to patients. Consequently the market acceptance of CryoSeal surgical sealant made from the patient`s own blood plasma may be significant."

[RudiDutschke]

Taiwan Cord Blood Stem Cell Bank System Continues to Expand
E-mail or Print this story

11 September 2003, 06:00am ET

Cord Blood Stem Cell Bank in Taiwan Orders 3rd BioArchive(R) System

RANCHO CORDOVA, Calif., Sept. 11 /PRNewswire-FirstCall/ -- THERMOGENESIS CORP. (Nasdaq: KOOL) announced today that the Company has recently received its third BioArchive order from Healthbanks. Healthbanks is a leading cord blood bank company in Taiwan serving a rapidly growing demand from expectant parents who want to store their baby`s own cord blood. In addition to this activity, Healthbanks is involved in several collaborative stem cell research initiatives including a recent agreement with a well known hospital in Taipei, where they will focus on strategies for cell expansion and stem cell applications for regenerative medicine.

S.K. Chang, President of Healthbanks commented, "We believe the BioArchive System is an integral part of our process and supports our customer and regulatory goals in providing the highest quality product to our customers."

Dan Segal, Vice President of Sales and Marketing said that, "This recent order from Taiwan is further evidence that Asia is and will continue to be an important driver of our BioArchive business as they continue to build new cord blood banks and establish growing inventories of cord blood samples."

Kevin Simpson, President and COO further noted that, "We expect to see continued demand for BioArchive in Asia, which have always been under served by traditional US and European bone marrow registries. Cord blood serves as a readily available source of stem cells for bone marrow rescue treatment, especially for diseases such as Thalassemia, which occurs at an incredibly high rate in Asia. Further, recent research suggests that there are stem cells in cord blood that have the potential to produce other cells outside the hematopoietic system such as neural, liver, heart and bone cells. Because there are serious ethical issues with sourcing stem cells from embryos and fetuses, scientists appear to be focusing on cord blood as a non-controversial source for these multi-potential stem cells."
Mentioned Last Change
KOOL 3.52 (Unchanged)

The BioArchive System plays a key role in the emerging world standards that are being adopted by cord blood banks for the processing and validation of stem cell units. It provides sterile cell processing disposables and a computer-driven robotic system to allow the cord blood banks to cryopreserve and archive up to 3,626 units of cord blood stem cells in -196 degrees C liquid nitrogen.

The BioArchive System can cryopreserve, archive and retrieve samples within liquid nitrogen without exposing the samples to detrimental transient warming events (TWE), which can reduce cell viability.

[RudiDutschke]

ThermoGenesis Hires New Management for Improved Market and Operational Focus
E-mail or Print this story

17 September 2003, 06:00am ET

RANCHO CORDOVA, Calif., Sept. 17 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (TG) (Nasdaq: KOOL) has announced today that it has hired a new Director of Marketing and Director of Manufacturing Operations with successful experience in its two primary markets: Hospital/Acute Care and Blood Processing. Kevin Simpson, President and COO of ThermoGenesis noted that "these individuals have played important management roles in successful, high growth, medical device companies in markets that are the primary focus of ThermoGenesis`s future growth."

Rudy Hulyebroeck, has joined TG as Director of Marketing with over 10 years of marketing experience having worked for Jomed, St. Jude Medical, Cordis, and Baxter in various Marketing and Engineering management positions. Rudy has a BS in Engineering and MBA and was responsible for the marketing plan for St. Jude`s Angio Seal device that was the leading vascular closure device in the cardiology market.

Kim Ellner has joined TG as Director of Manufacturing Operations responsible for production, outsourcing, purchasing, shipping/receiving, and material procurement and planning. Kim comes with over 14 years of medical device operations experience recently from Smith and Nephew/Endoscopy, and Stryker. Kim has held various positions including Manager of Business Process Improvement, Manufacturing Finance Manager, Production Supervisor, and other operations management positions, in support of high growth initiatives at Smith and Nephew, and Stryker.
Mentioned Last Change
KOOL 3.52 (Unchanged)

Mr. Simpson further noted that, "A search of VP of Research and Development with similar successful background is underway and will be filled within the near future."

[analle]

Hallo,

bei dieser Stammzellenbegeisterung auch diesen Wert im Auge behalten. Habe noch mal nachgekauft

[RudiDutschke]

ThermoGenesis Corp. Announces Fourth Quarter and Year End Results
E-mail or Print this story

24 September 2003, 06:00am ET

Fourth Quarter BioArchive Revenues Increase and Corporate Gross Margin Doubled
To 35% of Net Revenues

RANCHO CORDOVA, Calif., Sept. 24 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL) today reported its financial results for the fourth quarter and year ended June 30, 2003. The Company reported net revenues for the fourth quarter of $2,898,000 a 2% increase when compared to $2,830,000 reported in the fourth quarter of last year. The gross margin for the fourth quarter was $1,008,000 or 35% of net revenues compared to $483,000 or 17% for the fourth quarter ended June 30, 2002. Net loss for the quarter ended June 30, 2003, including clinical trial expenses of $326,000, was $991,000 a 33% decrease from the prior year fourth quarter net loss of $1,470,000, which included clinical trial expenses of $183,000.

Net revenues for the year ended June 30, 2003 was $10,187,000 compared to $9,549,000 for the year ended June 30, 2002, a 7% increase. The gross margin for the year ended June 30, 2003 was $2,287,000 or 22% of net revenues, compared to $1,991,000 or 21% of net revenues for the prior year. Net loss for the year ended June 30, 2003 was $5,603,000 compared to the prior year net loss of $5,038,000. Included in these losses were clinical trial expenses of $1,310,000 for the year ended June 30, 2003 as compared to $722,000 for the year ended June 30, 2002, an increase of 81%.

"The increase in gross margin in the fourth quarter indicates that our restructuring plan implemented in the last quarter of our fiscal year 2003 is working," stated Kevin Simpson, President and Chief Operating Officer. "This restructuring plan included an increase in revenues and selling prices of the BioArchive product line, reduction of our in-house direct and overhead costs of manufacturing, and an array of cost reduction activities to improve our operating margin." Although the improvement in gross margin is promising, there is insufficient data to indicate a trend at this time due to fluctuations in the volume and mix of products sold.

Renee Ruecker, Chief Financial Officer, stated, "We are especially pleased that the increasing momentum in BioArchive sales offset the decline in ThermoLine revenues which were inflated in the prior year as a result of a large order for plasma freezers received from Aventis Bio-Services, Inc. Revenues increased for both device and disposable sales in the BioArchive product line for the quarter and year ended June 30, 2003."

The Company continued its efforts in the fourth quarter to support the federal financing of a National Cord Blood Stem Cell Bank. The proposed legislation would provide for the collection and cryogenic archiving of 150,000 cord blood stem cell units to be used in the treatment of life threatening diseases. Although uncertain in light of current fiscal and budgetary debates in Congress, the legislation was introduced in the House of Representatives in July 2003 and the Company expects it to be introduced in the Senate shortly.

[RudiDutschke]

ThermoGenesis Signs Multi-Year OEM Agreement with Kawasumi Laboratories
E-mail or Print this story

29 September 2003, 09:00am ET

Manufacturing Agreement Provides ThermoGenesis with a Low Cost,

High Quality Supplier of Single-Use Sterile Blood Processing Disposables

RANCHO CORDOVA, Calif., Sept. 29 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL) announced today that it has signed a five (5) year agreement with Kawasumi Laboratories Inc. (KLI), a leading global manufacturer of devices and disposables for Blood Bank, Hospital IV and Dialysis markets. KLI currently provides the global market with KLI-branded products as well as OEM products for such companies as Haemonetics, Asahi Medical and Pall Medical. KLI products meet strict FDA, GMP and ISO9001 standards. This agreement allows ThermoGenesis to take advantage of KLI`s more than 47 years of high quality disposable manufacturing.

Kevin Simpson, President & COO of ThermoGenesis Corp., noted that, "This supply agreement completes one of our key objectives in positioning the company for profitable growth by securing a long term, low cost, high quality supplier of blood processing devices, disposables and applicators. This agreement is a manufacturing agreement only and covers selected BioArchive(R) and CryoSeal(R) platform products."

Mr. Choichiro Tsuji, Executive General Manager of KLI also remarked that, "We are very pleased to be working with ThermoGenesis, a pioneer in the area of "enabling technologies" for the cell therapeutic industry and surgical applications. We believe that the innovative products developed from the BioArchive and CryoSeal technologies provide the basis for a mutually beneficial relationship and will allow Kawasumi to support ThermoGenesis` leadership and growth into these rapidly developing markets."

[RudiDutschke]

ThermoGenesis Receives Orders for Three Bioarchive(R) Systems
E-mail or Print this story

8 October 2003, 09:01am ET

Asian Cord Blood Stem Cell Banks Continue to Adopt ThermoGenesis Technology

RANCHO CORDOVA, Calif., Oct. 8 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL) announced today that the Company received orders for three (3) BioArchive Systems for September. The orders came from Taiwan and Korea.

Kevin Simpson, President & COO of ThermoGenesis Corp. commented, "We are very pleased with these sales as existing cord blood bank customers expand and new customers begin their operations in the storage of umbilical cord blood stem cells. This is further evidence that the BioArchive System is rapidly becoming the international standard in this area of cell therapy and that our momentum in Asia is rising again since the SARS epidemic has subsided."

In North and South America, BioArchive Systems have been deployed in the US, Canada, Mexico, and Brazil. In Europe and the Middle East, BioArchive Systems have been placed at the major Cord Blood Stem Cell Banks in Austria, Germany, United Kingdom, France, Spain, Belgium, Finland, Netherlands, Russia and Israel. In the Asia region, ThermoGenesis` BioArchive Systems have been deployed in Japan, China, Taiwan, Vietnam, South Korea, Malaysia and India.

Dan Segal, Vice President of Sales & Marketing commented, "we continue to see strong demand for the BioArchive System from new customers as well as from our installed base of customers in Asia. Asia is and will continue to be an important driver of our BioArchive business. We believe this demonstrates our success in developing a demand for this product that is global and broad based."
Mentioned Last Change
KOOL 3.15 (Unchanged)

The BioArchive System plays a key role in the emerging world cord blood standards that are being adopted for the processing and storage of blood components. A computer-driven robotic system to allow users to cryopreserve and archive up to 3,626 units of blood components in -196 degrees C liquid nitrogen. The BioArchive System can cryopreserve, archive and retrieve samples within liquid nitrogen without exposing the samples to detrimental transient warming events (TWE), which can reduce cell viability.

[RudiDutschke]

Legislation to Create a National Cord Blood Stem Cell Bank Introduced In the Senate (S-1717)
E-mail or Print this story

21 October 2003, 12:09pm ET

Clinical Data Provided By ThermoGenesis Scientific Advisory Board Members
Persuasive to Senators

RANCHO CORDOVA, Calif., Oct. 21 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL) announced today that S-1717 titled "Cord Blood Stem Cell Act of 2003" was introduced on October 3, 2003 in the Senate "to establish a National Cord Blood Stem Cell Bank network to prepare, store and distribute human umbilical cord blood stem cells for the treatment of patients and to support peer-reviewed research using such cells." The lead sponsors were Senators Orrin Hatch (R, Utah), Arlen Specter (R, Pennsylvania), Sam Brownback (R, Kansas), Chris Dodd (D, Connecticut) and Dianne Feinstein (D, California). This legislation is similar in intent to HR-2852 which was recently introduced in the House of Representatives.

According to Philip Coelho, CEO, this landmark, bi-partisan legislation follows from the June 12th Senate Hearing presentations of clinical data from Dr.`s Pablo Rubinstein (New York Blood Center (NYBC)) and Joanne Kurtzberg (Duke University Medical Center (DUMC)) who are ThermoGenesis scientific advisory board members and pioneers of this form of cell therapy. Neonatal cord blood stem cells are used in the treatment of malignant, genetic and acquired blood diseases, such as leukemia, lymphoma, sickle cell anemia, thallassemia, and immunodeficiencies ("boy in the bubble"). Cord blood as a source of stem cells is available faster than bone marrow and provides survival rates for patients with these usually fatal diseases that can be as good, or better, than those following adult donor bone marrow stem cell transplants.

Philip Coelho further commented, "The federal financing of this large inventory of cord blood stem cell units provided by this legislation will complete the evolution of this unique cell therapy from pure research to routine clinical practice and is an excellent demonstration of U.S. medical research functioning well -- with both federal health agencies and academic research institutions each fulfilling their roles in promoting promising research through to tangible health benefits for U.S. citizens." The role of ThermoGenesis has been the development of the BioArchive(R) System -- an advanced robotic method of cryopreservation, archiving and retrieval that is used by the major cord blood banks in 21 countries.
Mentioned Last Change
KOOL 3.21 Down0.02dollars or (0.61%)

Kevin Simpson, President and COO of ThermoGenesis, noted that, "cord blood transplants are currently curing hundreds of U.S. patients from these otherwise lethal diseases each year. However, the 150,000-unit inventory which will be collected pursuant to this legislation should provide life saving stem cell transplant for the thousands of patients each year who need them and cannot currently get them from the `walking donor` bone marrow registries (as disclosed in the GAO Report, October 2002). This inventory will be a National treasure."

Following the first sibling-donor cord blood transplant in 1988, the NIH awarded Dr. Rubinstein a grant to develop the worlds first cord blood program at the NYBC, in order to establish the inventory of stem cell units necessary to provide unrelated, matched grafts for patients (1992). In 1993, Dr. Joanne Kurtzberg performed the first two successful cord blood transplants, in the unrelated setting, one of which cured a patient with acute lymphoblastic leukemia (ALL). By 1996, with more than 300 unrelated transplants accomplished, the FDA accepted the NYBC`s request for an Investigational New Drug (IND) Exemption which allowed the expansion of the clinical use of cord blood under conditions that documented the critical processing protocols and the clinical outcome data which would allow the FDA to understand how best to regulate this promising cell therapy. Today, the FDA, with these clinical outcome data in hand, is considering the licensing of this cell therapy product. The Agency`s involvement will assure that cord blood stem cell units utilized in routine patient treatment will be in compliance with the highest quality standards.

The BioArchive System plays a key role in the emerging world cord blood standards that are being adopted for the processing and storage of blood components. A computer-driven robotic system to allow users to cryopreserve and archive up to 3,626 units of blood components in -196 degrees C liquid nitrogen. The BioArchive System can cryopreserve, archive and retrieve samples within liquid nitrogen without exposing the samples to detrimental transient warming events (TWE), which can reduce cell viability.

About ThermoGenesis Corp.

After extensive research, ThermoGenesis Corp.`s newly introduced technology platforms lead the world in their ability to produce biological products from single units of blood. Umbilical cord blood banks are utilizing the Company`s BioArchive System as a critical enabling technology for the harvesting, processing and cryogenic archiving of stem cells for transplant. The CryoSeal(R) FS System is used to prepare hemostatic and adhesive surgical sealants from patient blood in about an hour. ThermoGenesis Corp. has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and blood banks since 1992.

The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.

[RudiDutschke]

ThermoGenesis and Mediware to Develop and Market First Integrated System to Enable Production and Distribution of Cell Therapy Products
E-mail or Print this story

3 November 2003, 08:32am ET

Developers Envision Seamless Cell Processing and Web-Based Tracking System

Making Personalized Cell Therapy Much Safer and More Accessible

RANCHO CORDOVA, Calif., and LENEXA, Kan., Nov. 3 /PRNewswire-FirstCall/ -- thermogenesis corp. (Nasdaq: KOOL) and Mediware Information Systems, Inc. (Nasdaq: MEDW) said they will jointly develop and market the industry`s first fully integrated system to make personalized cell therapy safer and more accessible.

The ThermoGenesis-Mediware system will manage and track the collecting, processing, cryopreserving, archiving, genetic matching, transplanting and patient outcomes of cell therapy products, such as neonatal cord blood stem cells. In this initial configuration, it will ensure safety, quality and security in the therapeutic use of cellular products by connecting birthing hospitals, stem cell banks, and transplant centers.

The new system will take advantage of ThermoGenesis long experience in collecting, processing and transporting stem cells and Mediware`s deep knowledge of blood bank management and safety control systems, which has been the cornerstone of its business for the past 18 years.

"The combination of cryogenic cell processing technologies from ThermoGenesis, and information systems from Mediware, will enhance the processes and controls essential to bringing cell therapy products from pure research to routine clinical practice in compliance with anticipated FDA cGTP (current Good Tissue Practice) regulations and Part 11 Electronic Records and Electronic Signature due for adoption soon," said Philip Coelho, Chairman & CEO of ThermoGenesis.

"We see this integrated system as the model around which all future cell therapy products will be processed and transplanted. In our opinion, cell therapy products will be personalized to each individual patient whether the source tissue is derived from the donor`s own body, or from another genetically matched live donor or cord blood," he added.

ThermoGenesis` BioArchive(R) System -- an advanced robotic method of cell selection, cryopreservation, archiving and retrieval used by the major cord blood banks in 21 countries -- will be combined with Mediware`s cellular product suite, resulting in a state-of-the-art production system.

Mediware CEO George Barry said, "This agreement continues Mediware`s long standing leadership and innovation in developing technologies to manage the use of biologic products. The ability to bring more safety, transparency and liquidity to the stem cell supply chain should accelerate broader use of this powerful therapeutic technology."
Mentioned Last Change
KOOL 3.21 Down0.02dollars or (0.61%)
MEDW 14.75 Down0.20dollars or (1.33%)

Mr. Barry added, "This new system will take advantage of state-of-the-art solutions to support and validate the complex processing of therapeutic cell populations from the moment of collection from the donor to the tracking of patient outcomes. It places both Mediware and ThermoGenesis at the leading edge of new frontiers being forged in the fields of personalized medicine."

About ThermoGenesis Corp.

After extensive research, ThermoGenesis Corp.`s newly introduced technology platforms lead the world in their ability to produce biological products from single units of blood. Umbilical cord blood banks are utilizing the Company`s BioArchive System as a critical enabling technology for the harvesting, processing and cryogenic archiving of stem cells for transplant. The CryoSeal(R) FS System is used to prepare hemostatic and adhesive surgical sealants from patient blood in about an hour. The BioArchive System plays a key role in the emerging global cord blood standards that are being adopted for the processing and storage of blood components. A computer-driven robotic system to allow users to cryopreserve and archive up to 3,626 units of blood components in -196 degrees C liquid nitrogen. The BioArchive System can cryopreserve, archive and retrieve samples within liquid nitrogen without exposing the samples to detrimental transient warming events (TWE), which can reduce cell viability.

About Mediware Information Systems, Inc.

Mediware provides clinical information systems for hospitals and integrated healthcare delivery systems. Its products include HEMOCARE LifeLine(TM), Hemocare(R), LifeLine(R) and LifeTrak(R) (blood bank), WORx(R), Pharmakon(R), and Digimedics(TM) (pharmacy), Surgiware(TM), Perioperative Solutions(TM) (operating room), as well as the JAC Stock Control System (pharmacy) in the United Kingdom. Mediware has over 1,100 systems installed in the U.S., Canada, the U.K., and elsewhere.

Certain statements in this press release may constitute "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, as the same may be amended from time to time (the "Act") and in releases made by the SEC from time to time. Such forward-looking statements are not based on historical facts and involve known and unknown risks, uncertainties and other factors disclosed in either company`s Annual Report for the year ended June 30, 2003, which may cause the actual results for either company`s annual report to be materially different from any future results expressed or implied by such forward-looking statements. Both Companies disclaim any obligation to update its forward-looking statements.

[RudiDutschke]

ThermoGenesis Corp. Announces First Quarter Results

RANCHO CORDOVA, Calif., Nov. 12 /PRNewswire-FirstCall/ -- THERMOGENESIS CORP. today announced results for its first quarter of fiscal 2004. Net revenues for the quarter ended September 30, 2003 increased 4% to $2,143,000, compared to $2,053,000 for the first quarter of fiscal 2003. The gross margin for the first quarter increased 65% to $589,000 or 27% of net revenues compared to $356,000 or 17% for the first quarter ended September 30, 2002.

The net loss for the quarter ended September 30, 2003, was $1,239,000 or $0.03 per basic and diluted share. This loss included clinical trial expenses of $325,000, and $110,000 of expenses associated with the move from three facilities to one consolidated facility. The net loss for the first quarter last year was $1,362,000 or $0.04 per basic and diluted share, which included clinical trial expenses of $171,000.

Revenues from the BioArchive product line for the quarter ended September 30, 2003 were $1.4 million, an increase of $400,000 or 42% over the first quarter of last year. A significant part of this increase is due to the sale of BioArchive disposables to existing cord blood stem cell bank customers, which represented $483,000 of the current quarter`s BioArchive revenues.

"The increase in the gross margin is primarily the result of targeted programs implemented in the fourth quarter of fiscal 2003 directed at driving towards profitable operations with revenues and margins led by recurring sales of our proprietary disposables. The improved results, despite having to overcome manufacturing inefficiencies due to facilities relocation and consolidation of our manufacturing processes this past July, continues to suggest a trend that will be tested in future quarters," stated Kevin Simpson, President and Chief Operating Officer. "The programs included reducing manufacturing overhead costs, consolidating operations, outsourcing manufacturing of disposables, accelerating FDA applications and focusing marketing, sales, and product development efforts in two key markets."

The Company continued its efforts in the first quarter to support the federal financing of a National Cord Blood Stem Cell Bank. The proposed legislation would provide for the collection and cryogenic archiving of 150,000 cord blood stem cell units to be used in the treatment of life threatening diseases. The legislation has bipartisan support and was introduced in the House of Representatives in July 2003 and in the Senate in October 2003. Although the Company anticipates benefit from the legislation, it is premature to quantify the impact to the Company, given that the passage of the legislation is not certain and the market is developing.

[RudiDutschke]

ThermoGenesis Corp. Adopts Rule 10b5-1 Plan for Insider Stock Sales
E-mail or Print this story

20 November 2003, 4:00pm ET

RANCHO CORDOVA, Calif., Nov. 20 /PRNewswire-FirstCall/ -- THERMOGENESIS CORP. (Nasdaq: KOOL) announced it has received notice its CEO has established a SEC Rule 10b5-1 stock trading program for corporate officers and others affected by insider trading rules.

The new SEC rule allows corporate insiders to pre-arrange purchases or sales of stock in a regular and orderly manner under a written plan that is submitted to the company`s secretary and general counsel. The pre-planned trades can be executed at a later date, as provided for in the plan, without regard to any material non-public information the individual might have knowledge of or the price of the stock at the time of the sale.

Implementation of Rule 10b5-1 trading programs allow corporate insiders to satisfy liquidity and diversification objectives. The programs can also minimize the market affect of insider purchases or sales by spreading them over a more extended period than the traditional trading "windows." The majority of the options owned by company insiders are "non-qualified" which results in a significant tax advantage to the company.
Mentioned Last Change
KOOL 5.69 (Unchanged)

ThermoGenesis` CEO, Philip Coelho, has adopted a program under the new rule which provides for liquidation of portions of his holdings over multiple quarters. Other insiders may adopt programs under the new rule. Commenting on the plan Mr. Coelho noted that he was ... "selling to generate cash to pay the tax liability for the exercise of 350,000 options which will expire on December 14, 2003 and to generate additional liquidity for family estate planning."

About THERMOGENESIS CORP.

After extensive research, THERMOGENESIS CORP.`s newly introduced technology platforms lead the world in their ability to produce biological products from single units of blood. Umbilical cord blood banks are utilizing the Company`s BioArchive (R) System as a critical enabling technology for the harvesting, processing and cryogenic archiving of stem cells for transplant, while its CryoSeal(R) System is used to prepare hemostatic and adhesive surgical sealants from patient blood in about an hour. THERMOGENESIS CORP. has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and blood banks since 1992.The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.

Consistent with SEC Regulation FD, the company does not undertake any obligation to update the forward looking information given today.

[RudiDutschke]

ThermoGenesis` BioArchive(R) System Adopted by the 49th Cord Blood Stem Cell Bank
E-mail or Print this story

3 December 2003, 3:51pm ET

CopyGene Becomes the First Cord Blood Bank in Denmark to Adopt the BioArchive
System

RANCHO CORDOVA, Calif., Dec. 3 /PRNewswire-FirstCall/ -- ThermoGenesis CORP. (Nasdaq: KOOL), announced today that the Company received an order for the BioArchive System from CopyGene in Denmark. The BioArchive System is utilized as a critical enabling technology for the processing and storage of umbilical cord blood stem cells, a new service that is being launched by CopyGene to serve the Danish market.

Klaus R. Pedersen, President & CEO of CopyGene commented, "In the fast expanding market for private storage of cord blood units it`s an important driver, to secure long-term storage based on the leading technology in the market. ThermoGenesis has become the bench-mark and we are proud to introduce our Scandinavia service on leading-edge solutions right from the beginning."

Kevin Simpson, President & COO of ThermoGenesis Corp. commented, "We are very pleased to add CopyGene as one of our newest customers. It is encouraging for us to see the BioArchive System incorporated into this new service being offered in Denmark." Dan Segal, VP Sales & Marketing commented, "With this order from CopyGene the network of BioArchive System users have now expanded to 49 cord blood banks in 22 countries in Europe, Asia, South and North America. Denmark represents the ninth European country to adopt the system."

The BioArchive System plays a key role in the emerging world cord blood standards that are being adopted for the processing and storage of stem cell units. A computer-driven robotic that is used to process up to 3,626 units of blood components in -196 degrees C liquid nitrogen, the BioArchive System can cryopreserve, archive and retrieve samples within liquid nitrogen without exposing the samples to detrimental transient warming events (TWE), which can reduce cell viability.

Regulatory Status
Mentioned Last Change
KOOL 5.69 (Unchanged)

The BioArchive System is a Class II blood and blood component freezer exempt from the pre-market notification procedures. The BioArchive System has potential applications involving archiving, storing, managing and retrieving other kinds of biological specimens, that may include stem cells, dendritic cells, T-cells, cell lines, sperm cells, eggs, heart valves, corneas, virus samples, biopsy samples and other blood, tissue and saliva samples. The BioArchive System is currently intended for storage of blood and blood components. Additional indications for use would require U.S. FDA clearance or approval.

About ThermoGenesis Corp.

After extensive research, ThermoGenesis Corp.`s newly introduced technology platforms lead the world in their ability to produce biological products from single units of blood. Umbilical cord blood banks are utilizing the Company`s BioArchive System as a critical enabling technology for the harvesting, processing and cryogenic archiving of stem cells for transplant. The CryoSeal(R) FS System is used to prepare hemostatic and adhesive surgical sealants from patient blood in about an hour. ThermoGenesis Corp. has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and blood banks since 1992.

About CopyGene

CopyGene is a private funded cord blood bank operating in Scandinavia, with storage and laboratory facilities in Copenhagen, Denmark. CopyGene has chain-of-control from collectors being sent to hospitals and birth clinics, through the testing and storage capabilities. From the time cord blood is extracted to final permanent storage is secured, less than 48 hours will pass. The market targeted is primarily families that have decided to secure transplant capabilities for their new-borns, and believe that stored stem cells may develop into a major advantage in connection with the future treatment of life threatening diseases.

The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.

[RudiDutschke]

Robinson Humphrey Initiates Coverage ---

Watch out now -- KOOL is no longer a secret

[fritzchenI]

Rudi-waren das Gewinnmitnahmen oder warum fällt wieder alles-enorme umsätze!
Gruss

[RudiDutschke]

Japan Stem Cell Research Programs Continue to Adopt ThermoGenesis` BioArchive(R) Systems
E-mail or Print this story

9 December 2003, 06:00am ET

ThermoGenesis Receives Orders for Three BioArchive Systems for Japan

RANCHO CORDOVA, Calif., Dec. 9 /PRNewswire-FirstCall/ -- THERMOGENESIS CORP. (Nasdaq: KOOL), announced that Air Water Inc., ThermoGenesis` exclusive distributor of BioArchive Systems in Japan, has purchased three BioArchive Systems to assist multiple stem cell clinical and research programs. One BioArchive System, which has been purchased by the Ministry of Education and Science, will be installed at University Of Tokyo, Institute Medical Science (IMS) IMS already employs BioArchives for their cord blood stem cell banking program. The other two BioArchives purchased by AWI will be installed at other stem cell research programs in Japan to be announced later.

Kevin Simpson, President & COO of THERMOGENESIS CORP. commented, "This order increases the total BioArchives in Japan to 10 for performing critical stem cell processing, cryopreservation and archiving functions in clinical and research programs. Stem cells are currently used as "personalized" treatments for lethal malignant and genetic diseases, such as leukemia, lymphoma, sickle cell anemia and thalassemia. However, researchers report the isolation of stem cells in cord blood that can be differentiated into tissues of the brain, bone, liver and heart which may have clinical value for the treatment of additional lethal or debilitating diseases. We are hopeful the BioArchive System may be of assistance in enabling the development and production of these new stem cell therapy products."

Dan Segal, Vice President of Sales and Marketing, noted, "With these orders, 74 BioArchive Systems will be deployed in 22 countries in North and South America, Europe and Asia. The BioArchive System continues to be the system of choice among Japan and the rest of the world`s leading cord blood stem cell bank programs and is beginning to be adopted by adult stem cell research programs as well."
Mentioned Last Change
KOOL 5.03 Down0.21dollars or (4.00%)

The BioArchive System plays a key role in the emerging world standards that are being adopted for the processing and storage of cord blood stem cell units. It features a computer-driven robotic system which the cord blood banks use to cryopreserve and archive up to 3,626 units of blood components at -196 degrees C. The BioArchive System can cryopreserve, archive and retrieve samples within liquid nitrogen without exposing the samples to detrimental transient warming events (TWE), which can reduce cell viability.

Regulatory Status

The BioArchive System is a Class II blood and blood component freezer exempt from the pre-market notification procedures. The BioArchive System has potential applications involving archiving, storing, managing and retrieving other kinds of biological specimens, that may include stem cells, dendritic cells, T-cells, cell lines, sperm cells, eggs, heart valves, corneas, virus samples, biopsy samples and other blood, tissue and saliva samples. The BioArchive System is currently intended for storage of blood and blood components. Additional indications for use would require U.S. FDA clearance or approval.

About THERMOGENESIS CORP.

After extensive research, THERMOGENESIS CORP.`s newly introduced technology platforms lead the world in their ability to produce biological products from single units of blood. Umbilical cord blood banks are utilizing the Company`s BioArchive System as a critical enabling technology for the harvesting, processing and cryogenic archiving of stem cells for transplant, while its CryoSeal(R) FS System is used to prepare hemostatic and adhesive surgical sealants from patient blood in about an hour. THERMOGENESIS CORP. has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and blood banks since 1992.

The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.

[fritzchenI]

die aktie fällt ja ins bodenlose-mist hätte verkaufen sollen

[RudiDutschke]

ThermoGenesis Continues Expansion of Global Stem Cell Network in Middle East
E-mail or Print this story

6 January 2004, 06:00am ET

BioArchive(R) Systems Ordered for First Cord Blood Bank in Turkey

RANCHO CORDOVA, Calif., Jan. 6 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), announced today that the Company received an order for two BioArchive Systems from the Company`s distributor, HITIT, on behalf of Baby Life A.S. Cord Blood Bank. The BioArchive Systems will be installed at Aegean University Faculty of Medicine and Mediterranean University Faculty of Medicine and will be utilized as a critical enabling technology for the cryopreservation of therapeutic units of cord blood stem cells for the treatment of leukemias, lymphomas, diverse inherited anemias, such as sickle cell anemia and thalassemia, and other genetic diseases.

Tankut Gedik, Vice President, Marketing & Sales of HITIT said, "We believe BioArchive is the only alternative for institutions and individuals in our country who seek security, standardization and maximum cell viability in their cord blood units."

Kevin Simpson, President & COO of ThermoGenesis Corp. commented, "Turkey represents the 23rd country in which the major cord blood banks have acquired the BioArchive System as we continue to see its adoption as the standard for cord blood banking customers worldwide."

BioArchive Systems have previously been deployed throughout North America, Europe, Middle East, and Asia. The Company estimates that more than 70% of the cord blood stem cell transplants performed to date have been supplied by Cord Blood Banks that are now using the BioArchive System to process, cryopreserve, and archive their stem cell units.
Mentioned Last Change
KOOL 6.239 (Unchanged)

The BioArchive System plays a key role in the emerging world standards that are being adopted for the processing and validation of stem cell units. It uses a computer-driven robotic system to archive up to 3,626 units in -196 degrees C liquid nitrogen. The BioArchive System is used by cord blood banks to freeze, track identification and perform robotic storage and retrieval of each unit. The BioArchive System can freeze, place and retrieve samples within liquid nitrogen without exposing the samples to detrimental transient warming events (TWE), which can reduce cell viability.

Regulatory Status

The BioArchive System is a Class II blood and blood component freezer exempt from the premarket notification procedures. The BioArchive System has potential applications involving archiving, storing, managing and retrieving other kinds of biological specimens, that may include stem cells, dendritic cells, T-cells, cell lines, sperm cells, eggs, heart valves, corneas, virus samples, biopsy samples and other blood, tissue and saliva samples. The BioArchive System is currently intended for storage of blood and blood components. Additional indications for use would require U.S. FDA clearance or approval.

About ThermoGenesis Corp.

After extensive research, ThermoGenesis Corp.`s newly introduced technology platforms lead the world in their ability to produce biological products from single units of blood. Umbilical cord blood banks are utilizing the Company`s BioArchive System as a critical enabling technology for cryogenic archiving of stem cells for transplant, while its CryoSeal(R) FS System is used to prepare hemostatic and adhesive surgical sealants from patient blood in about an hour. ThermoGenesis Corp. has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and blood banks since 1992.

The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.

[RudiDutschke]

Legislation to Create a National Cord Blood Stem Cell Bank Program Passed by Congress
E-mail or Print this story

23 January 2004, 06:00am ET

Clinical Data Provided by ThermoGenesis Scientific Advisory Board Members
Persuasive to Legislators

RANCHO CORDOVA, Calif., Jan. 23 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL) announced today that the initial $10 million appropriation to establish a National Cord Blood Stem Cell Bank Network was approved by the Senate. The lead sponsors were Senators Orrin Hatch (R, Utah), Arlen Specter (R, Pennsylvania), Sam Brownback (R, Kansas), Chris Dodd (D, Connecticut) and Dianne Feinstein (D, California). The appropriation was passed by the House last month. The goal of the authorizing legislation is to collect, over five (5) years, an inventory of 150,000 cord blood stem cell units to provide life saving stem cell transplant for the thousands of patients each year who need them and cannot currently get them from the "walking donor" bone marrow registries (as disclosed in the GAO Report, October 2002). This program, estimated to cost $150 million, will be administered by Health Resources and Services Administration (HRSA), who will provide funds to FDA-qualified cord blood banks to store and distribute human cord blood stem cells for the treatment of patients and to support peer-reviewed research using such cells. The role of ThermoGenesis has been the development of the BioArchive(R) System -- an advanced robotic method of cryopreservation, archiving and retrieval that is used by the major cord blood banks in 23 countries.

According to Philip Coelho, CEO, this landmark, bi-partisan legislation follows from the June 12th Senate Hearing presentations of clinical data from Dr.`s Pablo Rubinstein (New York Blood Center (NYBC)) and Joanne Kurtzberg (Duke University Medical Center (DUMC)) who are pioneers of this form of cell therapy and ThermoGenesis scientific advisory board members. Cord blood stem cells are used in the treatment of malignant, genetic and acquired blood diseases, such as leukemia, lymphoma, sickle cell anemia, thallassemia, and immunodeficiencies ("boy in the bubble"). Cord blood as a source of stem cells is available faster than bone marrow and provides survival rates for patients with these usually fatal diseases that can be as good, or better, than those following adult donor bone marrow stem cell transplants.
Mentioned Last Change
KOOL 6.239 (Unchanged)

Philip Coelho further commented, "The federal financing of this large inventory of cord blood stem cell units creates a national treasure and completes the evolution of this unique cell therapy from pure research to routine clinical practice. This is an excellent demonstration of U.S. medical research functioning well -- with both federal health agencies and academic research institutions each fulfilling their roles in promoting promising research through to tangible health benefits for U.S. citizens."

The BioArchive System plays a key role in the emerging world cord blood standards that are being adopted for the processing and storage of blood components. A computer-driven robotic system to allow users to cryopreserve and archive up to 3,626 units of blood components in -196 degrees C liquid nitrogen. The BioArchive System can cryopreserve, archive and retrieve samples within liquid nitrogen without exposing the samples to detrimental transient warming events (TWE), which can reduce cell viability.

About ThermoGenesis Corp.

After extensive research, ThermoGenesis Corp.`s newly introduced technology platforms lead the world in their ability to produce biological products from single units of blood. Umbilical cord blood banks are utilizing the Company`s BioArchive System as a critical enabling technology for cryogenic archiving of stem cells for transplant, while its CryoSeal(R) FS System is used to prepare hemostatic and adhesive surgical sealants from patient blood in about an hour. ThermoGenesis Corp. has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and blood banks since 1992.

The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.

[fritzchenI]

rudi-kannst mir auf deutsch kurz zusammenfassen-mein english is horrible

[analle]

http://world.altavista.com/


und überhaupt, es läuft super. Bis Du noch investiert.?

good luck

[fritzchenI]

weiss gar nicht wo ich mit dem ganzen Geld hin soll

[fritzchenI]

apropos wusste gar nicht dass es ausser Rudi und mich noch einen Kool -Aktionär in Deutschland gibt-habt ihr uns ertappt-im Nebel des Grauens sozusagen

[analle]

dér Markt ist nur grauenvoll weil sämtliche Sch,, steigt. Bei Kool ist dies ein stetigér, logischer Prozess und hat weniger mit dem Gesamtmarkt zu tun.

[fritzchenI]

...wenn ich den nur english könnte-möchte gern wissen warum ich so reich werde

[fritzchenI]

....und niemand hat mitleid mit mir und nimmt mich mit -und pickeldi und Frederick gehen nach Hause-komm mit

[analle]

kein Problem. hab eh nichts vor. Schick mir en Flieger.

[fritzchenI]

....ja und dann mach ich bei dir palim palem und bring dir ne flasche pommes Frites mit-oder soll ich doch lieber mit theo nach lodz fahren-aber dann muss ich wieder aufstehen

[analle]

na dann bleibe besser liegen und lerne mal ein wenig. Ich beneide menschen, die ohne Wissen, Geld verdienen und dabei liegen. Ich muss leider ab und zu mal aufstehen.

[asimex]

@fritzchen:

Es gibt noch einen weiteren kool-Aktionär außer Rudi und Dir, mich nämlich, und zwar schon sehr sehr lange.

asimex

[RudiDutschke]

ThermoGenesis Completes FDA Master File for the BioArchive(R) System
E-mail or Print this story

29 January 2004, 06:00am ET

Robotic Cryopreservation & Archiving System Technical and Outcome Data, And
Related Publications

RANCHO CORDOVA, Calif., Jan. 29 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL) announced today that it has completed a Master File on the BioArchive System which has been submitted to the FDA. The Master File summarizes pertinent information on the construction and operation of the BioArchive System, internal test reports on the performance of the controlled-rate freezing of cord blood stem cells, clinical outcome data for patients who have received transplants of cord blood stem cells cryopreserved and archived in the BioArchive System, and publications that relate to the performance of the BioArchive System.

The purpose of the Master File is to assist those institutions that wish to utilize the BioArchive System for the cryopreservation and archiving of cell populations which require FDA permission for clinical use.

The Company intends to update the Master File as new pertinent information becomes available and will allow it to be cross referenced in other regulatory submissions, thus reducing the burden of duplicative reports and communications with the FDA.

The BioArchive System plays a key role in the emerging world standards that are being adopted for the processing and validation of stem cell units. It uses a computer-driven robotic system to archive up to 3,626 units in -196 degrees C liquid nitrogen. The BioArchive System is used by cord blood banks to freeze, track identification and perform robotic storage and retrieval of each unit. The BioArchive System can freeze, place and retrieve samples within liquid nitrogen without exposing the samples to detrimental transient warming events (TWE), which can reduce cell viability.

[fritzchenI]

mist alle gewinne wieder flöten....20% kursverlust an einem Handelstag ist heftig-ist ja gar kein halt in der Aktie-weiss jemand ob es fundamentale Gründe für diesen
Rücksetzer gibt

[RudiDutschke]

ThermoGenesis Corp. Receives Remaining Patent Issued for the CryoSeal(R) Platform Products
E-mail or Print this story

4 February 2004, 06:01am ET

Patent Portfolio Now Complete for CryoSeal Methods of Producing Personalized

Surgical Glue or Thrombin from Patients` Plasma in One Hour

RANCHO CORDOVA, Calif., Feb. 4 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL) announced today that it has received the tenth patent which completes the portfolio protecting the CryoSeal platform products which utilize medical devices and companion single-use sterile disposables to harvest and concentrate the clotting and adhesive proteins fibrinogen, fibronectin, Factor VIII, Factor XIII, von Willebrands Factor and thrombin from patient plasma in about one hour. These wound healing proteins are used by surgeons to stop tissue bleeding, seal tissues and release growth factors from platelets.

Kevin Simpson, President & COO of ThermoGenesis Corp., said, "This latest patent, `Biological Adhesive Loading Station`, protects the method of sterile production of up to four (4) sealant kits from a single unit of blood plasma." In contrast to "personalized" CryoSeal surgical sealant, conventional fibrin sealants, sourced from thousands of units of purchased plasma, have recently been reported to contaminate surgical patients with Parvovirus B-19, a cause of hemolytic anemia. By using the CryoSeal FS System, these risks are eliminated by using autologous (patient`s own) blood for the preparation of these protein surgical sealants.
Mentioned Last Change
KOOL 5.09 (Unchanged)

Mr. Simpson also remarked that "this supports our marketing efforts in those countries where conventional fibrin sealants also contain aprotinin sourced from bovine lung tissue. This is particularly important for countries like Japan, where the government announced a ban on drugs containing bovine materials from 28 countries over fears that the human variant of `mad cow disease` would be transmitted to patients. Consequently the market acceptance of CryoSeal surgical sealant or thrombin made from the patient`s own blood plasma may be significant."

Regulatory Status

The CryoSeal FS System has received CE Mark approval from the European Union Competent Authorities and is being tested in European clinical trials by Dideco S.p.A, of Mirandola, Italy and Japanese clinical trials by Asahi Medical in Japan. The CryoSeal FS System is not yet available in the United States and will require completion of a Phase III clinical trial, currently underway at eight (8) clinical sites, and the submission of pre-market approval (PMA) to the U.S. FDA before sales can commence in the U.S.

About ThermoGenesis Corp.

After extensive research, ThermoGenesis Corp.`s newly introduced technology platforms lead the world in their ability to produce biological products from single units of blood. Umbilical cord blood banks are utilizing the Company`s BioArchive(R) System as a critical enabling technology for cryogenic archiving of stem cells for transplant, while its CryoSeal FS System is used to prepare hemostatic and adhesive surgical sealants from patient blood in about an hour. ThermoGenesis Corp. has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and blood banks since 1992.

NOTE: The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.

[fritzchenI]

so wies aussieht ist der offen hier wieder aus-das war ein kurzer Hype vorallem nach unten

[fritzchenI]

sieht so aus als sich kein sch... für die aktie interessiert-frage mich nur wieso-ist sie den so unkool

[RudiDutschke]

ThermoGenesis` Global Network of Cord Blood Stem Cell Banks Using the BioArchive(R) System Expands in USA and Europe
E-mail or Print this story

12 February 2004, 10:28am ET

52nd and 53rd Cord Blood Banks Adopt BioArchive System

RANCHO CORDOVA, Calif., Feb. 12 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), announced today that the Company received orders for BioArchive Systems from a soon to open private cord blood bank in the US and from its UK distributor, Deva Medical, for the Scottish National Blood Services in Glasgow, Scotland. The BioArchive Systems and processing disposables will be utilized as a critical enabling technology for the processing and cryopreservation of therapeutic units of cord blood stem cells.

Kevin Simpson, President & COO of ThermoGenesis Corp. commented, "These orders continue a trend in which major cord blood banks worldwide have acquired the BioArchive System as their standard for production of high quality cord blood stem cell units. The research and therapeutic intended use of these stored cord blood units necessitates a device that can provide the highest recovery of stored cord blood stem cell samples and we continue to be encouraged by the receptivity of the Bio-Archive system by cord blood bank operations world wide."

BioArchive Systems have previously been deployed in 23 countries throughout North America, Europe, Middle East, and Asia. The Company estimates that the majority of the cord blood stem cell transplants performed to date have been supplied by Cord Blood Banks that are now using the BioArchive System to process, cryopreserve, and archive their stem cell units.
Mentioned Last Change
KOOL 5.05 Down0.04dollars or (0.78%)

The BioArchive System plays a key role in the emerging world standards that are being adopted for the processing and validation of stem cell units. It uses a computer-driven robotic system to archive up to 3,626 units in -196 degrees Celsius liquid nitrogen. The BioArchive System is used by cord blood banks to freeze, track identification and perform robotic storage and retrieval of each unit. The BioArchive System can freeze, place and retrieve samples within liquid nitrogen without exposing the samples to detrimental transient warming events (TWE), which can reduce cell viability.

Regulatory Status

The BioArchive System is a Class II blood and blood component freezer exempt from the pre-market notification procedures. The Company has submitted to the FDA a Master File which summarizes pertinent information on the construction and operation of the BioArchive System. The BioArchive System is currently intended for storage of blood and blood components. Additional indications for use would require U.S. FDA clearance or approval.

About ThermoGenesis Corp.

After extensive research, ThermoGenesis Corp.`s newly introduced technology platforms lead the world in their ability to produce biological products from single units of blood. Umbilical cord blood banks are utilizing the Company`s BioArchive System as a critical enabling technology for cryogenic archiving of stem cells for transplant, while its CryoSeal(R) FS System is used to prepare hemostatic and adhesive surgical sealants from patient blood in about an hour. ThermoGenesis Corp. has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and blood banks since 1992.

The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.

[RudiDutschke]

ThermoGenesis Corp. Announces Second Quarter Results
E-mail or Print this story

13 February 2004, 06:00am ET

BioArchive(R) Revenues Continue to Increase - Corporate Gross Profit Almost
Doubles Over Prior Year

RANCHO CORDOVA, Calif., Feb. 13 /PRNewswire-FirstCall/ -- THERMOGENESIS CORP. (Nasdaq: KOOL) today announced results for its second quarter of fiscal 2004. Net revenues for the quarter ended December 31, 2003 increased 6% to $2,500,000, compared to $2,350,000 for the second quarter of fiscal 2003. For the six months ended December 31, 2003 the Company`s net revenues increased 5% to $4,643,000 compared to $4,403,000 for the first six months of the prior year. The gross profit for the second quarter almost doubled to $802,000 or 32% of net revenues compared to $412,000 or 18% for the second quarter ended December 31, 2002. For the six months ended December 31, 2003, the gross profit increased to $1,391,000 or 30% compared to $768,000 or 17% for the first six months of the prior year.

The net loss for the quarter ended December 31, 2003, was $1,223,000 or $0.03 per basic and diluted share compared to a $1,584,000 net loss of $0.04 per basic and diluted share for the quarter ended December 31, 2002. For the six months ended December 31, 2003, the net loss was $2,462,000 or $0.06 per basic and diluted share, a decrease from $2,946,000 or $0.08 per basic and diluted share for the six months ended December 31, 2002.

Revenues generated by the BioArchive product line for the quarter ended December 31, 2003 were $1.6 million, an increase of $600,000 or 60% over the second quarter of last year. The increase in BioArchive device revenue is predominately due to the infusion of government funding for public cord blood banking in Japan and Moscow and our strong distributor relationships in those areas. BioArchive disposable sales continue to increase largely due to the demand from private cord blood banks in Asia.

"The increase in the gross profit is the result of the mix of products sold during the quarter and the targeted programs implemented in the fourth quarter of fiscal 2003 directed at driving towards profitable operations with revenues and margins led by recurring sales of our proprietary disposables," stated Kevin Simpson, President and Chief Operating Officer. "The programs included reducing manufacturing overhead costs, consolidating operations, outsourcing manufacturing of disposables, accelerating FDA applications and focusing marketing, sales, and product development efforts in two key markets, blood banks and hospitals."

"In addition to the improvements noted in the Statements of Operations, we are extremely pleased with our improved liquidity and capital resources," stated Philip Coelho, Chief Executive Officer. The Company reported a cash balance of $8.3 million and working capital of $11.6 million at December 31, 2003 compared to $6.8 million of cash and $10.1 million of working capital at June 30, 2003. There was $4.2 million of cash generated from the exercise of options and warrants during the six months ended December 31, 2003. "Our strong cash position combined with our improving operations, will enable us to appropriately fund our strategic initiatives."

Company Conference Call

Management will host a conference call today, February 13, 2004 at 11:00am PST to review the financial results and other corporate events, followed by a Q&A session. The call can be accessed by dialing: 800-860-2442 within the U.S. or 412-858-4600 outside the U.S. and giving the conference name "THERMOGENESIS". Participants are asked to call the assigned number approximately 5 minutes before the conference call begins. A replay of the conference call will be available two hours after the call for the following five business days by dialing: 877-344-7529 within the U.S. or 412-858-1440 outside the U.S. and entering the following account number: 259 and the following conference number: 337391.

[RudiDutschke]

Russian Cord Blood Stem Cell Banks Adopt Thermogenesis` BioArchive(R) System
E-mail or Print this story

18 February 2004, 06:00am ET

Four additional BioArchive Systems Purchased

RANCHO CORDOVA, Calif., Feb. 18 /PRNewswire-FirstCall/ -- THERMOGENESIS CORP. (Nasdaq: KOOL) announced today that the Company has received an order for four (4) additional BioArchive Systems from the Company`s Russian distributor, Delrus Medical. Three (3) of the systems were shipped in December of 2003. These systems will be used to address the increased demand for stem cell processing and cryopreservation equipment for Russia`s expanding cord blood programs. The BioArchive System will be utilized as a critical enabling technology for our customer`s production of therapeutic units of cord blood stem cells.

Kevin Simpson, President and COO of THERMOGENESIS CORP. commented, "The Russian government has made a significant commitment to provide its citizens with these life saving units of stem cells as we continue to see adoption of the BioArchive System as a standard for cord blood banking customers worldwide."

"Recent research suggests that there are stem cells in a unit of cord blood that have the potential to produce other cells outside the hematopoietic system such as neural, liver and bone cells," said Philip Coelho, Chairman and CEO of THERMOGENESIS CORP. "Since there are serious ethical issues with sourcing stem cells from embryos and fetuses, scientists may begin to focus on cord blood as a non-controversial source for these multi-potential stem cells."
Mentioned Last Change
KOOL 5.38 Up0.16dollars or (3.06%)

BioArchive Systems have previously been deployed throughout North America, Europe, Middle East, and Asia. The Company estimates that more than 70% of the cord blood stem cell transplants performed to date have been supplied by Cord Blood Banks that are now using the BioArchive System to process, cryopreserve, and archive their stem cell units. The BioArchive System plays a key role in the emerging world standards that are being adopted for the processing and validation of stem cell units. It uses a computer-driven robotic system to archive up to 3,626 units in -196 degrees C liquid nitrogen. The BioArchive System is used by cord blood banks to freeze, track identification and perform robotic storage and retrieval of each unit. The BioArchive System can freeze, place and retrieve samples within liquid nitrogen without exposing the samples to detrimental transient warming events (TWE), which can reduce cell viability.

Regulatory Status

The BioArchive System is a Class II blood and blood component freezer exempt from the pre-market notification procedures. The Company has submitted to the FDA a Master File, which summarizes pertinent information on the construction and operation of the BioArchive System. The BioArchive System has potential applications involving archiving, storing, managing and retrieving other kinds of biological specimens, that may include stem cells, dendritic cells, T-cells, cell lines, sperm cells, eggs, heart valves, corneas, virus samples, biopsy samples and other blood, tissue and saliva samples. The BioArchive System is currently intended for storage of blood and blood components. Additional indications for use would require U.S. FDA clearance or approval.

About ThermoGenesis Corp.

After extensive research, ThermoGenesis Corp.`s newly introduced technology platforms lead the world in their ability to produce biological products from single units of blood. Umbilical cord blood banks are utilizing the Company`s BioArchive System as a critical enabling technology for cryogenic archiving of stem cells for transplant, while its CryoSeal(R) FS System is used to prepare hemostatic and adhesive surgical sealants from patient blood in about an hour. ThermoGenesis Corp. has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and blood banks since 1992.

The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.

[RudiDutschke]

Cord Blood Stem Cell Programs in Japan Continue Adoption Of ThermoGenesis` BioArchive(R) System
E-mail or Print this story

24 February 2004, 06:01am ET

ThermoGenesis Receives Additional Order for Two BioArchive Systems for Japan

RANCHO CORDOVA, Calif., Feb. 24 /PRNewswire-FirstCall/ -- THERMOGENESIS CORP. (Nasdaq: KOOL), announced that Air Water Inc., Japanese exclusive distributor, has received an order for two BioArchive Systems from the DBBPF (Donated Blood Business Promotion Foundation) who has received funding from the Ministry of Health, Labor and Welfare. One unit is scheduled for installation at Nihon University and the other will be at the Foundation`s own facility in Tokyo.

Kevin Simpson, President & COO of THERMOGENESIS CORP. commented, "This order increases the total BioArchives in Japan to 11 for performing critical stem cell processing, cryopreservation and archiving functions in clinical and research programs. The Company recently announced that it has completed a Master File on the BioArchive System which has been submitted to the FDA. One of the purposes of the Master File is to assist institutions such as these in Japan, and other parts of the world, who wish to utilize the BioArchive System for the cryopreservation and archiving of cell populations which could be utilized in the United States and other countries that require FDA permission for clinical use.

Dan Segal, Vice President of Sales and Marketing, noted, "With these orders, 85 BioArchive Systems will be deployed in 23 countries in North and South America, Europe and Asia. The BioArchive System continues to be the system of choice among Japan and the rest of the world`s leading cord blood stem cell bank programs."
Mentioned Last Change
KOOL 5.119 (Unchanged)

The BioArchive System plays a key role in the emerging world standards that are being adopted for the processing and storage of cord blood stem cell units. It features a computer-driven robotic system which the cord blood banks use to cryopreserve and archive up to 3,626 units of blood components at -196 degrees C. The BioArchive System can cryopreserve, archive and retrieve samples within liquid nitrogen without exposing the samples to detrimental transient warming events (TWE), which can reduce cell viability.

[RudiDutschke]

Asahi Medical Completes Clinical Trial on THERMOGENESIS` CryoSeal(R) System in Japan
E-mail or Print this story

3 March 2004, 11:38am ET

Asahi Medical Completes Clinical Trial and Prepares to Submit Application for
MHLW Approval

RANCHO CORDOVA, Calif., March 3 /PRNewswire-FirstCall/ -- THERMOGENESIS CORP. (Nasdaq: KOOL), announced that Asahi Medical Co., Ltd., a premier supplier of medical products and disposables and the exclusive licensed distributor of the CryoSeal System in Japan, has completed their 70-patient clinical trial on cardiovascular, orthopedic, neurosurgery and esophageal surgery patients. The clinical trial was designed to study efficacy, safety and usefulness of the "All-Autologous" CryoSeal Fibrin Sealant System. Asahi Medical expects to submit their license application including the clinical results to the Ministry of Health, Labour and Welfare in Japan (MHLW) by the first half of this year.

Kevin Simpson, President and COO commented, "This is a key milestone in the development of the CryoSeal System as a new safe alternative source of surgical sealant as Japan is the world`s largest market for conventional fibrin sealants. These conventional sealants are prepared from `pools` of thousands of units of purchased plasma and bovine lung tissue. Recent reports in Japanese medical journals have identified these `pooled` products as the source of parvovirus B19 which has been transmitted to patients and is a cause of hemolytic anemia. We are happy with the pace in which Asahi Medical completed this trial and look forward to supporting them to submit these results to MHLW for product licensure."

Regulatory Status
Mentioned Last Change
KOOL 4.80 Down0.151dollars or (3.04%)

The CryoSeal FS System has received CE Mark approval from the European Union Competent Authorities and is being marketed by Dideco Spa, of Mirandola, Italy. The CryoSeal FS System is not yet available in the United States and will require completion of a Phase III clinical trial, currently underway at 8 clinical sites, and the submission of PMA to the U.S. FDA before sales can commence in the U.S.

About ASAHI MEDICAL

Asahi Medical is a world leader in research, development, and production of devices and systems for blood treatment and purification based on advanced membrane separation and adsorption technologies. It serves the global market with dialysis products, plasma therapy products, and blood transfusion products for medical therapy in many countries.

About THERMOGENESIS CORP.

After extensive research, THERMOGENESIS CORP.`s newly introduced technology platforms lead the world in their ability to produce biological products from single units of blood. Umbilical cord blood banks are utilizing the Company`s BioArchive(R) System as a critical enabling technology for cryogenic archiving of stem cells for transplant, while its CryoSeal FS System is used to prepare hemostatic and adhesive surgical sealants from patient blood in about an hour. THERMOGENESIS CORP. has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and blood banks since 1992.

The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.

[RudiDutschke]

PR Newswire story
ThermoGenesis Corp. Raises $10.4 Million in Private Placement of Common Stock
E-mail or Print this story

10 March 2004, 1:45pm ET

RANCHO CORDOVA, Calif., March 10 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL) today announced that it has completed a private placement of 2.6 million shares of Common Stock at a price of $4.00 per share. All of the shares were sold by the Company. Upon closing, the Company will have approximately 44 million shares outstanding.

The Company intends to use the net proceeds of approximately $9.6 million for general corporate purposes. The placement agent for the offering was SunTrust Robinson Humphrey Capital Markets.

"We are extremely pleased with the continuing strong interest from institutions and our ability to complete this successful financing," said Philip H. Coelho, CEO of ThermoGenesis. "While we are highly confident about the prospects for the Company, we decided to take the opportunity to raise these additional funds to further strengthen our balance sheet and provide us with even greater flexibility as we continue to build ThermoGenesis Corp. into a world-class company."
Mentioned Last Change
KOOL 4.23 Down0.11dollars or (2.53%)

The shares of common stock were offered and sold in a private placement solely with institutional investors. Terms and conditions of the offering are further detailed in the Company`s filing on Form 8-K with the Securities and Exchange Commission. The offering was made pursuant to exemptions from registration under the Securities Act of 1933 and the Company, as soon as practical, will file a registration statement with the Securities and Exchange Commission relating to the resale of the shares of common stock by the purchasers in the private placement.

About ThermoGenesis Corp.

After extensive research, ThermoGenesis Corp`s technology platforms lead the world in their ability to produce biological products from single units of blood. Umbilical cord blood banks are utilizing the Company`s BioArchive(R) System as a critical enabling technology for the processing and cryogenic archiving of stem cells for transplant. The CryoSeal(R) FS System is used to prepare hemostatic and adhesive surgical sealants from patient blood in about an hour. The CryoSeal FS System is not available in the United States. ThermoGenesis Corp. has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and blood banks since 1992.

The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission

[RudiDutschke]

ThermoGenesis Achieves Record Third Quarter Shipments of Eight BioArchive(R) Systems
E-mail or Print this story

8 April 2004, 06:00am ET

RANCHO CORDOVA, Calif., April 8 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL) announced today eight (8) BioArchive Systems shipped in the last three months to cord blood banks and stem cell research institutes in the United Kingdom, Japan, Russia, Turkey and U.S.A. This demonstrates the increasing worldwide demand for the BioArchive as the premier system for cord blood banks and stem cell research institutes. Since 1998, eighty five (85) BioArchive Systems have been sold into 23 countries.

"This milestone illustrates the increased recognition of the BioArchive System as the standard for high quality cryopreservation, storage and retrieval of stored units by cord blood banks and stem cell research institutes worldwide," said Kevin Simpson, President and COO of ThermoGenesis. "We are also pleased with associated world-wide usage of the patented cord blood processing disposables for the BioArchive System."

Philip Coelho, Chairman & CEO of ThermoGenesis Corp commented, "This accomplishment results from the increasing use of cord blood stem cells by the world`s transplant physician community which is driven by peer review journal reports of excellent clinical outcomes of patients treated by cord blood stem cells." Current and proposed government funding in many countries is financing the growth of cord blood unit inventory worldwide.

[MacReu]

Na, da berappelt sich die gute alte KOOL wieder. Hat jemand von den Aktionären aktuelle Infos über KOOL? Gruß goldsack.de

[RudiDutschke]

ThermoGenesis Corp. Receives Japanese Patent for the CryoSeal(R) FS System
E-mail or Print this story

3 May 2004, 06:01am ET

First Autologous Entrant in $140 Million Japanese Fibrin Sealant Market

RANCHO CORDOVA, Calif., May 3 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL) announced today that it has received Japanese Patent No. 3537479, for the CryoSeal FS System which utilizes an automated medical device and single-use sterile disposable to harvest and concentrate wound healing proteins such as fibrinogen and fibronectin and the activating enzyme thrombin from autologous (patient`s own) plasma in about one hour. Surgeons apply this two component sealant to wound sites to stop "oozing" bleeding and seal tissues.

Kevin Simpson, President & COO of ThermoGenesis Corp., said, "This latest patent, `Fibrinogen Processing Apparatus, Method and Container` protects technology that provides sterile production of fibrin sealant kits, from a single unit of blood plasma." In contrast, the conventional fibrin sealants currently marketed in Japan are sourced from thousands of units of pooled plasma, and have recently been reported in peer review journals to have contaminated surgical patients with Parvovirus B-19, a cause of hemolytic anemia and also a non-enveloped virus not typically addressed with conventional pathogen reduction processes like solvent detergent or heat inactivation. By using the CryoSeal FS System, these, and other risks can be eliminated by using autologous (patient`s own) blood for the preparation of these protein surgical sealants."

Mr. Simpson also remarked that, "The CryoSeal patent for autologous sealant is especially significant in those countries where conventional fibrin sealants contain aprotinin, a component sourced from bovine lung tissue. In Japan the government announced a ban on drugs containing bovine materials from 28 countries over fears that the human variant of `mad cow disease` would be transmitted to patients."

Regulatory Status
Mentioned Last Change
KOOL 4.45 Down0.10dollars or (2.19%)

In Japan, the pivotal clinical trial of the CryoSeal System has recently been completed by the exclusive distributor, Asahi Medical Ltd. who is expected to file a pre-market approval (PMA) to the Japanese Ministry of Health in the near future. The CryoSeal FS System has also received CE Mark approval from the European Union Competent Authorities and is being tested in European clinical trials by Dideco S.p.A, of Mirandola, Italy. Additional field trials are underway in Canada and Brazil. The CryoSeal FS System is not yet available in the United States and will require completion of a Phase III clinical trial, currently underway at eight (8) clinical sites, and the submission of PMA to the U.S. FDA before sales can commence in the U.S.

[RudiDutschke]

SunTrust Robinson Humphrey, LLC (CBSS, KOOL, ROXI, NASI, HH, ONXX, EFD)
E-mail or Print this story

6 May 2004, 08:27am ET
CBSS: Ret Neutral - We are reiterating our Neutral rating on CBSS following its Analyst Meeting. We estimate CBSS should not benefit as substantially from a rising rate environment as many of its mid-cap peers. However, the fundamentals continue to be relatively strong, the balance sheet is becoming less complex (i.e. the runoff of the derivative portfolio) and with the lack of a clear successor, we are maintaining our Neutral rating. At this point, we believe the stock is better suited for investors with a time horizon of over three years.KOOL: Reit Buy - We believe KOOL should come in nicely ahead of our $2.8 million revenue estimate (we also believe the KOOL will exceed our net loss and GM estimates for the quarter). The company is set to report 3Q results on May 12. KOOL has already announced the sale of eight BioArchives in the March quarter (our estimate calls for six), and has a significant BioArchive backlog that should result in another better than expected top-line performance for the June quarter.ROXI: Reit Reduce - ROXI posted better than expected 4Q results. A well-received product cycle contributed to a 79% Q/Q increase in consumer software revenue. Likewise, we believe Napster is beginning to hit its stride at over $6MM in revenue in its first full quarter of operation. More notable was an aggressive restructuring, which eliminated $8MM in operating expenses. EPS of ($0.20) were well ahead of our ($0.44) estimate.NASI: Reit Buy - NASI announced yesterday that it has completed the acquisition of NOMOS, a leading supplier of planning and delivery technology for IMRT, issuing approximately 5.3 million shares of stock, roughly one million options, and $12 million in cash. Management provided top-line guidance for FY04 of $27 million, and we clearly expect the acquisition to be accretive to cash flow and earnings. Our CY04 revenue estimates are increasing from $18.1 million to $33.6 million and EPS is increasing from ($1.13) to ($1.04). Our CY05 revenue estimates are increasing from $24.7 million to $60.9 million and EPS is increasing from ($0.76) to ($0.30).HH: Reit Buy - HH reported 1Q04 net EPS of $0.05, in-line with both our estimate and the mean forecast. However, revenue fell short of our estimate by $3.6MM pressuring HH`s operating margin of 6.3% versus our 7.4% projection and 1Q03`s 10.4%. The softening in HH`s operating margin, also seen in 4Q03 at 6.7%, reflected amplified cost of sales from its Portamedic business, investments supporting Medical Direct`s growth, and a spike in SG&A expenses of 22.2% of revenue versus our 20.7% projection. The high SG&A expense level can be attributed to increased expenses from the integration of its acquisitions. We believe HH is directing much of its focus on pushing its margin back to traditional levels of the low double-digits over the next year, however a rebound in revenue will clearly be needed.ONXX: Ret Neutral - Onyx reported 1Q04 financial results. EPS of ($0.25), $0.08 better than our estimate primarily as a result of R&D expense of $6.7 million that was $2.6 million below our estimate. R&D is driven by the company`s BAY 43- 9006 development costs, which can be "lumpy" on a quarterly basis. Based on 1Q04 results, we are increasing our 2Q04 EPS estimate to ($0.30) from ($0.32) and our 2004 EPS estimate to ($1.23) from ($1.38). ONXX closed the quarter with $248 million in cash and we forecast a 2004 ending cash balance of $218 million.EFD: Ret Neutral - eFunds reported stronger than expected 1Q04 EPS of $0.19, $0.03 above our $0.16 estimate and $0.02 above the mean, compared to $0.10 a year ago. The $1.7 million top-line outperformance at $140.9 million versus our $139.2 million projection and last year`s $130.5 million combined with $1.9 million lower than expected operating expenses of $126.9 million versus our $128.5 million estimate resulted in 230 bps operating margin outperformance at 10% and 500 bps above last year. We are pleased at eFunds financial outperformance. The company is showing signs of traction by renewing its existing customer base and adding new clients. Additionally, eFunds has successfully contained its expenses to improve margins.Investors may note that the company has shown sequential margin improvements for the last five quarters - from 5% in 1Q03 to 10% in 1Q04. Click below to read more about subscribing to the full JAGnotes product.http://www.jagnotes.com/c/23/98.cfm?pagetitle=SubscribeNow Copyright 2004 JAGfn.com All Rights Reserved

[RudiDutschke]

ThermoGenesis Corp. Announces Third Quarter Results
E-mail or Print this story

12 May 2004, 06:00am ET

Company Achieves Record Revenues of $3.4 Million Led by BioArchive(R) Sales;

Third Quarter Gross Profit Doubles

RANCHO CORDOVA, Calif., May 12 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL) today announced results for its third quarter of fiscal 2004. Net revenues for the quarter ended March 31, 2004 increased 17% to $3,367,000, compared to $2,886,000 for the third quarter of fiscal 2003. For the nine months ended March 31, 2004 the Company`s net revenues increased 10% to $8,010,000 compared to $7,289,000 for the first nine months of the prior year. The gross profit for the third quarter doubled to $1,167,000 or 35% of net revenues compared to $511,000 or 18% for the third quarter ended March 31, 2003. For the nine months ended March 31, 2004, the gross profit increased to $2,558,000 or 32% compared to $1,279,000 or 18% for the first nine months of the prior year.

Our net loss for the quarter ended March 31, 2004, was $1,218,000 or $0.03 per basic and diluted share compared to a $1,666,000 net loss of $0.05 per basic and diluted share for the quarter ended March 31, 2003. For the nine months ended March 31, 2004, the net loss was $3,680,000 or $0.09 per basic and diluted share, a decrease from $4,612,000 or $0.13 per basic and diluted share for the nine months ended March 31, 2003.

The Company posted it`s highest quarterly revenues since it`s inception, led by the BioArchive product line which generated $2.2 million in revenues for the quarter ended March 31, 2004, an increase of $500,000 or 32% over the third quarter of last year. The increase was primarily generated from sales of BioArchive devices which is due to the infusion of government funding in Japan and the expansion of our technology which resulted in new product sales into new countries such as Scotland and Turkey.

"The increase in the gross profit margin is the result of higher average selling prices for BioArchive devices and ThermoLine(TM) freezers and the volume increase of the BioArchive product line as a percentage of total Company revenues. The products in the BioArchive product line have a higher gross profit margin than the other product lines," stated Kevin Simpson, President and Chief Operating Officer.

In addition to the improvements in the Statements of Operations, the Company`s balance sheet was further strengthened upon completion of an equity financing during the third quarter of fiscal 2004 which generated $9.8 million in net proceeds. "We are extremely pleased with our improved financial condition and resources," stated Philip Coelho, Chief Executive Officer. The Company reported a cash balance of $18 million and working capital of $20.9 million at March 31, 2004 compared to $6.8 million of cash and $10.1 million of working capital at June 30, 2003.

Company Conference Call

Management will host a conference call today, May 12, 2004 at 11:00 a.m. PDT to review the financial results and other corporate events, followed by a Q&A session. The call can be accessed by dialing: 800-860-2442 within the U.S. or [phone] outside the U.S. and giving the conference name "ThermoGenesis". Participants are asked to call the assigned number approximately five (5) minutes before the conference call begins. A replay of the conference call will be available two hours after the call for the following five business days by dialing: 877-344-7529 within the U.S. or [phone] outside the U.S. and entering the following account number: 019 and the following conference number: 343945.

About ThermoGenesis Corp.
Mentioned Last Change
KOOL 4.44 Down0.11dollars or (2.41%)

After extensive research, ThermoGenesis Corp`s technology platforms lead the world in their ability to produce biological products from single units of blood. Umbilical cord blood banks are utilizing the Company`s BioArchive System as a critical enabling technology for the processing and cryogenic archiving of stem cells for transplant. The CryoSeal(R) FS System is used to prepare hemostatic and adhesive surgical sealants from patient blood in about an hour. ThermoGenesis Corp. has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and blood banks since 1992.

Forward-Looking Statements

The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the Company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.

[RudiDutschke]

SunTrust Robinson Humphrey, LLC (UTI, SOTR, TNM, COCO, KOOL)
E-mail or Print this story

13 May 2004, 08:47am ET
UTI: Reit Neutral - Universal Technical reported second fiscal quarter (Mar) EPS of $0.28 vs. $0.21, beating our estimate of $0.25 and consensus of $0.24. Revenue of $63.7 million beat our $60.1 million target attributable to higher enrollments (13,000 vs. our 12,600 target) and acceleration in growth in average revenue per student, up 6.8% in the period. The EBIT margin of 21.2% topped our 19.8% forecast attributable to higher operating leverage.- We are raising our fiscal 2004 estimate from $1.02 to $1.06 to reflect the outperformance this quarter as well as an extra penny in the third quarter (now $0.22). For 2005, our estimate goes from $1.14 to $1.20 on higher revenue ($307 million, up 21%) and less EBIT margin compression (18.7%, down 100 basis points).SOTR: Reit Buy - Atlantic Station is the country`s largest urban development project: a 138-acre redevelopment at the nexus of I- 75 and I-85 in Midtown Atlanta. The development will ultimately have 12 million square feet of retail (including the first IKEA in the Southeast), office, residential and hotel space as well as 11 acres of public parks. SOTR will occupy five floors of office space in this new building. The company also has a full-service branch and ATM on the first floor. An estimated 500,000 people pass by this SouthTrust named building each day.- With the #4 deposit market share in the Atlanta MSA, SOTR has made an important commitment to continue its growth in this highly attractive market by relocating corporate banking operations and several company executives there.TNM: Reit Buy - Core revenue growth accelerated to an estimated 7% (from 4.2% in 3Q, 2.8% in 2Q and 1.6% in 1Q).Management described firm religious book demand in April and early May. Reported revenue grew $1.2% to $60.9 million, ahead of our $59.6 million forecast despite a challenging comparison a year ago. TNM posted 19.8% revenue growth a year ago attributable to a one-time bible sale and strong sales of The Savage Nation.Top line strength was the product of surprisingly strong Bible sales related to higher interest in Christian themes generated by the film The Passion and potentially market share gains.COCO: Reit Reduce - We believe that a number of recently-published statistics relating to healthcare employment are consistent with our view that the allied health sector is less attractive to potential students and workers in a rising economy; this is most meaningful to Corinthian among the education group because health is 54% of its total enrollment.KOOL: Reit Buy - KOOL reported record 3Q revenue of $3.4 million, ahead of our $2.8 million estimate (+17% y/y) and EPS of $(0.03), in-line with our estimate of $(0.03). The upside was mainly driven by strong BioArchive sales of $2.2 million, ahead of our $1.5 million estimates (selling eight units versus our estimate of six). We believe the BioArchive backlog stands at record levels (which bodes well for the June quarter). GM was strong, increasing nearly 100% year-over-year to 35% (vs. our estimate of 31%).�� We recently learned that the President`s budget for FY05 (to be released in October 2004) includes an additional $10 million of funds (on top of the $10 million that was appropriated earlier this year) towards the building of inventory of cord blood stem cell units. We believe this incremental funding is positive news and we continue to expect authorization of the full $150 million National Cord Blood Stem Cell Act some time in 2H04. Click below to read more about subscribing to the full JAGnotes product.http://www.jagnotes.com/c/23/98.cfm?pagetitle=SubscribeNow Copyright 2004 JAGfn.com All Rights Reserved